About   Help   FAQ
Mammalian Phenotype Ontology Annotations
Query Results - Summary
2596 genotypes with 4324 annotations displayed of selected term and subterms
Searched Term: abnormal classified tumor incidence
Allelic Composition
(Genetic Background)		 Annotated Term Reference
A4gnttm1Jnaka/A4gnttm1Jnaka
(B6.129S6-A4gnttm1Jnaka) 		increased gastric adenocarcinoma incidence J:184485
Abcb4tm1Bor/Abcb4tm1Bor
(either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * FVB/N)) 		increased hepatocellular carcinoma incidence J:21232
Abcb4tm1Bor/Abcb4tm1Bor
(FVB.129P2-Abcb4tm1Bor/J) 		increased hepatocellular carcinoma incidence J:217802
Abcb4tm1Bor/Abcb4tm1Bor
(CAnNCrl.12P2(FVB)-Abcb4tm1Bor) 		increased hepatocellular carcinoma incidence J:217802
Abraxas1tm1.1Bwng/Abraxas1+
(involves: 129S6/SvEvTac * C57BL/6NCrl * FVB/N) 		increased histiocytic sarcoma incidence J:269823
increased lung adenocarcinoma incidence J:269823
increased lymphoma incidence J:269823
Abraxas1tm1.1Bwng/Abraxas1tm1.1Bwng
(involves: 129S6/SvEvTac * C57BL/6NCrl * FVB/N) 		increased lymphoma incidence J:269823
Acot12em1Holi/Acot12em1Holi
(involves: C57BL/6J * C57BL/6N) 		increased hepatocellular carcinoma incidence J:335836
Acox1lampe1/Acox1lampe1
(involves: C57BL/6J) 		increased hepatocellular carcinoma incidence J:174942
Acox1tm1Jkr/Acox1tm1Jkr
(involves: 129P2/OlaHsd * C57BL/6J) 		increased hepatocellular carcinoma incidence J:35794
Acp3tm1Pivi/Acp3tm1Pivi
(B6.Cg-Acp3tm1Pivi) 		increased prostate gland adenocarcinoma incidence J:207558
Actbtm1(PyVT)Arge/Actb+
(involves: 129S1/Sv) 		increased hemangioma incidence J:87544
increased mammary adenocarcinoma incidence J:87544
Actbtm1(PyVT)Arge/Actb+
Waptm1(cre)Arge/Wap+
(involves: 129S1/Sv) 		increased mammary adenocarcinoma incidence J:87544
Actbtm2(Tag)Arge/Actb+
(involves: 129S1/Sv) 		increased sarcoma incidence J:87544
Actbtm2(Tag)Arge/Actb+
Tg(Hsp70-1-cre)1Arge/0
(involves: 129S1/Sv * C57BL/6J * CBA) 		increased leiomyosarcoma incidence J:87544
Adamts3tm1b(KOMP)Wtsi/Adamts3tm1b(KOMP)Wtsi
(C57BL/6N-Adamts3tm1b(KOMP)Wtsi/Wtsi) 		increased hemangioma incidence J:239583
Ahrtm1Gonz/Ahrtm1Gonz
(involves: 129S4/SvJae * C57BL/6N) 		increased liver adenoma incidence J:44690
Ahrtm1Yfk/Ahrtm1Yfk
(involves: 129S/SvEv * C57BL/6J) 		increased urinary bladder carcinoma incidence J:179919
Aicdatm1(cre)Mnz/Aicda+
Gt(ROSA)26Sortm2(sb11)Njen/Gt(ROSA)26Sor+
TgTn(sb-T2/Onc2)6070Njen/0
(involves: 129 * 129P2/OlaHsd * C57BL/6 * C57BL/6J) 		increased B cell derived lymphoma incidence J:153656
increased follicular lymphoma incidence J:153656
increased leukemia incidence J:153656
increased medulloblastoma incidence J:153656
increased skin squamous cell carcinoma incidence J:153656
increased T cell derived lymphoma incidence J:153656
AipGt(RRI002)Byg/Aip+
(involves: 129P2/OlaHsd * C57BL/6) 		increased pituitary adenoma incidence J:165349
increased prolactinoma incidence J:165349
Airetm1Pltn/Airetm1Pltn
(B6.129S4-Airetm1Pltn) 		increased B cell derived lymphoma incidence J:115076
Akt1Gt1Pnt/Akt1Gt1Pnt
Tg(MMTV-Erbb2)NK1Mul/Tg(MMTV-Erbb2)NK1Mul
(involves: 129 * C57BL/6 * FVB/N) 		increased mammary adenocarcinoma incidence J:117336
Akt1Gt1Pnt/Akt1Gt1Pnt
Tg(MMTV-PyVT)634Mul/0
(involves: 129 * C57BL/6 * FVB/N) 		increased mammary adenocarcinoma incidence J:117336
Akt2tm1.1Mbb/Akt2tm1.1Mbb
Tg(MMTV-Erbb2)NK1Mul/Tg(MMTV-Erbb2)NK1Mul
(involves: 129 * C57BL/6 * FVB/N) 		increased mammary adenocarcinoma incidence J:117336
Akt2tm1.1Mbb/Akt2tm1.1Mbb
Tg(MMTV-PyVT)634Mul/0
(involves: 129 * C57BL/6 * FVB/N) 		increased mammary adenocarcinoma incidence J:117336
Akt3tm1Mbb/Akt3tm1Mbb
Tg(MMTV-Erbb2)NK1Mul/Tg(MMTV-Erbb2)NK1Mul
(involves: 129 * C57BL/6 * FVB/N) 		increased mammary adenocarcinoma incidence J:117336
Akt3tm1Mbb/Akt3tm1Mbb
Tg(MMTV-PyVT)634Mul/0
(involves: 129 * C57BL/6 * FVB/N) 		increased mammary adenocarcinoma incidence J:117336
Aktiptm1a(EUCOMM)Hmgu/Aktiptm1a(EUCOMM)Hmgu
Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * C57BL/6N) 		increased lymphoma incidence J:276210
Aktiptm1a(EUCOMM)Hmgu/Aktiptm1a(EUCOMM)Hmgu
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6N) 		increased lymphoma incidence J:276210
Albtm1(cre/ERT2)Mtz/Alb+
Gt(ROSA)26Sortm1(Notch1)Dam/Gt(ROSA)26Sor+
(involves: 129S2/SvPas * 129S4/SvJaeSor * C57BL/6) 		increased cholangiocarcinoma incidence J:192740
Albtm1(cre/ERT2)Mtz/Alb+
Krastm4Tyj/Kras+
Ptentm2Mak/Ptentm2Mak
(involves: 129P2/OlaHsd * 129S2/SvPas * 129S4/SvJae) 		increased cholangiocarcinoma incidence J:254370
increased hepatocellular carcinoma incidence J:254370
Aldh2tm1a(EUCOMM)Wtsi/Aldh2tm1a(EUCOMM)Wtsi
Fancd2tm1Hou/Fancd2tm1Hou
(involves: 129S4/SvJae * C57BL/6J * C57BL/6N) 		increased acute lymphoblastic leukemia incidence J:193232
increased lymphoma incidence J:193232
increased T cell derived lymphoma incidence J:193232
Alktm1.1(ALK*F1174L)Heno/Alk+
Tg(Mpz-cre)94Imeg/0
Tg(Th-MYCN)41Waw/0
(involves: 129X1/SvJ * BALB/c * C57BL/6 * SJL) 		increased neuroblastoma incidence J:294092
Alktm1.1(ALK*F1174L)Heno/Alktm1.1(ALK*F1174L)Heno
Tg(Mpz-cre)94Imeg/0
Tg(Th-MYCN)41Waw/0
(involves: 129X1/SvJ * BALB/c * C57BL/6 * SJL) 		increased neuroblastoma incidence J:294092
Alktm1.1Ics/?
Tg(Th-MYCN)41Waw/0
(involves: 129S2/SvPas * 129X1/SvJ * BALB/c * C57BL/6 * C57BL/6J) 		increased neuroblastoma incidence J:261033, J:228124
Alktm2.1Ics/?
Tg(Th-MYCN)41Waw/0
(involves: 129S2/SvPas * 129X1/SvJ * BALB/c * C57BL/6 * C57BL/6J) 		increased neuroblastoma incidence J:261033, J:228124
Alox15tm1Fun/Alox15tm1Fun
(B6.129S2-Alox15tm1Fun/J) 		increased chronic myelocytic leukemia incidence J:119405
Amhr2tm3(cre)Bhr/Amhr2+
(involves: 129S/SvEv * C57BL/6) 		increased ovarian carcinoma incidence J:128934
Amhr2tm3(cre)Bhr/Amhr2+
KitW-v/KitW-v
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J * FVB/N) 		increased ovary adenoma incidence J:236161
Amhr2tm3(cre)Bhr/Amhr2+
Smad1tm2Rob/Smad1tm2.1Rob
Smad5tm1Huy/Smad5tm1Huy
(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6) 		increased ovarian carcinoma incidence J:128934
Amhr2tm3(cre)Bhr/Amhr2+
Smad1tm2Rob/Smad1tm2Rob
Smad5tm1Huy/Smad5tm1Zuk
(involves: 129P2/OlaHsd * 129S/SvEv * 129S7/SvEvBrd * C57BL/6) 		increased ovarian carcinoma incidence J:128934
Amhr2tm3(cre)Bhr/Amhr2+
Smad1tm2Rob/Smad1tm2Rob
Smad5tm1Huy/Smad5tm1Zuk
Smad9tm1Jfm/Smad9tm1Jfm
(involves: 129S/SvEv * 129S4/SvJaeSor * C57BL/6) 		increased ovarian carcinoma incidence J:128934
Anxa7tm1Pll/Anxa7+
(B6.Cg-Anxa7tm1Pll) 		increased hepatocellular carcinoma incidence J:93685
increased lymphoma incidence J:93685
ApcGt(XA018)Byg/Apc+
(B6.129P2-ApcGt(XA018)Byg) 		increased colon adenoma incidence J:202877
increased intestinal adenoma incidence J:202877
ApcM1Tno/Apc+
(either: B6JJcl.B6(D2JJcl)-ApcM1Tno or (involves: C57BL/6 * C57BL/6JJcl * DBA/2JJcl)) 		increased mammary adenocarcinoma incidence J:218227
increased osteosarcoma incidence J:218227
ApcMin/Apc+
(involves: AKR/J * C57BL/6J) 		increased intestinal adenocarcinoma incidence J:10209
increased intestinal adenoma incidence J:10209
ApcMin/Apc+
(C57BL/6J-ApcMin) 		increased colon adenoma incidence J:158733, J:160399
increased intestinal adenoma incidence J:158733, J:241611, J:1879, J:85142
ApcMin/Apc+
(involves: C57BL/6J) 		increased intestinal adenoma incidence J:299895, J:75393, J:94108
increased mammary adenocarcinoma incidence J:94108
ApcMin/Apc+
(involves: 129P2/OlaHsd * C57BL/6) 		increased intestinal adenoma incidence J:95893
ApcMin/Apc+
(B6(AKR)-ApcMin) 		increased intestinal adenocarcinoma incidence J:10209
increased intestinal adenoma incidence J:10209
ApcMin/Apc+
((AKR/J x C57BL/6J-ApcMin)F1) 		increased intestinal adenocarcinoma incidence J:21369
ApcMin/Apc+
(C57BL/6J-ApcMin/J) 		increased colon adenoma incidence J:331404
increased intestinal adenoma incidence J:331404
ApcMin/Apc+
Blmtm1Grdn/Blm+
(involves: 129P2/OlaHsd * 129S/SvEv * Black Swiss * C57BL/6J) 		increased colon adenoma incidence J:79058
increased intestinal adenoma incidence J:79058
ApcMin/Apc+
Ccdc80tm1.1Ftk/Ccdc80tm1.1Ftk
(involves: 129P2/OlaHsd * BALB/cJ * C57BL/6 * C57BL/6J * C57BL/6N) 		increased colon adenocarcinoma incidence J:216704
increased colon adenoma incidence J:216704
ApcMin/Apc+
Ccnd1tm1Dsn/Ccnd1tm1Dsn
(involves: C57BL/6J) 		increased intestinal adenoma incidence J:78500
ApcMin/Apc+
Cd44tm1Stpa/Cd44tm1Stpa
(involves: C57BL/6J * C57BL/6JIco) 		increased intestinal adenoma incidence J:204874
ApcMin/Apc+
Cd44tm1Stpa/Cd44tm2Stpa
(involves: C57BL/6J) 		increased intestinal adenoma incidence J:204874
ApcMin/Apc+
Col1a1tm9(tetO-Dnmt3b_i1)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
(involves: 129S4/SvJae * C57BL/6 * C57BL/6J) 		increased intestinal adenoma incidence J:127808
ApcMin/Apc+
Dcctm1Wbg/Dcc+
(involves: C57BL/6J) 		increased intestinal adenoma incidence J:39765
ApcMin/Apc+
Dnd1Ter/Dnd1+
(involves: 129P3/J * C57BL/6J) 		increased intestinal adenoma incidence J:221231
ApcMin/Apc+
Eregtm1Dwt/Eregtm1Dwt
(involves: 129S6/SvEvTac * C57BL/6J) 		increased intestinal adenoma incidence J:93327
ApcMin/Apc+
Esr1tm1.1Mma/Esr1+
(involves: 129S2/SvPas * C57BL/6J) 		increased carcinoma incidence J:118600
increased colon adenoma incidence J:118600
ApcMin/Apc+
Esr2tm1Mma/Esr2tm1Mma
(involves: 129S2/SvPas * C57BL/6J) 		increased colon adenoma incidence J:118600
ApcMin/Apc+
Foxl1tm1Khk/Foxl1tm1Khk
(involves: 129P2/OlaHsd * C57BL/6) 		increased colon adenoma incidence J:95893
ApcMin/Apc+
Glp2rtm1Ddr/Glp2r+
(involves: C57BL/6J) 		increased intestinal adenoma incidence J:141821
ApcMin/Apc+
Glp2rtm1Ddr/Glp2rtm1Ddr
(involves: C57BL/6J) 		increased intestinal adenoma incidence J:141821
ApcMin/Apc+
Gpa33tm1(GNAS)Wtsi/Gpa33+
Hprt1tm1(CMV-cre)Brd/?
(involves: 129S7/SvEvBrd * C57BL/6J) 		increased intestinal adenoma incidence J:168378
ApcMin/Apc+
Hdac2Gt(W035F03)Joe/Hdac2Gt(W035F03)Joe
(involves: 129S2/SvPas * C57BL/6J) 		increased small intestine adenocarcinoma incidence J:152134
ApcMin/Apc+
Hpgdstm1Urad/Hpgds+
(involves: 129 * C57BL/6J) 		increased intestinal adenoma incidence J:118232
ApcMin/Apc+
Hpgdstm1Urad/Hpgdstm1Urad
(involves: 129 * C57BL/6J) 		increased intestinal adenoma incidence J:118232
ApcMin/Apc+
Hsd11b2tm1.1Mzz/Hsd11b2tm1.1Mzz
Tg(Vil1-cre)997Gum/0
(involves: 129 * C57BL/6 * C57BL/6J) 		increased intestinal adenoma incidence J:205456
ApcMin/Apc+
Il22ra2tm2Vlcg/Il22ra2tm2Vlcg
(involves: 129S6/SvEvTac * C57BL/6J * C57BL/6NTac) 		increased intestinal adenoma incidence J:189217
ApcMin/Apc+
Mapkapk2tm1.2Gkl/Mapkapk2tm1.2Gkl
(involves: BALB/cJ * C57BL/6J) 		increased intestinal adenoma incidence J:262876
ApcMin/Apc+
Mbd4tm1Bird/Mbd4tm1Bird
(involves: 129P2/OlaHsd * C57BL/6J) 		increased intestinal adenoma incidence J:77896
ApcMin/Apc+
Mir10atm1.1Ahl/Mir10atm1.1Ahl
(B6.Cg-Mir10atm1.1Ahl Apcmin) 		increased intestinal adenoma incidence J:205135
ApcMin/Apc+
Mir708tm1Wtsi/Mir708tm1Wtsi
(involves: C57BL/6J * C57BL/6N) 		increased colon adenoma incidence J:317482
ApcMin/Apc+
Mom5C57BL/6J/Mom5C57BL/6J
(involves: C57BL/6J) 		increased intestinal adenoma incidence J:152194
ApcMin/Apc+
Msh2tm1Mak/Msh2tm1Mak
(involves: 129P2/OlaHsd * C57BL/6J) 		increased intestinal adenoma incidence J:75393
ApcMin/Apc+
Pms2tm1Lisk/Pms2tm1Lisk
(involves: 129S2/SvPas * C57BL/6J) 		increased intestinal adenoma incidence J:46419
ApcMin/Apc+
Ppardtm1Jps/Ppardtm1Jps
(involves: 129/Sv * AKR/J * C57BL/6 * C57BL/6J) 		increased intestinal adenocarcinoma incidence J:90337
ApcMin/Apc+
Ptentm1Hwu/Ptentm1Hwu
Tg(Vil1-cre)997Gum/0
(involves: 129S4/SvJae * BALB/c * C57BL/6J * SJL) 		increased intestinal adenoma incidence J:150553
ApcMin/Apc+
Ptgdstm1Ohy/Ptgdstm1Ohy
(involves: 129P2/OlaHsd * C57BL/6J) 		increased intestinal adenoma incidence J:118232
ApcMin/Apc+
Rab11atm1.1Ngao/Rab11atm1.1Ngao
Tg(Vil1-cre)997Gum/0
(involves: 129S4/SvJae * C57BL/6J * SJL/J) 		increased intestinal adenoma incidence J:278932
ApcMin/Apc+
Rab25tm1Jrgo/Rab25+
(B6.Cg-Rab25tm1Jrgo ApcMin) 		increased intestinal adenoma incidence J:158733
ApcMin/Apc+
Rab25tm1Jrgo/Rab25tm1Jrgo
(B6.Cg-Rab25tm1Jrgo ApcMin) 		increased colon adenoma incidence J:158733
increased intestinal adenoma incidence J:158733
ApcMin/Apc+
Recql4tm1Glu/Recql4tm1Glu
(involves: 129S7/SvEvBrd * C57BL/6J) 		increased adenoma incidence J:97101
increased colon adenoma incidence J:97101
ApcMin/Apc+
Slc5a8tm1.1Boet/Slc5a8tm1.1Boet
(involves: C57BL/6 * C57BL/6J) 		increased colon adenoma incidence J:139883
ApcMin/Apc+
Spata18tm1.2Hifa/Spata18+
(involves: C57BL/6J) 		increased classified tumor incidence J:254117
increased colon adenocarcinoma incidence J:254117
increased colon adenoma incidence J:254117
increased intestinal adenocarcinoma incidence J:254117
increased intestinal adenoma incidence J:254117
increased small intestine adenocarcinoma incidence J:254117
ApcMin/Apc+
Spata18tm1.2Hifa/Spata18tm1.2Hifa
(involves: C57BL/6J) 		increased classified tumor incidence J:254117
increased colon adenocarcinoma incidence J:254117
increased colon adenoma incidence J:254117
increased intestinal adenocarcinoma incidence J:254117
increased intestinal adenoma incidence J:254117
increased small intestine adenocarcinoma incidence J:254117
ApcMin/Apc+
Tcf7tm1Cle/Tcf7tm1Cle
(involves: 129P2/OlaHsd * C57BL/6J) 		increased intestinal adenoma incidence J:57721
increased mammary adenoacanthoma incidence J:57721
ApcMin/Apc+
Tcf7l2tm1.1(EGFP/cre)Mrc/Tcf7l2+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J) 		increased intestinal adenoma incidence J:170088
ApcMin/Apc+
Tcf7l2tm2.2Mrc/Tcf7l2+
(involves: C57BL/6J) 		increased intestinal adenoma incidence J:170088
ApcMin/Apc+
Tg(CAG-PGDS)S-55Hjl/0
(involves: C57BL/6J * FVB/N) 		increased intestinal adenoma incidence J:118232
ApcMin/Apc+
Tgfbr1tm1Bopa/Tgfbr1+
(involves: 129S1/SvImJ * C57BL/6J) 		increased intestinal adenocarcinoma incidence J:143706
ApcMin/Apc+
Tgfbr1tm1Bopa/Tgfbr1+
(B6.Cg-Tgfbr1tm1Bopa ApcMin) 		increased intestinal adenocarcinoma incidence J:143706
ApcMin/Apc+
Thbs1tm1Hyn/Thbs1tm1Hyn
(involves: C57BL/6J) 		increased carcinoma incidence J:79641
increased intestinal adenoma incidence J:79641
ApcMin/Apc+
Trp53tm1Mlh/Trp53tm1Mlh
(involves: 129P2/OlaHsd * C57BL/6 * SWR) 		increased pancreatic acinar cell carcinoma incidence J:29664
ApcMin/Apc+
Trp53tm2.1Tyj/Trp53tm2.1Tyj
Tg(Vil1-cre/ERT2)23Syr/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * DBA/2) 		increased colon adenoma incidence J:291671
increased intestinal adenoma incidence J:291671
ApcMin/Apc+
Zbtb33tm1.1Bird/Y
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J) 		increased intestinal adenoma incidence J:104155
ApcMin/ApcMin
Ppardtm1.1Rev/Ppardtm1.1Rev
(involves: C57BL/6J) 		increased intestinal adenoma incidence J:73557
ApcMin/ApcMin
Rr27tm1Rohl/Rr27+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J) 		increased colon adenoma incidence J:97083
increased intestinal adenoma incidence J:97083
ApcMin/Apctm1Tno
Ctnnb1tm4.1Wbm/Ctnnb1+
(involves: 129 * 129P2/OlaHsd * 129S4/SvJae * C57BL/6) 		increased hepatocellular carcinoma incidence J:156864
Apctm1.1Alew/Apc+
(B6.129-Apctm1.1Alew) 		increased adenoma incidence J:180057
increased intestinal adenoma incidence J:180057, J:180275
Apctm1.1Rsmi/Apc+
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N) 		increased desmoid tumor incidence J:159883
increased intestinal adenoma incidence J:159883
increased large intestine adenocarcinoma incidence J:159883
increased small intestine adenocarcinoma incidence J:159883
Apctm1.1Tno/Apc+
(involves: 129S4/SvJae * C57BL/6) 		increased intestinal adenoma incidence J:127452
Apctm1.1Tyj/Apc+
(involves: 129S4/SvJaeSor * C57BL/6) 		increased colon adenoma incidence J:160399
increased intestinal adenoma incidence J:160399
Apctm1Cip/Apc+
(involves: 129P2/OlaHsd * C57BL/6) 		increased colon adenoma incidence J:94108
increased intestinal adenocarcinoma incidence J:94108
increased intestinal adenoma incidence J:94108
increased mammary adenocarcinoma incidence J:94108
Apctm1Cip/Apc+
Cdhr5tm1Lex/Cdhr5tm1Lex
(involves: 129P2/OlaHsd * 129S5/SvEvBrd * C57BL/6) 		increased intestinal adenoma incidence J:301471
Apctm1Cip/Apc+
H19tm1Lda/H19+
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * CBA) 		increased adenoma incidence J:138826
increased intestinal adenocarcinoma incidence J:138826
Apctm1Cip/Apc+
H19tm1Lda/H19+
(involves: 129P2/OlaHsd * 129S2/SvPas) 		increased adenoma incidence J:138826
Apctm1Hsa/Apc+
(involves: 129P2/OlaHsd * C57BL/6) 		increased mammary adenocarcinoma incidence J:61978
Apctm1Kk/Apctm1Kk
Tg(Lck-cre)1Cwi/?
(involves: 129S6/SvEvTac * C57BL/6 * DBA/2) 		increased intestinal adenoma incidence J:104334
Apctm1Mmt/Apc+
(involves: 129S2/SvPas * C57BL/6J) 		increased intestinal adenoma incidence J:25200, J:79668
Apctm1Mmt/Apc+
Smad2tm1Kato/Smad2+
(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6J) 		increased intestinal adenoma incidence J:79668
Apctm1Mmt/Apc+
Smad2tm2Kato/Smad2+
(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6J) 		increased intestinal adenoma incidence J:79668
Apctm1Mmt/Apc+
Smad4tm1Mmt/Smad4+
(involves: 129S2/SvPas * C57BL/6) 		increased intestinal adenocarcinoma incidence J:46242
increased pancreatic ductal adenocarcinoma incidence J:46242
Apctm1Rak/Apc+
(involves: 129P2/OlaHsd * C57BL/6) 		increased hepatocellular carcinoma incidence J:20443
increased intestinal adenocarcinoma incidence J:20443
increased intestinal adenoma incidence J:20443
Apctm1Rak/Apc+
(involves: 129P2/OlaHsd * C57BL/6J) 		increased intestinal adenocarcinoma incidence J:65142
Apctm1Rak/Apc+
((C57BL/6J x 129P2/OlaHsd)F1) 		increased desmoid tumor incidence J:151494
Apctm1Rak/Apc+
Cdh1tm1Cbm/Cdh1+
(involves: 129P2/OlaHsd * C57BL/6J) 		increased intestinal adenocarcinoma incidence J:65142
Apctm1Rak/Apc+
Dcctm1.1Mehl/Dcctm1.1Mehl
(involves: 129P2/OlaHsd * C57BL/6) 		increased intestinal adenocarcinoma incidence J:181517
Apctm1Rak/Apc+
Mlh1tm1Rak/Mlh1tm1Rak
(involves: 129P2/OlaHsd * C57BL/6) 		increased adenocarcinoma incidence J:53451
increased adenoma incidence J:53451
increased carcinoma incidence J:53451
increased lymphoma incidence J:53451
Apctm1Rak/Apc+
Smad4E6sad/Smad4+
(B6.129P2-Apctm1Rak Smad4E6sad/+ +) 		increased intestinal adenoma incidence J:107273
Apctm1Rak/Apc+
Smad4E6sad/Smad4+
(B6.129P2-Apctm1Rak +/+ Smad4E6sad) 		increased intestinal adenocarcinoma incidence J:107273
increased intestinal adenoma incidence J:107273
Apctm1Rsmi/Apc+
Tg(Fabp1-cre)1Jig/0
(involves: 129P2/OlaHsd * FVB/N) 		increased intestinal adenocarcinoma incidence J:159883
increased intestinal adenoma incidence J:159883
increased large intestine adenocarcinoma incidence J:159883
increased small intestine adenocarcinoma incidence J:159883
Apctm1Tno/Apc+
(involves: 129 * 129S4/SvJae * C57BL/6) 		increased hepatocellular carcinoma incidence J:156864
Apctm1Tno/Apc+
Brf1tm1Arte/Brf1tm1Arte
Tg(Cyp1a1-cre)1Dwi/0
(involves: C57BL/6 * CBA) 		increased pancreatic ductal adenocarcinoma incidence J:285667
Apctm1Tno/Apc+
Ptentm2Mak/Ptentm2Mak
Tg(Cyp1a1-cre/ERT)1Dwi/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * CBA) 		increased intestinal adenocarcinoma incidence J:143082
Apctm1Tno/Apc+
Tg(CDX2-cre)101Erf/0
(involves: 129S4/SvJae * C57BL/6 * SJL) 		increased mammary adenocarcinoma incidence J:126018
Apctm1Tno/Apc+
Tg(Vil1-cre)997Gum/0
(involves: 129S4/SvJae * C57BL/6 * SJL) 		increased small intestine adenocarcinoma incidence J:126018
Apctm1Tno/Apctm1Tno
(involves: 129S4/SvJae * C57BL/6) 		increased colon adenoma incidence J:43301
Apctm1Tno/Apctm1Tno
(involves: 129 * 129S4/SvJae * C57BL/6) 		increased hepatocellular carcinoma incidence J:156864
Apctm1Tno/Apctm1Tno
Lgr5tm1(cre/ERT2)Cle/Lgr5+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6) 		increased intestinal adenoma incidence J:227334
Apctm1Tno/Apctm1Tno
Ptentm2Mak/Ptentm2Mak
(involves: 129P2/OlaHsd * 129S4/SvJae) 		increased ovarian carcinoma incidence J:120955
Apctm1Tno/Apctm1Tno
Tg(Cdh16-cre)91Igr/0
(involves: 129S4/SvJae * ICR) 		increased renal cystadenoma incidence J:95502
Apctm1Tno/Apctm1Tno
Tg(CDX2-cre*)189Erf/0
(involves: 129S4/SvJae * C57BL/6 * SJL) 		increased colon adenoma incidence J:148161
Apctm1Tno/Apctm1Tno
Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * C57BL/6J * DBA/2) 		increased prostate gland adenocarcinoma incidence J:120308
Apctm1Tyj/Apc+
Tg(Vil1-cre)20Syr/0
(involves: C57BL/6 * DBA/2) 		increased colon adenoma incidence J:160399
increased intestinal adenoma incidence J:160399
Apctm2.1Alew/Apc+
(B6.129-Apctm2.1Alew) 		increased adenoma incidence J:180057
increased intestinal adenoma incidence J:180057
Apctm2.1Cip/Apc+
Krastm4Tyj/Kras+
Tg(Fabp1-cre)1Jig/0
(involves: 129P2/OlaHsd * 129S4/SvJae * FVB) 		increased intestinal adenocarcinoma incidence J:132357
Apctm2.1Cip/Apc+
Lrig1tm1.1(cre/ERT2)Rjc/Lrig1+
(involves: 129 * 129P2/OlaHsd * C57BL/6) 		increased intestinal adenoma incidence J:186084
Apctm2.1Cip/Apc+
Tg(Fabp1-cre)1Jig/0
(involves: 129P2/OlaHsd * FVB/N) 		increased intestinal adenocarcinoma incidence J:132357
Apctm2.1Cip/Apc+
Tg(Vil1-cre)20Syr/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2) 		increased colon adenoma incidence J:160399
increased intestinal adenoma incidence J:160399
Apctm2.1Cip/Apc+
Tg(Vil1-cre/ERT2)23Syr/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2) 		increased colon adenoma incidence J:227287
increased intestinal adenoma incidence J:227287
Apctm2.1Cip/Apctm2.1Cip
(involves: 129P2/OlaHsd * C57BL/6N) 		increased hepatocellular carcinoma incidence J:94721
Apctm2.1Rak/Apc+
(involves: 129/Sv * C57BL/6J * SJL) 		increased intestinal adenoma incidence J:114152
Apctm2Mmt/Apc+
(involves: 129X1/SvJ) 		increased intestinal adenoma incidence J:81402
Apctm2Rak/Apc+
Krastm1.1Khai/Kras+
Tg(Fabp1-cre)1Jig/0
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * FVB/N * SJL) 		increased colon adenoma incidence J:276349
Apctm2Rak/Apc+
Krastm4Tyj/Kras+
Tg(Fabp1-cre)1Jig/0
(involves: 129S4/SvJae * C57BL/6 * FVB/N * SJL) 		increased colon adenoma incidence J:276349
Apctm2Rak/Apc+
Tg(Car1-cre)5Flt/0
(involves: 129/Sv * C57BL/6J * SJL) 		increased intestinal adenoma incidence J:164247
Apctm2Rak/Apc+
Trp53tm1Brn/Trp53tm1Brn
Tg(Pdx1-cre)6Tuv/0
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6J * FVB/N * SJL) 		increased cystadenoma incidence J:234310
Apctm2Rak/Apctm2Rak
(involves: 129/Sv * C57BL/6J * SJL) 		increased carcinoma incidence J:156532
increased colon adenoma incidence J:156532
Apctm2Rak/Apctm2Rak
Krastm4Tyj/Kras+
(involves: 129 * 129S4/SvJae * C57BL/6J * SJL) 		increased adenocarcinoma incidence J:156532
increased carcinoma incidence J:156532
increased colon adenoma incidence J:156532
Apctm2Rak/Apctm2Rak
Tg(Car1-cre)5Flt/0
(involves: 129/Sv * C57BL/6J * SJL) 		increased intestinal adenoma incidence J:164247
Apctm2Rfo/Apc+
(B6.129P2-Apctm2Rfo) 		increased mammary adenocarcinoma incidence J:151494
Apctm2Rfo/Apc+
((C57BL/6J x 129P2/OlaHsd)F1) 		increased desmoid tumor incidence J:151494
increased mammary adenocarcinoma incidence J:204440, J:151494
Apctm2Rfo/Apc+
(129P2/OlaHsd-Apctm2Rfo) 		increased mammary adenocarcinoma incidence J:151494
Apctm2Rfo/Apc+
Smad4E6sad/Smad4+
(involves: 129P2/OlaHsd * C57BL/6J) 		increased mammary adenocarcinoma incidence J:151494
Apctm2Tno/Apc+
(Not Specified) 		increased intestinal adenoma incidence J:47857
Apctm3Mmt/Apc+
(B6.129X1-Apctm3Mmt) 		increased intestinal adenoma incidence J:101604
Apctm4Mmt/Apc+
(B6.129X1-Apctm4Mmt) 		increased intestinal adenoma incidence J:101604
Apex1tm1Ecf/Apex1+
(either: (involves: 129/Sv) or (involves: 129/Sv * C57BL/6)) 		increased carcinoma incidence J:70397
increased lymphoma incidence J:70397
increased sarcoma incidence J:70397
Artm1Verh/Y
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * DBA/2) 		increased prostate gland adenocarcinoma incidence J:172730
Arid1atm1.1Mag/Arid1atm1.1Mag
Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+
(involves: 129S6/SvEvTac * CD-1) 		increased ovarian carcinoma incidence J:219794
Arid4atm1Alb/Arid4atm1Alb
(involves: 129S7/SvEvBrd) 		increased leukemia incidence J:141004
increased sarcoma incidence J:141004
Arid4atm1Alb/Arid4atm1Alb
Arid4btm1Alb/Arid4b+
(involves: 129S7/SvEvBrd) 		increased leukemia incidence J:141004
increased sarcoma incidence J:141004
Asxl1tm1.1Mjxu/Asxl1+
(involves: 129 * C57BL/6) 		increased leukemia incidence J:208085
increased malignant tumor incidence J:208085
increased sarcoma incidence J:208085
Atad5Gt(RRF055)Byg/Atad5+
(involves: 129P2/OlaHsd) 		increased hemangiosarcoma incidence J:176672
increased liver adenocarcinoma incidence J:176672
increased lung adenocarcinoma incidence J:176672
increased lung carcinoma incidence J:176672
increased lymphoma incidence J:176672
increased sarcoma incidence J:176672
increased spindle cell carcinoma incidence J:176672
increased T cell derived lymphoma incidence J:176672
Atf2tm3Nicj/Atf2tm3Nicj
Tg(KRT14-cre)1Efu/?
(involves: C57BL/6 * FVB/N) 		increased skin papilloma incidence J:131564
Atmtm1.1Mmpl/Atmtm1.1Mmpl
(involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6J) 		increased T cell derived lymphoma incidence J:226414
Atmtm1Awb/Atm+
Rad50tm2Jpt/Rad50tm2Jpt
(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6) 		increased lymphoma incidence J:103922
Atmtm1Awb/Atmtm1Awb
(either: 129S6/SvEvTac-Atmtm1Awb or (involves: 129S6/SvEvTac * NIH Black Swiss)) 		increased T cell derived lymphoma incidence J:34193
Atmtm1Awb/Atmtm1Awb
(involves: 129S6/SvEvTac * C57BL/6) 		increased T cell derived lymphoma incidence J:103922
Atmtm1Awb/Atmtm1Awb
(involves: 129S6/SvEvTac) 		increased T cell derived lymphoma incidence J:90941
Atmtm1Awb/Atmtm1Awb
(CByJ.129S6-Atmtm1Awb) 		increased T cell derived lymphoma incidence J:208539
Atmtm1Awb/Atmtm1Awb
(A.129S6-Atmtm1Awb) 		increased hepatocellular carcinoma incidence J:208539
Atmtm1Awb/Atmtm1Awb
(129S6/SvEvTac-Atmtm1Awb) 		increased T cell derived lymphoma incidence J:208539
Atmtm1Awb/Atmtm1Awb
(either: (129S6/SvEvTac-Atmtm1Awb x B6.129S6-Atmtm1Awb)F1 or (B6.129S6-Atmtm1Awb x 129S6/SvEvTac-Atmtm1Awb)F1) 		increased T cell derived lymphoma incidence J:208539
Atmtm1Awb/Atmtm1Awb
(either: (129S6/SvEvTac-Atmtm1Awb x A.129S6-Atmtm1Awb)F1 or (A.129S6-Atmtm1Awb x 129S6/SvEvTac-Atmtm1Awb)F1) 		increased T cell derived lymphoma incidence J:208539
Atmtm1Awb/Atmtm1Awb
(129S6/SvEvTac-Atmtm1Awb/J) 		increased T cell derived lymphoma incidence J:226414
Atmtm1Awb/Atmtm1Awb
Rad50tm2Jpt/Rad50tm2Jpt
(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6) 		increased lymphoma incidence J:103922
Atmtm1Awb/Atmtm1Awb
Rad52tm1Aps/Rad52tm1Aps
(involves: 129P2/OlaHsd * 129S6/SvEvTac) 		decreased lymphoma incidence J:90941
increased T cell derived lymphoma incidence J:90941
Atmtm1Bal/Atmtm1Bal
(involves: 129S4/SvJae) 		increased T cell derived lymphoma incidence J:35914
Atmtm1Fwa/Atmtm1Fwa
(involves: 129S4/SvJae * C57BL/6) 		increased T cell derived lymphoma incidence J:61201
Atmtm1Led/Atmtm1Led
(involves: 129S6/SvEvTac * Black Swiss) 		increased T cell derived lymphoma incidence J:69726
Atmtm1Mfl/Atm+
(involves: 129T2/SvEms * C57BL/6J) 		increased adenoma incidence J:78527
increased leukemia incidence J:78527
increased lymphoma incidence J:78527
increased sarcoma incidence J:78527
Atmtm1Mfl/Atmtm1Mfl
(involves: 129T2/SvEms * C57BL/6J) 		increased T cell derived lymphoma incidence J:69726
Atmtm1Pmc/Atmtm1Pmc
(involves: 129X1/SvJ * C57BL/6) 		increased lymphoma incidence J:47752
Atmtm2.1Fwa/Atmtm2.1Fwa
Tg(VAV1-cre)1Graf/0
(involves: 129S6/SvEvTac) 		increased T cell derived lymphoma incidence J:277750
Atmintm1.1Jhh/Atmintm1.1Jhh
Bcl2l11tm1.1Ast/Bcl2l11tm1.1Ast
Cd79atm1(cre)Reth/Cd79a+
Tg(IghMyc)22Bri/0
(B6.Cg-Bcl2l11tm1.1Ast Cd79atm1(Cre)Reth Atmintm1.1Jhh Tg(IghMyc)22Bri) 		increased lymphoma incidence J:230105
Atmintm1.1Jhh/Atmintm1.1Jhh
Cd79atm1(cre)Reth/Cd79a+
Tg(IghMyc)22Bri/0
(B6.Cg-Cd79atm1(Cre)Reth Atmintm1.1Jhh Tg(IghMyc)22Bri) 		decreased lymphoma incidence J:230105
Atp2a2tm1Ges/Atp2a2+
(involves: 129X1/SvJ * Black Swiss) 		increased esophageal papilloma incidence J:69754
increased skin papilloma incidence J:69754
increased squamous cell carcinoma incidence J:69754
increased tongue papilloma incidence J:69754
Atp2c1tm1Ges/Atp2c1+
(involves: 129X1/SvJ * Black Swiss) 		increased esophageal papilloma incidence J:124662
increased skin papilloma incidence J:124662
increased squamous cell carcinoma incidence J:124662
Atp11cambr/Y
(C57BL/6-Atp11cambr) 		increased hepatocellular carcinoma incidence J:171924
Atrxtm1Rjg/Y
Rb1tm3Tyj/Rb1tm3Tyj
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * 129S4/SvJae * CD-1) 		increased osteosarcoma incidence J:329449
Atrxtm1Rjg/Atrxtm1Rjg
Rb1tm3Tyj/Rb1tm3Tyj
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * 129S4/SvJae * CD-1) 		increased osteosarcoma incidence J:329449
AurkaGt(XQ0149)Wtsi/Aurka+
(involves: 129P2/OlaHsd * C57BL/6) 		increased lung carcinoma incidence J:143099
increased lymphoma incidence J:143099
increased squamous cell carcinoma incidence J:143099
Aurkbtm1.2Mama/Aurkb+
(involves: 129/Sv * BALB/cJ * C57BL/6 * CD-1 * SJL) 		increased adenocarcinoma incidence J:173575
increased liver adenocarcinoma incidence J:173575
increased skin papilloma incidence J:173575
Auts2em1(IMPC)Wtsi/Auts2em1(IMPC)Wtsi
(C57BL/6N-Auts2em1(IMPC)Wtsi/Wtsi) 		increased hemangioma incidence J:239583
B2mtm1Unc/B2mtm1Unc
Il2tm1Hor/Il2tm1Hor
(involves: 129 * C57BL/6) 		increased intestinal adenocarcinoma incidence J:51450
B2mtm1Unc/B2mtm1Unc
Prkdcscid/Prkdcscid
(NOD.Cg-B2mtm1Unc Prkdcscid) 		increased T cell derived lymphoma incidence J:102141
B3gnt6tm1Lx/B3gnt6tm1Lx
(involves: 129S1/Sv * C57BL/6J) 		increased adenocarcinoma incidence J:123826
increased carcinoma incidence J:123826
increased intestinal adenoma incidence J:123826
B3gnt6tm1Lx/B3gnt6tm1Lx
C1galt1tm1.1Rpmc/C1galt1tm1.1Rpmc
Tg(Vil1-cre/ERT2)23Syr/0
(involves: 129S1/Sv * C57BL/6 * C57BL/6J * DBA/2) 		increased duodenum adenocarcinoma incidence J:239765
B9d2tm1a(EUCOMM)Wtsi/B9d2tm1a(EUCOMM)Wtsi
(C57BL/6N-B9d2tm1a(EUCOMM)Wtsi/Wtsi) 		increased hemangioma incidence J:239583
Badtm1Sjk/Badtm1Sjk
(either: 129X1/SvJ or (involves: 129X1/SvJ * C57BL/6)) 		increased B cell derived lymphoma incidence J:84987
increased lymphoma incidence J:84987
Bak1tm1Thsn/Bak1tm1Thsn
Baxtm1Sjk/Baxtm2Sjk
Krastm4Tyj/Kras+
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6) 		increased adenocarcinoma incidence J:125101
Bap1em1Test/Bap1+
(involves: FVB) 		increased lung carcinoma incidence J:231692
increased mammary adenocarcinoma incidence J:231692
increased mesothelioma incidence J:231692
increased squamous cell carcinoma incidence J:213725
Bap1em2Test/Bap1+
(involves: FVB) 		increased lung carcinoma incidence J:231692
increased mammary adenocarcinoma incidence J:231692
increased mesothelioma incidence J:231692
increased pancreatic islet cell carcinoma incidence J:231692
Bap1em3Test/Bap1+
(involves: FVB) 		increased lung carcinoma incidence J:231692
increased lymphoma incidence J:231692
increased mammary adenocarcinoma incidence J:231692
Bap1tm1.1Geno/Bap1tm1.1Geno
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
(involves: C57BL/6 * C57BL/6NTac) 		increased leukemia incidence J:187380
Bard1tm1Thl/Bard1tm2Thl
Waptm1(cre)Arge/0
(involves: 129S1/Sv * C57BL/6J) 		increased mammary adenocarcinoma incidence J:134977
Bard1tm2Thl/Bard1tm2Thl
Brca1tm1Thl/Brca1tm1Thl
Waptm1(cre)Arge/0
(involves: 129/Sv * 129S1/Sv * C57BL/6J) 		increased mammary adenocarcinoma incidence J:134977
Bard1tm2Thl/Bard1tm2Thl
Waptm1(cre)Arge/0
(involves: 129/Sv * 129S1/Sv * C57BL/6J) 		increased mammary adenocarcinoma incidence J:134977
Bcl2tm1Mpin/Bcl2+
Tg(SFTPC-RAF1-BxB)1Urr/0
(involves: 129S2/SvPas * C57BL/6 * DBA/2) 		increased lung adenoma incidence J:79696
Bcl2tm1Mpin/Bcl2tm1Mpin
Tg(H2-K-BCL2)1Josd/0
Tg(SFTPC-RAF1-BxB)1Urr/0
(involves: 129S2/SvPas * C3H * C57BL/6 * DBA/2) 		increased lung adenoma incidence J:79696
Bcl2tm1Mpin/Bcl2tm1Mpin
Tg(SFTPC-RAF1-BxB)1Urr/0
(involves: 129S2/SvPas * C57BL/6 * DBA/2) 		increased lung adenoma incidence J:79696
Bcl2tm2.1Lbox/Bcl2+
(involves: 129S1/Sv * 129X1/SvJ * FVB/N) 		increased B cell derived lymphoma incidence J:175730
increased follicular lymphoma incidence J:175730
Bcl2tm2.1Lbox/Bcl2tm2.1Lbox
(involves: 129S1/Sv * 129X1/SvJ * FVB/N) 		increased B cell derived lymphoma incidence J:175730
increased follicular lymphoma incidence J:175730
Bcl2l11tm1.1Boui/Bcl2l11+
Tg(IghMyc)22Bri/0
(involves: C57BL/6 * SJL) 		increased B cell derived lymphoma incidence J:186117
increased T cell derived lymphoma incidence J:186117
Bcl2l11tm1.1Boui/Bcl2l11tm1.1Boui
Tg(IghMyc)22Bri/0
(involves: C57BL/6 * SJL) 		increased B cell derived lymphoma incidence J:186117
Bcl2l11tm2.1Boui/Bcl2l11+
Tg(IghMyc)22Bri/0
(involves: C57BL/6 * SJL) 		increased B cell derived lymphoma incidence J:186117
Bcl2l11tm2.1Boui/Bcl2l11tm2.1Boui
Tg(IghMyc)22Bri/0
(involves: C57BL/6 * SJL) 		increased B cell derived lymphoma incidence J:186117
Bcl2l11tm3.1Boui/Bcl2l11+
Tg(IghMyc)22Bri/0
(involves: C57BL/6 * SJL) 		increased B cell derived lymphoma incidence J:186117
Bcl2l11tm3.1Boui/Bcl2l11tm3.1Boui
Tg(IghMyc)22Bri/0
(involves: C57BL/6 * SJL) 		increased B cell derived lymphoma incidence J:186117
Bcl11btm2.1Jpk/Bcl11b+
Tg(Lck-cre)1Jtak/0
(involves: C57BL/6) 		increased lymphoma incidence J:210122
Becn1tm1Blev/Becn1+
(involves: 129X1/SvJ * C57BL/6J) 		increased follicular lymphoma incidence J:86953
increased hepatocellular carcinoma incidence J:86953
increased histiocytic sarcoma incidence J:86953
increased lung adenocarcinoma incidence J:86953
increased lung adenoma incidence J:86953
increased lung carcinoma incidence J:86953
increased lymphoma incidence J:86953
increased malignant tumor incidence J:86953
increased plasmacytoma incidence J:86953
Becn1tm1Htz/Becn1+
(involves: 129P2/OlaHsd * C57BL/6) 		increased B cell derived lymphoma incidence J:86982
increased hepatocellular carcinoma incidence J:86982
increased lung adenocarcinoma incidence J:86982
Bhlha15tm2(Kras)Skz/Bhlha15+
(involves: 129S6/SvEvTac * C57BL/6) 		increased hepatocellular carcinoma incidence J:105076
increased liver adenoma incidence J:105076
increased pancreas adenoma incidence J:105076
increased pancreatic acinar cell carcinoma incidence J:105076
Bhlha15tm2(Kras)Skz/Bhlha15+
Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6) 		increased hepatocellular carcinoma incidence J:105076
Bhmttm1.2Zei/Bhmttm1.2Zei
(involves: 129P2/OlaHsd * C57BL/6) 		increased hepatocellular carcinoma incidence J:177569
increased liver adenoma incidence J:177569
Bin1tm1Gcp/Bin1tm2Gcp
Tg(MMTV-Myc)141-3Led/0
Tg(Wap-cre)11738Mam/0
(involves: 129S6/SvEvTac * C57BL/6 * CD-1 * FVB/N * SJL) 		increased lymphoma incidence J:117330
increased mammary adenocarcinoma incidence J:117330
Bin3tm1Gcp/Bin3tm1Gcp
(involves: 129 * C57BL/6) 		increased lung adenocarcinoma incidence J:133313
increased lymphoma incidence J:133313
Blmtm1Ches/Blmtm3Brd
(involves: 129S/SvEv * C57BL/6 * NIH Black Swiss) 		increased lymphoma incidence J:86827
Blmtm1Ches/Blmtm4Ches
Tg(LGB-cre)74Acl/0
(involves: 129S6/SvEvTac * C57BL/6 * CBA * SJL) 		increased mammary adenocarcinoma incidence J:112115
Blmtm3Brd/Blmtm3Brd
(involves: 129S7/SvEvBrd * C57BL/6) 		increased lymphoma incidence J:66261
Blnktm1Dkit/Blnktm1Dkit
(involves: C57BL/6) 		increased leukemia incidence J:84040
Blnktm1Dkit/Blnktm1Dkit
Cd19tm1(cre)Cgn/Cd19tm1(cre)Cgn
(involves: 129P2/OlaHsd * C57BL/6 * NZB) 		increased leukemia incidence J:84040
Blnktm1Pjln/Blnktm1Pjln
Btktm1Gsv/Y
(involves: 129P2/OlaHsd * BALB/c * C57BL/6) 		increased B cell derived lymphoma incidence J:94768
Bmftm1.1Ast/Bmftm1.1Ast
(B6.Cg-Bmftm1.1Anst) 		increased T cell derived lymphoma incidence J:133084
Bmi1tm1(cre/ERT)Mrc/Bmi1+
Ctnnb1tm1Mmt/Ctnnb1+
(involves: 129S1/Sv * 129X1/SvJ) 		increased intestinal adenoma incidence J:138364
Bmi1tm1Brn/Bmi1tm1Brn
Apctm2Cip/Apc+
Cdkn2atm1Cjs/Cdkn2atm1Cjs
Tg(Vil1-cre)20Syr/0
(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * DBA/2) 		increased intestinal adenoma incidence J:204354
Bmpr1atm2.1Bhr/Bmpr1atm2.1Bhr
Ctnnb1tm1Mmt/Ctnnb1+
Krt14tm1.1(cre)Wbm/Krt14+
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * 129X1/SvJ) 		increased squamous cell carcinoma incidence J:199091
Boktm1.1Ast/Boktm1.1Ast
Tg(IghMyc)22Bri/0
(involves: BALB/cJ * C57BL * C57BL/6 * SJL) 		increased lymphoma incidence J:203179
Bomb1NSF/N/Bomb1NSF/N
(involves: NFS/N * SL/Kh) 		increased lymphoma incidence J:55364
Bomb1SL/Kh/Bomb1SL/Kh
(involves: NFS/N * SL/Kh) 		increased lymphoma incidence J:55364
Braftm1.1Brd/Braf+
Cdkn2atm1.1Brn/Cdkn2atm1.1Brn
Tg(Vil1-cre)997Gum/0
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * SJL) 		increased carcinoma incidence J:199307
increased intestinal adenoma incidence J:199307
Braftm1.1Brd/Braf+
Tg(Vil1-cre)997Gum/0
(involves: 129S7/SvEvBrd * C57BL/6 * SJL) 		increased carcinoma incidence J:199307
increased intestinal adenoma incidence J:199307
Braftm1Bbd/Braf+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * CD-1) 		increased lung adenoma incidence J:170095
Braftm1Cpri/Braf+
(involves: 129P2/OlaHsd) 		increased lung adenoma incidence J:187371
Braftm1Cpri/Braf+
Tg(Mx1-cre)1Cgn/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA) 		increased leukemia incidence J:104375
Braftm1Cpri/Braftm1Cpri
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(Tyr-cre/ERT2)1Lru/0
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * DBA/2 * SJL) 		increased melanoma incidence J:147434
Braftm1Cpri/Braftm1Cpri
Tg(TPO-cre)1Shk/0
(involves: 129P2/OlaHsd * FVB/NCr) 		increased thyroid carcinoma incidence J:168249
Braftm1Cpri/Braftm1Cpri
Tg(Tyr-cre/ERT2)1Lru/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2) 		increased melanoma incidence J:147434
Braftm1Mmcm/Braf+
(involves: 129P2/OlaHsd) 		increased lung adenocarcinoma incidence J:121715
increased lung adenoma incidence J:121715
Braftm1Mmcm/Braf+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6) 		increased thyroid carcinoma incidence J:208854
Braftm1Mmcm/Braf+
Ezh2tm1.1Nesh/Ezh2+
Tg(Tyr-cre/ERT2)13Bos/0
(involves: 129 * 129P2/OlaHsd * C57BL/6 * FVB) 		increased melanoma incidence J:239472
Braftm1Mmcm/Braf+
Polr2atm1(cre/ERT2)Bbd/Polr2a+
(involves: 129P2/OlaHsd * C57BL/6 * SJL) 		increased lung adenoma incidence J:121715
Braftm1Mmcm/Braf+
Ptentm1Mro/Ptentm1Mro
Tg(Tyr-cre/ERT2)1Lru/0
(B6.Cg-Braftm1Mmcm Tg(Tyr-cre/ERT2)1Lru Ptentm1Mro) 		increased cutaneous melanoma incidence J:188523
Braftm1Mmcm/Braf+
Ptentm1Rdp/Ptentm1Rdp
Tg(Tyr-cre/ERT2)13Bos/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * FVB/N) 		increased cutaneous melanoma incidence J:151023
Braftm1Mmcm/Braf+
Ptentm2.1Ppp/Pten+
Tg(Tyr-cre/ERT2)13Bos/0
(involves: 129P2/OlaHsd * 129S1/Sv * FVB) 		increased cutaneous melanoma incidence J:151023
Braftm1Mmcm/Braf+
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(Tyr-cre/ERT2)13Bos/0
(involves: 129P2/OlaHsd * 129S1/Sv * FVB) 		increased cutaneous melanoma incidence J:151023
Braftm1Mmcm/Braf+
Tg(Tg-cre/ERT2)#Mmcm/0
(involves: 129P2/OlaHsd) 		increased thyroid carcinoma incidence J:172205
Braftm1Mmcm/Braf+
Tg(TPO-cre/ERT2)1139Tyj/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6NTac) 		increased thyroid carcinoma incidence J:208854
Braftm1Mmcm/Braf+
Tg(TPO-cre/ERT2)1139Tyj/0
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6NTac) 		increased thyroid carcinoma incidence J:208854
Braftm1Mmcm/Braf+
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd) 		increased lung adenocarcinoma incidence J:121715
Braftm1Mmcm/Braf+
Trp53tm1Brn/Trp53tm3.1Tyj
Tg(TPO-cre/ERT2)1139Tyj/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6NTac) 		increased thyroid carcinoma incidence J:208854
Braftm1Mmcm/Braf+
Trp53tm3.1Tyj/Trp53+
Tg(TPO-cre/ERT2)1139Tyj/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6NTac) 		increased thyroid carcinoma incidence J:208854
Braftm1Mmcm/Braftm1Mmcm
Nkx3-1tm4(cre/ERT2)Mms/Nkx3-1+
Ptentm1Hwu/Pten+
(involves: 129P2/OlaHsd * 129S4/SvJae * 129S6/SvEvTac * C57BL/6) 		increased prostate gland adenocarcinoma incidence J:191327
Braftm1Rima/Braf+
Tg(GFP/KRAS2/ALPP)1Brn/0
Tg(Tyr-cre/ERT2)1Lru/0
(involves: C57BL/6 * DBA/2 * FVB/N) 		increased melanoma incidence J:161180
Braftm1Sva/Braftm1Sva
Krastm1Bbd/Kras+
(involves: 129S1/Sv * 129X1/SvJ) 		increased lung non-small cell carcinoma incidence J:172200
Braftm1Tuv/Braftm1Tuv
Gt(ROSA)26Sortm1(sb13)Tuv/Gt(ROSA)26Sor+
Tg(Tyr-cre/ERT2)13Bos/0
TgTn(sb-T2/Onc)#Dla/0
(involves: 129S6/SvEvTac * FVB/N) 		increased melanoma incidence J:177503
Braftm2Cpri/Braf+
Krastm4Tyj/Kras+
(involves: 129S4/SvJae * C57BL/6) 		increased lung adenoma incidence J:187371
Braftm2Cpri/Braf+
Tg(CMV-cre)1Cgn/0
(B6.Cg-Braftm2Cpri Tg(CMV-cre)1Cgn) 		increased intestinal adenoma incidence J:187371
increased skin papilloma incidence J:187371
Brca1tm1Aash/Brca1tm1Aash
Tg(LGB-cre)74Acl/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA) 		increased salivary adenocarcinoma incidence J:119996
Brca1tm1Aash/Brca1tm1Aash
Trp53tm1Brd/Trp53+
Tg(LGB-cre)74Acl/0
(involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6 * CBA) 		increased mammary gland ductal carcinoma incidence J:119996
increased salivary adenocarcinoma incidence J:119996
Brca1tm1Arge/Brca1tm1Thl
Waptm1(cre)Arge/0
(involves: 129S/SvEv * 129S1/Sv * C57BL/6J) 		increased mammary adenocarcinoma incidence J:134977
Brca1tm1Bhk/Brca1+
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi
(C.129-Cdkn2ctm1Yxi Brca1tm1Bhk) 		increased mammary adenocarcinoma incidence J:198018
Brca1tm1Brn/Brca1tm1Brn
Tg(Krt18-EGFP,-TAg121)36Ysng/0
Trp53tm1Brn/Trp53tm2Tyj
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2 * FVB/N) 		increased carcinoma incidence J:189304
increased ovarian carcinoma incidence J:189304
Brca1tm1Cxd/Brca1tm2Cxd
Tg(KRT5-cre)5132Jlj/0
(involves: 129S6/SvEvTac * C57BL/6) 		increased squamous cell carcinoma incidence J:85354
Brca1tm1Cxd/Brca1tm2Cxd
Tg(KRT5-cre)5132Jlj/0
Tg(KRT5-E2F1)2Dgj/0
(involves: 129S6/SvEvTac * C57BL/6 * SJL) 		increased squamous cell carcinoma incidence J:85354
Brca1tm1Cxd/Brca1tm2Cxd
Tg(KRT5-E2F1)2Dgj/0
(involves: 129S6/SvEvTac * C57BL/6 * SJL) 		increased papilloma incidence J:85354
increased squamous cell carcinoma incidence J:85354
Brca1tm1Cxd/Brca1tm2Cxd
Tg(MMTV-cre)4Mam/0
(involves: 129S6/SvEvTac * Black Swiss * FVB) 		increased mammary adenocarcinoma incidence J:54533
Brca1tm1Thl/Brca1tm1Thl
Waptm1(cre)Arge/0
(involves: 129S1/Sv * C57BL/6J) 		increased mammary adenocarcinoma incidence J:134977
Brca1tm2.1Cxd/Brca1tm2.1Cxd
Trp53tm1Brd/Trp53+
(involves: 129S6/SvEvTac * 129S7/SvEvBrd) 		increased carcinoma incidence J:122899
increased T cell derived lymphoma incidence J:81541
Brca1tm2.1Cxd/Brca1tm2.1Cxd
Trp53tm1Brd/Trp53tm1Brd
(involves: 129S6/SvEvTac * 129S7/SvEvBrd) 		increased T cell derived lymphoma incidence J:81541
Brca1tm2Cxd/Brca1+
Tg(KRT5-E2F1)2Dgj/0
(involves: 129S6/SvEvTac * C57BL/6 * SJL) 		increased squamous cell carcinoma incidence J:85354
Brca1tm2Mak/Brca1tm2Mak
Chek2tm1Mak/Chek2tm1Mak
Tg(Lck-cre)548Jxm/?
(involves: 129P2/OlaHsd * C57BL/6 * CBA) 		increased T cell derived lymphoma incidence J:90512
Brca1tm2Mak/Brca1tm2Mak
Chek2tm1Mak/Chek2tm1Mak
Tg(Wap-cre)11738Mam/?
(involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL) 		increased mammary adenocarcinoma incidence J:90512
Brca1tm2Mak/Brca1tm2Mak
Tg(Lck-cre)548Jxm/?
Trp53tm1Brd/Trp53tm1Brd
(involves: 129P2/OlaHsd * C57BL/6 * CBA) 		increased T cell derived lymphoma incidence J:90512
Brca1tm2Mak/Brca1tm2Mak
Trp53tm1Brd/Trp53+
Tg(Wap-cre)11738Mam/?
(involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL) 		increased mammary adenocarcinoma incidence J:90512
Brca1tm3Cxd/Brca1tm3Cxd
(involves: 129S6/SvEvTac * FVB/N) 		increased lipoma incidence J:94114
increased lymphoma incidence J:94114
Brca1tm4Cxd/Brca1tm4Cxd
(involves: 129S6/SvEvTac * NIH Black Swiss) 		increased mammary gland ductal carcinoma incidence J:112308
Brca1tm5.1Cxd/Brca1tm5.1Cxd
(involves: 129S6/SvEvTac * FVB/N) 		increased lymphoma incidence J:155810
increased T cell derived lymphoma incidence J:155810
Brca2tm1Arge/Brca2tm2Arge
Waptm1(cre)Arge/Wap+
(involves: 129S/SvEv * C57BL/6) 		increased mammary adenocarcinoma incidence J:70564
Brca2tm1Brn/Brca2+
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/0
(involves: 129P2/OlaHsd * FVB/N) 		increased mammary adenocarcinoma incidence J:73028
Brca2tm1Brn/Brca2tm1Brn
Ptch1tm1Mps/Ptch1+
Trp53tm1Tyj/Trp53+
Tg(Nes-cre)1Kln/0
(involves: 129 * C57BL/6 * SJL) 		increased medulloblastoma incidence J:144617
Brca2tm1Brn/Brca2tm1Brn
Ptch1tm1Mps/Ptch1+
Trp53tm1Tyj/Trp53tm1Tyj
Tg(Nes-cre)1Kln/0
(involves: 129 * C57BL/6 * SJL) 		increased medulloblastoma incidence J:144617
Brca2tm1Brn/Brca2tm1Brn
Trp53tm1Brn/Trp53+
Tg(KRT14-cre)8Brn/0
(involves: 129P2/OlaHsd * FVB/N) 		increased mammary adenocarcinoma incidence J:73028
Brca2tm1Brn/Brca2tm1Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/0
(involves: 129P2/OlaHsd * FVB/N) 		increased mammary adenocarcinoma incidence J:73028
Brca2tm1Brn/Brca2tm1Brn
Trp53tm1Tyj/Trp53+
Tg(Nes-cre)1Kln/0
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL) 		increased medulloblastoma incidence J:144617
Brca2tm1Brn/Brca2tm1Brn
Trp53tm1Tyj/Trp53tm1Tyj
Tg(Nes-cre)1Kln/0
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL) 		increased medulloblastoma incidence J:144617
Brca2tm1Brn/Brca2tm1Cam
Krastm4Tyj/Kras+
Trp53tm3Tyj/Trp53+
Tg(Pdx1-cre)6Tuv/0
(involves: 129P2/OlaHsd * 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N) 		increased pancreatic acinar cell carcinoma incidence J:166678
increased pancreatic ductal adenocarcinoma incidence J:166678
Brca2tm1Cam/Brca2+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
(involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N) 		increased pancreatic ductal adenocarcinoma incidence J:166678
Brca2tm1Cam/Brca2+
Krastm4Tyj/Kras+
Trp53tm3Tyj/Trp53+
Tg(Pdx1-cre)6Tuv/0
(involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N) 		increased pancreatic ductal adenocarcinoma incidence J:166678
Brca2tm1Cam/Brca2tm1Brn
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
(involves: 129P2/OlaHsd * 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N) 		increased pancreatic ductal adenocarcinoma incidence J:166678
Brca2tm1Cam/Brca2tm1Brn
Tg(Pdx1-cre)6Tuv/0
Trp53tm3Tyj/Trp53+
(involves: 129P2/OlaHsd * 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N) 		increased malignant tumor incidence J:166678
increased sarcoma incidence J:166678
Brca2tm1Cam/Brca2tm1Cam
(involves: 129S/SvEv * MF1) 		increased T cell derived lymphoma incidence J:46812
Brca2tm1Cbl/Brca2tm1Cbl
(either: (involves: 129S2/SvPas * C57BL/10) or (involves: 129S2/SvPas * C57BL/6 * DBA/2)) 		increased T cell derived lymphoma incidence J:44386
Brca2tm1Hst/Brca2tm1Hst
(involves: 129S7/SvEvBrd * C57BL/6) 		increased carcinoma incidence J:82434
increased lymphoma incidence J:82434
Brca2tm1Kamc/Brca2tm1Kamc
Trp53tm1Tyj/Trp53+
(involves: 129P2/OlaHsd * 129S2/SvPas * BALB/c * C57BL/6) 		increased osteosarcoma incidence J:109193
Brca2tm1Mak/Brca2tm2Mak
Trp53tm1Brd/Trp53tm1Brd
Tg(Lck-cre)548Jxm/0
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * CBA) 		increased lymphoma incidence J:79697
increased malignant tumor incidence J:79697
increased osteosarcoma incidence J:79697
Brca2tm2Arge/Brca2tm2Arge
Waptm1(cre)Arge/Waptm1(cre)Arge
(involves: 129S1/Sv * C57BL/6) 		increased mammary adenocarcinoma incidence J:70564
Brf1tm1Arte/Brf1tm1Arte
Krastm4Tyj/Kras+
Trp53tm2Tyj/Trp53+
Tg(Pdx1-cre)6Tuv/0
(involves: 129S4/SvJae * 129S7/SvEvBrd * FVB/N) 		increased pancreatic ductal adenocarcinoma incidence J:285667
Brip1Gt(RRI409)Byg/Brip1Gt(RRI409)Byg
(involves: 129P2/OlaHsd) 		increased adenocarcinoma incidence J:227115
increased adenoma incidence J:227115
increased Harderian gland adenoma incidence J:227115
increased lymphoma incidence J:227115
increased pituitary adenoma incidence J:227115
Btg3tm1Tya/Btg3tm1Tya
(involves: 129P2/OlaHsd * C57BL/6J) 		increased lung adenoma incidence J:149382
increased lung carcinoma incidence J:149382
Bub1tm1.1Jvd/Bub1tm2Jvd
(involves: 129/Sv * C57BL/6) 		increased lymphoma incidence J:135093
increased sarcoma incidence J:135093
Bub1tm2Jvd/Bub1tm2Jvd
(involves: 129/Sv * C57BL/6) 		increased hepatocellular carcinoma incidence J:135093
increased sarcoma incidence J:135093
Bub1bGt(neo-btk)1Dai/Bub1b+
(involves: 129S4/SvJae) 		increased colon adenoma incidence J:88094
increased intestinal adenocarcinoma incidence J:88094
Bub1btm1.1Hsl/Bub1b+
(involves: 129 * C57BL/6) 		increased adenocarcinoma incidence J:201641
increased B cell derived lymphoma incidence J:201641
increased fibrosarcoma incidence J:201641
increased hemangiosarcoma incidence J:201641
increased hepatocellular carcinoma incidence J:201641
increased leukemia incidence J:201641
increased lung adenocarcinoma incidence J:201641
increased lymphoma incidence J:201641
increased rectum adenocarcinoma incidence J:201641
increased sarcoma incidence J:201641
Cables1tm1Lrz/Cables1tm1Lrz
(involves: 129S1/Sv) 		increased endometrial carcinoma incidence J:87478
Calcatm1.1(cre/ERT2)Ptch/Calca+
Trp53tm1Brn/Trp53tm1Brn
Rb1tm2Brn/Rb1tm2Brn
(involves: 129 * 129P2/OlaHsd * FVB/N) 		increased lung small cell carcinoma incidence J:190366
Calcatm1.1(cre/ERT2)Ptch/Calca+
Trp53tm1Brn/Trp53tm1Brn
Rb1tm2Brn/Rb1tm2Brn
Ptentm1Hwu/Ptentm1Hwu
(involves: 129 * 129P2/OlaHsd * 129S4/SvJae * BALB/c * FVB/N) 		increased lung small cell carcinoma incidence J:190366
Cbx6tm1a(EUCOMM)Wtsi/Cbx6tm1a(EUCOMM)Wtsi
(C57BL/6N-Cbx6tm1a(EUCOMM)Wtsi/Wtsi) 		increased hemangioma incidence J:239583
Cbx7tm1Afus/Cbx7+
(involves: C57BL/6J) 		increased hepatocellular carcinoma incidence J:184383
increased liver adenoma incidence J:184383
increased lung adenoma incidence J:184383
Cbx7tm1Afus/Cbx7tm1Afus
(involves: C57BL/6J) 		increased carcinoma incidence J:184383
increased hepatocellular carcinoma incidence J:184383
increased liver adenoma incidence J:184383
increased lung carcinoma incidence J:184383
Ccdc80tm1.1Ftk/Ccdc80tm1.1Ftk
(involves: 129P2/OlaHsd * BALB/cJ * C57BL/6N) 		increased hepatocellular carcinoma incidence J:216704
Ccdc80tm1Ppal/Ccdc80tm1Ppal
(Not Specified) 		increased ovarian carcinoma incidence J:217742
increased thyroid adenoma incidence J:217742
Ccn6tm1.1Cgkl/Ccn6tm1.1Cgkl
Tg(MMTV-cre)1Mam/0
(FVB/N-Ccn6tm1.1Cgkl Tg(MMTV-cre)1Mam) 		increased mammary adenocarcinoma incidence J:241259
Ccn6tm1.1Cgkl/Ccn6tm1.1Cgkl
Tg(MMTV-cre)1Mam/0
Tg(MMTV-PyVT)634Mul/0
(FVB/N-Ccn6tm1.1Cgkl Tg(MMTV-cre)1Mam Tg(MMTV-PyVT)634Mul) 		increased mammary adenocarcinoma incidence J:241259
Ccnctm1.1Pisc/Ccnctm1.1Pisc
Tg(Lck-LMO1)11Sjk/0
Tg(Mx1-cre)1Cgn/0
(Not Specified) 		increased T cell derived lymphoma incidence J:217695
Ccnd1tm1Dsn/Ccnd1tm1Dsn
Cdkn1btm1Mlf/Cdkn1btm1Mlf
(involves: 129 * C57BL/6) 		increased pituitary adenoma incidence J:66707
Ccnd1tm4Pisc/Ccnd1tm4Pisc
Tg(MMTV-Erbb2)NK1Mul/0
(involves: 129S4/SvJae * C57BL/6 * FVB/N) 		increased mammary adenocarcinoma incidence J:156591
Ccnd3tm1Pisc/Ccnd3tm1Pisc
Tg(Lck)4220Rmp/0
(involves: C57BL/6J * DBA/2) 		decreased lymphoma incidence J:88120
increased T cell derived lymphoma incidence J:88120
Ccnd3tm1Pisc/Ccnd3tm1Pisc
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas) 		increased T cell derived lymphoma incidence J:88120
Ccndbp1tm1Riet/Ccndbp1tm1Riet
(involves: 129P2/OlaHsd * C57BL/6) 		increased hepatocellular carcinoma incidence J:121623
increased liver adenoma incidence J:121623
Cd3etm1Mal/Cd3etm1Mal
Tg(Tcrb-TCF3/PBX1)23Gusa/0
(involves: C3H * C57BL/6 * C57BL/6J) 		increased acute lymphoblastic leukemia incidence J:95693
increased leukemia incidence J:95693
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm1(ITK/SYK)Jrld/Gt(ROSA)26Sor+
(involves: 129P2/OlaHsd) 		increased T cell derived lymphoma incidence J:160931
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm2(CARD11*L225LI)Jrld/Gt(ROSA)26Sor+
(involves: 129P2/OlaHsd) 		increased B cell derived lymphoma incidence J:228288
Cd19tm1(cre)Cgn/Cd19+
Inpp5dtm1Rav/Inpp5dtm1Rav
Ptentm1Hwu/Ptentm1Hwu
(involves: 129P2/OlaHsd * 129S4/SvJae) 		increased follicular lymphoma incidence J:166155
increased lymphoma incidence J:166155
increased malignant tumor incidence J:166155
increased plasmacytoma incidence J:166155
increased splenic marginal zone lymphoma incidence J:166155
Cd19tm1(cre)Cgn/Cd19+
Mirc30tm1.1Rdf/Mirc30tm1.1Rdf
(involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6) 		increased B cell derived lymphoma incidence J:156946
increased leukemia incidence J:156946
Cd19tm1(cre)Cgn/Cd19+
Ptpn11tm1Ckq/Ptpn11+
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J) 		increased acute lymphoblastic leukemia incidence J:177285
increased B cell derived lymphoma incidence J:177285
Cd28tm1Mak/Cd28tm1Mak
Rc3h1san/Rc3h1+
(involves: 129S2/SvPas * C57BL/6 * C57BL/6JSfdAnu) 		decreased lymphoma incidence J:189087
increased T cell derived lymphoma incidence J:189087
Cd34tm1Szk/Cd34tm1Szk
(involves: 129P2/OlaHsd * C57BL/6J) 		increased skin papilloma incidence J:121305
Cd44tm1Mak/Cd44tm1Mak
Trp53tm1Tyj/Trp53+
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * C57BL/6J) 		increased lymphoma incidence J:76201
Cd79atm1(cre)Reth/Cd79a+
Dynll1tm1.1Jhh/Dynll1tm1.1Jhh
Tg(IghMyc)22Bri/0
(B6.Cg-Dynll1tm1.1Jhh Cd79atm1(Cre)Reth Tg(IghMyc)22Bri) 		decreased lymphoma incidence J:230105
Cdc20tm1.1Pzg/Cdc20+
(involves: 129S7/SvEvBrd * C57BL/6) 		increased lymphoma incidence J:150421
Cdc73Gt(RRE190)Byg/Cdc73+
(B6.129P2-Cdc73Gt(RRE190)Byg) 		increased parathyroid adenoma incidence J:243366
Cdc73tm1Btt/Cdc73+
Tg(PTH-cre)4167Slib/0
(Not Specified) 		increased parathyroid adenoma incidence J:243366
Cdc73tm1Btt/Cdc73tm1Btt
Tg(PTH-cre)4167Slib/0
(Not Specified) 		increased parathyroid adenoma incidence J:243366
Cdh1tm1Jjon/Cdh1+
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/0
(involves: 129P2/OlaHsd * FVB/N) 		increased mammary adenocarcinoma incidence J:116152
increased squamous cell carcinoma incidence J:116152
Cdh1tm1Jjon/Cdh1+
Trp53tm1Brn/Trp53tm1Brn
Tg(Wap-cre)51Nki/0
(involves: 129P2/OlaHsd * FVB/N) 		increased mammary adenocarcinoma incidence J:171765
Cdh1tm1Jjon/Cdh1tm1Jjon
Trp53tm1Brn/Trp53+
Tg(KRT14-cre)8Brn/0
(involves: 129P2/OlaHsd * FVB/N) 		increased mammary adenocarcinoma incidence J:116152
Cdh1tm1Jjon/Cdh1tm1Jjon
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/0
(involves: 129P2/OlaHsd * FVB/N) 		increased mammary adenocarcinoma incidence J:116152
Cdh1tm2Kem/Cdh1+
Smad4tm2.1Cxd/Smad4tm2.1Cxd
Trp53tm1Brn/Trp53tm1Brn
Tg(MMTV-cre)7Mul/0
(involves: 129 * C57BL/6 * FVB/N) 		increased mammary adenocarcinoma incidence J:212549
Cdh1tm2Kem/Cdh1+
Smad4tm2.1Cxd/Smad4tm2.1Cxd
Trp53tm1Brn/Trp53tm1Brn
Tg(Pdx1-cre)6Tuv/0
(involves: 129 * C57BL/6 * FVB/N) 		increased duodenum adenocarcinoma incidence J:212549
increased gastric adenocarcinoma incidence J:212549
increased squamous cell carcinoma incidence J:212549
Cdh1tm2Kem/Cdh1+
Smad4tm2.1Cxd/Smad4tm2.1Cxd
Trp53tm1Brn/Trp53tm1Brn
Tg(Vil1-cre)20Syr/0
(involves: 129 * C57BL/6 * DBA/2) 		increased intestinal adenocarcinoma incidence J:212549
Cdh1tm2Kem/Cdh1tm2Kem
Smad4tm2.1Cxd/Smad4tm2.1Cxd
Trp53tm1Brn/Trp53tm1Brn
Tg(Pdx1-cre)6Tuv/0
(involves: 129 * C57BL/6 * FVB/N) 		increased gastric adenocarcinoma incidence J:212549
Cdk4tm1.1Bbd/Cdk4+
Krastm1Bbd/Kras+
Tg(CMV-cre)1Cgn/?
(involves: 129S1/Sv * 129X1/SvJ * BALB/cJ * C57BL/6) 		increased hemangiosarcoma incidence J:86101
increased lung adenoma incidence J:86101
increased papilloma incidence J:86101
increased pituitary adenoma incidence J:86101
increased sarcoma incidence J:86101
Cdk4tm1.1Bbd/Cdk4tm1.1Bbd
Tg(Mt1-Hgf)#Lmb/0
(B6.Cg-Cdk4tm1.1Bbd Tg(Mt1-Hgf)#Lmb) 		increased cutaneous melanoma incidence J:111992
Cdk4tm1.1Bbd/Cdk4tm1.1Bbd
Tg(Tyr-NRAS*Q61K)1Bee/0
(FVB.Cg-Cdk4tm1.1Bbd Tg(Tyr-NRAS*Q61K)1Bee) 		increased cutaneous melanoma incidence J:222847
Cdk4tm2.1Bbd/Cdk4tm2.1Bbd
Krastm1Bbd/Krastm2Bbd
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
(involves: 129S1/Sv * 129X1/SvJ) 		increased adenocarcinoma incidence J:161780
Cdk5rap2an/Cdk5rap2an
(Not Specified) 		increased ovary adenoma incidence J:15165
Cdk5rap2an/Cdk5rap2an
Tyrp1B-lt/Tyrp1B-lt
(WBB6F1) 		increased histiocytic sarcoma incidence J:102334
Cdk6tm1Bbd/Cdk6tm1Bbd
Krastm1Bbd/Kras+
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
(involves: 129S1/Sv * 129X1/SvJ) 		increased adenoma incidence J:161780
increased lung non-small cell carcinoma incidence J:161780
Cdk6tm1Phin/Cdk6+
Tg(Lck-Akt1*E40K)E-3Pnt/0
(involves: 129S4/SvJae) 		increased T cell derived lymphoma incidence J:144975
Cdk11bGt(XG836)Byg/Cdk11bGt(XG836)Byg
(involves: 129P2/OlaHsd * C57BL/6J) 		increased skin papilloma incidence J:125424
Cdkn1atm1(HBsAg)Xya/Cdkn1a+
(either: (involves: 129S6/SvEvTac * C57BL/6) or (involves: 129S6/SvEvTac * Black Swiss)) 		increased hepatocellular carcinoma incidence J:88078
Cdkn1atm1(HBsAg)Xya/Cdkn1atm1(HBsAg)Xya
(either: (involves: 129S6/SvEvTac * C57BL/6) or (involves: 129S6/SvEvTac * Black Swiss)) 		increased hepatocellular carcinoma incidence J:88078
Cdkn1atm1Led/Cdkn1atm1Led
(NIH.Cg-Cdkn1atm1Led) 		decreased lymphoma incidence J:87536
Cdkn1atm1Led/Cdkn1atm1Led
Ctnnb1tm1Mmt/Ctnnb1tm1Mmt
Tg(Upk2-cre)6Xrw/0
(involves: 129S6/SvEvTac * 129X1/SvJ * FVB/N) 		increased urinary bladder carcinoma incidence J:234236
Cdkn1atm1Tyj/Cdkn1a+
(involves: 129S1/SvImJ * 129S2/SvPas * C57BL/6J) 		increased malignant tumor incidence J:83967
Cdkn1atm1Tyj/Cdkn1atm1Tyj
(involves: 129S2/SvPas * C57BL/6) 		increased B cell derived lymphoma incidence J:70894
increased carcinoma incidence J:70894
increased hemangiosarcoma incidence J:70894
increased histiocytic sarcoma incidence J:70894
increased lung carcinoma incidence J:70894
increased sebaceous gland adenoma incidence J:70894
increased T cell derived lymphoma incidence J:70894
Cdkn1atm1Tyj/Cdkn1atm1Tyj
(involves: 129/Sv * 129S2/SvPas * C57BL/6) 		increased squamous cell carcinoma incidence J:72780
Cdkn1atm1Tyj/Cdkn1atm1Tyj
(involves: 129S1/SvImJ * 129S2/SvPas * C57BL/6J) 		increased malignant tumor incidence J:83967
Cdkn1atm1Tyj/Cdkn1atm1Tyj
Cdkn2atm1Rdp/Cdkn2atm1Rdp
(involves: 129/Sv * 129S2/SvPas * C57BL/6 * C57BL/6J * SJL) 		increased squamous cell carcinoma incidence J:72780
Cdkn1atm1Tyj/Cdkn1atm1Tyj
Csnk1a1tm1.1Ybn/Csnk1a1tm1.1Ybn
Tg(Vil1-cre/ERT2)23Syr/0
(involves: 129 * C57BL/6 * CD-1 * DBA/2) 		increased carcinoma incidence J:204886
Cdkn1atm1Tyj/Cdkn1atm1Tyj
Fahtm1Mgo/Fahtm1Mgo
(involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6) 		increased hepatocellular carcinoma incidence J:138701
increased renal carcinoma incidence J:138701
Cdkn1atm1Tyj/Cdkn1atm1Tyj
Ptentm1Hwu/Ptentm1Hwu
Tg(Fabp1-cre)1Jig/0
(involves: 129S2/SvPas * 129S4/SvJae * FVB/N) 		increased urinary bladder carcinoma incidence J:106662
Cdkn1atm1Tyj/Cdkn1atm1Tyj
Tg(MMTV-vHaras)SH1Led/0
(involves: 129S2/SvPas * C57BL/6J * CD-1 * FVB/N) 		increased mammary adenocarcinoma incidence J:66183
increased salivary adenocarcinoma incidence J:66183
Cdkn1atm2(HBx)Xya/Cdkn1a+
(either: (involves: 129S6/SvEvTac * C57BL/6) or (involves: 129S6/SvEvTac * Black Swiss)) 		increased hepatocellular carcinoma incidence J:88078
Cdkn1atm2(HBx)Xya/Cdkn1atm2(HBx)Xya
(either: (involves: 129S6/SvEvTac * C57BL/6) or (involves: 129S6/SvEvTac * Black Swiss)) 		increased hepatocellular carcinoma incidence J:88078
Cdkn1btm1Ako/Cdkn1b+
KitW-v/KitW-v
(involves: 129S1/Sv * C57BL/6J) 		increased ovary adenoma incidence J:236161
Cdkn1btm1Ako/Cdkn1b+
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(TPO-cre)1Shk/0
(129S1.Cg-Cdkn1btm1Ako Tg(TPO-cre)1Shk Ptentm2.1Ppp) 		increased thyroid adenoma incidence J:165293
increased thyroid carcinoma incidence J:165293
Cdkn1btm1Ako/Cdkn1btm1Ako
(involves: 129S1/Sv) 		increased lung adenocarcinoma incidence J:120835
Cdkn1btm1Ako/Cdkn1btm1Ako
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi
(involves: 129/Sv * 129S1/Sv * C57BL/6 * DBA/2) 		increased carcinoma incidence J:50053
increased pituitary adenoma incidence J:50053
Cdkn1btm1Ako/Cdkn1btm1Ako
KitW-v/KitW-v
(involves: 129S1/Sv * C57BL/6J) 		increased ovary adenoma incidence J:236161
Cdkn1btm1Ako/Cdkn1btm1Ako
Men1tm1.1Ctre/Men1+
(involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6) 		increased lung adenoma incidence J:120835
Cdkn1btm1Jro/Cdkn1btm1Jro
Rb1tm3Tyj/Rb1tm3Tyj
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J * CD-1 * FVB/N) 		increased osteosarcoma incidence J:318035
Cdkn1btm1Kin/Cdkn1btm1Kin
(involves: 129P2/OlaHsd * C57BL/6) 		increased pituitary adenoma incidence J:33402
Cdkn1btm1Mlf/Cdkn1b+
Crebbptm1Jvd/Crebbptm1Jvd
Tg(MMTV-cre)4Mam/0
(involves: 129 * C57BL/6 * CBA * FVB) 		increased T cell derived lymphoma incidence J:88323
Cdkn1btm1Mlf/Cdkn1b+
Ptch1tm1Mps/Ptch1+
(involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6) 		increased hemangiosarcoma incidence J:205254
increased lymphoma incidence J:205254
increased medulloblastoma incidence J:205254
increased rhabdomyosarcoma incidence J:205254
Cdkn1btm1Mlf/Cdkn1b+
Tg(TG-TPR/NTRK1)#Rstn/0
(involves: 129S4/SvJaeSor * C3H * C57BL/6 * C57BL/6J) 		increased thyroid carcinoma incidence J:210015
Cdkn1btm1Mlf/Cdkn1btm1Mlf
(involves: 129S4/SvJaeSor * C57BL/6J) 		increased pituitary adenoma incidence J:33400
Cdkn1btm1Mlf/Cdkn1btm1Mlf
Ptch1tm1Mps/Ptch1+
(involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6) 		increased hemangiosarcoma incidence J:205254
increased lymphoma incidence J:205254
increased medulloblastoma incidence J:205254
increased rhabdomyosarcoma incidence J:205254
Cdkn1btm1Mlf/Cdkn1btm1Mlf
Tg(TG-TPR/NTRK1)#Rstn/0
(involves: 129S4/SvJaeSor * C3H * C57BL/6 * C57BL/6J) 		increased thyroid carcinoma incidence J:210015
Cdkn1btm1Mlf/Cdkn1btm1Mlf
Trp53tm1Brd/Trp53tm1Brd
(involves: C3H * C57BL/6J * NIH) 		increased sarcoma incidence J:87536
increased T cell derived lymphoma incidence J:87536
Cdkn1btm1Mlf/Cdkn1btm1Mlf
Trp53tm1Brd/Trp53tm1Brd
(involves: 129S4/SvJaeSor * 129S7/SvEvBrd * C57BL/6J) 		increased sarcoma incidence J:87536
increased T cell derived lymphoma incidence J:87536
Cdkn2aem1Cjs/Cdkn2aem1Cjs
(B6.Cg-Cdkn2aem1Cjs) 		increased acute lymphoblastic leukemia incidence J:244260
Cdkn2atm1(GFP)Cjs/Cdkn2atm1(GFP)Cjs
(involves: 129S1/Sv * C57BL/6) 		increased hemangiosarcoma incidence J:87339
increased histiocytic sarcoma incidence J:87339
increased lymphoma incidence J:87339
increased sarcoma incidence J:87339
Cdkn2atm1.1Brn/Cdkn2a+
Nf2tm2Gth/Nf2tm2Gth
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S7/SvEvBrd) 		increased mesothelioma incidence J:132943
increased rhabdomyosarcoma incidence J:132943
Cdkn2atm1.1Brn/Cdkn2atm1.1Brn
Nf2tm2Gth/Nf2tm2Gth
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S7/SvEvBrd) 		increased mesothelioma incidence J:132943
increased rhabdomyosarcoma incidence J:132943
Cdkn2atm1.1Brn/Cdkn2atm1.1Brn
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S7/SvEvBrd) 		increased mesothelioma incidence J:132943
Cdkn2atm1.1Gsu/Cdkn2atm1.1Gsu
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
(involves: 129S4/SvJae * 129S4/SvJaeSor * C57BL/6J * FVB/N) 		increased adenocarcinoma incidence J:198619
increased pancreas adenoma incidence J:198619
Cdkn2atm1Cjs/Cdkn2a+
(involves: 129X1/SvJ * C57BL/6 * NIH/OlaHsd) 		increased carcinoma incidence J:93298
increased papilloma incidence J:93298
Cdkn2atm1Cjs/Cdkn2a+
Tg(CKMM-tTA)A3Rhvh/0
Tg(tetO-Hgf,-EGFP)24Tcre/0
(involves: 129X1/SvJ * FVB) 		increased rhabdomyosarcoma incidence J:237183
Cdkn2atm1Cjs/Cdkn2atm1Cjs
(involves: 129X1/SvJ * C57BL/6) 		increased acute lymphoblastic leukemia incidence J:244260
increased carcinoma incidence J:44427
increased fibrohistocytoma incidence J:44427
increased fibrosarcoma incidence J:44427
increased lymphoma incidence J:44427
increased T cell derived lymphoma incidence J:44427
Cdkn2atm1Cjs/Cdkn2atm1Cjs
(involves: 129X1/SvJ * C57BL/6 * NIH/OlaHsd) 		increased carcinoma incidence J:93298
increased papilloma incidence J:93298
increased squamous cell carcinoma incidence J:93298
Cdkn2atm1Cjs/Cdkn2atm1Cjs
Pax7tm1Pgr/Pax7+
Tg(CKMM-tTA)A3Rhvh/0
Tg(tetO-Hgf,-EGFP)24Tcre/0
(involves: 129S2/SvPas * 129X1/SvJ * FVB) 		increased rhabdomyosarcoma incidence J:237183
increased sarcoma incidence J:237183
Cdkn2atm1Cjs/Cdkn2atm1Cjs
Pax7tm1Pgr/Pax7tm1Pgr
Tg(CKMM-tTA)A3Rhvh/0
Tg(tetO-Hgf,-EGFP)24Tcre/0
(involves: 129S2/SvPas * 129X1/SvJ * FVB) 		increased rhabdomyosarcoma incidence J:237183
increased sarcoma incidence J:237183
Cdkn2atm1Cjs/Cdkn2atm1Cjs
Sclt1Tg(CAG-sb10)1Dla/0
TgTn(sb-T2/Onc)68Dla/0
(involves: 129X1/SvJ * FVB/N) 		increased leukemia incidence J:99991
increased lung adenocarcinoma incidence J:99991
increased lymphoma incidence J:99991
increased osteosarcoma incidence J:99991
increased sarcoma incidence J:99991
Cdkn2atm1Cjs/Cdkn2atm1Cjs
Sclt1Tg(CAG-sb10)1Dla/0
TgTn(sb-T2/Onc)76Dla/0
(involves: 129X1/SvJ * FVB/N) 		increased leukemia incidence J:99991
increased lung adenocarcinoma incidence J:99991
increased lymphoma incidence J:99991
increased osteosarcoma incidence J:99991
increased sarcoma incidence J:99991
Cdkn2atm1Cjs/Cdkn2atm1Cjs
Tacstd2tm1Lsm/Tacstd2tm1Lsm
(involves: 129X1/SvJ * C57BL/6) 		increased carcinoma incidence J:182647
increased skin squamous cell carcinoma incidence J:182647
increased spindle cell carcinoma incidence J:182647
Cdkn2atm1Cjs/Cdkn2atm1Cjs
Tg(CKMM-tTA)A3Rhvh/0
Tg(tetO-Hgf,-EGFP)24Tcre/0
(involves: 129X1/SvJ * FVB) 		increased rhabdomyosarcoma incidence J:237183
Cdkn2atm1Cjs/Cdkn2atm1Cjs
Trp53tm1Brd/Trp53tm1Brd
(involves: 129S7/SvEvBrd * 129X1/SvJ * C57BL/6 * NIH/OlaHsd) 		increased carcinoma incidence J:93298
Cdkn2atm1Nesh/Cdkn2atm1Nesh
(involves: 129S6/SvEvTac * FVB/N) 		increased lung carcinoma incidence J:88365
increased osteosarcoma incidence J:88365
increased sarcoma incidence J:88365
increased small lymphocytic lymphoma incidence J:88365
Cdkn2atm1Nesh/Cdkn2atm1Nesh
X/Tg(Tyr-HRAS)60Lc
(involves: 129S6/SvEvTac * C57BL/6J * CBA/J * FVB) 		increased melanoma incidence J:85075
Cdkn2atm1Rdp/Cdkn2a+
Nf1tm1Tyj/Nf1+
(involves: 129S2/SvPas * 129S6/SvEvTac) 		increased neurofibrosarcoma incidence J:131914
Cdkn2atm1Rdp/Cdkn2a+
Terctm1Rdp/Terctm1Rdp
(involves: 129/Sv * C57BL/6J * SJL) 		increased lymphoma incidence J:120065
increased sarcoma incidence J:120065
Cdkn2atm1Rdp/Cdkn2a+
Tg(CAG-Bgeo,-tTA,-EGFP)2A11Kuw/0
Tg(Pdx1-cre)6Tuv/0
Tg(tetO-MYC)36Bop/0
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6J * FVB/N * SJL) 		increased pancreatic ductal adenocarcinoma incidence J:197052
Cdkn2atm1Rdp/Cdkn2a+
X/Tg(Tyr-HRAS)60Lc
(involves: 129/Sv * C57BL/6J * CBA/J * FVB/N * SJL) 		increased intraocular melanoma incidence J:140820
Cdkn2atm1Rdp/Cdkn2a+
Tg(Tyr-NRAS*Q61K)1Bee/?
(involves: 129/Sv * C57BL/6 * DBA/2 * SJL) 		increased cutaneous melanoma incidence J:98545
Cdkn2atm1Rdp/Cdkn2atm1Rdp
(involves: 129/Sv * C57BL/6 * SJL) 		increased B cell derived lymphoma incidence J:53805
increased cutaneous melanoma incidence J:98545
increased fibrosarcoma incidence J:53805
increased hemangiosarcoma incidence J:53805
increased sarcoma incidence J:53805
Cdkn2atm1Rdp/Cdkn2atm1Rdp
(involves: 129/Sv * C57BL/6J * FVB/N * SJL) 		increased lymphoma incidence J:88365
increased sarcoma incidence J:88365
Cdkn2atm1Rdp/Cdkn2atm1Rdp
(involves: 129/Sv * C57BL/6 * C57BL/6J * SJL) 		increased squamous cell carcinoma incidence J:72780
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Col1a1tm1(CAG-EGFR)Char/Col1a1tm1(CAG-EGFR)Char
Ptentm1Hwu/Ptentm1Hwu
(involves: 129/Sv * 129S4/SvJae * C57BL/6 * SJL) 		increased glioblastoma incidence J:146494
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Col1a1tm1(CAG-EGFR)Char/Col1a1tm2(CAG-EGFR*)Char
Ptentm1Hwu/Ptentm1Hwu
(involves: 129/Sv * 129S4/SvJae * C57BL/6 * SJL) 		increased glioblastoma incidence J:146494
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Col1a1tm2(CAG-EGFR*)Char/Col1a1tm2(CAG-EGFR*)Char
Ptentm1Hwu/Ptentm1Hwu
(involves: 129/Sv * 129S4/SvJae * C57BL/6 * SJL) 		increased glioblastoma incidence J:146494
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Ctnnb1tm1Mmt/Ctnnb1tm1Mmt
Ptentm1Rps/Ptentm1Rps
Tg(Tyr-cre/ERT2)13Bos/0
(involves: 129/Sv * C57BL/6J * FVB * SJL) 		increased melanoma incidence J:155731
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+
Pdgfratm12Sor/Pdgfra+
(involves: 129 * C57BL/6J * SJL) 		increased fibrosarcoma incidence J:146617
increased sarcoma incidence J:146617
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Ptentm1Rdp/Ptentm1Rdp
Tg(tetO-BRAF*V600E)29Lc/0
Tg(Tyr-cre/ERT2)13Bos/0
(involves: 129/Sv * C57BL/6J * FVB * SJL) 		increased melanoma incidence J:221902
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Krastm4Tyj/Kras+
(involves: 129/Sv * 129S4/SvJae * C57BL/6 * FVB/N * SJL) 		increased lung adenocarcinoma incidence J:124682
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Nf1tm1Tyj/Nf1+
(involves: 129S2/SvPas * 129S6/SvEvTac) 		increased leukemia incidence J:131914
increased lymphoma incidence J:131914
increased neurofibrosarcoma incidence J:131914
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Ptentm1Rps/Ptentm1Rps
Tg(Tyr-cre/ERT2)13Bos/0
(involves: 129/Sv * 129S1/Sv * C57BL/6J * FVB/N * SJL) 		increased melanoma incidence J:155731
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Rnf2tm1Mvi/Rnf2tm1Mvi
Tg(Mx1-cre)1Cgn/0
(involves: 129 * C57BL/6 * C57BL/10 * CBA * SJL) 		increased lymphoma incidence J:130397
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Terctm1Rdp/Terctm1Rdp
(involves: 129/Sv * C57BL/6J * SJL) 		increased lymphoma incidence J:120065
increased sarcoma incidence J:120065
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(Mt1-Hgf)19Lmb/0
(involves: 129/Sv * C57BL/6J * FVB/N * SJL) 		increased melanoma incidence J:79704
increased rhabdomyosarcoma incidence J:79704
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-Kras2)12Hev/0
(involves: 129 * C57BL/6J * FVB/N * SJL) 		increased lung adenocarcinoma incidence J:166963, J:73468
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(tetO-BRAF*V600E)29Lc/0
Tg(Tyr-rtTA)37Lc/0
(involves: 129/Sv * C57BL/6J * SJL) 		increased prostate gland adenocarcinoma incidence J:144358
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(tetO-Nras*Q61K)#Lc/0
Tg(Tyr-rtTA)37Lc/0
(FVB.Cg-Cdkn2atm1Rdp Tg(tetO-Nras*Q61K)#Lc Tg(Tyr-rtTA)37Lc) 		increased cutaneous melanoma incidence J:238049
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(Tyr-BRAF*V600E)470Fgh/0
(involves: 129/Sv * C57BL/6J * CBA * SJL) 		increased melanoma incidence J:151455
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(Tyr-BRAF*V600E)476Fgh/0
(involves: 129/Sv * C57BL/6J * CBA * SJL) 		increased melanoma incidence J:151455
Cdkn2atm1Rdp/Cdkn2atm1Rdp
X/Tg(Tyr-HRAS)60Lc
(involves: 129/Sv * C57BL/6J * CBA/J * SJL) 		increased melanoma incidence J:164588
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(Tyr-NRAS*Q61K)1Bee/?
(involves: 129/Sv * C57BL/6 * DBA/2 * SJL) 		increased cutaneous melanoma incidence J:98545
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(Tyr-NRAS*Q61K)1Bee/0
(involves: 129/Sv * C57BL/6J * DBA/2 * SJL) 		increased cutaneous melanoma incidence J:193443
Cdkn2atm2.1Brn/Cdkn2atm2.1Brn
(involves: 129P2/OlaHsd * FVB/N) 		increased carcinoma incidence J:71393
increased lymphoma incidence J:71393
increased melanoma incidence J:71393
increased sarcoma incidence J:71393
Cdkn2atm2.1Nesh/Cdkn2a+
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53+
Tg(Tyr-cre/ERT2)13Bos/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB) 		increased melanoma incidence J:164588
increased spindle cell carcinoma incidence J:164588
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh
Ezh2tm1.1Nesh/Ezh2+
Nrastm1.1Nesh/Nras+
Tg(Tyr-cre/ERT2)13Bos/0
(involves: 129 * 129S4/SvJae * 129P2/OlaHsd * C57BL/6 * FVB) 		increased melanoma incidence J:239472
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh
Krastm4Tyj/Kras+
Tg(Tyr-cre/ERT2)13Bos/0
(involves: 129S4/SvJae * C57BL/6 * FVB) 		increased melanoma incidence J:164588
increased spindle cell carcinoma incidence J:164588
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh
Krastm4Tyj/Kras+
Tg(Tyr-cre/ERT2)13Bos/0
(B6J.Cg-Tg(Tyr-cre/ERT2)13Bos Cdkn2atm2.1Nesh Krastm4Tyj) 		increased cutaneous melanoma incidence J:220627
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Tg(Tyr-cre/ERT2)13Bos/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB) 		increased melanoma incidence J:164588
increased spindle cell carcinoma incidence J:164588
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh
Nrastm1.1Nesh/Nras+
Tg(Tyr-cre/ERT2)13Bos/0
(involves: 129 * 129S4/SvJae * 129P2/OlaHsd * C57BL/6 * FVB) 		increased melanoma incidence J:239472
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh
Nrastm1.1Nesh/Nrastm1.1Nesh
Stk11tm1.1Rdp/Stk11tm1.1Rdp
Tg(Tyr-cre/ERT2)13Bos/0
(B6J.Cg-Tg(Tyr-cre/ERT2)13Bos Nrastm1.1Nesh Cdkn2atm2.1Nesh Stk11tm1.1Rdp) 		increased cutaneous melanoma incidence J:220627
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh
Nrastm1.1Nesh/Nrastm1.1Nesh
Tg(Tyr-cre/ERT2)13Bos/0
(B6J.Cg-Tg(Tyr-cre/ERT2)13Bos Nrastm1.1Nesh Cdkn2atm2.1Nesh) 		increased cutaneous melanoma incidence J:220627
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh
Nrastm1Tyj/Nrastm1Tyj
Tg(Tyr-cre/ERT2)13Bos/0
(B6J.Cg-Tg(Tyr-cre/ERT2)13Bos Nrastm1Tyj Cdkn2atm2.1Nesh) 		increased cutaneous melanoma incidence J:220627
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh
Trp53tm1Brn/Trp53tm1Brn
Tg(Tyr-cre/ERT2)13Bos/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB) 		increased melanoma incidence J:164588
Cdkn2atm2.1Rdp/Cdkn2a+
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53+
Tg(Pdx1-cre)89.1Dam/0
(involves: 129 * C57BL/6 * CBA * FVB/N) 		increased pancreatic ductal adenocarcinoma incidence J:108298
Cdkn2atm2.1Rdp/Cdkn2a+
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Tg(Pdx1-cre)89.1Dam/0
(involves: 129 * C57BL/6 * CBA * FVB/N) 		increased pancreatic ductal adenocarcinoma incidence J:108298
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
(involves: 129S6/SvEvTac * FVB/N) 		increased lymphoma incidence J:88365
increased osteosarcoma incidence J:88365
increased sarcoma incidence J:88365
increased small lymphocytic lymphoma incidence J:88365
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Krastm4Tyj/Kras+
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * FVB/N) 		increased lung adenocarcinoma incidence J:124682
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
(involves: 129S4/SvJae * 129S6/SvEvTac * FVB/N) 		increased adenocarcinoma incidence J:198619
increased pancreas adenoma incidence J:198619
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53+
Tg(Pdx1-cre)89.1Dam/0
(involves: 129 * C57BL/6 * CBA * FVB/N) 		increased pancreatic ductal adenocarcinoma incidence J:108298
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Tg(Pdx1-cre)89.1Dam/0
(involves: 129 * C57BL/6 * CBA * FVB/N) 		increased pancreatic ductal adenocarcinoma incidence J:108298
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Nf1tm1Tyj/Nf1+
(involves: 129S2/SvPas * 129S6/SvEvTac) 		increased lymphoma incidence J:131914
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
X/Tg(Tyr-HRAS)60Lc
(involves: 129S6/SvEvTac * C57BL/6J * CBA/J * FVB) 		increased melanoma incidence J:85075
Cdkn2atm2Brn/Cdkn2a+
Nf2tm2Gth/Nf2tm2Gth
(involves: 129P2/OlaHsd) 		increased leukemia incidence J:132943
increased uterus leiomyoma incidence J:132943
Cdkn2atm2Brn/Cdkn2atm2Brn
Nf2tm2Gth/Nf2+
(involves: 129P2/OlaHsd) 		increased leukemia incidence J:132943
increased uterus leiomyoma incidence J:132943
Cdkn2atm2Brn/Cdkn2atm2Brn
Nf2tm2Gth/Nf2tm2Gth
(involves: 129P2/OlaHsd) 		increased leukemia incidence J:132943
increased rhabdomyosarcoma incidence J:132943
increased uterus leiomyoma incidence J:132943
Cdkn2atm2Brn/Cdkn2atm2Brn
Tg(Tyr-cre/ERT,-Hras1*,-Trap1a)10BJvde/0
(involves: C57BL/6 * FVB/N) 		increased classified tumor incidence J:107175
increased cutaneous melanoma incidence J:107175
increased neurofibrosarcoma incidence J:107175
Cdkn2atm4Rdp/Cdkn2a+
Krastm4Tyj/Kras+
Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ) 		increased pancreatic ductal adenocarcinoma incidence J:116130
Cdkn2atm4Rdp/Cdkn2a+
Krastm4Tyj/Kras+
Smad4tm1Rdp/Smad4tm1Rdp
Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129 * FVB/N) 		increased pancreatic ductal adenocarcinoma incidence J:116130
Cdkn2atm4Rdp/Cdkn2a+
Krastm4Tyj/Kras+
Smad4tm1Rdp/Smad4tm1Rdp
Tg(Pdx1-cre)89.1Dam/0
(involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * CBA * FVB/N) 		increased pancreatic ductal adenocarcinoma incidence J:116130
Cdkn2atm4Rdp/Cdkn2a+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)89.1Dam/0
(involves: 129S4/SvJae * C57BL/6 * CBA) 		increased pancreatic ductal adenocarcinoma incidence J:116130
Cdkn2atm4Rdp/Cdkn2a+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)89.1Dam/0
(involves: 129S4/SvJae * C57BL/6 * CBA * FVB/N) 		increased pancreatic ductal adenocarcinoma incidence J:108298
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Krastm4Tyj/Kras+
(involves: 129S4/SvJae) 		increased lung adenocarcinoma incidence J:195492
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Krastm4Tyj/Kras+
(involves: 129S4/SvJae * C57BL/6) 		increased sarcoma incidence J:125101
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Krastm4Tyj/Kras+
Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ) 		increased pancreatic ductal adenocarcinoma incidence J:116130
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Krastm4Tyj/Kras+
Smad4tm1Rdp/Smad4tm1Rdp
Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129 * FVB/N) 		increased pancreatic ductal adenocarcinoma incidence J:116130
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Krastm4Tyj/Kras+
Smad4tm1Rdp/Smad4tm1Rdp
Tg(Pdx1-cre)89.1Dam/0
(involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * CBA * FVB/N) 		increased pancreatic ductal adenocarcinoma incidence J:116130
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Krastm4Tyj/Kras+
Tg(Pdx1-cre)89.1Dam/0
(involves: 129S4/SvJae * C57BL/6 * CBA * FVB/N) 		increased malignant tumor incidence J:87196
increased pancreatic ductal adenocarcinoma incidence J:116130, J:108298, J:87196
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Krastm4Tyj/Kras+
Tg(Pdx1-cre)89.1Dam/0
(involves: 129S4/SvJae * C57BL/6 * CBA) 		increased pancreatic ductal adenocarcinoma incidence J:187012
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Myf6tm1(cre)Mrc/Myf6+
Pax3tm1Mrc/Pax3tm1Mrc
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL) 		increased rhabdomyosarcoma incidence J:93444
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Nf1tm1Par/Nf1tm1Par
(involves: 129S1/Sv * 129X1/SvJ) 		increased neurofibrosarcoma incidence J:234760
increased rhabdomyosarcoma incidence J:234760
increased sarcoma incidence J:234760
Cdkn2btm1Bbd/Cdkn2btm1Bbd
(involves: 129S1/Sv * C57BL/6) 		increased adenocarcinoma incidence J:63299
increased sarcoma incidence J:63299
Cdkn2btm1Bbd/Cdkn2btm1Bbd
Cdkn2ctm1Bbd/Cdkn2ctm1Bbd
(involves: 129S1/Sv * C57BL/6) 		increased lymphoma incidence J:63299
increased pituitary adenoma incidence J:63299
increased sarcoma incidence J:63299
Cdkn2ctm1Bbd/Cdkn2c+
Trp53tm1Tyj/Trp53+
(involves: 129S1/Sv * 129S2/SvPas * C57BL/6) 		increased medulloblastoma incidence J:102702
Cdkn2ctm1Bbd/Cdkn2c+
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S1/Sv * 129S2/SvPas * C57BL/6) 		increased medulloblastoma incidence J:102702
Cdkn2ctm1Bbd/Cdkn2ctm1Bbd
(involves: 129S1/Sv * C57BL/6) 		increased B cell derived lymphoma incidence J:63299
increased hemangiosarcoma incidence J:63299
increased pituitary adenoma incidence J:63299
increased renal carcinoma incidence J:63299
increased T cell derived lymphoma incidence J:63299
Cdkn2ctm1Bbd/Cdkn2ctm1Bbd
Cdkn2dtm1Maro/Cdkn2dtm1Maro
(involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6) 		increased pituitary adenoma incidence J:68829
Cdkn2ctm1Bbd/Cdkn2ctm1Bbd
Ptch1tm1Mps/Ptch1+
(involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ) 		increased medulloblastoma incidence J:102702
Cdkn2ctm1Bbd/Cdkn2ctm1Bbd
Ptch1tm1Mps/Ptch1+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6) 		increased medulloblastoma incidence J:205254
Cdkn2ctm1Bbd/Cdkn2ctm1Bbd
Trp53tm1Brn/Trp53tm1Tyj
Tg(Nes-cre)1Kln/0
(involves: 129P2/OlaHsd * 129S1/Sv * 129S2/SvPas * C57BL/6 * SJL) 		increased medulloblastoma incidence J:102702
Cdkn2ctm1Bbd/Cdkn2ctm1Bbd
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S1/Sv * 129S2/SvPas * C57BL/6) 		increased medulloblastoma incidence J:102702
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi
(involves: 129/Sv * C57BL/6 * DBA/2) 		increased pituitary adenoma incidence J:50053
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi
(B6.129-Cdkn2ctm1Yxi) 		increased lung adenocarcinoma incidence J:120835
increased lung adenoma incidence J:120835
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi
Men1tm1.1Ctre/Men1+
(involves: 129/Sv * 129S6/SvEvTac * C57BL/6) 		increased adenocarcinoma incidence J:120835
increased lung adenocarcinoma incidence J:120835
increased lung adenoma incidence J:120835
Cdsntm1.1Ics/Cdsntm1.1Ics
Tg(KRT14-cre)1Ipc/0
(involves: 129S2/SvPas * C57BL/6 * SJL) 		increased skin papilloma incidence J:153292
Cdx2tm1Fbe/Cdx2+
(involves: 129S1/Sv * C57BL/6J) 		increased colon adenoma incidence J:38772
increased intestinal adenoma incidence J:38772
Cdx2tm1Mmt/Cdx2+
(involves: 129X1/SvJ * C57BL/6) 		increased colon hamartoma incidence J:47050
Cebpatm1Gonz/Cebpatm1Gonz
Tg(KRT5-cre)5132Jlj/0
(involves: 129X1/SvJ * C57BL/6 * DBA/2J) 		increased skin papilloma incidence J:123139
increased squamous cell carcinoma incidence J:123139
Cebpatm8.1Nerl/Cebpatm8.1Nerl
(involves: 129P2/OlaHsd * BALB/cJ * C57BL/6) 		increased leukemia incidence J:136134
Cep57em1Jvd/Cep57+
(involves: 129 * C57BL/6) 		increased lung adenoma incidence J:264300
Cep57em2Jvd/Cep57+
(involves: FVB/N) 		increased lung adenoma incidence J:264300
Cers2Gt(S16-4B1)Sor/Cers2Gt(S16-4B1)Sor
(involves: 129S4/SvJaeSor * C57BL/6) 		increased hepatocellular carcinoma incidence J:156841
Chd2Gt(RRBO46)Byg/Chd2+
(involves: 129P2/OlaHsd * C57BL/6) 		increased lymphoma incidence J:146176
increased T cell derived lymphoma incidence J:146176
Chek1tm1Sje/Chek1+
Tg(Wnt1)1Hev/0
(Not Specified) 		increased mammary adenocarcinoma incidence J:62919
Chek1tm2.1Sje/Chek1+
Trp53tm1Brn/Trp53+
Tg(MMTV-cre)#Mam/0
(involves: 129P2/OlaHsd * FVB) 		increased mammary adenocarcinoma incidence J:162126
Chek2tm1Mak/Chek2tm1Mak
Rad50tm2Jpt/Rad50tm2Jpt
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6) 		increased lymphoma incidence J:103922
Chfrtm1Jc/Chfr+
(involves: 129S/SvEv * C57BL/6) 		increased lymphoma incidence J:97428
Chfrtm1Jc/Chfrtm1Jc
(involves: 129S/SvEv * C57BL/6) 		increased lymphoma incidence J:97428
Chordc1tm1Mbra/Chordc1+
(involves: 129 * C57BL/6) 		increased chronic myelocytic leukemia incidence J:222040
Chuktm1Yhu/Chuktm1Yhu
Tg(Krt1-15-cre/PGR*)22Cot/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL) 		increased carcinoma incidence J:141162
increased skin papilloma incidence J:141162
Chuktm2Yhu/Chuktm2Yhu
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6) 		increased skin squamous cell carcinoma incidence J:197037
Chuktm2Yhu/Chuktm2Yhu
Tg(Lor-CHUK)8Yhu/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/N) 		increased lung squamous cell carcinoma incidence J:197037
Chuktm2Yhu/Chuktm2Yhu
Tg(Lor-CHUK)8Yhu/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N) 		increased squamous cell carcinoma incidence J:197037
Cks1btm1Sir/Cks1b+
Tg(IghMyc)22Bri/?
(involves: C57BL * C57BL/6 * SJL) 		increased lymphoma incidence J:121564
Cks1btm1Sir/Cks1btm1Sir
Tg(IghMyc)22Bri/?
(involves: C57BL * C57BL/6 * SJL) 		increased lymphoma incidence J:121564
Col1a1tm1(CAG-EGFR*T790M*C797S*L858R)Mje/Col1a1+
(involves: 129S4/SvJae * BALB/c * C57BL/6) 		increased lung adenocarcinoma incidence J:235747
Col1a1tm1(CAG-Mir22)Ppp/Col1a1tm1(CAG-Mir22)Ppp
Tg(Mx1-cre)1Cgn/0
(Not Specified) 		increased leukemia incidence J:199366
increased T cell derived lymphoma incidence J:199366
Col1a1tm1(tetO-EML4/ALK)Kkw/Col1a1+
Tg(Scgb1a1-rtTA)1Jaw/0
(involves: 129 * C57BL/6) 		increased lung carcinoma incidence J:166724
Col1a1tm1(tetO-EWSR1/ATF1)Yasu/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
(involves: 129S4/SvJae * C57BL/6) 		increased sarcoma incidence J:194505
Col1a1tm1(tetO-EWSR1/ATF1)Yasu/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
H2az2Tg(Wnt1-cre)11Rth/H2az2+
Tg(CAG-cat,-lacZ)11Miya/0
(involves: 129S4/SvJae * C57BL/6 * CBA/J * DBA/2) 		increased sarcoma incidence J:194505
Col1a1tm1(tetO-EWSR1/ATF1)Yasu/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(EYFP)Cos
Tg(Mpz-cre)94Imeg/0
(involves: 129S4/SvJae * 129X1/SvJ * C57BL/6) 		increased sarcoma incidence J:194505
Col1a1tm1(tetO-Fos)Wag/Col1a1+
Tg(KRT5-rtTA)T2D6Sgkd/0
(involves: 129S4/SvJae * C57BL/6 * FVB/N) 		increased papilloma incidence J:201145
Col1a1tm1(tetO-URI1)Ndj/Col1a1+
Tg(Cebpb-tTA)#Bjd/0
(B6.Cg-Col1a1tm1(tetO-URI1)Ndj Tg(Cebpb-tTA)#Bjd) 		increased hepatocellular carcinoma incidence J:217463
increased liver adenoma incidence J:217463
Col1a1tm1(tetO-URI1)Ndj/Col1a1+
Tg(Cebpb-tTA)#Bjd/0
Trp53tm1Gev/Trp53+
(B6.Cg-Trp53tm1Gev Col1a1tm1(tetO-URI1)Ndj Tg(Cebpb-tTA)#Bjd) 		increased hepatocellular carcinoma incidence J:217463
Col1a1tm1(tetO-URI1)Ndj/Col1a1tm1(tetO-URI1)Ndj
Tg(Cebpb-tTA)#Bjd/0
(B6.Cg-Col1a1tm1(tetO-URI1)Ndj Tg(Cebpb-tTA)#Bjd) 		increased hepatocellular carcinoma incidence J:217463
Col1a1tm1(tetO-YAP1*)Fcam/Col1a1+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Tg(KRT14-cre)1Amc/0
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * CBA) 		increased skin squamous cell carcinoma incidence J:171057
Col1a1tm1(tetO-YAP1*)Fcam/Col1a1+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * DBA/2) 		increased prostate gland adenocarcinoma incidence J:222916
Col1a1tm2(tetO-IDH2*R140Q)Ppp/Col1a1tm2(tetO-IDH2*R140Q)Ppp
Flt3tm1.1Dosm/Flt3tm1.1Dosm
Gt(ROSA)26Sortm1(rtTA*M2)Jae/?
(involves: 129 * C57BL/6) 		increased leukemia incidence J:210097
Col1a1tm2(tetO-IDH2*R140Q)Ppp/Col1a1tm2(tetO-IDH2*R140Q)Ppp
Gt(ROSA)26Sortm1(rtTA*M2)Jae/?
(involves: 129S4/SvJae * C57BL/6) 		increased leukemia incidence J:210097
Col1a1tm3(tetO-GFP/RNAi:Apc)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
(involves: 129S4/SvJae * C57BL/6) 		increased leukemia incidence J:171191
increased lymphoma incidence J:171191
increased T cell derived lymphoma incidence J:171191
Col1a1tm4(CAG-FGFR2_iIIIb*K660N)Kkw/Col1a1+
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S4/SvJae * BALB/c * C57BL/6) 		increased lung adenocarcinoma incidence J:214230
Col1a1tm4(tetO-GFP/RNAi:Apc)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
(involves: 129S4/SvJae * C57BL/6) 		increased leukemia incidence J:171191
increased lymphoma incidence J:171191
increased T cell derived lymphoma incidence J:171191
Col1a1tm5(tetO-GFP/RNAi:Cdkn2a)Slowe/Col1a1+
Gt(ROSA)26Sortm1(Luc)Kael/Gt(ROSA)26Sortm1(rtTA*M2)Jae
Krastm4Tyj/Kras+
Tg(Scgb1a1-rtTA)1Jaw/0
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6) 		increased lung adenoma incidence J:171191
Col1a1tm6(tetO-MSI2)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
(involves: 129S4/SvJae * C57BL/6) 		increased leukemia incidence J:163322
Cop1Gt(XR0653)1.1Wtsi/Cop1Gt(XR0653)1.1Wtsi
(involves: 129P2/OlaHsd * C57BL/6 * CBA) 		increased B cell derived lymphoma incidence J:178271
increased histiocytic sarcoma incidence J:178271
increased T cell derived lymphoma incidence J:178271
increased testicular teratoma incidence J:178271
Cop1tm2.1Vmd/Cop1+
Tg(Pbsn-cre)4Prb/0
(B6N.CgCop1tm2.1Vmd Ptentm1Hwu Tg(Pbsn-cre)4Prb) 		increased prostate gland adenocarcinoma incidence J:172653
Coro1ctm1c(KOMP)Wtsi/Coro1ctm1c(KOMP)Wtsi
Ptentm2Mak/Ptentm2Mak
Trp53tm1Brn/Trp53tm1Brn
Tg(GFAP-cre/Esr1*,-lacZ)ASbk/0
(involves: 129P2/OlaHsd * C57BL/6N * FVB/NJ) 		increased glioblastoma incidence J:290447
Cpt1cGt(XL823)Byg/Cpt1c+
Nf1tm1Tyj/Nf1+
Trp53tm1Tyj/Trp53+
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6) 		decreased sarcoma incidence J:228258
Crebbptm1Dli/Crebbp+
(involves: 129S6/SvEvTac * C57BL/6) 		increased histiocytic sarcoma incidence J:60630
increased leukemia incidence J:60630
Crebbptm1Jvd/Crebbptm1Jvd
Tg(Lck-cre)548Jxm/0
(involves: 129 * C57BL/6 * CBA) 		increased T cell derived lymphoma incidence J:105505
Crebbptm1Jvd/Crebbptm1Jvd
Tg(MMTV-cre)4Mam/0
(involves: 129 * C57BL/6 * FVB) 		increased T cell derived lymphoma incidence J:88323
Crkltm1Hkp/Crkltm1Hkp
Tg(BCR/ABL)623Hkp/?
(involves: 129S1/Sv * 129X1/SvJ * Black Swiss * C57BL/6 * CBA) 		increased B cell derived lymphoma incidence J:76680
increased leukemia incidence J:76680
Csf2tm1Dran/Csf2tm1Dran
Ifngtm1Ts/Ifngtm1Ts
Il3tm1Glli/Il3tm1Glli
(involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6) 		increased B cell derived lymphoma incidence J:83086
increased carcinoma incidence J:83086
increased ovarian carcinoma incidence J:83086
Csf2tm1Mlg/Csf2tm1Mlg
Ifngtm1Ts/Ifngtm1Ts
Il3tm1Glli/Il3tm1Glli
(B6.129S-Csf2tm1Mlg Il3tm1Glli Ifngtm1TsIfngtm1Ts) 		increased pituitary adenoma incidence J:145518
Csnk1a1tm1.1Ybn/Csnk1a1+
Tg(Vil1-cre/ERT2)23Syr/0
Trp53tm1Brn/Trp53tm1Brn
(involves: 129 * C57BL/6 * CD-1 * DBA/2) 		increased carcinoma incidence J:204886
Csnk1a1tm1.1Ybn/Csnk1a1tm1.1Ybn
Tg(Vil1-cre/ERT2)23Syr/0
Trp53tm1Brn/Trp53tm1Brn
(involves: 129 * C57BL/6 * CD-1 * DBA/2) 		increased carcinoma incidence J:204886
Ctnnb1tm1.2Wvv/Ctnnb1+
(involves: 129P2/OlaHsd * C57BL/6J) 		increased intestinal adenocarcinoma incidence J:185942
increased intestinal adenoma incidence J:185942
Ctnnb1tm1Mmt/Ctnnb1+
(involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ) 		increased intestinal adenoma incidence J:169830
Ctnnb1tm1Mmt/Ctnnb1+
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Prom1tm1(cre/ERT2)Gilb/Prom1+
(involves: 129S6/SvEvTac * 129X1/SvJ) 		increased intestinal adenocarcinoma incidence J:144215
Ctnnb1tm1Mmt/Ctnnb1+
Igs2tm1(CAG-Met)Zsu/Igs2+
Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2 * FVB/N) 		increased prostate gland adenocarcinoma incidence J:284956
Ctnnb1tm1Mmt/Ctnnb1+
Krt19tm1(cre)Mmt/Krt19+
(involves: 129X1/SvJ) 		increased intestinal adenoma incidence J:58367
Ctnnb1tm1Mmt/Ctnnb1+
Pik3catm1Gilb/Pik3ca+
Trp53tm1Brn/Trp53+
Tg(Fabp7-cre,-lacZ)3Gtm/0
(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * CBA) 		increased medulloblastoma incidence J:186709
Ctnnb1tm1Mmt/Ctnnb1+
Ptentm1Hwu/Ptentm1Hwu
Tg(Upk2-cre)6Xrw/0
(involves: 129S4/SvJae * 129X1/SvJ * FVB/N) 		increased urinary bladder carcinoma incidence J:164579
Ctnnb1tm1Mmt/Ctnnb1+
Tg(Fabp1-cre)1Mmt/?
(involves: 129X1/SvJ) 		increased intestinal adenoma incidence J:58367
Ctnnb1tm1Mmt/Ctnnb1+
Tg(Msx2-rtTA)885Lma/0
Tg(tetO-cre)1Jaw/0
(involves: 129 * 129X1/SvJ * C57BL/6) 		increased urinary bladder carcinoma incidence J:202618
Ctnnb1tm1Mmt/Ctnnb1+
Tg(Mx1-cre)1Cgn/0
(involves: 129S1/Sv * C57BL/6 * CBA) 		increased hepatoblastoma incidence J:112659
Ctnnb1tm1Mmt/Ctnnb1+
Tg(Pbsn-cre)4Prb/0
(involves: 129X1/SvJ * C57BL/6 * DBA/2) 		increased prostate gland adenocarcinoma incidence J:143034, J:284956
Ctnnb1tm1Mmt/Ctnnb1+
Trp53tm1Brn/Trp53+
Tg(Fabp7-cre,-lacZ)3Gtm/0
(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * CBA) 		increased medulloblastoma incidence J:186709
Ctnnb1tm1Mmt/Ctnnb1tm1Mmt
Krastm4Tyj/Kras+
Tg(Upk2-cre)6Xrw/0
(involves: 129S4/SvJae * 129X1/SvJ * FVB/N) 		increased urinary bladder carcinoma incidence J:234236
Ctnnb1tm1Mmt/Ctnnb1tm1Mmt
Ptentm1Hwu/Ptentm1Hwu
Tg(Upk2-cre)6Xrw/0
(involves: 129S4/SvJae * 129X1/SvJ * FVB/N) 		increased urinary bladder carcinoma incidence J:164579
Ctnnb1tm1Mmt/Ctnnb1tm1Mmt
Tg(Mx1-cre)1Cgn/0
(involves: 129S1/Sv * C57BL/6 * CBA) 		increased hepatoblastoma incidence J:112659
Ctnnb1tm1Mmt/Ctnnb1tm1Mmt
Tg(Upk2-cre)6Xrw/0
Tg(Upk2-HRAS*Q61L)5Xrw/0
(involves: 129X1/SvJ * FVB/N) 		increased urinary bladder carcinoma incidence J:234236
Ctnnb1tm2Kem/Ctnnb1+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Tg(Col2a1-cre)1Bhr/0
Tg(tetO-Vegfa)90Ala/0
(involves: 129 * C57BL/6 * FVB/N * ICR * SJL) 		increased hemangioma incidence J:156474
Ctsgtm1Ley/Ctsgtm2.1(PML/RARA)Ley
(involves: 129X1/SvJ * C57BL/6) 		increased leukemia incidence J:84230
Ctsgtm2.1(PML/RARA)Ley/Ctsg+
(involves: 129X1/SvJ * C57BL/6) 		increased leukemia incidence J:84230, J:86458
Ctsgtm2.1(PML/RARA)Ley/Ctsg+
(involves: 129 * 129X1/SvJ * C57BL/6) 		increased acute promyelocytic leukemia incidence J:166479
Ctsgtm2.1(PML/RARA)Ley/Ctsg+
Elanetm1Sds/Elanetm1Sds
(involves: 129S/SvEv * 129X1/SvJ * C57BL/6) 		increased leukemia incidence J:86458
Ctsgtm2.1(PML/RARA)Ley/Ctsgtm2.1(PML/RARA)Ley
(involves: 129X1/SvJ * C57BL/6) 		increased leukemia incidence J:84230
Ctsgtm3.1(PML/RARA)Ley/Ctsg+
(involves: 129 * C57BL/6) 		increased acute promyelocytic leukemia incidence J:166479
Cul9tm1.2Yxi/Cul9+
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N) 		increased insulinoma incidence J:170976
increased lymphoma incidence J:170976
increased sarcoma incidence J:170976
Cul9tm1.2Yxi/Cul9+
Tg(IghMyc)22Bri/0
(involves: 129P2/OlaHsd * C57BL * C57BL/6 * FVB/N * SJL) 		increased B cell derived lymphoma incidence J:170976
increased lymphoma incidence J:170976
Cul9tm1.2Yxi/Cul9tm1.2Yxi
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N) 		increased lymphoma incidence J:170976
increased sarcoma incidence J:170976
Cul9tm1.2Yxi/Cul9tm1.2Yxi
Tg(IghMyc)22Bri/0
(involves: 129P2/OlaHsd * C57BL * C57BL/6 * FVB/N * SJL) 		increased B cell derived lymphoma incidence J:170976
increased lymphoma incidence J:170976
Cxcr6tm1Lex/Cxcr6+
(involves: 129S/SvEvBrd * C57BL/6J) 		increased medulloblastoma incidence J:120952
Cxcr6tm1Lex/Cxcr6tm1Lex
(involves: 129S/SvEvBrd * C57BL/6J) 		increased medulloblastoma incidence J:120952
Cyldtm1Ref/Cyld+
(B6.129-Cyldtm1Ref) 		increased skin papilloma incidence J:108769
Cyldtm1Ref/Cyldtm1Ref
(B6.129-Cyldtm1Ref) 		increased skin papilloma incidence J:108769
Cytiptm1Tes/Cytiptm1Tes
(involves: 129S1/Sv * FVB/N) 		increased sarcoma incidence J:110320
Dcctm1.1Mehl/Dcctm1.1Mehl
(Not Specified) 		increased intestinal adenocarcinoma incidence J:181517
increased intestinal adenoma incidence J:181517
Dcctm1Nki/Dcctm1Nki
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/?
(involves: 129P2/OlaHsd * FVB/N) 		increased classified tumor incidence J:181090
increased mammary adenocarcinoma incidence J:181090
increased spindle cell carcinoma incidence J:181090
Dclre1atm1Rleg/Dclre1a+
(involves: 129S7/SvEvBrd) 		increased histiocytic sarcoma incidence J:102381
increased lymphoma incidence J:102381
Dclre1atm1Rleg/Dclre1a+
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129S7/SvEvBrd) 		increased sarcoma incidence J:102381
Dclre1atm1Rleg/Dclre1atm1Rleg
(involves: 129S7/SvEvBrd) 		increased adenoma incidence J:102381
increased histiocytic sarcoma incidence J:102381
increased lung adenoma incidence J:102381
increased lymphoma incidence J:102381
increased ovarian teratoma incidence J:102381
increased sarcoma incidence J:102381
Dclre1atm1Rleg/Dclre1atm1Rleg
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129S7/SvEvBrd) 		increased lymphoma incidence J:102381
increased T cell derived lymphoma incidence J:102381
Dcntm1Ioz/Dcn+
Trp53tm1Brd/Trp53tm1Brd
(involves: 129/Sv * Black Swiss * C57BL/6) 		increased T cell derived lymphoma incidence J:53511
Dcntm1Ioz/Dcntm1Ioz
Trp53tm1Brd/Trp53tm1Brd
(involves: 129/Sv * Black Swiss * C57BL/6) 		increased hemangiosarcoma incidence J:53511
increased T cell derived lymphoma incidence J:53511
Ddb2tm1Vri/Ddb2+
(involves: 129P2/Ola * SKH1) 		increased squamous cell carcinoma incidence J:103406
Ddb2tm1Vri/Ddb2tm1Vri
(involves: 129P2/Ola * SKH1) 		increased squamous cell carcinoma incidence J:103406
Ddit3tm1.1Irt/Ddit3tm1.1Irt
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
Tg(Mup3-Plau)350-2Eps/?
(involves: C57BL/6 * DBA) 		increased hepatocellular carcinoma incidence J:233146
Del(4C4-C5)1Lap/Del(4C4-C5)1Lap
(involves: 129S6/SvEvTac) 		increased hemangiosarcoma incidence J:158126
increased osteosarcoma incidence J:158126
increased sarcoma incidence J:158126
increased teratoma incidence J:158126
Del(4Cdkn2a-Cdkn2b)1Brn/+
(involves: 129P2/OlaHsd) 		increased intestinal adenoma incidence J:125189
increased leukemia incidence J:125189
increased lymphoma incidence J:125189
increased sarcoma incidence J:125189
Del(4Cdkn2a-Cdkn2b)2Brn/+
(involves: 129P2/OlaHsd * FVB/N) 		increased intestinal adenocarcinoma incidence J:125189
increased leukemia incidence J:125189
increased lymphoma incidence J:125189
increased melanoma incidence J:125189
increased sarcoma incidence J:125189
Del(4D4Mit190-D4Mit51)2Aam/+
(involves: 129S7/SvEvBrd) 		increased lymphoma incidence J:121726
increased squamous cell carcinoma incidence J:121726
Del(14Trim13-Dleu2)4Rdf/+
(involves: 129S1/Sv * 129S4/SvJaeSor * C57BL/6) 		increased B cell derived lymphoma incidence J:156946
Del(14Trim13-Dleu2)4Rdf/Del(14Trim13-Dleu2)4Rdf
(involves: 129S1/Sv * 129S4/SvJaeSor * C57BL/6) 		increased B cell derived lymphoma incidence J:156946
increased leukemia incidence J:156946
Del(14Trim13-Rnaseh2b)6Rdf/+
Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6) 		increased chronic lymphocytic leukemia incidence J:179879
increased lymphoma incidence J:179879
increased small lymphocytic lymphoma incidence J:179879
Del(15Krt7-Krt18)1Tmm/+
Igs11tm1Tmm/Igs11+
Krt1ctm1Tmm/Krt1c+
Tg(ACTB-KRAS*G12V,-luc)#Lche/0
(involves: 129S7/SvEvBrd * C57BL/6 * FVB/N) 		increased lung adenocarcinoma incidence J:199528
increased lung adenoma incidence J:199528
DgkdGt(RRT600)Byg/Dgkd+
(involves: 129P2/OlaHsd * C57BL/6) 		increased sarcoma incidence J:126380
Dh/Dh+
H2d/H2d
(NZB.Cg-Dh) 		decreased lymphoma incidence J:12036
Dicer1tm1Mmk/Dicer1tm1Mmk
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129 * C57BL/6 * CD-1) 		increased leukemia incidence J:158901
increased myeloid sarcoma incidence J:158901
Dicer1tm1Snj/Dicer1tm1Snj
Trp53tm1Brn/Trp53+
Tg(KRT5-cre/PGR)1Der/0
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6N * FVB/N * ICR) 		increased basal cell carcinoma incidence J:216813
Dicer1tm1Snj/Dicer1tm1Snj
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT5-cre/PGR)1Der/0
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6N * FVB/N * ICR) 		increased skin squamous cell carcinoma incidence J:216813
Dicer1tm1Tara/Dicer1tm1Tara
Ptentm1Hwu/Ptentm1Hwu
Amhr2tm3(cre)Bhr/Amhr2+
(involves: 129P2/OlaHsd * 129S4/SvJae * 129S7/SvEvBrd) 		increased carcinoma incidence J:182161
increased ovarian carcinoma incidence J:182161
Dicer1tm1Tara/Dicer1tm1Tara
Ptentm1Hwu/Ptentm1Hwu
Trp53tm2Tyj/Trp53+
Amhr2tm3(cre)Bhr/Amhr2+
(involves: 129P2/OlaHsd * 129S4/SvJae * 129S7/SvEvBrd) 		increased carcinoma incidence J:222579
increased ovarian carcinoma incidence J:222579
Diras2em1Gpt/Diras2em1Gpt
Krastm4Tyj/Kras+
Ptf1atm1(cre)Hnak/Ptf1a+
(involves: 129S4/SvJae * C57BL/6J * C57BL/6JGpt) 		increased pancreatic ductal adenocarcinoma incidence J:348744
Dkc1tm1Ppp/Y
(involves: 129S1/Sv) 		increased B cell derived lymphoma incidence J:81054
increased fibrosarcoma incidence J:81054
increased lung carcinoma incidence J:81054
increased malignant tumor incidence J:81054
increased mammary adenocarcinoma incidence J:81054
increased renal carcinoma incidence J:81054
Dlg2tm1a(EUCOMM)Wtsi/Dlg2tm1a(EUCOMM)Wtsi
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(Col1a1-cre)1Kry/0
(involves: 129 * 129P2/OlaHsd * C57BL/6N * FVB/N) 		increased osteosarcoma incidence J:269943
Dmtf1tm1Cjs/Dmtf1+
Krastm2Tyj/Kras+
(involves: 129S2/SvPas * C57BL/6) 		increased cholangiocarcinoma incidence J:126002
increased lung adenocarcinoma incidence J:126002
increased lung adenoma incidence J:126002
increased neurofibroma incidence J:126002
increased osteosarcoma incidence J:126002
increased skin papilloma incidence J:126002
increased T cell derived lymphoma incidence J:126002
Dmtf1tm1Cjs/Dmtf1+
Krastm3Tyj/Kras+
(involves: 129S4/SvJae * C57BL/6) 		increased lung adenocarcinoma incidence J:126002
increased lung adenoma incidence J:126002
increased skin papilloma incidence J:126002
increased T cell derived lymphoma incidence J:126002
Dmtf1tm1Cjs/Dmtf1tm1Cjs
Krastm2Tyj/Kras+
(involves: 129S2/SvPas * C57BL/6) 		increased lung adenocarcinoma incidence J:126002
increased lung adenoma incidence J:126002
increased skin papilloma incidence J:126002
increased T cell derived lymphoma incidence J:126002
Dmtf1tm1Cjs/Dmtf1tm1Cjs
Krastm3Tyj/Kras+
(involves: 129S4/SvJae * C57BL/6) 		increased lung adenocarcinoma incidence J:126002
increased lung adenoma incidence J:126002
increased skin papilloma incidence J:126002
increased T cell derived lymphoma incidence J:126002
Dna2tm1.1Lzhg/Dna2+
(involves: 129S1/Sv) 		increased lung adenocarcinoma incidence J:198831
increased lymphoma incidence J:198831
Dnai7Gt(VICTR21)709Lex/Dnai7+
(involves: 129S5/SvEvBrd) 		increased lung adenocarcinoma incidence J:111629
Dnai7Gt(VICTR21)709Lex/Dnai7Gt(VICTR21)709Lex
(involves: 129S5/SvEvBrd) 		increased lung adenocarcinoma incidence J:111629
increased lung adenoma incidence J:111629
Dnd1Ter/?
(129S1/Sv-KitW Oca2p Tyrc-ch) 		increased testicular teratoma incidence J:29502
Dnd1Ter/Dnd1+
(129S1/Sv-KitW Oca2p Tyrc-ch) 		increased testicular teratoma incidence J:7954
Dnd1Ter/Dnd1+
(involves: 129S1/Sv * C57BL/6) 		increased testicular teratoma incidence J:7954
Dnd1Ter/Dnd1Ter
(129S1/Sv-KitW Oca2p Tyrc-ch) 		increased testicular teratoma incidence J:7954
Dnd1Ter/Dnd1Ter
(involves: 129S1/Sv * C57BL/6) 		increased testicular teratoma incidence J:7954
Dnmt1tm1(tetO-BCL2)Sjk/Dnmt1+
Tg(IghMyc)22Bri/0
Tg(MMTVtTA)1Mam/0
(involves: 129S4/SvJae * C57BL/6) 		increased B cell derived lymphoma incidence J:93549
increased leukemia incidence J:93549
Dnmt1tm1Jae/Dnmt1+
Mlh1tm1Lisk/Mlh1tm1Lisk
(involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6) 		increased intestinal adenocarcinoma incidence J:75745
increased intestinal adenoma incidence J:75745
increased lymphoma incidence J:75745
Dnmt1tm1Jae/Dnmt1tm1Pwl
Mlh1tm1Lisk/Mlh1tm1Lisk
(involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6) 		increased lymphoma incidence J:75745
Dnmt1tm1Pwl/Dnmt1+
Mlh1tm1Lisk/Mlh1tm1Lisk
(involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6) 		increased intestinal adenocarcinoma incidence J:75745
increased intestinal adenoma incidence J:75745
increased lymphoma incidence J:75745
Dock1tm2.1Jfco/Dock1+
Tg(MMTV-Erbb2*,-cre)1Mul/0
(involves: C57BL/6 * FVB/NJ) 		increased mammary adenocarcinoma incidence J:196659
Dock1tm2.1Jfco/Dock1tm2.1Jfco
Tg(MMTV-Erbb2*,-cre)1Mul/0
(involves: C57BL/6 * FVB/NJ) 		increased mammary adenocarcinoma incidence J:196659
Dok1tm1Ppp/Dok1+
Tg(Tec-BCR/ABL1)5Hhi/0
(involves: 129S1/Sv) 		increased leukemia incidence J:95334
Dok1tm1Ppp/Dok1tm1Ppp
(129S1/Sv-Dok1tm1Ppp) 		increased lung adenocarcinoma incidence J:158011
Dok1tm1Ppp/Dok1tm1Ppp
Dok2tm1Ppp/Dok2tm1Ppp
(129S1/Sv-Dok1tm1Ppp Dok2tm1Ppp) 		increased leukemia incidence J:95334
increased lung adenocarcinoma incidence J:158011
Dok1tm1Ppp/Dok1tm1Ppp
Dok2tm1Ppp/Dok2tm1Ppp
Dok3tm1Ppp/Dok3tm1Ppp
(129S1/Sv-Dok1tm1Ppp Dok2tm1Ppp Dok3tm1Ppp) 		increased chronic myelocytic leukemia incidence J:158011
increased lung adenocarcinoma incidence J:158011
Dok1tm1Ppp/Dok1tm1Ppp
Dok3tm1Ppp/Dok3tm1Ppp
(129S1/Sv-Dok1tm1Ppp Dok3tm1Ppp) 		increased lung adenocarcinoma incidence J:158011
Dok1tm1Ppp/Dok1tm1Ppp
Tg(Tec-BCR/ABL1)5Hhi/0
(involves: 129S1/Sv) 		increased leukemia incidence J:95334
Dok1tm1Yyam/Dok1tm1Yyam
Dok2tm1Yyam/Dok2tm1Yyam
(B6.129-Dok1tm1Yyam Dok2tm1Yyam) 		increased leukemia incidence J:95335
increased sarcoma incidence J:95335
Dok1tm1Yyam/Dok1tm1Yyam
Dok2tm1Yyam/Dok2tm1Yyam
Dok3tm1Brs/Dok3tm1Brs
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6) 		increased histiocytic sarcoma incidence J:163407
Dok1tm1Yyam/Dok1tm1Yyam
Dok2tm1Yyam/Dok2tm1Yyam
Tg(Tec-BCR/ABL1)5Hhi/0
(involves: C57BL/6) 		increased leukemia incidence J:95335
Dok1tm1Yyam/Dok1tm1Yyam
Tg(Tec-BCR/ABL1)5Hhi/0
(involves: C57BL/6) 		increased leukemia incidence J:95335
Dok2tm1Ppp/Dok2+
Tg(Tec-BCR/ABL1)5Hhi/0
(involves: 129S1/Sv) 		increased leukemia incidence J:95334
Dok2tm1Ppp/Dok2tm1Ppp
(129S1/Sv-Dok2tm1Ppp) 		increased lung adenocarcinoma incidence J:158011
Dok2tm1Ppp/Dok2tm1Ppp
Tg(Tec-BCR/ABL1)5Hhi/0
(involves: 129S1/Sv) 		increased leukemia incidence J:95334
Dok2tm1Yyam/Dok2tm1Yyam
Tg(Tec-BCR/ABL1)5Hhi/0
(involves: C57BL/6) 		increased leukemia incidence J:95335
Dok3tm1Ppp/Dok3tm1Ppp
(129S1/Sv-Dok3tm1Ppp) 		increased lung adenocarcinoma incidence J:158011
Drd2tm1Ebo/Drd2tm1Ebo
(involves: 129S2/SvPas * C57BL/6) 		increased pituitary adenoma incidence J:41857
Ds/Ds+
(involves: 129T1/Sv * DA/Hu * DBA/1J) 		increased skin hamartoma incidence J:13012
E2f1tm1Meg/E2f1tm1Meg
(either: (involves: 129/Sv * 129S4/SvJae) or (involves: 129/Sv * 129S4/SvJae * C57BL/6)) 		increased T cell derived lymphoma incidence J:33100
E2f1tm1Njd/E2f1+
Rb1tm1Tyj/Rb1+
(either: 129S2/SvPas or (involves: 129S2/SvPas * C57BL/6)) 		increased thyroid adenoma incidence J:47108
E2f1tm1Njd/E2f1tm1Njd
(involves: 129S2/SvPas * C57BL/6) 		increased histiocytic sarcoma incidence J:33099
increased lung adenocarcinoma incidence J:33099
increased lung non-small cell carcinoma incidence J:33099
increased lymphoma incidence J:33099
E2f1tm1Njd/E2f1tm1Njd
Rb1tm1Tyj/Rb1+
(either: 129S2/SvPas or (involves: 129S2/SvPas * C57BL/6)) 		increased hemangioma incidence J:47108
increased thyroid adenoma incidence J:47108
Eaf2tm1Zhow/Eaf2+
(involves: 129P2/OlaHsd * C57BL/6J) 		increased lung adenocarcinoma incidence J:145228
increased lymphoma incidence J:145228
Eaf2tm1Zhow/Eaf2tm1Zhow
(involves: 129P2/OlaHsd * C57BL/6J) 		increased B cell derived lymphoma incidence J:145228
increased hepatocellular carcinoma incidence J:145228
increased lung adenocarcinoma incidence J:145228
Ednrbtm1Ywa/Ednrb+
Tg(Mt1-RET)304Ina/0
(involves: 129S7/SvEvBrd * BALB/c * C57BL/6) 		increased melanoma incidence J:155735
Eef1a1tm1(Kras*)Arge/Eef1a1+
Waptm1(cre)Arge/Wap+
(involves: 129S1/Sv) 		increased mammary adenocarcinoma incidence J:146290
Eef1a1tm2Arge/Eef1a1+
Tg(Mx1-cre)1Cgn/0
(involves: C57BL/6 * CBA) 		increased acute lymphoblastic leukemia incidence J:197167
Eef1e1Gt(OST377244)Lex/Eef1e1+
(involves: 129S5/SvEvBrd * C57BL/6) 		increased malignant tumor incidence J:96923
Efna1tm1a(EUCOMM)Wtsi/Efna1tm1a(EUCOMM)Wtsi
(involves: C57BL/6 * C57BL/6N) 		increased hibernoma incidence J:213427
Egfrwa2/Egfr+
Fostm2(Fosl1)Wag/Fostm2(Fosl1)Wag
Tg(KRT5-SOS1)892A6Wag/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA) 		increased skin papilloma incidence J:175064
Egfrwa2/Egfr+
Fostm3.1Wag/Fostm3.1Wag
Tg(KRT5-SOS1)892A6Wag/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL) 		increased skin papilloma incidence J:175064
Egfrwa2/Egfr+
Fostm4.1Wag/Fostm4.1Wag
Tg(KRT5-SOS1)892A6Wag/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA) 		increased skin papilloma incidence J:175064
Egfrwa2/Egfr+
Fostm5.1Wag/Fostm5.1Wag
Tg(KRT5-SOS1)892A6Wag/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL) 		increased skin papilloma incidence J:175064
Egfrwa2/Egfr+
Fostm6.1Wag/Fostm6.1Wag
Tg(KRT5-SOS1)892A6Wag/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL) 		increased skin papilloma incidence J:175064
Egfrwa2/Egfr+
Rps6ka3tm1.1Kry/Y
Tg(KRT5-SOS1)892A6Wag/0
(involves: 129X1/SvJ * C57BL/6 * CBA) 		increased skin papilloma incidence J:175064
Egfrwa2/Egfr+
Tg(KRT5-SOS1)892A6Wag/0
(involves: C57BL/6 * CBA) 		increased skin papilloma incidence J:175064
Egr1tm1Jmi/Egr1tm1Jmi
(involves: 129 * C57BL/6) 		increased skin papilloma incidence J:99386
increased T cell derived lymphoma incidence J:123870
Elavl1tm1.1Dkon/Elavl1tm1.1Dkon
Lyz2tm1(cre)Ifo/Lyz2+
(B6.129P2-Elavl1tm1.1Dkon Lyz2tm1(cre)Ifo) 		increased colon adenocarcinoma incidence J:184388
increased colon adenoma incidence J:184388
Emv30b/Emv30b
Prkdcscid/Prkdcscid
(NOD.Cg-Emv30b Prkdcscid/Dvs) 		increased T cell derived lymphoma incidence J:29951
Entpd5tm1Rre/Entpd5tm1Rre
(involves: 129S5/SvEvBrd * C57BL/6J) 		increased hepatocellular carcinoma incidence J:163795
increased liver adenoma incidence J:163795
Epm2aTg(TcraK,TcrbK)TG-BFlv/Epm2a+
(involves: C57BL/6 * C57BL/10 * C57BR/cd * CBA/J) 		increased T cell derived lymphoma incidence J:112696
Ergtm1.1Sho/Ergtm1.1Sho
Ptentm1Hwu/Ptentm1Hwu
Tmprss2tm3Sho/Tmprss2tm3Sho
Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2) 		increased prostate gland adenocarcinoma incidence J:212219
Errfi1tm1.1Jwj/Errfi1tm1.1Jwj
(involves: 129 * C57BL/6 * FVB/N * SJL) 		increased skin papilloma incidence J:129106
Errfi1tm1Jwj/Errfi1tm1Jwj
Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sor+
(involves: 129/Sv * 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL) 		increased skin papilloma incidence J:153715
Errfi1tm1Jwj/Errfi1tm1Jwj
Pgrtm2(cre)Lyd/Pgr+
(involves: 129S1/Sv * 129X1/SvJ) 		increased endometrial carcinoma incidence J:150007
Errfi1tm1Jwj/Errfi1tm1Jwj
Pgrtm2(cre)Lyd/Pgr+
Ptentm1Hwu/Ptentm1Hwu
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ) 		increased endometrial carcinoma incidence J:162027
Errfi1tm1Kln/Errfi1tm1Kln
(involves: 129P2/OlaHsd * C57BL/6N) 		increased adenoma incidence J:109556
increased carcinoma incidence J:109556
increased skin papilloma incidence J:109556
Esl1NFS/N/Esl1SL/Kh
(involves: SL/Kh * NFS/N) 		increased B cell derived lymphoma incidence J:16441
Esl1SL/Kh/Esl1SL/Kh
(involves: SL/Kh * NFS/N) 		increased B cell derived lymphoma incidence J:16441
Espl1Gt(XL058)Byg/Espl1+
Trp53tm1Tyj/Trp53+
(B6.129-Trp53tm1Tyj Espl1Gt(XL058)Byg) 		increased carcinoma incidence J:174926
Espl1Gt(XL058)Byg/Espl1+
Trp53tm1Tyj/Trp53tm1Tyj
(B6.129-Trp53tm1Tyj Espl1Gt(XL058)Byg) 		increased carcinoma incidence J:174926
increased lymphoma incidence J:174926
Esr1tm1Ksk/Esr1tm1Ksk
Tg(Wnt1)1Hev/0
(involves: 129P2/OlaHsd * C57BL/6 * SJL) 		increased mammary adenocarcinoma incidence J:54215
Esr2tm1Unc/Esr2tm1Unc
(involves: 129P2/OlaHsd * C57BL/6J) 		increased chronic myelocytic leukemia incidence J:83617
Etn3Ppd/Y
(either: (involves: CD-1) or (involves: C3H/HeJ * CD-1)) 		increased skin papilloma incidence J:112867
Etn3Ppd/?
(either: (involves: CD-1) or (involves: C3H/HeJ * CD-1)) 		increased skin papilloma incidence J:112867
Etv6tm1(RUNX1)Haho/Etv6+
Tg(Mx1-cre)1Cgn/0
(involves: 129S1/Sv * C57BL/6 * CBA) 		increased leukemia incidence J:151639
Etv6tm1.1(RUNX1,hsb5)Lvdw/Etv6+
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6J) 		increased leukemia incidence J:174866
Etv6tm1.1(RUNX1,hsb5)Lvdw/Etv6+
TgTn(sb-T2/Onc)76Dla/0
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6J * FVB/N) 		increased leukemia incidence J:174866
Etv6tm3(NTRK3)Sho/Etv6+
Tg(MMTV-cre)FMam/0
(involves: 129S1/Sv * FVB/N) 		increased chronic myelocytic leukemia incidence J:130323
Ewsr1tm1(ERG)Thr/Ewsr1+
Rag1tm1(cre)Thr/Rag1+
(involves: 129S/SvEv) 		increased leukemia incidence J:98679
increased T cell derived lymphoma incidence J:98679
Exo1tm1Wed/Exo1tm1Wed
(involves: 129/Sv * C57BL/6J * SJL) 		increased lymphoma incidence J:82426
Exo1tm2Wed/Exo1tm2Wed
(involves: 129 * C57BL/6) 		increased adenoma incidence J:198719
increased lymphoma incidence J:198719
increased sarcoma incidence J:198719
Exo1tm3.1Wed/Exo1tm3.1Wed
(involves: 129 * C57BL/6) 		increased adenoma incidence J:198719
increased lymphoma incidence J:198719
increased sarcoma incidence J:198719
Exo1tm3.1Wed/Exo1tm3.1Wed
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6) 		increased lymphoma incidence J:198719
increased sarcoma incidence J:198719
Ezh2tm1.1Nesh/Ezh2+
Cd19tm1(cre)Cgn/Cd19+
(involves: 129 * 129P2/OlaHsd * C57BL/6) 		increased B cell derived lymphoma incidence J:239472
increased leukemia incidence J:239472
Ezh2tm1.1Nesh/Ezh2tm1.1Nesh
Cd19tm1(cre)Cgn/Cd19+
(involves: 129 * 129P2/OlaHsd * C57BL/6) 		increased B cell derived lymphoma incidence J:239472
Ezh2tm2Sho/Ezh2tm2.1Sho
Tg(Mx1-cre)1Cgn/0
(involves: 129S1/Sv * C57BL/6 * CBA) 		increased leukemia incidence J:182211
Ezh2tm2Sho/Ezh2tm2Sho
Tg(Mx1-cre)1Cgn/0
(involves: 129S1/Sv * C57BL/6 * CBA) 		increased leukemia incidence J:182211
F2rtm1Pago/F2rtm1Pago
Tg(MMTV-PyVT)634Mul/0
(B6.Cg-F2rtm1Pago Tg(MMTV-PyVT)634Mul) 		increased adenoma incidence J:138924
increased mammary adenocarcinoma incidence J:138924
F2rl1tm1Bpd/F2rl1tm1Bpd
Tg(MMTV-PyVT)634Mul/0
(B6.Cg-F2rl1tm1Bpd Tg(MMTV-PyVT)634Mul) 		increased adenoma incidence J:138924
increased mammary adenocarcinoma incidence J:138924
F3tm1(F3)Lasn/F3tm1(F3)Lasn
(involves: 129S/SvEvBrd * C57BL/6) 		increased lung adenoma incidence J:133293
increased lung carcinoma incidence J:133293
Fahtm1Mgo/Fahtm1Mgo
(involves: 129S7/SvEvBrd * C57BL/6) 		increased hepatocellular carcinoma incidence J:138701
Fahtm1Mgo/Fahtm1Mgo
(involves: 129S7/SvEvBrd * C57BL) 		increased hepatocellular carcinoma incidence J:27735
increased liver adenoma incidence J:27735
Fancd2Gt(OST57859)Lex/Fancd2Gt(OST57859)Lex
(involves: 129S5/SvEvBrd * C57BL/6) 		increased adenoma incidence J:146616
increased carcinoma incidence J:146616
Fancd2tm1Hou/Fancd2tm1Hou
(129S4/SvJae-Fancd2tm1Hou) 		increased adenoma incidence J:84892
increased carcinoma incidence J:84892
Fancd2tm1Hou/Fancd2tm1Hou
(involves: 129S4/SvJae * C57BL/6J) 		increased adenoma incidence J:84892
increased carcinoma incidence J:84892
Fancftm1Nki/Fancftm1Nki
(involves: 129P2/OlaHsd * FVB) 		increased adenoma incidence J:180025
Fasldel1Hong/Fasldel1Hong
(either: (involves: 129 * BALB/c * C57BL/6) or (involves: 129X1/SvJ * C3H/HeJ * C57BL/6)) 		increased lymphoma incidence J:112563
Faslgld/Faslgld
(involves: C3H/HeJ * C57BL/6) 		increased histiocytic sarcoma incidence J:153501
Fasltm1.1Ast/Fasltm1.1Ast
(involves: BALB/cJ * C57BL/6) 		increased histiocytic sarcoma incidence J:153501
Fbxo4tm1.1Jadi/Fbxo4+
(Not Specified) 		increased hemangioma incidence J:178645
increased hepatic hemangioma incidence J:178645
increased hepatocellular carcinoma incidence J:178645
increased histiocytic sarcoma incidence J:178645
increased lymphoma incidence J:178645
increased myeloid sarcoma incidence J:178645
Fbxo4tm1.1Jadi/Fbxo4tm1.1Jadi
(Not Specified) 		increased hemangioma incidence J:178645
increased hepatic hemangioma incidence J:178645
increased hepatocellular carcinoma incidence J:178645
increased histiocytic sarcoma incidence J:178645
increased lymphoma incidence J:178645
increased myeloid sarcoma incidence J:178645
Fbxw7tm1Iaai/Fbxw7tm1Iaai
Tg(Lck-cre)1Cwi/0
(involves: 129/Sv * C57BL/6) 		increased T cell derived lymphoma incidence J:137138
Fbxw7tm1Iken/Fbxw7tm1Iken
Krastm4Tyj/Kras+
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129S4/SvJae * C57BL/6 * C57BL/6N * DBA) 		increased cholangiocarcinoma incidence J:258194
Fbxw7tm1Kei/Fbxw7tm1Kei
Tg(Lck-cre)1Cwi/?
(involves: 129P2/OlaHsd * C57BL/6) 		increased lymphoma incidence J:128523
Fbxw7tm1Kei/Fbxw7tm1Kei
Trp53tm1Tyj/Trp53tm1Tyj
Tg(Lck-cre)1Cwi/?
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6) 		increased lymphoma incidence J:128523
increased T cell derived lymphoma incidence J:128523
Fdxrtm1Xch/Fdxr+
(B6.Cg-Fdxrtm1Xch) 		increased B cell derived lymphoma incidence J:244082
increased hemangioma incidence J:244082
increased hemangiosarcoma incidence J:244082
increased hepatocellular carcinoma incidence J:244082
increased lung carcinoma incidence J:244082
increased lymphoma incidence J:244082
increased myeloid sarcoma incidence J:244082
increased plasmacytoma incidence J:244082
increased sarcoma incidence J:244082
increased T cell derived lymphoma incidence J:244082
Fen1tm1Rak/Fen1+
(involves: 129/Sv * C57BL/6 * SJL/J) 		increased B cell derived lymphoma incidence J:77962
Fen1tm1Rak/Fen1+
Apctm1Rak/Apc+
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * SJL/J) 		increased malignant tumor incidence J:77962
Fen1tm2Klng/Fen1tm2Klng
(involves: 129X1/SvJ * C57BL/6) 		increased B cell derived lymphoma incidence J:138901
increased lung adenoma incidence J:138901
increased sarcoma incidence J:138901
Fen1tm3.1Bhsh/Fen1+
(Not Specified) 		increased lung adenoma incidence J:231218
Fen1tm3.1Bhsh/Fen1tm3.1Bhsh
(Not Specified) 		increased lung adenocarcinoma incidence J:231218
increased lung adenoma incidence J:231218
Fgfr2tm1Dsn/Fgfr2tm1Dsn
Tg(KRT5-cre)5132Jlj/0
(involves: 129P2/OlaHsd * C57BL/6J * DBA/2J) 		increased skin papilloma incidence J:119723
Fgfr3tm4Cxd/Fgfr3+
Krastm4Tyj/Kras+
Tg(Upk2-cre)6Xrw/0
(involves: 129S4/SvJae * 129S6/SvEvTac * FVB/N) 		increased skin papilloma incidence J:174242
Fgfr4tm1Axul/Fgfr4+
Tg(WapTgfa)215Bri/0
(B6.Cg-Fgfr4tm1Axul Tg(WapTgfa)215Bri) 		increased mammary adenocarcinoma incidence J:156750
Fgfr4tm1Axul/Fgfr4tm1Axul
Tg(WapTgfa)215Bri/0
(B6.Cg-Fgfr4tm1Axul Tg(WapTgfa)215Bri) 		increased mammary adenocarcinoma incidence J:156750
Fgfr4tm1Axul/Fgfr4tm1Axul
Tg(WapTgfa)215Bri/0
(FVB.Cg-Fgfr4tm1Axul Tg(WapTgfa)215Bri) 		increased mammary adenocarcinoma incidence J:156750
Fhittm1Tko/Fhit+
(involves: 129X1/SvJ) 		increased B cell derived lymphoma incidence J:93269
increased lymphoma incidence J:93269
increased papilloma incidence J:93269
Fhittm1Tko/Fhittm1Tko
(involves: 129X1/SvJ) 		increased B cell derived lymphoma incidence J:93269
increased hepatocellular carcinoma incidence J:93269
increased lymphoma incidence J:93269
increased papilloma incidence J:93269
FlcnGt(RRX115)Byg/Flcn+
(involves: 129P2/OlaHsd * C57BL/6) 		increased lymphoma incidence J:147582
Flcntm1Btt/Flcntm1Btt
Tg(Cdh16-cre)91Igr/0
(involves: 129S4/SvJaeSor * C57BL/6 * ICR) 		increased renal carcinoma incidence J:143922
Fli1tm1Ber/Fli1+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1) 		increased leukemia incidence J:33052
Fli1tm1Ber/Fli1tm1Ber
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1) 		increased leukemia incidence J:33052
Flt3tm1Dgg/Flt3+
Kmt2atm1Clgr/Kmt2a+
(involves: 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6J) 		increased leukemia incidence J:189096
Flt3tm1Dgg/Flt3tm1Dgg
Kmt2atm1Clgr/Kmt2a+
(involves: 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6J) 		increased leukemia incidence J:189096
Flt3tm2.1Dosm/Flt3+
(B6.129(C)-Flt3tm2.1Dosm) 		increased B cell derived lymphoma incidence J:205200
increased hemangiosarcoma incidence J:205200
increased histiocytic sarcoma incidence J:205200
Flvcr2tm1a(EUCOMM)Hmgu/Flvcr2tm1a(EUCOMM)Hmgu
(C57BL/6N-Flvcr2tm1a(EUCOMM)Hmgu/Wtsi) 		increased hemangioma incidence J:239583
Fn1tm1Bwg/Fn1tm1Bwg
Tg(RIP1-Tag)2Dh/0
(involves: 129S4/SvJae * BALB/c * C57BL/6J) 		increased carcinoma incidence J:93027
Fn1tm1Ksek/Fn1tm1Ksek
Tg(RIP1-Tag)2Dh/0
(involves: 129S4/SvJae * C57BL/6J) 		increased carcinoma incidence J:93027
Fntbtm1.1Mbrg/Fntbtm1.2Mbrg
Krastm4Tyj/Kras+
Pggt1btm1Mbrg/Pggt1btm1.1Mbrg
(involves: 129P2/OlaHsd * 129S4/SvJae * BALB/cJ * C57BL/6 * FVB/N) 		increased lung adenoma incidence J:158937
increased lung carcinoma incidence J:158937
Fntbtm1Bbd/Fntbtm1Bbd
Krastm1Bbd/Kras+
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL) 		increased lung adenocarcinoma incidence J:98944
increased lung adenoma incidence J:98944
Foc1NFS/N/Foc1NFS/N
(involves: SL/Kh * NFS/N) 		increased B cell derived lymphoma incidence J:16441
Fostm1Wag/Fostm1Wag
Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * C57BL/6) 		increased rhabdomyosarcoma incidence J:89283
Fostm1Wag/Fostm1Wag
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6) 		increased rhabdomyosarcoma incidence J:89283
Foxa1tm1Khk/Foxa1tm1Khk
Foxa2tm1Khk/Foxa2tm1Khk
Tg(Alb1-cre)1Khk/0
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL) 		increased hepatocellular carcinoma incidence J:181296
Foxm1tm1Rhc/Foxm1tm1Rhc
(involves: 129X1/SvJ) 		increased hepatocellular carcinoma incidence J:89472
Foxm1tm1Rhc/Foxm1tm1Rhc
Tg(Tek-cre)1Ywa/0
(involves: 129X1/SvJ * C57BL/6 * SJL) 		increased lung adenoma incidence J:167773
Foxn1nu-str/Foxn1nu-str
(AKR/J-Foxn1nu-str/J) 		decreased lymphoma incidence J:30715
increased sarcoma incidence J:30715
Foxn1nu/Foxn1nu
(involves: BALB/c) 		increased plasmacytoma incidence J:40405
Foxo1tm1Rdp/Foxo1tm1Rdp
Foxo3tm1Rdp/Foxo3tm1Rdp
Foxo4tm1Rdp/Foxo4tm1Rdp
Tg(Mx1-cre)1Cgn/0
(involves: 129S6/SvEvTac * C57BL/6 * CBA * FVB/N) 		increased hamartoma incidence J:118179
increased hemangioma incidence J:118179
increased hemangiosarcoma incidence J:118179
increased T cell derived lymphoma incidence J:118179
Foxo1tm1Rdp/Foxo1tm1Rdp
Foxo3tm1Rdp/Foxo3tm1Rdp
Tg(Mx1-cre)1Cgn/0
(involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6 * CBA * FVB/N) 		increased hemangioma incidence J:118179
increased hemangiosarcoma incidence J:118179
increased hepatic hemangioma incidence J:118179
Foxo1tm1Rdp/Foxo1tm1Rdp
Foxo4tm1Rdp/Foxo4tm1Rdp
Tg(Mx1-cre)1Cgn/0
(involves: 129S6/SvEvTac * C57BL/6 * CBA * FVB/N) 		increased hamartoma incidence J:118179
increased hemangioma incidence J:118179
increased hemangiosarcoma incidence J:118179
increased hepatic hemangioma incidence J:118179
Foxo1tm1Rdp/Foxo1tm1Rdp
Tg(Mx1-cre)1Cgn/0
(involves: 129S1/Sv * C57BL/6 * CBA * FVB/N) 		increased hemangioma incidence J:118179
Foxo3mommeR1/Foxo3mommeR1
Tg(HBA1-GFP)1Ew/Tg(HBA1-GFP)1Ew
(FVB/NJ-Foxo3mommeR1 Tg(HBA1-Gfp)1Ew) 		increased ovarian teratoma incidence J:170710
Foxo3tm1.1Rdp/Foxo3+
Foxo4tm1.1Rdp/Foxo4tm1.1Rdp
(involves: 129S1/Sv * 129S6/SvEvTac * FVB/N) 		increased pituitary adenoma incidence J:118179
Foxo3tm1.1Rdp/Foxo3tm1.1Rdp
(involves: 129S6/SvEvTac * FVB/N) 		increased hemangiosarcoma incidence J:118179
increased prolactinoma incidence J:118179
Foxo3tm1.1Rdp/Foxo3tm1.1Rdp
Foxo4tm1.1Rdp/Foxo4tm1.1Rdp
(involves: 129S1/Sv * 129S6/SvEvTac * FVB/N) 		increased lung adenoma incidence J:118179
increased ovarian teratoma incidence J:118179
increased pituitary adenoma incidence J:118179
Foxq1sa/Foxq1sa
Lystbg/Lystbg
(involves: 101/Rl * C3H/Rl * C57BL/6J * C57BL10/Rl) 		increased lymphoma incidence J:5311
Fpr2tm1.2Jimw/Fpr2tm1.2Jimw
(involves: 129X1/SvJ) 		increased colon adenoma incidence J:197568
Fshrtm1Saco/Fshrtm1Saco
(involves: 129) 		increased ovarian carcinoma incidence J:70933
Fzr1tm1.1Mama/Fzr1+
(involves: BALB/cJ * C57BL/6 * SJL) 		increased mammary adenocarcinoma incidence J:137456
G6pc1tm1.1Ics/G6pc1tm1.1Ics
Albtm1(cre/ERT2)Mtz/Alb+
(involves: 129S2/SvPas * C57BL/6J) 		increased liver adenoma incidence J:195257
Gadd45atm1Ajf/Gadd45atm1Ajf
Xpctm1Ecf/Xpctm1Ecf
(either: (involves: 129/Sv * 129P2/OlaHsd * C57BL/6) or (involves: 129/Sv * 129X1/SvJ * C57BL/6)) 		increased lung adenocarcinoma incidence J:101421
increased lung adenoma incidence J:101421
Gcgrtm1Jcp/Gcgrtm1Jcp
(DBA/1LacJ-Gcgrtm1Jcp) 		increased glucagonoma incidence J:176507
Gfertm1.1Crg/Gfertm1.1Crg
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129 * C57BL/6 * DBA) 		increased hepatocellular carcinoma incidence J:227242
Gli1tm3(cre/ERT2)Alj/Gli1+
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sortm1(Smo/EYFP)Amc
(involves: 129S6/SvEvTac * 129X1/SvJ) 		increased medulloblastoma incidence J:139574
Gnai2tm1Lbi/Gnai2tm1Lbi
(involves: 129S7/SvEvBrd * C57BL/6J) 		increased intestinal adenocarcinoma incidence J:24434
Gnai2tm1Lbi/Gnai2tm1Lbi
(involves: 129S7/SvEvBrd) 		increased intestinal adenocarcinoma incidence J:24434
Gnmttm1Ymac/Gnmttm1Ymac
(involves: 129 * C57BL/6) 		increased hepatic hemangioma incidence J:146081
increased hepatocellular carcinoma incidence J:146081
Gon4ljusty/Gon4ljusty
(C3HeB/FeJ-Gon4ljusty) 		increased salivary adenocarcinoma incidence J:197352
Gpr37l1tm1.2Gtva/Gpr37l1tm1.2Gtva
Ptch1tm1Zim/Ptch1+
(STOCK Gpr37l1tm1.2Gtva Ptch1tm1Zim/Cnrm) 		increased medulloblastoma incidence J:272049
Gprc5atm1Rlo/Gprc5atm1Rlo
(involves: 129 * C57BL/6) 		increased lung adenocarcinoma incidence J:127821
increased lung adenoma incidence J:127821
Gpx7tm1Whle/Gpx7tm1Whle
(involves: 129P2/OlaHsd * C57BL/6) 		increased leukemia incidence J:193993
increased lung adenocarcinoma incidence J:193993
increased lymphoma incidence J:193993
increased mammary adenocarcinoma incidence J:193993
increased sarcoma incidence J:193993
Grb2tm1Paw/Grb2+
Ptentm1Mak/Pten+
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6) 		increased endometrial carcinoma incidence J:93530
increased lymphoma incidence J:93530
Grb2tm1Paw/Grb2+
Ptentm2Mak/Ptentm2Mak
Tg(Lck-cre)548Jxm/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA) 		increased T cell derived lymphoma incidence J:93530
Grb2tm1Paw/Grb2+
Tg(MMTV-PyVT)634Mul/?
(involves: 129S1/Sv * 129X1/SvJ * FVB/N) 		increased mammary adenocarcinoma incidence J:51424
Grhl3tm1Jane/Grhl3+
Ptentm1Mak/Pten+
(involves: 129P2/OlaHsd * 129S1/Sv) 		increased skin papilloma incidence J:178952
increased skin squamous cell carcinoma incidence J:178952
Grhl3tm1Jane/Grhl3tm3.1Jane
Tg(KRT14-cre)8Brn/0
(involves: 129S1/Sv * C57BL/6 * FVB/N) 		increased skin papilloma incidence J:178952
increased skin squamous cell carcinoma incidence J:178952
Grm1Tg(p18A4.B)1352Szc/0
(Not Specified) 		increased cutaneous melanoma incidence J:83183, J:32786
Gstp1/Gstp2tm1Wolf/Gstp1/Gstp2tm1Wolf
(involves: 129P2/OlaHsd * MF1) 		increased skin papilloma incidence J:47638
Gstp1/Gstp2tm1Wolf/Gstp1/Gstp2tm1Wolf
(involves: 129P2/OlaHsd * MF1) 		increased skin papilloma incidence J:47638
Gt(ROSA)26Sortm1(CAG-AR)Zsu/Gt(ROSA)26Sor+
Tg(Osr1-cre)4Mrt/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * FVB/N) 		increased malignant tumor incidence J:234601
increased prostate gland adenocarcinoma incidence J:234601
Gt(ROSA)26Sortm1(CAG-AR)Zsu/Gt(ROSA)26Sortm1(CAG-AR)Zsu
Tg(Osr1-cre)4Mrt/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * FVB/N) 		increased prostate gland adenocarcinoma incidence J:234601
Gt(ROSA)26Sortm1(CAG-Bmi1,-EGFP)Nki/Gt(ROSA)26Sor+
Ptentm1Mro/Pten+
Tg(Pbsn-cre)4Prb/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N) 		increased prostate gland adenocarcinoma incidence J:184533
Gt(ROSA)26Sortm1(CAG-Bmi1,-EGFP)Nki/Gt(ROSA)26Sor+
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(Gfap-cre)2Brn/0
(either: (involves: 129 * 129P2/OlaHsd * FVB/N) or (involves: 129 * 129P2/OlaHsd * C57BL/6 * FVB/N)) 		increased carcinoma incidence J:187257
increased medulloblastoma incidence J:187257
Gt(ROSA)26Sortm1(CAG-Errfi1)Jwj/?
Pgrtm2(cre)Lyd/Pgr+
Ptentm1Hwu/Ptentm1Hwu
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6) 		increased papilloma incidence J:218222
Gt(ROSA)26Sortm1(CAG-MYCN,-luc)Jhsc/Gt(ROSA)26Sor+
Tg(Dbh-icre)1Gsc/0
(involves: 129S6/SvEvTac * C57BL/6) 		increased neuroblastoma incidence J:222527
Gt(ROSA)26Sortm1(CAG-PIK3CA*H1047R,-EGFP)Balj/Gt(ROSA)26Sor+
Tg(MMTV-cre)7Mul/0
(involves: BALB/c * FVB/N) 		increased mammary adenocarcinoma incidence J:173655
Gt(ROSA)26Sortm1(CAG-PIK3CA*H1047R,-EGFP)Balj/Gt(ROSA)26Sor+
Tg(Wap-cre)1Gsc/0
(involves: BALB/c * C57BL/6 * FVB/N) 		increased mammary adenocarcinoma incidence J:173655
Gt(ROSA)26Sortm1(CAG-Sox2,-EGFP)Blh/Gt(ROSA)26Sor+
Tg(Sftpc-cre)1Blh/0
(involves: 129S/SvEv * C57BL/6 * DBA/2) 		increased lung adenocarcinoma incidence J:161806
Gt(ROSA)26Sortm1(CAG-Sox2,-EGFP)Blh/Gt(ROSA)26Sortm1(CAG-Sox2,-EGFP)Blh
Scgb1a1tm1(cre/ERT)Blh/Scgb1a1+
(involves: 129S6/SvEv * C57BL/6) 		increased lung adenocarcinoma incidence J:161806
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
Tacc3tm1.1Tno/Tacc3+
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6) 		increased T cell derived lymphoma incidence J:179414
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
Tacc3tm1.1Tno/Tacc3tm1.2Tno
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6) 		decreased lymphoma incidence J:179414
increased T cell derived lymphoma incidence J:179414
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+
Pdgfratm12Sor/Pdgfra+
(involves: 129 * C57BL/6) 		increased sarcoma incidence J:146617
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+
Ptentm1Hwu/Ptentm1Hwu
(involves: 129 * 129S4/SvJae * BALB/c * C57BL/6) 		increased skin squamous cell carcinoma incidence J:130367
increased T cell derived lymphoma incidence J:130367
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sortm3(SS18/EGFP)Mrc
(involves: 129 * 129S1/Sv * 129X1/SvJ) 		increased sarcoma incidence J:147728
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sortm4(EWSR1/ATF1)Mrc
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6) 		increased sarcoma incidence J:217462
Gt(ROSA)26Sortm1(EWSR1/FLI1)Sbk/Gt(ROSA)26Sor+
Tg(Mx1-cre)1Cgn/?
(involves: 129S1/Sv * C57BL/6 * CBA) 		increased leukemia incidence J:129039
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Ighg1tm1(cre)Cgn/Ighg1+
Prdm1tm2Masu/Prdm1tm2Masu
(involves: 129P2/OlaHsd * 129X1/SvJ) 		increased B cell derived lymphoma incidence J:167612
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm1Brn/Trp53+
(involves: 129P2/OlaHsd * 129S4/SvJae * 129X1/SvJ * FVB/N) 		increased pancreatic ductal adenocarcinoma incidence J:280854
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)89.1Dam/0
Trp53tm1Brn/Trp53+
(involves: 129 * C57BL/6 * CBA) 		increased pancreatic ductal adenocarcinoma incidence J:289183
Gt(ROSA)26Sortm1(GNAQ*)Cvrk/Gt(ROSA)26Sor+
Tg(Mitf-cre)7114Gsb/0
(C3FeJ.Cg-Gt(ROSA)26Sortm1(GNAQ*)Cvkr Tg(Mitf-cre)7114Gsb/Cvrk) 		increased intraocular melanoma incidence J:225597
Gt(ROSA)26Sortm1(gp80,EGFP)Eces/Gt(ROSA)26Sor+
Cd19tm1(cre)Cgn/Cd19+
(either: (involves: 129/Sv * 129P2/OlaHsd * C57BL/6) or (involves: 129/Sv * 129P2/OlaHsd * BALB/c * C57BL/6)) 		increased histiocytic sarcoma incidence J:172031
increased sarcoma incidence J:172031
Gt(ROSA)26Sortm1(gp80,EGFP)Eces/Gt(ROSA)26Sor+
Ighg1tm1(cre)Cgn/Ighg1+
(either: (involves: 129/Sv * 129P2/OlaHsd * C57BL/6) or (involves: 129/Sv * 129P2/OlaHsd * BALB/c * C57BL/6)) 		increased histiocytic sarcoma incidence J:172031
increased sarcoma incidence J:172031
Gt(ROSA)26Sortm1(H1/tetO-RNAi:Pdpk1)Mrl/Gt(ROSA)26Sor+
Ptentm1.1Hwu/Pten+
(involves: 129S4/SvJae * C57BL/6NTac) 		increased lymphoma incidence J:170965
increased thyroid adenoma incidence J:170965
Gt(ROSA)26Sortm1(H1/tetO-RNAi:Pdpk1)Mrl/Gt(ROSA)26Sortm9(cre/ESR1)Arte
Ptentm1Hwu/Ptentm1Hwu
(involves: 129S4/SvJae * C57BL/6) 		increased acute lymphoblastic leukemia incidence J:170965
Gt(ROSA)26Sortm1(ITK/SYK)Jrld/Gt(ROSA)26Sor+
Tg(Cd4-cre)1Cwi/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2) 		increased T cell derived lymphoma incidence J:160931
Gt(ROSA)26Sortm1(JAG1)Xin/Gt(ROSA)26Sor+
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)20Fwan/?
(involves: 129S4/SvJae * C57BL/6 * FVB/NCrl) 		increased prostate gland adenocarcinoma incidence J:238768
Gt(ROSA)26Sortm1(MAML1)Wsp/Gt(ROSA)26Sor+
Tg(Tagln-cre)1Jjl/0
(involves: CD-1 * FVB/N) 		increased squamous cell carcinoma incidence J:112093
Gt(ROSA)26Sortm1(MYC/ERT2)Gev/Gt(ROSA)26Sortm1(MYC/ERT2)Gev
Krastm4Tyj/Krastm4Tyj
(involves: 129S4/SvJae * C57BL/6 * FVB/N) 		increased lung adenoma incidence J:142030
Gt(ROSA)26Sortm1(Notch1)Dam/Gt(ROSA)26Sor+
Hes1tm1.1Frad/Hes1tm1.1Frad
Tg(Mx1-cre)1Cgn/0
(involves: 129S4/SvJaeSor * C57BL/6 * CBA) 		decreased lymphoma incidence J:167000
Gt(ROSA)26Sortm1(Notch1)Dam/Gt(ROSA)26Sor+
Ptentm1Hwu/Ptentm1Hwu
Tg(Adipoq-cre)1Evdr/0
(involves: 129S4/SvJae * 129S4/SvJaeSor * C57BL/6J * FVB/NJ) 		increased liposarcoma incidence J:237232
Gt(ROSA)26Sortm1(Notch1)Dam/Gt(ROSA)26Sor+
Tg(Adipoq-cre)1Evdr/0
(involves: 129S4/SvJaeSor * C57BL/6J * FVB/NJ) 		increased liposarcoma incidence J:237232
Gt(ROSA)26Sortm1(Notch1)Dam/Gt(ROSA)26Sor+
Tg(Mx1-cre)1Cgn/0
(involves: 129S4/SvJaeSor * C57BL/6 * CBA) 		increased leukemia incidence J:167000
Gt(ROSA)26Sortm1(NOTCH1/GFP)Xhsu/Gt(ROSA)26Sor+
Tg(Lck-cre)548Jxm/0
(B6.Cg-Gt(ROSA)26Sortm1(NOTCH1/GFP)Xhsu Tg(Lck-cre)548Jxm) 		increased T cell derived lymphoma incidence J:185287
Gt(ROSA)26Sortm1(pb)Peli/Gt(ROSA)26Sor+
TgTn(pb-sb-ATP1)S1Brd/0
(involves: 129S7/SvEvBrd * FVB) 		increased carcinoma incidence J:166063
increased sarcoma incidence J:166063
Gt(ROSA)26Sortm1(pb)Peli/Gt(ROSA)26Sor+
TgTn(pb-sb-ATP1)S2Brd/0
(involves: 129S7/SvEvBrd * FVB) 		increased carcinoma incidence J:166063
increased sarcoma incidence J:166063
Gt(ROSA)26Sortm1(pb)Peli/Gt(ROSA)26Sor+
TgTn(pb-sb-ATP2)H27Brd/0
(involves: 129S7/SvEvBrd * C57BL/6) 		increased leukemia incidence J:166063
increased lymphoma incidence J:166063
Gt(ROSA)26Sortm1(pb)Peli/Gt(ROSA)26Sor+
TgTn(pb-sb-ATP2)H32Brd/0
(involves: 129S7/SvEvBrd * C57BL/6) 		increased leukemia incidence J:166063
increased lymphoma incidence J:166063
Gt(ROSA)26Sortm1(pb)Peli/Gt(ROSA)26Sor+
TgTn(pb-sb-ATP2)S1Brd/0
(involves: 129S7/SvEvBrd * FVB) 		increased leukemia incidence J:166063
increased lymphoma incidence J:166063
Gt(ROSA)26Sortm1(pb)Peli/Gt(ROSA)26Sor+
TgTn(pb-sb-ATP2)S2Brd/0
(involves: 129S7/SvEvBrd * FVB) 		increased leukemia incidence J:166063
increased lymphoma incidence J:166063
Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+
Tg(MMTV-cre)#Tfln/0
(involves: 129S6/SvEvTac) 		increased mammary adenocarcinoma incidence J:170898
Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+
Tg(MMTV-cre)#Tfln/0
Trp53tm1Brn/Trp53+
(involves: 129P2/OlaHsd * 129S6/SvEvTac) 		increased lymphoma incidence J:170898
increased mammary adenocarcinoma incidence J:170898
increased T cell derived lymphoma incidence J:170898
Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+
Trp53tm1Brn/Trp53tm1Brn
Tg(MMTV-cre)#Tfln/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac) 		increased lymphoma incidence J:170898
increased T cell derived lymphoma incidence J:170898
Gt(ROSA)26Sortm1(RAC1*)Jkis/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
(involves: 129S4/SvJae) 		increased lung adenocarcinoma incidence J:187582
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Ptf1atm1.1(cre)Cvw/Ptf1a+
Tg(tetO-Kras2)12Hev/0
Trp53tm1Tyj/Trp53+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * FVB/N) 		increased pancreatic ductal adenocarcinoma incidence J:184378
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Ptf1atm1.1(cre)Cvw/Ptf1a+
Tg(tetO-Kras*G12D)#Rdp/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N) 		increased pancreatic ductal adenocarcinoma incidence J:186194
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Ptf1atm1.1(cre)Cvw/Ptf1a+
Tg(tetO-Kras*G12D)#Rdp/0
Trp53tm1Brn/Trp53+
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N) 		increased pancreatic ductal adenocarcinoma incidence J:186194
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Ptf1atm1.1(cre)Cvw/Ptf1a+
Tg(tetO-Kras*G12D)#Rdp/0
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S/Sv * 129X1/SvJ * C57BL/6 * FVB/N) 		increased pancreatic ductal adenocarcinoma incidence J:186194
Gt(ROSA)26Sortm1(sb11)Njen/Gt(ROSA)26Sor+
Hprt1tm1(sb-Onco-Array)Peli/Y
(involves: 129S7/SvEvBrd) 		increased hemangioma incidence J:166283
increased hemangiosarcoma incidence J:166283
increased lung adenocarcinoma incidence J:166283
increased lung adenoma incidence J:166283
increased lymphoma incidence J:166283
increased medulloblastoma incidence J:166283
increased rhabdomyosarcoma incidence J:166283
increased skin squamous cell carcinoma incidence J:166283
Gt(ROSA)26Sortm1(sb11)Njen/Gt(ROSA)26Sor+
Hprt1tm1(sb-Onco-Array)Peli/Hprt1+
(involves: 129S7/SvEvBrd) 		increased hemangioma incidence J:166283
increased hemangiosarcoma incidence J:166283
increased lung adenocarcinoma incidence J:166283
increased lung adenoma incidence J:166283
increased lymphoma incidence J:166283
increased medulloblastoma incidence J:166283
increased rhabdomyosarcoma incidence J:166283
increased skin squamous cell carcinoma incidence J:166283
Gt(ROSA)26Sortm1(sb11)Njen/Gt(ROSA)26Sor+
TgTn(sb-T2/Onc2)6057Njen/0
(involves: C3H * C57BL/6) 		increased B cell derived lymphoma incidence J:102234
increased lymphoma incidence J:102234
increased medulloblastoma incidence J:102234
increased T cell derived lymphoma incidence J:102234
Gt(ROSA)26Sortm1(sb11)Njen/Gt(ROSA)26Sor+
TgTn(sb-T2/Onc2)6070Njen/0
(involves: C3H * C57BL/6) 		increased B cell derived lymphoma incidence J:102234
increased lymphoma incidence J:102234
increased medulloblastoma incidence J:102234
increased T cell derived lymphoma incidence J:102234
Gt(ROSA)26Sortm1(sb11)Njen/Gt(ROSA)26Sor+
TgTn(sb-T2/Onc2)6113Njen/0
(involves: C3H * C57BL/6) 		increased B cell derived lymphoma incidence J:102234
increased lymphoma incidence J:102234
increased T cell derived lymphoma incidence J:102234
Gt(ROSA)26Sortm1(sb11)Njen/Gt(ROSA)26Sor+
TgTn(sb-T2/Onc3)12740Njen/0
(involves: C3H * C57BL/6J) 		increased adenoma incidence J:153656
increased B cell derived lymphoma incidence J:153656
increased basal cell carcinoma incidence J:153656
increased blastoma incidence J:153656
increased carcinoma incidence J:153656
increased hemangioma incidence J:153656
increased hemangiosarcoma incidence J:153656
increased hepatocellular carcinoma incidence J:153656
increased liver adenoma incidence J:153656
increased lung carcinoma incidence J:153656
increased lymphoma incidence J:153656
increased melanoma incidence J:153656
increased sarcoma incidence J:153656
increased skin squamous cell carcinoma incidence J:153656
increased squamous cell carcinoma incidence J:153656
increased T cell derived lymphoma incidence J:153656
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/?
Tg(CAG-cre/Esr1*)5Amc/?
(involves: 129X1/SvJ * C57BL/6 * CBA) 		increased basal cell carcinoma incidence J:114992
increased medulloblastoma incidence J:114992
increased rhabdomyosarcoma incidence J:114992
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sor+
Hk2tm1.1Uku/Hk2+
Tg(GFAP-cre)25Mes/0
(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * FVB/N) 		increased medulloblastoma incidence J:210113
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sor+
Hk2tm1.1Uku/Hk2tm1.1Uku
Tg(GFAP-cre)25Mes/0
(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * FVB/N) 		increased medulloblastoma incidence J:210113
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sortm1(Smo/EYFP)Amc
Olig2tm2(TVA,cre)Rth/Olig2+
(involves: 129 * 129X1/SvJ) 		increased medulloblastoma incidence J:139574
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sortm1(Smo/EYFP)Amc
Tg(Atoh1-cre/Esr1*)14Fsh/0
(involves: 129X1/SvJ * FVB/N) 		increased medulloblastoma incidence J:139574
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sortm1(Smo/EYFP)Amc
Tg(GFAP-cre)25Mes/0
(involves: 129X1/SvJ * FVB/N) 		increased medulloblastoma incidence J:139574
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sortm1(Smo/EYFP)Amc
Tg(Krt1-5-cre/ERT)1Ipc/0
(involves: 129X1/SvJ * C57BL/6 * SJL) 		increased basal cell carcinoma incidence J:158915
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sortm1(Smo/EYFP)Amc
Tlx3tm1(cre)Qima/Tlx3+
(involves: 129X1/SvJ) 		increased medulloblastoma incidence J:139574
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sortm2(EGFP/cre)Alj
Pgbd5tm1.1Aken/Pgbd5tm1.1Aken
(involves: 129 * C57BL/6J * C57BL/6NTac * SW) 		increased medulloblastoma incidence J:346387
Gt(ROSA)26Sortm1(SPOP*F133V)Mrbn/Gt(ROSA)26Sor+
Ptentm2.1Ppp/Pten+
Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * C57BL/6 * DBA/2) 		increased prostate gland adenocarcinoma incidence J:239660
Gt(ROSA)26Sortm1(SPOP*F133V)Mrbn/Gt(ROSA)26Sor+
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * C57BL/6 * DBA/2) 		increased prostate gland adenocarcinoma incidence J:239660
Gt(ROSA)26Sortm1(TMPRSS2/ERG)Key/Gt(ROSA)26Sortm1(TMPRSS2/ERG)Key
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * C57BL/6 * DBA/2) 		increased prostate gland adenocarcinoma incidence J:200002
Gt(ROSA)26Sortm1(tTA,tetO-Mir21)Fjsl/Gt(ROSA)26Sor+
Tg(Nes-cre)1Wmz/0
(involves: C57BL/6 * C57BL/6J * SJL/J) 		increased lymphoma incidence J:163919
Gt(ROSA)26Sortm1(tTA,tetO-Mir155)Fjsl/Gt(ROSA)26Sor+
Tg(Nes-cre)1Wmz/0
(involves: 129 * C57BL/6 * FVB/N * SJL/J) 		increased B cell derived lymphoma incidence J:185598
Gt(ROSA)26Sortm1(Tva)Dsa/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Ptf1atm1(cre)Hnak/Ptf1a+
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6J) 		increased pancreatic ductal adenocarcinoma incidence J:140423
Gt(ROSA)26Sortm1(Tva)Dsa/Gt(ROSA)26Sor+
Ptf1atm1(cre)Hnak/Ptf1a+
(involves: 129S6/SvEvTac * C57BL/6J) 		increased pancreatic ductal adenocarcinoma incidence J:140423
Gt(ROSA)26Sortm1.1(rtTA2S*M2)Whsu/Gt(ROSA)26Sor+
Ncstntm1.1Akli/Ncstntm1.1Akli
Tg(tetO-cre)1Jaw/0
(involves: 129 * 129S6/SvEvTac * C57BL/6) 		increased urinary bladder carcinoma incidence J:227748
Gt(ROSA)26Sortm1Jus/Gt(ROSA)26Sor+
Tg(MMTV-cre)4Mam/0
(involves: C57BL/6J * C57BL/6N * FVB/N) 		increased acute lymphoblastic leukemia incidence J:202090
Gt(ROSA)26Sortm1Jus/Gt(ROSA)26Sor+
Tg(Mx1-cre)1Cgn/0
(involves: C57BL/6 * C57BL/6J * C57BL/6N * CBA) 		increased acute lymphoblastic leukemia incidence J:202090
Gt(ROSA)26Sortm2(CAG-Lin28b,-luc)Jhsc/Gt(ROSA)26Sor+
Tg(Dbh-icre)1Gsc/0
(involves: 129S6/SvEvTac * 129X1/SvJ * C57BL/6) 		increased neuroblastoma incidence J:241988
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
Tg(GFP/KRAS2/ALPP)1Brn/0
(involves: 129P2/OlaHsd * FVB/N) 		increased lymphoma incidence J:127226
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
Tg(RasE)290Biat/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2) 		increased lung adenocarcinoma incidence J:226601
increased pancreatic ductal adenocarcinoma incidence J:226601
Gt(ROSA)26Sortm2(Lmp1/CD40)Uzs/Gt(ROSA)26Sor+
Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * BALB/c * C57BL/6) 		increased B cell derived lymphoma incidence J:137122
Gt(ROSA)26Sortm2(myc*T58A)Rcse/Gt(ROSA)26Sortm2(myc*T58A)Rcse
Tg(Wap-cre)11738Mam/0
(involves: 129 * C57BL/6 * SJL) 		increased mammary adenocarcinoma incidence J:169403
Gt(ROSA)26Sortm2(Pik3ca*)Dsa/Gt(ROSA)26Sor+
Ptf1atm1(cre)Hnak/Ptf1a+
(involves: 129S6/SvEvTac) 		increased carcinoma incidence J:197054
increased pancreatic ductal adenocarcinoma incidence J:197054
Gt(ROSA)26Sortm2(sb11)Njen/Gt(ROSA)26Sor+
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
TgTn(sb-T2/Onc)68Dla/0
(involves: C57BL/6 * DBA/2 * FVB/N) 		increased hepatocellular carcinoma incidence J:147264
increased liver adenoma incidence J:147264
Gt(ROSA)26Sortm2(sb11)Njen/Gt(ROSA)26Sor+
Tg(Vil1-cre)20Syr/0
TgTn(sb-T2/Onc)68Dla/0
(involves: C57BL/6 * DBA/2 * FVB/N) 		increased intestinal adenoma incidence J:146887
increased small intestine adenocarcinoma incidence J:146887
Gt(ROSA)26Sortm2(sb11)Njen/Gt(ROSA)26Sor+
Tg(Vil1-cre)20Syr/0
TgTn(sb-T2/Onc)76Dla/0
(involves: C57BL/6 * DBA/2 * FVB/N) 		increased intestinal adenoma incidence J:146887
increased small intestine adenocarcinoma incidence J:146887
Gt(ROSA)26Sortm2(sb11)Njen/Gt(ROSA)26Sor+
Trp53tm3Tyj/Trp53+
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
TgTn(sb-T2/Onc)68Dla/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2 * FVB/N) 		increased hepatocellular carcinoma incidence J:147264
increased liver adenoma incidence J:147264
Gt(ROSA)26Sortm2(SS18)Mrc/Gt(ROSA)26Sortm2(SS18)Mrc
Myf5tm1(cre)Mrc/Myf5tm1(cre)Mrc
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6) 		increased sarcoma incidence J:120967
Gt(ROSA)26Sortm2.1(sb11)Njen/Gt(ROSA)26Sor+
TgTn(sb-T2/Onc2)6070Njen/0
(involves: 129 * C57BL/6 * C57BL/6J) 		increased leukemia incidence J:153656
increased T cell derived lymphoma incidence J:153656
Gt(ROSA)26Sortm2Thl/Gt(ROSA)26Sor+
Ptentm1Hwu/Ptentm1Hwu
Trp53tm1Thl/Trp53tm1Thl
Tyrc-Brd/Tyrc-Brd
(involves: 129/Sv * 129S4/SvJae * C57BL/6) 		increased glioblastoma incidence J:172585
Gt(ROSA)26Sortm2Thl/Gt(ROSA)26Sor+
Ptentm1Hwu/Ptentm1Hwu
Tyrc-Brd/Tyrc-Brd
(involves: 129/Sv * 129S4/SvJae * C57BL/6) 		increased glioblastoma incidence J:172585
Gt(ROSA)26Sortm3(SS18/EGFP)Mrc/Gt(ROSA)26Sortm3(SS18/EGFP)Mrc
Myf5tm1(cre)Mrc/Myf5tm1(cre)Mrc
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6) 		increased sarcoma incidence J:120967
Gt(ROSA)26Sortm4(CAG-hsb5)Nki/Gt(ROSA)26Sor+
Npm1tm1Gsva/Npm1+
TgTn(pb-sb-GrOnc)#aGsva/0
Tg(Mx1-cre)1Cgn/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA) 		increased acute promyelocytic leukemia incidence J:172071
increased B cell derived lymphoma incidence J:172071
increased hemangiosarcoma incidence J:172071
increased leukemia incidence J:172071
increased lymphoma incidence J:172071
Gt(ROSA)26Sortm4(CAG-hsb5)Nki/Gt(ROSA)26Sor+
Tg(Mx1-cre)1Cgn/0
Tg(Tal1-tTA)19Dgt/0
Tg(tetO-BCR/ABL1)2Dgt/0
TgTn(pb-sb-GrOnc)#aGsva/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA/J * DBA/2 * FVB/N) 		increased chronic myelocytic leukemia incidence J:227558
Gt(ROSA)26Sortm4(CAG-hsb5)Nki/Gt(ROSA)26Sor+
Tg(Mx1-cre)1Cgn/0
Tg(tetO-BCR/ABL1)2Dgt/0
TgTn(pb-sb-GrOnc)#aGsva/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA/J * FVB/N) 		increased leukemia incidence J:227558
Gt(ROSA)26Sortm4(Ikbkb)Rsky/Gt(ROSA)26Sor+
Ighg1tm1(cre)Cgn/Ighg1+
Prdm1tm2Masu/Prdm1tm2Masu
(involves: 129P2/OlaHsd * C57BL/6) 		increased B cell derived lymphoma incidence J:167612
Gt(ROSA)26Sortm5(ASPSCR1/TFE3)Mrc/Gt(ROSA)26Sortm1(cre/ERT)Nat
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6) 		increased sarcoma incidence J:217462
Gt(ROSA)26Sortm7(Pik3ca*,EGFP)Rsky/Gt(ROSA)26Sor+
Tg(CAG-cre/Esr1*)5Amc/0
(B6.Cg-Gt(ROSA)26Sortm7(Pik3ca*,EGFP)Rsky Tg(CAG-cre/Esr1*)5Amc) 		increased classified tumor incidence J:264410
Gt(ROSA)26Sortm7(Pik3ca*,EGFP)Rsky/Gt(ROSA)26Sortm13(CAG-MYC,-CD2*)Rsky
Ighg1tm1(cre)Cgn/Ighg1+
(involves: 129P2/OlaHsd * C57BL/6) 		increased B cell derived lymphoma incidence J:191824
Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
Hmga2tm1.1Mmw/Hmga2+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm2Tyj/Trp53+
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * C57BL/6NCrl * FVB/N) 		increased pancreatic ductal adenocarcinoma incidence J:245611
Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Prdm1tm1Clme/Prdm1tm1Clme
Tg(Pdx1-cre)6Tuv/0
Trp53tm2Tyj/Trp53+
(involves: 129 * C57BL/6NCrl * FVB/N) 		increased pancreatic ductal adenocarcinoma incidence J:245611
Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm2Tyj/Trp53+
(involves: 129 * C57BL/6NCrl * FVB/N) 		increased pancreatic ductal adenocarcinoma incidence J:245611
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Ptentm1Hwu/Ptentm1Hwu
(involves: 129S4/SvJae * C57BL/6) 		increased acute lymphoblastic leukemia incidence J:170965
Gt(ROSA)26Sortm10(Lmp1)Rsky/Gt(ROSA)26Sor+
Tcrbtm1Mom/Tcrbtm1Mom
Tcrdtm1Mom/Tcrdtm1Mom
Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * 129S2/SvPas * BALB/cJ) 		increased B cell derived lymphoma incidence J:181546
increased plasmacytoma incidence J:181546
Gt(ROSA)26Sortm11(Lmp1)Rsky/Gt(ROSA)26Sor+
Tcrbtm1Mom/Tcrbtm1Mom
Tcrdtm1Mom/Tcrdtm1Mom
Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6) 		increased B cell derived lymphoma incidence J:181546
increased plasmacytoma incidence J:181546
Gt(ROSA)26Sortm18(Zeb2)Jhai/Gt(ROSA)26Sor+
Tg(Tek-cre)1Ywa/0
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * C57BL/6 * CD-1 * SJL) 		increased T cell derived lymphoma incidence J:263520
Gt(ROSA)26Sortm18(Zeb2)Jhai/Gt(ROSA)26Sortm18(Zeb2)Jhai
Tg(Cd4-cre)1Cwi/0
(involves: C57BL/6 * CD-1 * DBA/2) 		increased T cell acute lymphoblastic leukemia incidence J:263520
Gt(ROSA)26Sortm18(Zeb2)Jhai/Gt(ROSA)26Sortm18(Zeb2)Jhai
Tg(Tek-cre)1Ywa/0
(involves: C57BL/6 * CD-1 * SJL) 		increased T cell acute lymphoblastic leukemia incidence J:263520
Gt(ROSA)26Sortm18(Zeb2)Jhai/Gt(ROSA)26Sortm18(Zeb2)Jhai
Tg(Tek-cre)1Ywa/0
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * C57BL/6 * CD-1 * SJL) 		increased leukemia incidence J:263520
increased T cell derived lymphoma incidence J:263520
Gtf2ird1Tg(Alb1-Myc)166.8Sst/0
Tg(MtTGFA)42Lmb/0
(involves: C57BL/6 * CBA * CD-1) 		increased hepatocellular carcinoma incidence J:4527
Gtf2ird1Tg(Alb1-Myc)166.8Sst/Gtf2ird1+
(involves: C57BL/6 * CBA) 		increased hepatocellular carcinoma incidence J:34434, J:101128
increased liver adenoma incidence J:34434
Gtf2ird1Tg(Alb1-Myc)166.8Sst/Gtf2ird1+
Tg(Alb-E2F1)8Sst/0
(involves: C57BL/6 * CBA) 		increased hepatocellular carcinoma incidence J:101128
Gtf2ird1Tg(Alb1-Myc)166.8Sst/Gtf2ird1+
Tg(MtTGFA)42Lmb/0
(involves: C57BL/6 * CBA * CD-1) 		increased hepatocellular carcinoma incidence J:34434
increased liver adenoma incidence J:34434
H2u/H2u
Tg(TCRA)B1Jg/0
(B10.PL-H2u H2-T18a/(73NS)Sn-Tg(TCRA)B1Jg/J) 		increased T cell derived lymphoma incidence J:92992
H2u/H2u
Tg(TCRA)B1Jg/0
Tg(TCRB)C14Jg/0
(B10.PL-H2u H2-T18a/(73NS)Sn-Tg(TCRA)B1Jg Tg(TCRB)C14Jg) 		increased T cell derived lymphoma incidence J:92992
H2axtm1Fwa/H2ax+
Trp53tm1Brd/Trp53tm1Brd
(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6) 		increased B cell derived lymphoma incidence J:84879
increased lymphoma incidence J:84879
increased sarcoma incidence J:84879
increased T cell derived lymphoma incidence J:84879
increased teratoma incidence J:84879
H2axtm1Fwa/H2axtm1Fwa
(involves: 129S6/SvEvTac) 		increased T cell derived lymphoma incidence J:84879
H2axtm1Fwa/H2axtm1Fwa
Trp53tm1Brd/Trp53tm1Brd
(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6) 		increased B cell derived lymphoma incidence J:84879
increased colon adenocarcinoma incidence J:84879
increased sarcoma incidence J:84879
increased T cell derived lymphoma incidence J:84879
H2axtm1Nus/H2axtm1Nus
Trp53tm1Brd/Trp53tm1Brd
(involves: 129S7/SvEvBrd * C57BL/6J) 		increased lymphoma incidence J:86590
Hace1tm1Pngr/Hace1tm1Pngr
(involves: 129P2/OlaHsd * C57BL/6) 		increased T cell derived lymphoma incidence J:125183
Hat1tm1.1Mrpa/Hat1+
(B6.Cg-Hat1tm1.1Mrpa) 		increased histiocytic sarcoma incidence J:296531
Hcktm1Ern/Hcktm1Ern
(involves: 129S1/Sv * C57BL/6) 		increased lung adenocarcinoma incidence J:111432
Hdac1tm1.1Shmc/Hdac1tm1.1Shmc
Hdac2tm1.1Shmc/Hdac2tm1.1Shmc
Tg(Lck-cre)1Cwi/0
(involves: 129S7/SvEvBrd) 		increased T cell derived lymphoma incidence J:194769
HelqGt(RRF112)Byg/Helq+
(involves: 129P2/OlaHsd * C57BL/6) 		increased intestinal adenoma incidence J:206104
increased pituitary adenoma incidence J:206104
HelqGt(RRF112)Byg/HelqGt(RRF112)Byg
(involves: 129P2/OlaHsd * C57BL/6) 		increased pituitary adenoma incidence J:206104
Hephl1cw/Hephl1cw
(CWD/LeJ) 		increased B cell derived lymphoma incidence J:24875
increased lymphoma incidence J:24875
Hic1tm1Sbb/Hic1+
(involves: 129S4/SvJae * C57BL/6) 		increased carcinoma incidence J:81448
increased hepatocellular carcinoma incidence J:81448
increased lung adenocarcinoma incidence J:81448
increased lymphoma incidence J:81448
increased malignant tumor incidence J:81448
increased pancreatic islet cell carcinoma incidence J:81448
increased sarcoma incidence J:81448
increased squamous cell carcinoma incidence J:81448
Hif1atm3Rsjo/Hif1atm3Rsjo
Hprt1tm1(Pck1-cre)Vhh/Y
Vhltm1Jae/Vhltm1Jae
(involves: 129 * BALB/c * C57BL/6) 		increased hepatic hemangioma incidence J:97652
Hip1tm4Tsr/Hip1+
Runx1tm3Dow/Runx1+
Tg(Mx1-cre)1Cgn/0
(involves: 129X1/SvJ * C57BL/6 * CBA) 		increased chronic myelocytic leukemia incidence J:151974
Hip1tm4Tsr/Hip1+
Tg(Mx1-cre)1Cgn/0
(involves: 129X1/SvJ * C57BL/6 * CBA) 		increased hepatocellular carcinoma incidence J:151974
increased T cell derived lymphoma incidence J:151974
Hivep3tm1Lcw/Hivep3tm1Lcw
(chimera involves: 129S/SvEv * 129X1/SvJ) 		increased teratoma incidence J:79652
Hmga1tm1Afus/Hmga1tm1Afus
(involves: 129S7/SvEvBrd * C57BL/6) 		increased B cell derived lymphoma incidence J:106702
increased leukemia incidence J:106702
Hmgn1tm1Mbus/Hmgn1tm1Mbus
(involves: 129X1/SvJ) 		increased hemangioma incidence J:100773
increased malignant tumor incidence J:100773
Hmgxb3tm1a(EUCOMM)Wtsi/Hmgxb3tm1a(EUCOMM)Wtsi
(C57BL/6N-Hmgxb3tm1a(EUCOMM)Wtsi/Wtsi) 		increased hemangioma incidence J:239583
Hprt1tm1(CAG-BRF1)Gu/Hprt1+
Krastm4Tyj/Kras+
Trp53tm2Tyj/Trp53+
Tg(Pdx1-cre)6Tuv/0
(involves: 129P2/OlaHsd * 129S4/SvJae * 129S7/SvEvBrd * FVB/N) 		increased pancreatic ductal adenocarcinoma incidence J:285667
Hprt1tm1(CUX1)Anep/Hprt1+
(FVB.129P2-Hprt1tm1(CUX1)Anep) 		increased mammary adenocarcinoma incidence J:152682
Hprt1tm1(Pbsn*-cre/ERT2)Jir/Y
Ptentm2Mak/Ptentm2Mak
(involves: 129P2/OlaHsd * C57BL/6) 		increased prostate gland adenocarcinoma incidence J:144357
Hprt1tm1(Pck1-cre)Vhh/Y
Vhltm1Jae/Vhltm1Jae
(involves: 129P2/OlaHsd * 129S4/SvJae * BALB/c * C57BL/6) 		increased hepatic hemangioma incidence J:97652
Hprt1tm2(CUX1)Anep/Hprt1+
(FVB.129P2-Hprt1tm2(CUX1)Anep) 		increased mammary adenocarcinoma incidence J:152682
Hrhr/Hrhr
(HRS/J) 		increased leukemia incidence J:5726, J:5908, J:24786
Hrhr/Hrhr
Msh2tm1Htr/Msh2tm1Htr
(involves: 129P2/OlaHsd) 		increased lymphoma incidence J:79734
increased skin papilloma incidence J:79734
increased skin squamous cell carcinoma incidence J:79734
Hrhr/Hrhr
Msh2tm1Htr/Msh2tm1Htr
Xpatm1Tnka/Xpatm1Tnka
(involves: 129P2/OlaHsd * C57BL/6 * CBA) 		increased lymphoma incidence J:79734
increased skin papilloma incidence J:79734
increased skin squamous cell carcinoma incidence J:79734
Hrhr/Hrhr
Tg(KRT14-Birc5)19Gros/0
(involves: C3H * C57BL/6 * SKH1) 		increased squamous cell carcinoma incidence J:95011
Hrastm1Jaf/Hras+
Tg(CAG-cre)13Miya/0
(involves: 129S6/SvEvTac * Black Swiss * C57BL/6) 		increased hemangiosarcoma incidence J:148393
increased papilloma incidence J:148393
increased skin papilloma incidence J:148393
Hrastm2Xbr/Hrastm2Xbr
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N) 		increased mammary adenocarcinoma incidence J:137729
Hspa5tm1Alee/Hspa5+
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)4Prb/?
(involves: 129 * 129S4/SvJae * C57BL/6 * DBA/2) 		increased prostate gland adenocarcinoma incidence J:142106
Htatip2tm1Hx/Htatip2+
(involves: 129P2/OlaHsd * C57BL/6J) 		increased carcinoma incidence J:87066
increased hemangiosarcoma incidence J:87066
increased hepatocellular carcinoma incidence J:87066
increased malignant tumor incidence J:87066
increased neuroblastoma incidence J:87066
increased urinary bladder transitional cell carcinoma incidence J:87066
Htatip2tm1Hx/Htatip2tm1Hx
(involves: 129P2/OlaHsd * C57BL/6J) 		increased carcinoma incidence J:87066
increased duodenum adenocarcinoma incidence J:87066
increased hepatocellular carcinoma incidence J:87066
increased malignant tumor incidence J:87066
increased sarcoma incidence J:87066
increased uterus leiomyoma incidence J:87066
Icostm1Flv/Icostm1Flv
Rc3h1san/Rc3h1+
(involves: 129S1/Sv * C57BL/6 * C57BL/6JSfdAnu) 		decreased lymphoma incidence J:189087
increased T cell derived lymphoma incidence J:189087
Id1tm1Zhu/Id1tm1Zhu
Tcf3tm1Wein/Tcf3tm1Wein
(involves: 129S1/Sv * 129S4/SvJaeSor * C57BL/6) 		increased T cell derived lymphoma incidence J:44278
Ifngtm1Ts/Ifngtm1Ts
(B6.129S7-Ifngtm1Ts) 		increased lymphoma incidence J:77491
increased sarcoma incidence J:77491
increased T cell derived lymphoma incidence J:77491
Ifngtm1Ts/Ifngtm1Ts
(C.129S7-Ifngtm1Ts) 		increased lung adenocarcinoma incidence J:77491
Ifngtm1Ts/Ifngtm1Ts
Prf1tm1Sdz/Prf1tm1Sdz
(C.Cg-Prf1tm1Sdz Ifngtm1Ts) 		increased B cell derived lymphoma incidence J:77491
increased lymphoma incidence J:77491
Igh-Vtm1(Igh-Vx24)Hmb/Igh-Vtm1(Igh-Vx24)Hmb
(involves: 129/Sv * C57BL/6) 		increased lymphoma incidence J:54380
increased T cell derived lymphoma incidence J:54380
Ightm1(Myc)Janz/Igh+
(involves: 129X1/SvJ * C57BL/6) 		increased B cell derived lymphoma incidence J:160845, J:96785
increased plasmacytoma incidence J:160845, J:96785
Ightm1(Myc)Janz/Igh+
Mdm4tm1.1Wahl/Mdm4tm1.1Wahl
(involves: 129S/Sv * C57BL/6) 		increased B cell derived lymphoma incidence J:150341
increased lymphoma incidence J:150341
Ightm1(Myc)Janz/Igh+
Tg(Emu-FGFR3)A5Wmk/0
(involves: 129X1/SvJ * C57BL/6 * FVB/N) 		increased B cell derived lymphoma incidence J:160845
increased plasmacytoma incidence J:160845
Ightm1(Myc)Janz/Igh+
Tg(Emu-FGFR3)D3Wmk/0
(involves: 129X1/SvJ * C57BL/6 * FVB/N) 		increased B cell derived lymphoma incidence J:160845
increased plasmacytoma incidence J:160845
Ightm1(PAX5)Mbu/Igh+
(B6.Cg-Ightm1(PAX5)Mbu) 		increased lymphoma incidence J:118111
increased T cell derived lymphoma incidence J:118111
Ightm1(PAX5)Mbu/Ightm1(PAX5)Mbu
(B6.Cg-Ightm1(PAX5)Mbu) 		increased lymphoma incidence J:118111
increased T cell derived lymphoma incidence J:118111
Ightm1.1(Tag)Rwhe/Igh+
(involves: 129P2/OlaHsd * C57BL/6) 		increased chronic lymphocytic leukemia incidence J:150315
increased leukemia incidence J:150315
Ightm1.1(Tag)Rwhe/Igh+
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6) 		increased chronic lymphocytic leukemia incidence J:150315
increased leukemia incidence J:150315
Ightm2.1(Tag)Rwhe/Igh+
(involves: 129P2/OlaHsd * C57BL/6) 		increased chronic lymphocytic leukemia incidence J:150315
increased leukemia incidence J:150315
Ightm2.1(Tag)Rwhe/Igh+
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6) 		increased chronic lymphocytic leukemia incidence J:150315
increased leukemia incidence J:150315
Ighatm1(Myc)Janz/Igha+
(involves: 129S1/Sv * C57BL/6) 		increased B cell derived lymphoma incidence J:90901
Ighatm1(Myc)Janz/Igha+
Tg(Igk-V21-Bax)1967Bvn/0
(involves: 129S1/Sv * C57BL/6 * FVB/N) 		increased leukemia incidence J:90901
increased plasmacytoma incidence J:90901
Ighatm1(Myc)Janz/Igha+
Tg(Tnfsf13b)1Fma/0
(involves: 129S1/Sv * C57BL/6 * DBA/2J) 		increased chronic lymphocytic leukemia incidence J:166158
Ighmtm1(Bcl6)Rdf/?
(involves: 129/Sv * C57BL/6) 		increased B cell derived lymphoma incidence J:98937
Ighmtm1Cgn/Ighmtm1Cgn
Tg(IghelMD4)4Ccg/Tg(IghelMD4)4Ccg
(NOD.Cg-Ighmtm1Cgn Tg(IghelMD4)4Ccg/DvsJ) 		increased lymphoma incidence J:80859
Ighmtm1Cgn/Ighmtm1Cgn
Tg(IghMyc)22Bri/0
(involves: 129S2/SvPas * C57BL * SJL) 		increased lymphoma incidence J:187318
Igs2tm1(CAG-Met)Zsu/Igs2+
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)4Prb/0
(involves: 129 * C57BL/6 * DBA/2 * FVB/N) 		increased carcinoma incidence J:268934
increased prostate gland adenocarcinoma incidence J:268934
Ikbkgtm1.1Chtr/Y
Tg(Alb1-cre)7Gsc/0
(involves: C57BL/6 * FVB/N * SJL) 		increased hepatocellular carcinoma incidence J:151485
Ikbkgtm1.1Chtr/Ikbkgtm1.1Chtr
Tg(Alb1-cre)7Gsc/0
(involves: C57BL/6 * FVB/N * SJL) 		increased hepatocellular carcinoma incidence J:151485
Ikbkgtm1.1Chtr/Ikbkgtm1.1Chtr
Tg(Alb1-cre)7Gsc/0
(involves: FVB/N) 		increased hepatocellular carcinoma incidence J:160521
Ikbkgtm1.1Mpa/Ikbkgtm1.1Mpa
Tg(Alb1-cre)7Gsc/0
(involves: C57BL/6 * FVB/N) 		increased hepatocellular carcinoma incidence J:118336
Ikzf1plstc/Ikzf1+
(C57BL/6JSfdAnu-Ikzf1plstc) 		increased leukemia incidence J:84569
increased T cell derived lymphoma incidence J:84569
Ikzf1tm1(Pax5)Mbu/Ikzf1+
Tg(Lck-cre)1Cwi/0
(involves: 129P2/OlaHsd * C57BL/6) 		increased T cell derived lymphoma incidence J:118111
Ikzf1tm1.1(Pax5)Mbu/Ikzf1+
(involves: 129P2/OlaHsd * C57BL/6) 		increased lymphoma incidence J:118111
increased T cell derived lymphoma incidence J:118111
Ikzf1tm1Kast/Ikzf1+
Tg(BCR/ABL)623Hkp/0
(involves: 129S2/SvPas * C57BL/6 * CBA) 		increased acute lymphoblastic leukemia incidence J:160846
Ikzf1tm1Kge/Ikzf1+
(involves: 129S4/SvJae * C57BL/6) 		increased leukemia incidence J:29355
Ikzf1tm1Kge/Ikzf1+
(involves: 129S4/SvJae * BALB/c) 		increased leukemia incidence J:29355
Ikzf1tm2.1Smale/Ikzf1tm2.1Smale
(B6.Cg-Ikzf1tm2.1Smale) 		increased lymphoma incidence J:208211
Ikzf1tm3.1Mbu/Ikzf1tm3.1Mbu
Il7rtm1.1(icre)Hrr/Il7r+
(involves: 129P2/OlaHsd * C57BL/6 * SJL) 		increased T cell derived lymphoma incidence J:209928
Ikzf1tm3Kge/Ikzf1tm3Kge
Tg(CD2-icre)4Kio/?
(involves: C57BL/10 * CBA/Ca) 		increased T cell derived lymphoma incidence J:209927
Ikzf3tm1Kge/Ikzf3tm1Kge
(involves: 129S4/SvJae * C57BL/6) 		increased B cell derived lymphoma incidence J:50626
Il6tm1Kopf/Il6+
Ncoa5tm1Hxia/Ncoa5+
(involves: 129S2/SvPas * C57BL/6) 		increased hepatocellular carcinoma incidence J:207622
Il6sttm1Ern/Il6st+
Smad3tm1Par/Smad3+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6) 		increased adenoma incidence J:100160
Il6sttm1Ern/Il6sttm1Ern
(involves: 129S1/Sv * C57BL/6) 		increased adenoma incidence J:87206, J:79073
Il10tm1Cgn/Il10tm1Cgn
(involves: 129P2/OlaHsd * C57BL/6) 		increased intestinal adenocarcinoma incidence J:68476
increased large intestine adenocarcinoma incidence J:35020
Il10tm1Cgn/Il10tm1Cgn
(B6.129P2-Il10tm1Cgn/J) 		increased colon adenocarcinoma incidence J:149347
Il10tm1Cgn/Il10tm1Cgn
Tg(MUC1)79.24Gend/0
(B6.Cg-Il10tm1Cgn Tg(MUC1)79.24Gend) 		increased colon adenocarcinoma incidence J:149347
Il12rb2tm1Jm/Il12rb2tm1Jm
(B6;129S1-Il12rb2tm1Jm/J) 		increased lung carcinoma incidence J:106805
increased plasmacytoma incidence J:106805
Immp2lTg(HLA-A/H2-D)2Enge/0
Tg(Mt1-RET)304Ina/0
(involves: BALB/c * C57BL/6 * CBA/Ca) 		increased melanoma incidence J:130879
Ing1Gt(OST206270)Lex/Ing1+
(involves: 129S5/SvEvBrd * C57BL/6) 		increased B cell derived lymphoma incidence J:118602
Ing1Gt(OST206270)Lex/Ing1Gt(OST206270)Lex
(involves: 129S5/SvEvBrd * C57BL/6) 		increased B cell derived lymphoma incidence J:118602
Ing1tm1Avg/Ing1tm1Avg
(involves: 129S1/Sv * C57BL/6) 		increased B cell derived lymphoma incidence J:105658
Ing2tm1.1Ccha/Ing2tm1.1Ccha
(involves: 129 * C57BL/6J * FVB/N) 		increased Harderian gland adenoma incidence J:167311
increased histiocytic sarcoma incidence J:167311
increased sarcoma incidence J:167311
Ino80tm1.1Schg/Ino80+
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6J) 		decreased lymphoma incidence J:221224
increased sarcoma incidence J:221224
increased T cell derived lymphoma incidence J:221224
Inpp5dm1Anu/Inpp5dm1Anu
(C57BL/6JAnu-Inpp5dm1Anu) 		increased B cell derived lymphoma incidence J:104190
Ints15em1Takas/Ints15em1Takas
(involves: C57BL/6 * DBA/2) 		increased retina hemangioma incidence J:337973
Ints15em2Takas/Ints15+
(involves: C57BL/6 * DBA/2) 		increased retina hemangioma incidence J:337973
Iqgap1tm1Aber/Iqgap1tm1Aber
Iqgap2tm1Vs/Iqgap2tm1Vs
(involves: 129S4/SvJae) 		increased hepatocellular carcinoma incidence J:132670
Iqgap2tm1Vs/Iqgap2tm1Vs
(either: 129S4/SvJae-Iqgap2tm1Vs or B6.129S4-Iqgap2tm1Vs) 		increased hemangioma incidence J:132670
increased hepatocellular carcinoma incidence J:132670
Iqgap2tm1Vs/Iqgap2tm1Vs
(involves: 129S4/SvJae) 		increased hepatocellular carcinoma incidence J:205882
Irf1tm1Mak/Irf1tm1Mak
(B6.129S2-Irf1tm1Mak/J) 		increased lymphoma incidence J:91927
Irf1tm1Mak/Irf1tm1Mak
Tg(HRAS)2Jic/?
(involves: 129S2/SvPas * BALB/c * C57BL/6) 		increased hemangiosarcoma incidence J:55418
Irf1tm1Mak/Irf1tm1Mak
Trp53tm1Sia/Trp53tm1Sia
(involves: 129S2/SvPas * C57BL/6 * CBA) 		increased hemangiosarcoma incidence J:55418
increased lymphoma incidence J:55418
increased teratoma incidence J:55418
Irf8myls/Irf8myls
Slc11a1r/Slc11a1r
(BXH2/TyJ) 		increased chronic myelocytic leukemia incidence J:97931
Irf8myls/Irf8myls
Slc11a1r/Slc11a1r
(involves: A/J * BXH2/TyJ) 		increased chronic myelocytic leukemia incidence J:97931
Irf8tm1Hor/Irf8+
(either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * C57BL/6)) 		increased chronic myelocytic leukemia incidence J:36038
Irf8tm1Hor/Irf8tm1Hor
(either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * C57BL/6)) 		increased chronic myelocytic leukemia incidence J:36038
increased lymphoma incidence J:36038
Is(14)1Rdf Is(14)2Rdf/Del(14Trim13-Dleu2)4Rdf
Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6) 		increased B cell derived lymphoma incidence J:156946
increased leukemia incidence J:156946
Is(14)1Rdf Is(14)5Rdf/Del(14Trim13-Rnaseh2b)6Rdf
Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6) 		increased chronic lymphocytic leukemia incidence J:179879
increased lymphoma incidence J:179879
increased small lymphocytic lymphoma incidence J:179879
Is(14)1Rdf/Is(14)1Rdf
Is(14)5Rdf/Is(14)5Rdf
Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6) 		increased chronic lymphocytic leukemia incidence J:179879
increased lymphoma incidence J:179879
increased small lymphocytic lymphoma incidence J:179879
Itgavtm2Hyn/Itgavtm2.1Hyn
Tg(Tek-cre)1Ywa/?
(involves: 129S2/SvPas * C57BL/6 * FVB * SJL) 		increased intestinal adenocarcinoma incidence J:125508
Jak2tm1(JAK2)Argr/Jak2+
Dppa3tm1(cre)Peli/Dppa3+
(involves: 129S5/SvEvBrd * 129S7/SvEvBrd * C57BL/6) 		increased chronic myelocytic leukemia incidence J:233169
Junbtm3Wag/Junbtm3Wag
Meox2tm1(cre)Sor/Meox2+
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6) 		increased chronic myelocytic leukemia incidence J:88126
Kat5tm1Jwl/Kat5+
Tg(IghMyc)22Bri/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL * C57BL/6 * SJL) 		increased B cell derived lymphoma incidence J:125164
Kat5tm1Jwl/Kat5+
Tg(IghMyc)22Bri/0
Trp53tm1Tyj/Trp53+
(involves: 129 * C57BL * C57BL/6 * SJL) 		increased B cell derived lymphoma incidence J:125164
Kcne2tm1a(EUCOMM)Wtsi/Kcne2tm1a(EUCOMM)Wtsi
(C57BL/6N-Kcne2tm1a(EUCOMM)Wtsi) 		increased adenoma incidence J:230226
Kdm5atm1Kael/Kdm5atm1Kael
Men1tm2.1Mmey/Men1tm2.1Mmey
Tg(Ins2-cre)23Herr/0
(involves: 129S6/SvEvTac * C57BL/6 * CBA/J * FVB/N) 		increased insulinoma incidence J:175625
Kdm6atm1Cdcn/Y
Tg(CAG-cre/Esr1*)5Amc/0
(involves: C57BL/6J * CBA) 		increased chronic myelocytic leukemia incidence J:263565
Kdm6atm1Cdcn/Y
Tg(CAG-cre/Esr1*)5Amc/0
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6J * CBA * FVB/N) 		increased chronic myelocytic leukemia incidence J:263565
Kdm6atm1Cdcn/Kdm6atm1Cdcn
Tg(CAG-cre/Esr1*)5Amc/0
(involves: C57BL/6J * CBA) 		increased chronic myelocytic leukemia incidence J:263565
KitW-v/Kit+
Tg(Mt1-RET)304Ina/0
(involves: BALB/c * C57BL/6) 		increased melanoma incidence J:88074
KitW-v/KitW-v
Tg(Mt1-RET)304Ina/0
(involves: BALB/c * C57BL/6) 		increased melanoma incidence J:88074
KitW/KitW-v
(involves: C57BL/6 * WB) 		increased esophageal papilloma incidence J:6393
increased papilloma incidence J:6393
KitlSl-17H/KitlSl-17H
(C3H/HeH-KitlSl-17H) 		increased adenoma incidence J:2880
KitlSl-d/KitlSl-d
Tg(Mt1-RET)304Ina/0
(involves: BALB/c * C57BL/6 * DBA/2) 		increased melanoma incidence J:88074
KitlSl-J/Kitl+
(involves: 129) 		increased testicular teratoma incidence J:50508
KitlSl/Kitl+
(involves: 129/Sv * C3H) 		increased testicular teratoma incidence J:50508
KitlSl/KitlSl-d
(involves: C57BL/6 * WC) 		increased leukemia incidence J:5758
increased papilloma incidence J:2777
Klf10tm1Wkle/Klf10tm1Wkle
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6) 		increased papilloma incidence J:182595
Klf14em1Cgw/Klf14em1Cgw
(C57BL/6J-Klf14em1Cgw) 		increased lung adenoma incidence J:227200
increased lymphoma incidence J:227200
Klrk1tm1Dhr/Klrk1tm1Dhr
Tg(IghMyc)22Bri/?
(involves: C57BL/6 * CD-1) 		increased B cell derived lymphoma incidence J:134509
Kmt2atm1(AFF1)Ksy/Kmt2a+
(involves: 129S1/Sv * C57BL/6 * FVB) 		increased B cell derived lymphoma incidence J:110241
increased leukemia incidence J:110241
increased malignant tumor incidence J:110241
Kmt2atm1(MLL1/ERT)Divo/?
(involves: 129S4/SvJae * C57BL/6) 		increased acute promyelocytic leukemia incidence J:189329
Kmt2atm1.1(Sh3gl1)Lcc/Kmt2a+
Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6) 		increased leukemia incidence J:205605
Kmt2atm1Saam/Kmt2a+
Tg(Mx1-cre)1Cgn/0
(involves: 129S1/Sv * C57BL/6 * CBA) 		increased leukemia incidence J:140628
Kmt2atm1Thr/Kmt2a+
Mllt3tm2Thr/Mllt3+
Tg(Lck-cre)1Thr/?
(involves: 129S/SvEv) 		increased leukemia incidence J:100794
increased T cell derived lymphoma incidence J:100794
Kmt2atm2(MLLT3)Thr/Kmt2a+
(involves: 129P2/OlaHsd) 		increased leukemia incidence J:56340
Kmt2atm2(MLLT3)Thr/Kmt2atm2(MLLT3)Thr
(involves: 129P2/OlaHsd * C57BL/6 * FVB) 		increased B cell derived lymphoma incidence J:110241
increased leukemia incidence J:110241
Kmt2dtm1.1Kaig/Kmt2d+
Ighg1tm1(cre)Cgn/Ighg1+
Tg(Vav-BCL2)69Jad/0
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J) 		increased B cell derived lymphoma incidence J:228913
increased follicular lymphoma incidence J:228913
Kmt2dtm1.1Kaig/Kmt2dtm1.1Kaig
Ighg1tm1(cre)Cgn/Ighg1+
Tg(Vav-BCL2)69Jad/0
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J) 		increased B cell derived lymphoma incidence J:228913
increased follicular lymphoma incidence J:228913
Krasa/Krasa
(multiple strains) 		increased lung adenoma incidence J:17778, J:17850
Krastm1.1Hbji/Krastm1.1Hbji
Trp53tm5Tyj/Trp53tm5Tyj
(involves: 129S4/SvJae) 		increased lung adenoma incidence J:220921
Krastm1.1Khai/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm3.1Tyj/Trp53+
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * FVB/N) 		increased pancreatic ductal adenocarcinoma incidence J:276349
Krastm1Bbd/Kras+
(involves: 129S1/Sv * 129X1/SvJ) 		increased lung non-small cell carcinoma incidence J:172200
Krastm1Bbd/Kras+
Map2k1tm1Chrn/Map2k1tm1Chrn
(involves: 129S1/Sv * 129X1/SvJ) 		increased lung non-small cell carcinoma incidence J:172200
Krastm1Bbd/Kras+
Map2k1tm1Chrn/Map2k1tm1Chrn
Map2k2tm1Chrn/Map2k2tm1Chrn
(involves: 129/Sv * 129S1/Sv * 129X1/SvJ * C57BL/6J * SJL) 		decreased classified tumor incidence J:172200
Krastm1Bbd/Kras+
Map2k2tm1Chrn/Map2k2tm1Chrn
(involves: 129/Sv * 129S1/Sv * 129X1/SvJ * C57BL/6J * SJL) 		increased lung non-small cell carcinoma incidence J:172200
Krastm1Bbd/Kras+
Mapk1tm1.1Hed/Mapk1tm1.1Hed
(involves: 129S1/Sv * 129X1/SvJ) 		increased lung non-small cell carcinoma incidence J:172200
Krastm1Bbd/Kras+
Mapk1tm1.1Hed/Mapk1tm1.1Hed
Mapk3tm1Gpg/Mapk3tm1Gpg
(involves: 129/Sv * 129S1/Sv * 129X1/SvJ) 		decreased classified tumor incidence J:172200
Krastm1Bbd/Kras+
Mapk3tm1Gpg/Mapk3tm1Gpg
(involves: 129/Sv * 129S1/Sv * 129X1/SvJ) 		increased lung non-small cell carcinoma incidence J:172200
Krastm1Bbd/Kras+
Mapk14tm1Nbr/Mapk14tm2Nbr
Polr2atm1(cre/ERT2)Bbd/Polr2a+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL) 		increased lung adenocarcinoma incidence J:122397
increased lung adenoma incidence J:122397
Krastm1Bbd/Kras+
Mapk14tm2Nbr/Mapk14+
Polr2atm1(cre/ERT2)Bbd/Polr2a+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL) 		increased lung adenoma incidence J:122397
Krastm1Bbd/Kras+
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
(involves: 129S1/Sv * 129X1/SvJ) 		increased adenoma incidence J:161780
increased lung non-small cell carcinoma incidence J:161780
Krastm1Bbd/Kras+
Raf1tm2Bacc/Raf1tm2Bacc
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ) 		decreased classified tumor incidence J:172200
Krastm1Bbd/Kras+
Tg(CMV-cre)1Cgn/?
(involves: 129S1/Sv * 129X1/SvJ * BALB/cJ * C57BL/6) 		increased lung adenocarcinoma incidence J:86101
increased lung adenoma incidence J:86101
increased papilloma incidence J:86101
increased sarcoma incidence J:86101
Krastm1Bbd/Kras+
Tg(CMV-cre/ERT)1Ipc/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL) 		increased lung adenocarcinoma incidence J:86101
increased lung adenoma incidence J:86101
Krastm1Bbd/Kras+
Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2) 		increased prostate gland adenocarcinoma incidence J:143034
Krastm1Bbd/Kras+
Trp53tm1Brd/Trp53+
Tg(Cela1-tTA)#Eps/?
Tg(tetO-cre)3Jig/?
(involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ * FVB/N) 		increased pancreatic ductal adenocarcinoma incidence J:119988
Krastm1Bbd/Krastm1Bbd
Tg(Cela1-tTA)#Eps/?
Tg(tetO-cre)3Jig/?
(involves: 129S1/Sv * 129X1/SvJ * FVB/N) 		increased pancreatic ductal adenocarcinoma incidence J:119988
Krastm1Bbd/Krastm2Bbd
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
(involves: 129S1/Sv * 129X1/SvJ) 		increased lung non-small cell carcinoma incidence J:161780
Krastm2Tyj/Kras+
(involves: 129S2/SvPas * C57BL/6) 		increased lung adenocarcinoma incidence J:68981
increased lung adenoma incidence J:68981
increased skin papilloma incidence J:68981
increased T cell derived lymphoma incidence J:68981
Krastm2Tyj/Kras+
(involves: 129S2/SvPas) 		increased carcinoma incidence J:129627
increased fibrosarcoma incidence J:129627
increased hemangiosarcoma incidence J:129627
increased lung adenocarcinoma incidence J:136369
increased lymphoma incidence J:129627
increased mesothelioma incidence J:129627
increased papilloma incidence J:129627
increased sarcoma incidence J:129627
increased skin papilloma incidence J:68981
increased squamous cell carcinoma incidence J:129627
increased T cell derived lymphoma incidence J:68981
Krastm2Tyj/Kras+
Trp53tm1Glo/Trp53+
(involves: 129S2/SvPas * 129S7/SvEvBrd) 		increased fibrosarcoma incidence J:129627
increased hemangiosarcoma incidence J:129627
increased lung adenoma incidence J:129627
increased lymphoma incidence J:129627
increased mesothelioma incidence J:129627
increased papilloma incidence J:129627
increased squamous cell carcinoma incidence J:129627
Krastm2Tyj/Kras+
Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * C57BL/6) 		increased fibrosarcoma incidence J:68981
increased hemangiosarcoma incidence J:68981
increased skin papilloma incidence J:68981
increased T cell derived lymphoma incidence J:68981
Krastm2Tyj/Kras+
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6) 		increased fibrosarcoma incidence J:68981
increased hemangiosarcoma incidence J:68981
increased skin papilloma incidence J:68981
increased T cell derived lymphoma incidence J:68981
Krastm3Tyj/Kras+
(involves: 129S4/SvJae * C57BL/6) 		increased lung adenocarcinoma incidence J:68981
increased lung adenoma incidence J:68981
increased skin papilloma incidence J:68981
increased T cell derived lymphoma incidence J:68981
Krastm3Tyj/Kras+
(involves: 129S4/SvJae) 		increased skin papilloma incidence J:68981
increased T cell derived lymphoma incidence J:68981
Krastm3Tyj/Kras+
Mir21atm1.1Eno/Mir21atm1.1Eno
(involves: 129S/SvEv * 129S4/SvJae * C57BL/6) 		increased lung adenoma incidence J:164198
increased T cell derived lymphoma incidence J:164198
Krastm3Tyj/Kras+
Tg(CAG-Mir21,-EGFP)#Eno/0
(involves: 129S4/SvJae * C3H * C57BL/6) 		increased lung non-small cell carcinoma incidence J:164198
Krastm3Tyj/Krastm3Tyj
(involves: 129S4/SvJae) 		increased skin papilloma incidence J:237900
increased T cell derived lymphoma incidence J:237900
Krastm3Tyj/Krastm3Tyj
Mir301tm1Yoli/Mir301tm1Yoli
(involves: 129S4/SvJae * C57BL/6J) 		decreased lymphoma incidence J:237900
Krastm4Tyj/Kras+
(involves: 129S4/SvJae) 		increased lung adenocarcinoma incidence J:207982, J:333347
increased lung adenoma incidence J:207982, J:333347
Krastm4Tyj/Kras+
(involves: 129S4/SvJae) 		increased lung adenocarcinoma incidence J:147590
increased lung adenoma incidence J:158937
increased lung carcinoma incidence J:158937
Krastm4Tyj/Kras+
(B6.129S4-Krastm4Tyj) 		increased lung adenocarcinoma incidence J:177379
increased lung adenoma incidence J:177379
Krastm4Tyj/Kras+
(involves: 129S4/SvJae * C57BL/6) 		increased lung adenoma incidence J:203686
Krastm4Tyj/Kras+
(involves: 129S4/SvJae * C57BL/6 * FVB/N) 		increased lung adenocarcinoma incidence J:124682
Krastm4Tyj/Kras+
Gt(ROSA)26Sortm1(sb13)Tuv/Gt(ROSA)26Sor+
Tg(Pdx1-cre)6Tuv/0
TgTn(sb-T2/Onc)#Dla/0
(involves: 129S4/SvJae * 129S6/SvEvTac * FVB/N) 		increased pancreatic ductal adenocarcinoma incidence J:186717
Krastm4Tyj/Kras+
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor+
Tg(Flt3-cre)#Ccb/0
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6) 		increased leukemia incidence J:247853
Krastm4Tyj/Kras+
Krt19tm1(cre/ERT)Ggu/Krt19+
(involves: 129S4/SvJae * 129S6/SvEvTac) 		increased skin papilloma incidence J:172048
Krastm4Tyj/Kras+
Map2k7tm1.1Twad/Map2k7tm1.2Twad
(B6.Cg-Krastm4Tyj Map2k7tm1.1Twad/Map2k7tm1.2Twad) 		increased lung adenocarcinoma incidence J:170904
Krastm4Tyj/Kras+
Map2k7tm1.1Twad/Map2k7tm1.2Twad
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129P2/OlaHsd * 129S2/SvPas * 129S4/SvJae * C57BL/6) 		increased lung adenocarcinoma incidence J:170904
Krastm4Tyj/Kras+
Mapkapk2tm1.1Yaff/Mapkapk2tm1.1Yaff
(involves: 129S4/SvJae * C57BL/6) 		increased lung adenoma incidence J:203686
Krastm4Tyj/Kras+
Mapkapk2tm1.1Yaff/Mapkapk2tm1.1Yaff
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6) 		increased lung adenoma incidence J:203686
Krastm4Tyj/Kras+
Myod1tm1.1(cre/ERT,TVA)Gcg/Myod1+
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6) 		increased sarcoma incidence J:205518
Krastm4Tyj/Kras+
Pax7tm2.1(cre/ERT2)Fan/Pax7+
Trp53tm1Brn/Trp53tm1Brn
(involves: 129/Sv * 129P2/OlaHsd * 129X1/SvJ * C57BL/6) 		increased sarcoma incidence J:205518
Krastm4Tyj/Kras+
Pdpk1tm1Mlw/Pdpk1tm1Mlw
Tg(Cela1-cre/ERT)1Dam/0
(involves: 129S4/SvJae) 		increased lung non-small cell carcinoma incidence J:197054
Krastm4Tyj/Kras+
Pggt1btm1Mbrg/Pggt1b+
Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6) 		increased lung adenocarcinoma incidence J:122107
increased lung adenoma incidence J:122107
Krastm4Tyj/Kras+
Pggt1btm1Mbrg/Pggt1btm1Mbrg
Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6) 		increased lung adenoma incidence J:122107
Krastm4Tyj/Kras+
Ptentm1Hwu/Pten+
Tg(Gfap-cre)77.6Mvs/0
(involves: 129S4/SvJae * BALB/c * C57BL/6NHsd) 		increased classified tumor incidence J:154673
increased neurofibroma incidence J:154673
increased neurofibrosarcoma incidence J:154673
Krastm4Tyj/Kras+
Ptentm1Hwu/Pten+
Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2) 		increased prostate gland adenocarcinoma incidence J:184935
Krastm4Tyj/Kras+
Ptentm1Hwu/Pten+
Tg(Pdx1-cre)89.1Dam/0
(involves: 129S4/SvJae * BALB/c * C57BL/6) 		increased pancreatic ductal adenocarcinoma incidence J:164210
Krastm4Tyj/Kras+
Ptentm1Hwu/Pten+
Tg(Upk2-cre)6Xrw/0
(involves: 129S4/SvJae * FVB/N) 		increased skin papilloma incidence J:174242
Krastm4Tyj/Kras+
Ptentm1Hwu/Ptentm1Hwu
(involves: 129S4/SvJae * C57BL/6J) 		increased endometrial carcinoma incidence J:96296
Krastm4Tyj/Kras+
Ptentm1Hwu/Ptentm1Hwu
Scgb1a1tm1.1(cre)Fjd/Scgb1a1+
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ) 		increased lung adenocarcinoma incidence J:131721
increased lung adenoma incidence J:131721
increased lung carcinoma incidence J:131721
Krastm4Tyj/Kras+
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2) 		increased prostate gland adenocarcinoma incidence J:184935
Krastm4Tyj/Kras+
Ptentm1Hwu/Ptentm1Hwu
Tg(Pdx1-cre)89.1Dam/0
(involves: 129S4/SvJae * BALB/c * C57BL/6 * CBA) 		increased pancreatic ductal adenocarcinoma incidence J:164210
Krastm4Tyj/Kras+
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(TPO-cre)1Shk/0
(129.Cg-Krastm4Tyj Tg(Tpo-cre)1Shk Ptentm2.1Ppp) 		increased thyroid carcinoma incidence J:147732
Krastm4Tyj/Kras+
Ptentm2Mak/Pten+
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA) 		increased cholangiocarcinoma incidence J:254370
increased hepatocellular carcinoma incidence J:254370
Krastm4Tyj/Kras+
Ptentm2Mak/Ptentm2Mak
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA) 		increased cholangiocarcinoma incidence J:254370
Krastm4Tyj/Kras+
Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ) 		increased pancreatic ductal adenocarcinoma incidence J:116130, J:87973
Krastm4Tyj/Kras+
Ptf1atm1.1(cre)Cvw/Ptf1a+
(B6.129(Cg)-Krastm4Tyj Ptf1atm1.1(cre)Cvw) 		increased pancreatic ductal adenocarcinoma incidence J:138959
Krastm4Tyj/Kras+
Ptf1atm1.1(cre)Cvw/Ptf1a+
Tg(MUC1)79.24Gend/0
(B6.Cg-Krastm4Tyj Ptf1atm1.1(cre)Cvw Tg(MUC1)79.24Gend) 		increased pancreatic ductal adenocarcinoma incidence J:138959
Krastm4Tyj/Kras+
Raf1tm2Bacc/Raf1tm2Bacc
Ptf1atm1(cre)Hnak/Ptf1a+
(involves: 129P2/OlaHsd * 129S4/SvJae) 		increased pancreatic ductal adenocarcinoma incidence J:197054
Krastm4Tyj/Kras+
Rb1tm3Tyj/Rb1tm3Tyj
(involves: 129S4/SvJae) 		increased lung adenocarcinoma incidence J:147590
Krastm4Tyj/Kras+
Rbl2tm2Tyj/Rbl2tm2Tyj
(involves: 129S4/SvJae) 		increased lung adenocarcinoma incidence J:147590
Krastm4Tyj/Kras+
Rnf7Gt(XE423)Byg/Rnf7+
(involves: 129P2/OlaHsd * 129S4/SvJae) 		increased lung adenocarcinoma incidence J:207982
increased lung adenoma incidence J:207982
Krastm4Tyj/Kras+
Scgb1a1tm1(cre/ERT)Blh/Scgb1a1+
Trp53tm5Tyj/Trp53+
(involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6) 		increased adenocarcinoma incidence J:182218
increased lung adenoma incidence J:182218
Krastm4Tyj/Kras+
Scgb1a1tm1.1(cre)Fjd/Scgb1a1+
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ) 		increased lung adenoma incidence J:131721
Krastm4Tyj/Kras+
Scribtm1.1Phum/Scrib+
Tg(Pbsn-cre)20Fwan/0
(involves: 129S4/SvJae * FVB/NCrl) 		increased prostate gland adenocarcinoma incidence J:178461
Krastm4Tyj/Kras+
Scribtm1.1Phum/Scribtm1.1Phum
Tg(Pbsn-cre)20Fwan/0
(involves: 129S4/SvJae * FVB/NCrl) 		increased carcinoma incidence J:178461
increased prostate gland adenocarcinoma incidence J:178461
Krastm4Tyj/Kras+
Sftpctm1(cre/ERT2)Blh/Sftpc+
Trp53tm5Tyj/Trp53+
(involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6) 		increased adenocarcinoma incidence J:182218
increased lung adenoma incidence J:182218
Krastm4Tyj/Kras+
Sftpctm1.1(cre/ERT2)Ptch/Sftpc+
(involves: 129P2/OlaHsd * C57BL/6 * FVB) 		increased lung adenoma incidence J:195738
Krastm4Tyj/Kras+
Sftpctm1.1(cre/ERT2)Ptch/Sftpc+
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB) 		increased lung adenocarcinoma incidence J:195738
increased lung adenoma incidence J:195738
Krastm4Tyj/Kras+
Siva1tm1.1Att/Siva1tm1.2Att
(involves: 129S4/SvJae * C57BL/6) 		abnormal lung adenoma incidence J:223572
Krastm4Tyj/Kras+
Siva1tm1.2Att/Siva1+
(involves: 129S4/SvJae * C57BL/6) 		abnormal lung adenoma incidence J:223572
Krastm4Tyj/Kras+
Smad4tm1Rdp/Smad4tm1Rdp
Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129 * FVB/N) 		increased pancreatic ductal adenocarcinoma incidence J:116130
Krastm4Tyj/Kras+
Smad4tm2.1Cxd/Smad4tm2.1Cxd
Tg(Krt1-15-cre/PGR*)22Cot/0
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * C57BL/6J * SJL/J) 		increased adenoma incidence J:203922
increased papilloma incidence J:203922
increased skin squamous cell carcinoma incidence J:203922
Krastm4Tyj/Kras+
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129S4/SvJae * C57BL/6 * DBA) 		increased cholangiocarcinoma incidence J:184949
Krastm4Tyj/Kras+
Stk11tm1.1Rdp/Stk11tm1.1Rdp
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * FVB/N) 		increased lung adenocarcinoma incidence J:124682
increased lung large cell carcinoma incidence J:124682
increased lung squamous cell carcinoma incidence J:124682
Krastm4Tyj/Kras+
Stk11tm1.1Rdp/Stk11tm1.2Rdp
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * FVB/N) 		increased lung adenocarcinoma incidence J:124682
increased lung large cell carcinoma incidence J:124682
increased lung squamous cell carcinoma incidence J:124682
Krastm4Tyj/Kras+
Tg(CAG-Bgeo,-tsA58T)T26Ichi/0
Tg(Pdx1-cre)6Tuv/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB/N) 		increased pancreatic ductal adenocarcinoma incidence J:214846
Krastm4Tyj/Kras+
Tg(CAG-HPV16E6E7,-luc)#Mspi/0
Tg(KRT14-cre/ERT)20Efu/0
(involves: 129S4/SvJae * C57BL/6 * CD-1 * FVB/N * FVB/NJ) 		increased oral papilloma incidence J:210533
Krastm4Tyj/Kras+
Tg(Cela1-cre/ERT)1Dam/0
(involves: 129S4/SvJae) 		increased lung non-small cell carcinoma incidence J:197054
Krastm4Tyj/Kras+
Tg(IVL-cre/ERT2)1Blpn/0
(involves: 129S4/SvJae * C57BL/6) 		increased skin papilloma incidence J:172048
Krastm4Tyj/Kras+
Tg(Krt1-15-cre/PGR*)22Cot/0
(involves: 129S4/SvJae * C57BL/6J * SJL/J) 		increased skin papilloma incidence J:172048
Krastm4Tyj/Kras+
Tg(Krt1-15-cre/PGR*)22Cot/0
(involves: 129S4/SvJae * C57BL/6 * C57BL/6J * SJL/J) 		increased papilloma incidence J:203922
Krastm4Tyj/Kras+
Tg(KRT5-cre/PGR)1Der/?
(involves: 129/Sv * C57BL/6 * FVB * ICR) 		increased skin papilloma incidence J:124222
Krastm4Tyj/Kras+
Tg(Mx1-cre)1Cgn/0
(involves: 129S4/SvJae * BALB/c * C57BL/6 * CBA) 		increased esophageal papilloma incidence J:88163
increased lung adenoma incidence J:88163
increased lymphoblastic lymphoma incidence J:88163
increased oral papilloma incidence J:88163
increased papilloma incidence J:88163
increased skin papilloma incidence J:88163
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/?
(involves: 129S4/SvJae * FVB/N) 		increased pancreatic ductal adenocarcinoma incidence J:87973
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm1Gev/Trp53tm1Gev
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB/N) 		increased pancreatic ductal adenocarcinoma incidence J:220300
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm3.1Tyj/Trp53+
(involves: 129S4/SvJae * C57BL/6 * FVB/N) 		increased pancreatic ductal adenocarcinoma incidence J:276349
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm3Tyj/Trp53+
(involves: 129S4/SvJae * C57BL/6 * FVB/N) 		increased pancreatic ductal adenocarcinoma incidence J:166678
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Usp9xtm1Tuv/Y
(involves: 129S4/SvJae * FVB/N) 		increased oral papilloma incidence J:186717
increased skin papilloma incidence J:186717
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Usp9xtm1Tuv/Usp9x+
(involves: 129S4/SvJae * FVB/N) 		increased oral papilloma incidence J:186717
increased skin papilloma incidence J:186717
Krastm4Tyj/Kras+
Tg(Pdx1-cre)89.1Dam/0
(involves: 129S4/SvJae * C57BL/6 * CBA) 		increased pancreatic ductal adenocarcinoma incidence J:116130, J:164210
Krastm4Tyj/Kras+
Tg(Scgb1a1-cre)1Kkw/?
(involves: 129 * C57BL/6 * FVB/N) 		increased lung adenocarcinoma incidence J:107260
Krastm4Tyj/Kras+
Tg(Tyr-cre/ERT2)13Bos/0
(involves: 129S4/SvJae * FVB) 		increased melanoma incidence J:164588
Krastm4Tyj/Kras+
Tgfbr2tm1.2Hlm/Tgfbr2+
Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * DBA/2) 		increased pancreatic ductal adenocarcinoma incidence J:116129
Krastm4Tyj/Kras+
Tgfbr2tm1.2Hlm/Tgfbr2tm1.2Hlm
(B6.129-Krastm4Tyj Tgfbr2tm1.2Hlm) 		increased lung adenocarcinoma incidence J:177379
Krastm4Tyj/Kras+
Tgfbr2tm1.2Hlm/Tgfbr2tm1.2Hlm
Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * DBA/2) 		increased pancreatic ductal adenocarcinoma incidence J:116129
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53+
(involves: 129P2/OlaHsd * 129S4/SvJae) 		increased lung adenoma incidence J:103407
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53+
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA) 		increased cholangiocarcinoma incidence J:184949
increased hamartoma incidence J:184949
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53+
Tg(KRT5-cre/PGR)1Der/?
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * FVB * ICR) 		increased carcinoma incidence J:124222
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53+
Tg(Pdx1-cre)89.1Dam/0
(involves: 129 * C57BL/6 * CBA * FVB/N) 		increased pancreatic ductal adenocarcinoma incidence J:108298
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S4/SvJae) 		increased adenocarcinoma incidence J:103407
increased lung adenocarcinoma incidence J:195492, J:154041, J:103407
increased lung adenoma incidence J:203686, J:103407
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6) 		increased sarcoma incidence J:155389, J:125101
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB/N) 		increased lung adenocarcinoma incidence J:124682
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Krt19tm1(cre/ERT)Ggu/Krt19+
(involves: 129P2/OlaHsd * 129S4/SvJae * 129S6/SvEvTac) 		increased carcinoma incidence J:172048
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA) 		increased cholangiocarcinoma incidence J:184949
increased hamartoma incidence J:184949
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT5-cre/PGR)1Der/?
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * FVB * ICR) 		increased squamous cell carcinoma incidence J:124222
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre/ERT)20Efu/0
(involves: 129P2/OlaHsd * 129S4/SvJae * CD-1) 		increased skin squamous cell carcinoma incidence J:172048
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Tg(Pdx1-cre)89.1Dam/0
(involves: 129 * C57BL/6 * CBA * FVB/N) 		increased pancreatic ductal adenocarcinoma incidence J:108298
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Tg(Tyr-cre/ERT2)13Bos/0
(involves: 129P2/OlaHsd * 129S4/SvJae * FVB) 		increased melanoma incidence J:164588
increased spindle cell carcinoma incidence J:164588
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm2Tyj
(involves: 129P2/OlaHsd * 129S4/SvJae) 		increased adenocarcinoma incidence J:103407
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm2Tyj
Ptf1atm1(cre)Hnak/Ptf1a+
(involves: 129P2/OlaHsd * 129S4/SvJae) 		increased pancreatic ductal adenocarcinoma incidence J:197054
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm3Glo
Tg(KRT5-cre/PGR)1Der/?
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * FVB * ICR) 		increased carcinoma incidence J:124222
increased spindle cell carcinoma incidence J:124222
Krastm4Tyj/Kras+
Trp53tm1Lejo/Trp53tm1Lejo
(involves: 129S4/SvJae) 		increased lung adenocarcinoma incidence J:187012
increased lung non-small cell carcinoma incidence J:187012
Krastm4Tyj/Kras+
Trp53tm2Tyj/Trp53+
(involves: 129S4/SvJae) 		increased lung adenocarcinoma incidence J:191425
increased lung non-small cell carcinoma incidence J:191425
Krastm4Tyj/Kras+
Trp53tm2Tyj/Trp53+
Tg(Pdx1-cre)6Tuv/0
(involves: 129S4/SvJae * C57BL/6 * FVB/N) 		increased esophageal papilloma incidence J:98936
increased pancreatic ductal adenocarcinoma incidence J:98936
increased papilloma incidence J:98936
increased T cell derived lymphoma incidence J:98936
increased teratocarcinoma incidence J:98936
Krastm4Tyj/Kras+
Trp53tm3Glo/Trp53+
Tg(KRT5-cre/PGR)1Der/?
(involves: 129/Sv * C57BL/6 * FVB * ICR) 		increased carcinoma incidence J:124222
Krastm4Tyj/Krastm4Tyj
Yap1tm1.1Dupa/Yap1tm1.1Dupa
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA) 		increased hepatocellular carcinoma incidence J:162628
Krastm5Tyj/Kras+
Pdx1tm1.1(flpo)Most/Pdx1+
Trp53tm1.1Dgk/Trp53+
(involves: 129S1/Sv * 129S1/SvImJ * 129X1/SvJ * Black Swiss * C57BL/6) 		increased pancreatic ductal adenocarcinoma incidence J:248550
Krastm5Tyj/Kras+
Pdx1tm1.1(flpo)Most/Pdx1+
Trp53tm1.1Dgk/Trp53tm1.1Dgk
(involves: 129S1/Sv * 129S1/SvImJ * 129X1/SvJ * Black Swiss * C57BL/6) 		increased pancreatic ductal adenocarcinoma incidence J:248550
Krastm5Tyj/Kras+
Trp53tm1.1Dgk/Trp53tm1.1Dgk
(involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6) 		increased lung adenocarcinoma incidence J:180576
increased sarcoma incidence J:180576
Krastm5Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sortm1(cre/ERT2)Tyj
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6) 		increased sarcoma incidence J:172206
Krit1tm1Kwhi/Krit1tm1.1Kwhi
Tg(Pdgfb-icre/ERT2,-EGFP)1Frut/0
(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NCrl * CBA) 		increased retina hemangioma incidence J:215458
Krt9tm1(KOMP)Vlcg/Krt9tm1(KOMP)Vlcg
(involves: C57BL/6J * C57BL/6NTac) 		increased skin papilloma incidence J:206051
Krt14tm1(Krt10)Pko/Krt14tm1(Krt10)Pko
(B6.Cg-Krt14tm1(Krt10)Pko) 		increased skin papilloma incidence J:117347
Krt14tm1.1(cre)Wbm/Krt14+
Tg(KRT14-Snai1)1Efu/0
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * CD-1) 		increased basal cell carcinoma incidence J:229072
increased skin squamous cell carcinoma incidence J:229072
Krt18tm1Tmm/Krt18tm1Tmm
(involves: 129P2/OlaHsd) 		increased hepatocellular carcinoma incidence J:309021
Lats1tm1Tx/Lats1tm1Tx
(involves: 129S2/SvPas * C57BL/6J) 		increased sarcoma incidence J:52536
Lect2tm1Ymg/Lect2tm1Ymg
Tg(Pklr-Myc)73Ak/0
(B6.Cg-Lect2tm1Ymg Tg(Pklr-Myc)73Ak) 		increased hepatocellular carcinoma incidence J:184496
increased malignant tumor incidence J:184496
Lgals3tm1Ftl/Lgals3tm1Ftl
(involves: 129S2/SvPas * CD-1) 		increased hepatocellular carcinoma incidence J:221030
Lgr5tm1(cre/ERT2)Cle/Lgr5+
Lrig1tm1.1(cre/ERT2)Rjc/Lrig1tm1.1(cre/ERT2)Rjc
(involves: 129 * 129P2/OlaHsd * C57BL/6) 		increased intestinal adenoma incidence J:186084
Lig1tm3Dwm/Lig1tm3Dwm
(involves: 129P2/OlaHsd * C57BL/6) 		increased adenocarcinoma incidence J:77902
increased lymphoma incidence J:77902
Lig4tm1Fwa/Lig4tm1Fwa
Trp53tm1Brd/Trp53tm1Brd
(involves: 129S6/SvEvTac * 129S7/SvEvBrd) 		increased lymphoma incidence J:63078
Lig4tm1Icrf/Lig4tm1Icrf
Trp53tm1Tyj/Trp53tm1Tyj
(either: (involves: 129P2/OlaHsd * 129S2/SvPas) or (involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ)) 		increased B cell derived lymphoma incidence J:111068
increased medulloblastoma incidence J:111068
Lig4tm1Pmc/Lig4tm1Pmc
Trp53tm1Tyj/Trp53+
Xrcc2tm2Pmc/Xrcc2tm2Pmc
Tg(Nes-cre)1Kln/0
(involves: 129S1/Sv * 129S2/SvPas * C57BL/6 * SJL) 		increased medulloblastoma incidence J:144617
Lig4tm1Pmc/Lig4tm1Pmc
Trp53tm1Tyj/Trp53tm1Tyj
Tg(Nes-cre)1Kln/0
(involves: 129S1/Sv * 129S2/SvPas * C57BL/6 * SJL) 		increased medulloblastoma incidence J:144617
Lig4tm1Pmc/Lig4tm1Pmc
Trp53tm1Tyj/Trp53tm1Tyj
Xrcc2tm2Pmc/Xrcc2tm2Pmc
Tg(Nes-cre)1Kln/0
(involves: 129S1/Sv * 129S2/SvPas * C57BL/6 * SJL) 		increased medulloblastoma incidence J:144617
Lig4tm2.1Fwa/Lig4tm2.1Fwa
(involves: 129S6/SvEvTac) 		increased colon adenocarcinoma incidence J:157574
increased medulloblastoma incidence J:157574
increased T cell derived lymphoma incidence J:157574
ll/ll
X/Yaa
(BXSB/MpJScr-ll) 		increased lymphoma incidence J:10973
increased T cell derived lymphoma incidence J:10973
llaSL/Kh/llaSL/Kh
(involves: AKR/JMs * SL/Kh) 		increased lymphoma incidence J:41197, J:33016
Lmo2tm2(cre)Thr/Lmo2+
Kmt2atm1Thr/Kmt2a+
Mllt1tm1Thr/Mllt1+
(involves: 129S/SvEv) 		increased leukemia incidence J:84518, J:100794
Lmo7tm1Miyo/Lmo7+
(involves: 129X1/SvJ * C57BL/6 * DBA/2) 		increased lung adenocarcinoma incidence J:150612
Lmo7tm1Miyo/Lmo7+
(involves: 129X1/SvJ * C57BL/6) 		increased lung adenocarcinoma incidence J:150612
Lmo7tm1Miyo/Lmo7tm1Miyo
(involves: 129X1/SvJ * C57BL/6 * DBA/2) 		increased lung adenocarcinoma incidence J:150612
Lmo7tm1Miyo/Lmo7tm1Miyo
(involves: 129X1/SvJ * C57BL/6) 		increased lung adenocarcinoma incidence J:150612
Lpoem1Zlu/Lpoem1Zlu
(involves: C57BL/6 * SJL) 		increased histiocytic sarcoma incidence J:307289
increased lung carcinoma incidence J:307289
increased lymphoma incidence J:307289
increased sarcoma incidence J:307289
Ltbp4Gt(U3Cre)1Vmel/Ltbp4Gt(U3Cre)1Vmel
(B6.129S2-Ltbp4Gt(U3Cre)1Vmel) 		increased large intestine adenocarcinoma incidence J:78819
Ly6atm2(RUNX1)Grau/Ly6a+
(involves: 129X1/SvJ * C57BL/6J) 		increased squamous cell carcinoma incidence J:93408
LyarGt(RRG292)Byg/LyarGt(RRG292)Byg
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6) 		increased T cell derived lymphoma incidence J:263530
Lyr2SL/Ni/Lyr2SL/Ni
(involves: SL/Kh * SL/Ni) 		decreased lymphoma incidence J:32436
LyrBALB/cHeA/LyrBALB/cHeA
(involves: BALB/cHeA * STS/A) 		increased lymphoma incidence J:10558
LyrSTS/A/LyrSTS/A
(involves: BALB/cHeA * STS/A) 		decreased lymphoma incidence J:10558
Lzts1tm1Cro/Lzts1+
(involves: 129 * C57BL/6J) 		increased carcinoma incidence J:119989
increased gastric adenocarcinoma incidence J:119989
increased hepatocellular carcinoma incidence J:119989
increased lung adenoma incidence J:119989
increased lymphoma incidence J:119989
Lzts1tm1Cro/Lzts1tm1Cro
(involves: 129 * C57BL/6J) 		increased carcinoma incidence J:119989
increased gastric adenocarcinoma incidence J:119989
increased hepatocellular carcinoma incidence J:119989
increased lung adenocarcinoma incidence J:119989
increased lymphoma incidence J:119989
increased sarcoma incidence J:119989
Mad1l1tm1.1Ktj/Mad1l1+
(involves: BALB/c * C57BL/6J) 		increased carcinoma incidence J:117337
increased hemangiosarcoma incidence J:117337
increased hepatocellular carcinoma incidence J:117337
increased lung adenocarcinoma incidence J:117337
increased osteosarcoma incidence J:117337
increased rhabdomyosarcoma incidence J:117337
increased sarcoma incidence J:117337
Mad2l1tm1Sorg/Mad2l1+
(involves: 129S2/SvPas * C57BL/6) 		increased lung adenocarcinoma incidence J:67456
Map2k7tm1.1Twad/Map2k7tm1.2Twad
Tg(MMTV-cre)4Mam/0
Tg(MMTV-Erbb2)1Pv/0
(involves: 129P2/OlaHsd * C57BL/6 * CD-1 * DBA * FVB/N) 		increased mammary adenocarcinoma incidence J:170904
Map3k7tm1Aki/Map3k7tm1Aki
Tg(Alb1-cre)7Gsc/0
(involves: 129P2/OlaHsd * FVB/N) 		increased hepatocellular carcinoma incidence J:160521
Mapk14tm1Nbr/Mapk14tm2Nbr
Polr2atm1(cre/ERT2)Bbd/Polr2a+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL) 		increased lung adenocarcinoma incidence J:122397
increased lung adenoma incidence J:122397
Mapkapk5tm1Pqs/Mapkapk5+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6) 		increased skin papilloma incidence J:117893
Mapkapk5tm1Pqs/Mapkapk5+
Tg(SV40-NRAS*G12D)1Sco/?
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6) 		increased lymphoma incidence J:117893
Mapkapk5tm1Pqs/Mapkapk5tm1Pqs
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6) 		increased skin papilloma incidence J:117893
Mapkapk5tm1Pqs/Mapkapk5tm1Pqs
Tg(SV40-NRAS*G12D)1Sco/?
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6) 		increased lymphoma incidence J:117893
Mapttm1(EGFP)Klt/Mapttm1(EGFP)Klt
Tg(MAPT)8cPdav/?
(involves: 129S4/SvJae * C57BL/6 * Swiss Webster) 		increased follicular lymphoma incidence J:174270
increased lymphoma incidence J:174270
Mc1re/Mc1re
Xpctm1Brd/Xpctm1Brd
Tg(KRT14-Kitl)1Takk/0
(involves: 129S7/SvEvBrd * C57BL/6 * SJL) 		increased squamous cell carcinoma incidence J:112959
Mc4rtm1Lowl/Mc4rtm1Lowl
(involves: 129S4/SvJae * C57BL/6J) 		increased hepatocellular carcinoma incidence J:177386
Mcctm1.1Maija/Mcctm1.1Maija
Tg(Vil1-cre)997Gum/0
(involves: C57BL/6 * C57BL/6J * SJL) 		increased large intestine adenocarcinoma incidence J:294342
MclrRF/J/MclrSWR/J
(involves: RF/J * SWR/J) 		increased T cell derived lymphoma incidence J:9614
MclrSWR/J/MclrSWR/J
(involves: RF/J * SWR/J) 		increased T cell derived lymphoma incidence J:9614
Mcm2Gt(AB0178)Wtsi/Mcm2+
Mcm4chaos3/Mcm4chaos3
(involves: 129P2/OlaHsd * C3HeB/FeJ * C57BL/6J) 		increased leukemia incidence J:165667
increased T cell derived lymphoma incidence J:165667
Mcm3Gt(RRR002)Byg/Mcm3+
Mcm4chaos3/Mcm4chaos3
Mcm6Gt(YHD248)Byg/Mcm6+
(involves: 129P2/OlaHsd * C3HeB/FeJ * C57BL/6J) 		increased lymphoma incidence J:165667
Mcm3Gt(RRR002)Byg/Mcm3+
Mcm4chaos3/Mcm4Gt(RRE056)Byg
(involves: 129P2/OlaHsd * C3HeB/FeJ * C57BL/6J) 		increased lymphoma incidence J:165667
Mcm3tm1.1Geno/Mcm3+
(involves: 129S2/SvPas * C57BL/6) 		increased lymphoma incidence J:227638
Mcm3tm1.2Geno/Mcm3+
(involves: 129S2/SvPas * C57BL/6) 		increased lymphoma incidence J:227638
Mcm4chaos3/Mcm4chaos3
(involves: C57BL/6J) 		increased lymphoma incidence J:165667
increased T cell derived lymphoma incidence J:165667
Mcm4chaos3/Mcm4chaos3
(C3.B6-Mcm4chaos3) 		increased hepatocellular carcinoma incidence J:117494
increased lung adenocarcinoma incidence J:117494
increased mammary adenocarcinoma incidence J:117494
Mcm4Sdla/Mcm4+
(involves: C57BL/6) 		increased acute lymphoblastic leukemia incidence J:194117
Mcm8tm1.1Geno/Mcm8tm1.1Geno
(involves: 129S2/SvPas * C57BL/6J) 		increased ovary adenoma incidence J:187623
Mcm9Gt(AW0655)Wtsi/Mcm9Gt(AW0655)Wtsi
(involves: 129P2/OlaHsd * C3HeB/FeJ) 		increased adenoma incidence J:177420
increased hepatocellular carcinoma incidence J:177420
Mcm9Gt(AW0655)Wtsi/Mcm9Gt(XG743)Byg
(involves: 129P2/OlaHsd * C3HeB/FeJ) 		increased hepatocellular carcinoma incidence J:177420
Mcm9Gt(XG743)Byg/Mcm9Gt(XG743)Byg
(involves: 129P2/OlaHsd * C3HeB/FeJ) 		increased hepatocellular carcinoma incidence J:177420
Mdm2tm1.1Ypz/Mdm2tm1.1Ypz
Tg(IghMyc)22Bri/0
(B6.Cg-Mdm2tm1.1Ypz Tg(IghMyc)22Bri) 		increased lymphoma incidence J:164200
Mdm2tm2.1Snj/Mdm2tm2.1Snj
(involves: 129S4/SvJae * C57BL/6) 		increased B cell derived lymphoma incidence J:189297
increased T cell derived lymphoma incidence J:189297
Mdm2tm3.1Glo/Mdm2tm3.1Glo
(B6.129S6-Mdm2tm3.1Glo) 		increased lymphoma incidence J:164201
increased mammary adenocarcinoma incidence J:164201
Mdm2tm3.1Glo/Mdm2tm3.1Glo
Trp53tm3.1Glo/Trp53+
(B6.129S-Mdm2tm3.1Glo Trp53tm3.1Glo) 		increased adenocarcinoma incidence J:164201
increased carcinoma incidence J:164201
increased fibrosarcoma incidence J:164201
increased hemangiosarcoma incidence J:164201
increased histiocytic sarcoma incidence J:164201
increased leiomyosarcoma incidence J:164201
increased lipoma incidence J:164201
increased liver adenocarcinoma incidence J:164201
increased liver adenoma incidence J:164201
increased lung adenoma incidence J:164201
increased lymphoma incidence J:164201
increased mammary adenocarcinoma incidence J:164201
increased osteosarcoma incidence J:164201
increased papilloma incidence J:164201
increased sarcoma incidence J:164201
increased squamous cell carcinoma incidence J:164201
Mdm2tm4.1Glo/Mdm2tm4.1Glo
(B6.129S6-Mdm2tm4.1Glo) 		increased sarcoma incidence J:164201
Mdm2tm4.1Glo/Mdm2tm4.1Glo
Trp53tm3.1Glo/Trp53+
(B6.129S-Mdm2tm4.1Glo Trp53tm3.1Glo) 		increased adenocarcinoma incidence J:164201
increased carcinoma incidence J:164201
increased fibrosarcoma incidence J:164201
increased histiocytic sarcoma incidence J:164201
increased liver adenocarcinoma incidence J:164201
increased lymphoma incidence J:164201
increased osteosarcoma incidence J:164201
increased sarcoma incidence J:164201
increased squamous cell carcinoma incidence J:164201
Mdm4tm1Glo/Mdm4+
Tg(IghMyc)22Bri/0
(involves: 129S6/SvEvTac * C57BL * C57BL/6 * SJL) 		increased B cell derived lymphoma incidence J:123661
Mef2btm2Rdf/Mef2b+
Tg(BCL2/IGH)M23Tjd/0
Tg(Cr2-cre)3Cgn/0
(involves: C3H/He * C57BL/6) 		increased follicular lymphoma incidence J:265465
increased lymphoma incidence J:265465
Mef2btm2Rdf/Mef2b+
Tg(Cr2-cre)3Cgn/0
(involves: C57BL/6) 		increased B cell derived lymphoma incidence J:265465
Men1tm1.1Ctre/Men1+
(involves: 129S6/SvEvTac * FVB/N) 		increased pancreatic islet cell adenoma incidence J:133299
increased parathyroid adenoma incidence J:133299
Men1tm1.1Ctre/Men1+
(involves: 129S6/SvEvTac * C57BL/6) 		increased lung adenocarcinoma incidence J:120835
Men1tm1.1Ctre/Men1+
Rb1tm1Tyj/Rb1+
(involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6J * FVB/N) 		increased thyroid C-cell carcinoma incidence J:133299
Men1tm1.1Gfk/Men1+
(involves: 129T2/SvEms * C57BL/6) 		increased adrenal gland adenoma incidence J:116086
increased glucagonoma incidence J:116086
increased insulinoma incidence J:116086
increased pancreas adenoma incidence J:116086
increased parathyroid adenoma incidence J:116086
increased pituitary adenoma incidence J:116086
increased prolactinoma incidence J:116086
Men1tm1.2Ctre/Men1+
Tg(Ins2-cre)1Dh/0
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N) 		increased insulinoma incidence J:85042
Men1tm1.2Ctre/Men1+
Tg(Ins2-cre)1Heed/0
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N) 		increased insulinoma incidence J:85042
Men1tm1.2Ctre/Men1+
Tg(Ins2-cre)25Mgn/0
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N) 		increased insulinoma incidence J:85042
Men1tm1.2Ctre/Men1tm1.2Ctre
Tg(Ins2-cre)1Dh/0
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N) 		increased insulinoma incidence J:85042
Men1tm1.2Ctre/Men1tm1.2Ctre
Tg(Ins2-cre)1Heed/0
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N) 		increased insulinoma incidence J:85042
Men1tm1.2Ctre/Men1tm1.2Ctre
Tg(Ins2-cre)25Mgn/0
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N) 		increased insulinoma incidence J:85042
Men1tm1.2Zqw/Men1tm1.2Zqw
Tg(Ins2-cre)23Herr/0
(involves: 129P2/OlaHsd * C57BL/6J * CBA/J) 		increased insulinoma incidence J:85133
Men1tm1Ctre/Men1+
(either: (involves: 129S6/SvEvTac * FVB/N) or (involves: 129S6/SvEvTac * Black Swiss * FVB/N)) 		increased carcinoma incidence J:67128
increased lung adenocarcinoma incidence J:67128
increased parathyroid adenoma incidence J:67128
increased pituitary adenoma incidence J:67128
increased prolactinoma incidence J:67128
increased thyroid adenoma incidence J:67128
Men1tm1Ctre/Men1tm1Ctre
Tg(Pdx1-cre)89.1Dam/0
(involves: 129S6/SvEvTac * C57BL/6 * CBA * FVB/N) 		increased insulinoma incidence J:146440
Men1tm1Gfk/Men1tm1Gfk
Tg(Ins2-cre)25Mgn/0
(involves: 129T2/SvEms * C57BL/6 * C57BL/6J * DBA) 		increased insulinoma incidence J:89898
increased prolactinoma incidence J:89898
Men1tm1Rvt/Men1+
(involves: 129 * C57BL/6) 		increased pancreatic islet cell adenoma incidence J:191261
increased parathyroid adenoma incidence J:191261
Men1tm1Zqw/Men1+
(involves: 129/Sv * 129P2/OlaHsd) 		increased adrenal gland adenoma incidence J:85302
increased adrenocortical adenoma incidence J:85302
increased glucagonoma incidence J:85302
increased insulinoma incidence J:85302
increased intestinal adenoma incidence J:85302
increased pancreatic islet cell adenoma incidence J:85302
increased pancreatic islet cell carcinoma incidence J:85302
increased parathyroid adenoma incidence J:85302
increased prolactinoma incidence J:85302
increased thyroid carcinoma incidence J:85302
Men1tm2.1Gfk/Men1+
(involves: 129T2/SvEms * C57BL/6) 		increased insulinoma incidence J:116086
increased pancreas adenoma incidence J:116086
increased parathyroid adenoma incidence J:116086
increased pituitary adenoma incidence J:116086
Men1tm2.1Mmey/Men1tm2.1Mmey
Tg(Ins2-cre)23Herr/0
(involves: 129S6/SvEvTac * C57BL/6 * CBA/J * FVB/N) 		increased insulinoma incidence J:175625
Mettm1Gvw/Met+
(involves: 129 * C57BL/6J) 		increased carcinoma incidence J:94722
increased histiocytic sarcoma incidence J:94722
increased lymphoma incidence J:94722
increased squamous cell carcinoma incidence J:94722
Mettm2Gvw/Met+
(involves: 129 * C57BL/6J) 		increased hemangiosarcoma incidence J:94722
increased histiocytic sarcoma incidence J:94722
increased lymphoma incidence J:94722
Mettm3Gvw/Mettm3Gvw
(involves: 129 * C57BL/6J) 		increased hemangiosarcoma incidence J:94722
Mettm4Gvw/Met+
(involves: 129 * C57BL/6J) 		increased lymphoma incidence J:94722
increased sarcoma incidence J:94722
Mettm4Gvw/Met+
(involves: 129 * C57BL/6J * FVB/N) 		increased hemangiosarcoma incidence J:151890
increased mammary adenocarcinoma incidence J:151890
increased myoepithelioma incidence J:151890
increased sarcoma incidence J:151890
increased squamous cell carcinoma incidence J:151890
Mfge8tm1Mcu/Mfge8tm1Mcu
Tg(RIP1-Tag)2Dh/?
(involves: 129X1/SvJ * C57BL/6J * C57BL/6NCr * DBA/2J) 		increased adenoma incidence J:123138
increased carcinoma incidence J:123138
Mgmttm1Mse/Mgmttm1Mse
(involves: 129S/SvEv) 		increased T cell derived lymphoma incidence J:47642
Mgmttm1Mse/Mgmttm1Mse
Mlh1tm1Mse/Mlh1tm1Mse
(involves: 129S/SvEv) 		increased lung adenoma incidence J:47642
increased T cell derived lymphoma incidence J:47642
Miftm1Gfr/Miftm1Gfr
(C57BL/6-Miftm1Gfr) 		increased fibrosarcoma incidence J:84791
Mir34atm1.2Arte/Mir34a+
Tg(Neurod2-Smo*A1)199Jols/0
(involves: C57BL/6 * C57BL/6N) 		increased medulloblastoma incidence J:221990
Mir34atm1.2Arte/Mir34atm1.2Arte
Tg(Neurod2-Smo*A1)199Jols/0
(involves: C57BL/6 * C57BL/6N) 		increased medulloblastoma incidence J:221990
Mir122tm1.1Apts/Mir122tm1.1Apts
(involves: 129 * C57BL/6) 		increased hepatocellular carcinoma incidence J:190066
Mir122tm1.1Kgh/Mir122+
(involves: 129S1/Sv * 129X1/SvJ) 		increased hepatocellular carcinoma incidence J:190067
Mir122tm1.1Kgh/Mir122tm1.1Kgh
(involves: 129S1/Sv * 129X1/SvJ) 		increased hepatocellular carcinoma incidence J:190067
Mir122tm1.2Kgh/Mir122+
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA) 		increased hepatocellular carcinoma incidence J:190067
Mir122tm1.2Kgh/Mir122tm1.2Kgh
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA) 		increased hepatocellular carcinoma incidence J:190067
Mir146tm1.1Bal/Mir146tm1.1Bal
(involves: C57BL/6) 		increased B cell derived lymphoma incidence J:173230
increased follicular lymphoma incidence J:173230
increased myeloid sarcoma incidence J:173230
increased T cell derived lymphoma incidence J:173230
Mir146tm2.1Bal/Mir146tm2.1Bal
(involves: 129S1/Sv * C57BL/6 * FVB/N) 		increased follicular lymphoma incidence J:173671
Mirc1tm2.1Aven/Mirc1tm2.1Aven
Tg(ARR2/Pbsn-MYC)7Key/0
(involves: 129S4/SvJae * C57BL/6 * FVB/N * SJL/J) 		increased prostate gland adenocarcinoma incidence J:223213
Mirc1tm2.1Aven/Mirc1tm2.1Aven
Tg(IghMyc)22Bri/?
(involves: 129S4/SvJae * C57BL/6 * SJL/J) 		increased B cell derived lymphoma incidence J:223213
Mirc30em1Hhzg/Mirc30em1Hhzg
Tg(Vav1-cre)#Cgp/0
(involves: 129S4/SvJae * C57BL/6 * C57BL/6NRj) 		increased chronic lymphocytic leukemia incidence J:320883
Mirc30tm1.2Rdf/Mirc30tm1.2Rdf
(involves: 129S1/Sv * 129S4/SvJaeSor * C57BL/6) 		increased B cell derived lymphoma incidence J:156946
increased leukemia incidence J:156946
Mldhrtm1Zhgn/Mldhrtm1Zhgn
Tg(GFAP-cre)25Mes/0
(involves: FVB/N) 		increased glioblastoma incidence J:303725
Mleu1SWR/J/?
Tg(CTSG-PML/RARA)135Ley/0
(involves: C3H/HeJ * C57BL/6J * SWR/J) 		increased leukemia incidence J:139159
Mleu2SWR/J/?
Tg(CTSG-PML/RARA)135Ley/0
(involves: C3H/HeJ * C57BL/6J * SWR/J) 		increased leukemia incidence J:139159
Mleu3C57BL/6J/Mleu3SWR/J
Tg(CTSG-PML/RARA)135Ley/0
(involves: C3H/HeJ * C57BL/6J * SWR/J) 		increased leukemia incidence J:139159
Mleu4SWR/J/?
Tg(CTSG-PML/RARA)135Ley/0
(involves: C3H/HeJ * C57BL/6J * SWR/J) 		increased leukemia incidence J:139159
Mleu5SWR/J/?
Tg(CTSG-PML/RARA)135Ley/0
(involves: C3H/HeJ * C57BL/6J * SWR/J) 		increased leukemia incidence J:139159
Mlh1tm1Lisk/Mlh1tm1Lisk
(involves: 129S7/SvEvBrd) 		increased lymphoma incidence J:34291
Mlh1tm1Lisk/Mlh1tm1Lisk
(involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6) 		increased intestinal adenocarcinoma incidence J:75745
increased intestinal adenoma incidence J:75745
increased lymphoma incidence J:75745
Mlh1tm1Mse/Mlh1tm1Mse
(involves: 129S/SvEv) 		increased T cell derived lymphoma incidence J:47642
Mlh1tm1Rak/Mlh1+
(involves: 129P2/OlaHsd * C57BL/6) 		increased adenocarcinoma incidence J:53451
increased carcinoma incidence J:53451
increased lung carcinoma incidence J:53451
increased lymphoma incidence J:53451
increased squamous cell carcinoma incidence J:53451
increased T cell derived lymphoma incidence J:53451
Mlh1tm1Rak/Mlh1tm1Rak
(involves: 129P2/OlaHsd * C57BL/6) 		increased adenoma incidence J:53451
increased B cell derived lymphoma incidence J:98929, J:53451
increased carcinoma incidence J:53451
increased lymphoma incidence J:53451
increased T cell derived lymphoma incidence J:53451
Mlh1tm1Rak/Mlh1tm1Rak
(involves: 129P2/OlaHsd) 		increased lymphoma incidence J:133352
increased small intestine adenocarcinoma incidence J:133352
Mlh1tm1Rak/Mlh1tm1Rak
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J) 		increased intestinal adenocarcinoma incidence J:153684
increased intestinal adenoma incidence J:153684
increased lymphoma incidence J:153684
increased T cell derived lymphoma incidence J:153684
Mlh1tm1Wed/Mlh1tm1Wed
(involves: 129/Sv * C57BL/6J * SJL) 		increased basal cell carcinoma incidence J:133352
increased lymphoma incidence J:133352
Mmp8tm1Otin/Mmp8tm1Otin
(involves: 129X1/SvJ * C57BL/6J) 		increased fibrosarcoma incidence J:86393
increased papilloma incidence J:86393
Mmp9tm1Tvu/Mmp9tm1Tvu
Tg(KRT14-HPV16)wt1Dh/0
(involves: 129S6/SvEvTac * C57BL/6 * DBA/2 * FVB/N) 		increased skin squamous cell carcinoma incidence J:65699
Mmp11tm1Mrio/Mmp11tm1Mrio
Tg(MMTV-vHaras)SH1Led/Tg(MMTV-vHaras)SH1Led
(involves: 129S2/SvPas * 129X1/SvJ * C57BL/6J * CD-1 * FVB) 		increased carcinoma incidence J:86074
Mnttm1Awb/Mnttm1.1Awb
Tg(MMTV-cre)4Mam/?
(involves: 129S6/SvEvTac * FVB/N) 		increased mammary adenocarcinoma incidence J:110115
Mnttm1Phu/Mnttm1Phu
Tg(MMTV-cre)4Mam/?
(involves: FVB) 		increased mammary adenocarcinoma incidence J:85481
Mob1atm1.1Asuz/Mob1atm1.1Asuz
Mob1bGt(CC0690)Wtsi/Mob1bGt(CC0690)Wtsi
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(B6.Cg-Mob1bGt(CC0690)Wtsi Mob1atm1.1Asuz Speer6-ps1Tg(Alb-cre)21Mgn) 		increased cholangiocarcinoma incidence J:228499
increased hepatocellular carcinoma incidence J:228499
increased liver adenoma incidence J:228499
Mob1atm1.2Asuz/Mob1a+
Mob1bGt(CC0690)Wtsi/Mob1bGt(CC0690)Wtsi
(involves: 129P2/OlaHsd * C57BL/6) 		increased fibrosarcoma incidence J:193981
increased osteosarcoma incidence J:193981
Mob1atm1.2Asuz/Mob1atm1.2Asuz
Mob1bGt(CC0690)Wtsi/Mob1b+
(involves: 129P2/OlaHsd * C57BL/6) 		increased fibrosarcoma incidence J:193981
increased osteosarcoma incidence J:193981
Mostm1Sia/Mostm1Sia
(involves: C57BL/6 * CBA) 		increased teratoma incidence J:19086
Mp53d1BALB/c/Mp53d1MSM
(involves: BALB/c-Trp53tm1Brd * MSM) 		decreased lymphoma incidence J:81940
Mp53d2BALB/c/Mp53d2MSM
(involves: BALB/c-Trp53tm1Brd * MSM) 		decreased lymphoma incidence J:81940
Mre11atm1Jpt/Mre11a+
Rad50tm2Jpt/Rad50tm2Jpt
(involves: 129S7/SvEvBrd * C57BL/6) 		increased lymphoma incidence J:103922
Mre11atm1Jpt/Mre11atm1Jpt
Rad50tm2Jpt/Rad50tm2Jpt
(involves: 129S7/SvEvBrd * C57BL/6) 		increased lymphoma incidence J:103922
Msh2tm1Htr/Msh2+
(involves: 129P2/OlaHsd) 		increased hemangiosarcoma incidence J:45433
increased osteosarcoma incidence J:45433
Msh2tm1Htr/Msh2tm1Htr
(either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * FVB)) 		increased T cell derived lymphoma incidence J:27469
Msh2tm1Htr/Msh2tm1Htr
(involves: 129P2/OlaHsd) 		increased lymphoma incidence J:45433
increased T cell derived lymphoma incidence J:45433
Msh2tm1Htr/Msh2tm1Htr
(involves: 129P2/OlaHsd * FVB) 		increased lymphoma incidence J:45433
increased T cell derived lymphoma incidence J:45433
Msh2tm1Htr/Msh2tm1Htr
Smug1tm1a(EUCOMM)Hmgu/Smug1tm1a(EUCOMM)Hmgu
Ungtm1Tld/Ungtm1Tld
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N) 		increased lymphoma incidence J:197809
Msh2tm1Htr/Msh2tm1Htr
Smug1tm1a(EUCOMM)Hmgu/Smug1tm1a(EUCOMM)Hmgu
Ungtm1Tld/Ungtm1Tld
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N) 		increased lymphoma incidence J:197809
Msh2tm1Mak/Msh2+
Mutyhtm1Jhmi/Mutyhtm1Jhmi
Ogg1tm1Tld/Ogg1tm1Tld
(involves: 129 * C57BL/6J) 		increased lung adenocarcinoma incidence J:89742
increased lung adenoma incidence J:89742
increased lymphoma incidence J:89742
Msh2tm1Mak/Msh2tm1Mak
(involves: 129P2/OlaHsd * C57BL/6J) 		increased lymphoma incidence J:28397
Msh2tm1Mak/Msh2tm1Mak
Mutyhtm1Jhmi/Mutyhtm1Jhmi
Ogg1tm1Tld/Ogg1tm1Tld
(involves: 129 * C57BL/6J) 		increased lung adenoma incidence J:89742
increased lymphoma incidence J:89742
Msh2tm1Rak/Msh2+
(involves: 129P2/OlaHsd) 		increased liver adenoma incidence J:64667
increased lymphoma incidence J:64667
Msh2tm1Rak/Msh2tm1Rak
(involves: 129P2/OlaHsd) 		increased lymphoma incidence J:64667
Msh2tm1Rak/Msh2tm1Rak
(involves: 129P2/OlaHsd * C57BL/6) 		increased lymphoma incidence J:98929
Msh2tm1Rak/Msh2tm2.1Rak
Tg(Vil1-cre)20Syr/0
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * DBA/2 * SJL) 		increased intestinal adenocarcinoma incidence J:161577
increased intestinal adenoma incidence J:161577
Msh2tm1Wed/Msh2tm1Wed
(involves: C57BL/6) 		increased intestinal adenocarcinoma incidence J:86278
increased lymphoma incidence J:86278
Msh2tm1Wed/Msh2tm1Wed
(involves: 129 * C57BL/6 * SJL) 		increased intestinal adenocarcinoma incidence J:88092
increased lymphoma incidence J:88092
Msh2tm1Whl/Msh2tm1Whl
(involves: 129P2/OlaHsd * C57BL/6J) 		increased lymphoblastic lymphoma incidence J:79016
increased squamous cell carcinoma incidence J:79016
Msh2tm1Whl/Msh2tm1Whl
Rb1tm1Brd/Rb1+
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J) 		increased lymphoblastic lymphoma incidence J:79016
increased thyroid C-cell carcinoma incidence J:79016
Msh2tm2.1Rak/Msh2tm2.1Rak
Tg(Vil1-cre)20Syr/0
(involves: 129/Sv * C57BL/6 * FVB/N * SJL) 		increased intestinal adenoma incidence J:161577
increased lymphoma incidence J:161577
increased small intestine adenocarcinoma incidence J:161577
Msh2tm2.1Rak/Msh2tm3.1Rak
Tg(Vil1-cre)20Syr/0
(involves: 129/Sv * C57BL/6 * DBA/2 * SJL) 		increased intestinal adenocarcinoma incidence J:161577
increased intestinal adenoma incidence J:161577
Msh2tm2.2Rak/Msh2tm2.2Rak
(involves: 129/Sv * C57BL/6 * FVB/N * SJL) 		increased lymphoma incidence J:161577
Msh3tm1Htr/Msh3tm1Htr
Msh6tm1Htr/Msh6tm1Htr
(involves: 129P2/OlaHsd * FVB/N) 		increased lymphoma incidence J:59561
Msh3tm1Rak/Msh3tm1Rak
(involves: 129/Sv * C57BL/6J * SJL) 		increased intestinal adenocarcinoma incidence J:60604
Msh3tm1Rak/Msh3tm1Rak
Msh6tm1Rak/Msh6tm1Rak
(involves: 129/Sv * C57BL/6J * SJL) 		increased intestinal adenocarcinoma incidence J:60604
increased lymphoma incidence J:60604
Msh6tm1Htr/Msh6tm1Htr
(involves: 129P2/OlaHsd * FVB/N) 		increased lymphoma incidence J:59561
Msh6tm1Rak/Msh6tm1Rak
(involves: 129/Sv * C57BL/6J * SJL) 		increased lymphoma incidence J:44428
Msh6tm1Wed/Msh6+
(involves: 129/Sv * C57BL/6J * SJL) 		increased lymphoma incidence J:92555
Msh6tm1Wed/Msh6tm1Wed
(involves: 129/Sv * C57BL/6J * SJL) 		increased basal cell carcinoma incidence J:92555
increased intestinal adenoma incidence J:92555
increased lymphoma incidence J:92555
Msmbtm1Xuan/Msmbtm1Xuan
(either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * CD-1)) 		increased prostate gland adenocarcinoma incidence J:96884
Msmr1MSM/Ms/Msmr1MSM/Ms
(involves: MSM/Ms * SL/Kh) 		decreased lymphoma incidence J:34941
Msmr1MSM/Ms/Msmr1SL/Kh
(involves: MSM/Ms * SL/Kh) 		decreased lymphoma incidence J:34941
Msmr1SL/Kh/Msmr1SL/Kh
(involves: MSM/Ms * SL/Kh) 		increased lymphoma incidence J:34941
Msmr1SL/Kh/Msmr1SL/Kh
Msmr2SL/Kh/Msmr2SL/Kh
(involves: MSM/Ms * SL/Kh) 		increased B cell derived lymphoma incidence J:34941
Msmr2MSM/Ms/Msmr2MSM/Ms
(involves: MSM/Ms * SL/Kh) 		decreased lymphoma incidence J:34941
Msmr2MSM/Ms/Msmr2SL/Kh
(involves: MSM/Ms * SL/Kh) 		decreased lymphoma incidence J:34941
Msmr2SL/Kh/Msmr2SL/Kh
(involves: MSM/Ms * SL/Kh) 		increased lymphoma incidence J:34941
Mtbptm1Glo/Mtbp+
Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6J) 		increased leukemia incidence J:135509
increased lymphoma incidence J:135509
Mtf1Thyls-BALB/c/Mtf1Thyls-BALB/c
(involves: BALB/c * MSM) 		increased T cell derived lymphoma incidence J:71358
Mtf1Thyls-BALB/c/Mtf1Thyls-MSM
(involves: BALB/c * MSM) 		increased T cell derived lymphoma incidence J:85264, J:71358
Mtss1Gt(CSC156)Byg/Mtss1Gt(CSC156)Byg
(B6.129P2-Mtss1Gt(CSC156)Byg) 		increased B cell derived lymphoma incidence J:186118
Mtus1Gt(RRA048)Byg/Mtus1Gt(RRA048)Byg
(involves: 129P2/OlaHsd * C57BL/6) 		increased B cell derived lymphoma incidence J:212144
Mtv2a/Mtv2a
(DDD.GR-Mtv2a) 		increased mammary adenocarcinoma incidence J:109201
Muc2tm1Avel/Muc2tm1Avel
(involves: 129P2/OlaHsd * C57BL/6) 		increased intestinal adenocarcinoma incidence J:75047
Mus81tm1Raz/Mus81+
(involves: 129P2/OlaHsd) 		increased adenoma incidence J:91570
increased carcinoma incidence J:91570
increased lymphoma incidence J:91570
Mus81tm1Raz/Mus81tm1Raz
(involves: 129P2/OlaHsd) 		increased B cell derived lymphoma incidence J:91570
increased carcinoma incidence J:91570
increased lymphoma incidence J:91570
Mutyhtm1Jhmi/Mutyhtm1Jhmi
Ogg1tm1Tld/Ogg1tm1Tld
(involves: 129 * C57BL/6J) 		increased hemangioma incidence J:89742
increased lung adenoma incidence J:89742
increased lymphoma incidence J:89742
Mybl2tm1.1Jof/Mybl2+
Tg(Zp3-cre)3Mrt/0
(involves: 129S2/SvPas * C57BL/6 * FVB/N) 		increased leukemia incidence J:196804
Myctm1Lbox/Myc+
(involves: 129S1/Sv * 129X1/SvJ * FVB/N) 		increased B cell derived lymphoma incidence J:97900
Myctm1Lbox/Myctm1Lbox
(involves: 129S1/Sv * 129X1/SvJ * FVB/N) 		increased B cell derived lymphoma incidence J:97900
Myctm2Fwa/Myc+
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * CD-1) 		decreased osteosarcoma incidence J:319454
Myf6tm1(cre)Mrc/Myf6+
Pax3tm1Mrc/Pax3+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL) 		increased rhabdomyosarcoma incidence J:93444
Myf6tm1(cre)Mrc/Myf6+
Pax3tm1Mrc/Pax3tm1Mrc
Trp53tm1Brn/Trp53+
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL) 		increased rhabdomyosarcoma incidence J:93444
Myf6tm1(cre)Mrc/Myf6+
Pax3tm1Mrc/Pax3tm1Mrc
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL) 		increased rhabdomyosarcoma incidence J:93444
Myh14tm2Rsad/Myh14+
(involves: 129S/SvEv * C57BL/6) 		increased lymphoma incidence J:171110
Myh14tm2Rsad/Myh14tm2Rsad
(involves: 129S/SvEv * C57BL/6) 		increased lymphoma incidence J:171110
Mzf1tm1Ppp/Mzf1tm1Ppp
(involves: 129) 		increased hepatocellular carcinoma incidence J:70407
Nabp2tm1.1Kkha/Nabp2tm1.1Kkha
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
(involves: C57BL/6 * C57BL/6NTac) 		increased B cell derived lymphoma incidence J:195140
increased hepatocellular carcinoma incidence J:195140
increased leukemia incidence J:195140
increased T cell derived lymphoma incidence J:195140
Nabp2tm1Schg/Nabp2tm1Schg
Trp53tm1Brd/Trp53tm1Brd
(involves: 129S7/SvEvBrd * C57BL/6) 		increased lymphoma incidence J:228558
Nbnem3Jpt/Nbnem3Jpt
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas) 		increased hemangiosarcoma incidence J:251434
increased histiocytic sarcoma incidence J:251434
increased leiomyosarcoma incidence J:251434
increased rhabdomyosarcoma incidence J:251434
increased squamous cell carcinoma incidence J:251434
Nbnem4Jpt/Nbnem4Jpt
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas) 		increased hemangiosarcoma incidence J:251434
increased histiocytic sarcoma incidence J:251434
increased leiomyosarcoma incidence J:251434
increased rhabdomyosarcoma incidence J:251434
increased squamous cell carcinoma incidence J:251434
Nbnem7Jpt/Nbntm2Zqw
Tg(VAV1-cre)1Graf/0
(involves: 129P2/OlaHsd) 		increased T cell acute lymphoblastic leukemia incidence J:277750
increased T cell derived lymphoma incidence J:277750
Nbntm1Jpt/Nbntm1Jpt
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129S7/SvEvBrd) 		increased lymphoma incidence J:75956
increased teratoma incidence J:75956
Nbntm1Xu/Nbntm1Xu
(Not Specified) 		increased T cell derived lymphoma incidence J:75272
Nbntm1Zqw/Nbn+
(involves: 129S2/SvPas * C57BL/6) 		increased B cell derived lymphoma incidence J:86563
increased liver adenocarcinoma incidence J:86563
increased liver adenoma incidence J:86563
increased lung adenocarcinoma incidence J:86563
increased lymphoma incidence J:86563
increased mammary adenocarcinoma incidence J:86563
increased T cell derived lymphoma incidence J:86563
increased thyroid adenoma incidence J:86563
Nbntm2Zqw/Nbntm2Zqw
Trp53tm1Brd/Trp53tm1Brd
Tg(Nes-cre)1Wme/0
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * CBA) 		increased lymphoma incidence J:98316
increased sarcoma incidence J:98316
Ncoa3tm1Jxu/Ncoa3+
Tg(MMTV-vHaras)SH1Led/0
(involves: 129S6/SvEvTac * C57BL/6J * CD-1) 		increased mammary adenocarcinoma incidence J:88789
Ncoa3tm1Jxu/Ncoa3tm1Jxu
(involves: 129S6/SvEvTac * C57BL/6J) 		increased B cell derived lymphoma incidence J:109522
increased lymphoma incidence J:109522
Ncoa5tm1Hxia/Ncoa5+
(involves: 129 * C57BL/6) 		increased hepatocellular carcinoma incidence J:207622
Ncoa5tm1Hxia/Ncoa5+
(C.129(B6)-Ncoa5tm1Hxia) 		increased hepatocellular carcinoma incidence J:207622
Ncstntm1.1Akli/Ncstntm1.1Akli
Tet2tm1.1Iaai/Tet2tm1.1Iaai
Tg(VAV1-cre)1Graf/0
(involves: 129S/SvEv * C57BL/6) 		increased leukemia incidence J:196407
Ncstntm1.1Akli/Ncstntm1.1Akli
Tg(Mx1-cre)1Cgn/0
(involves: 129 * C57BL/6 * CBA * SJL) 		increased leukemia incidence J:172442
Ncstntm1.1Akli/Ncstntm1.1Akli
Tg(Upk2-cre,-EGFP)#Akli/0
(involves: 129) 		increased urinary bladder carcinoma incidence J:227748
Ncstntm1.1Akli/Ncstntm1.1Akli
Tg(VAV1-cre)1Graf/0
(involves: 129 * C57BL/6 * SJL) 		increased leukemia incidence J:172442
Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+
Rragatm2Dmsa/Rragatm2Dmsa
(involves: 129S/SvEv * 129S4/SvJae * C57BL/6) 		increased lymphoma incidence J:213516
Ndrg2tm1Kmori/Ndrg2+
(involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj) 		increased hepatocellular carcinoma incidence J:210264
increased lung carcinoma incidence J:210264
increased T cell derived lymphoma incidence J:210264
Ndrg2tm1Kmori/Ndrg2tm1Kmori
(involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj) 		increased hepatocellular carcinoma incidence J:210264
increased lung carcinoma incidence J:210264
increased T cell derived lymphoma incidence J:210264
Nell1tm1Kuv/Nell1tm1Kuv
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(BGLAP-cre)1Clem/0
(involves: 129 * FVB/NJ) 		decreased osteosarcoma incidence J:326989
Nf1tm1.1Kest/Nf1tm1c(KOMP)Wtsi
Tg(Dhh-cre)1Mejr/0
(involves: 129S4/SvJaeSor * C57BL/6 * C57BL/6N * C57BL/6NTac * FVB/N) 		increased neurofibroma incidence J:234172
Nf1tm1c(KOMP)Wtsi/Nf1tm1c(KOMP)Wtsi
Tg(Dhh-cre)1Mejr/0
(involves: 129S4/SvJaeSor * C57BL/6 * C57BL/6N * FVB/N) 		increased neurofibroma incidence J:234172
Nf1tm1Fcr/Nf1+
Ptentm1Hwu/Ptentm1Hwu
Tg(Mx1-cre)1Cgn/0
(B6.Cg-Tg(Mx1-cre)1Cgn Nf1tm1Fcr Ptentm1Hwu) 		increased T cell acute lymphoblastic leukemia incidence J:232645
Nf1tm1Fcr/Nf1+
Trp53tm1Brd/Trp53+
(B6.129-Trp53tm1Brd Nf1tm1Fcr) 		increased malignant tumor incidence J:95933
increased sarcoma incidence J:95933
Nf1tm1Fcr/Nf1+
Trp53tm1Tyj/Trp53+
(involves: 129S/SvEv * 129S2/SvPas * C57BL/6) 		increased carcinoma incidence J:58877
increased fibrohistocytoma incidence J:58877
increased leiomyosarcoma incidence J:58877
increased lymphoma incidence J:58877
increased malignant triton tumor incidence J:58877
increased neuroblastoma incidence J:58877
increased neurofibrosarcoma incidence J:58877
increased rhabdomyosarcoma incidence J:58877
increased sarcoma incidence J:58877
Nf1tm1Fcr/Nf1+
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S/SvEv * 129S2/SvPas * C57BL/6) 		increased lymphoma incidence J:58877
Nf1tm1Par/Nf1tm1Tyj
Tg(Mpz-cre)1Brn/0
(involves: 129/Sv * FVB/N) 		increased neurofibroma incidence J:131914
Nf1tm1Tyj/?
Nstr1C57BL/6J/Nstr1C57BL/6J
Trp53tm1Tyj/?
(involves: 129S2/SvPas * A/J * C57BL/6J) 		increased neurofibrosarcoma incidence J:105038
Nf1tm1Tyj/Nf1+
(involves: 129S2/SvPas * C57BL/6) 		increased fibrosarcoma incidence J:18542
increased leukemia incidence J:18542
increased lung adenocarcinoma incidence J:18542
increased lymphoma incidence J:18542
increased neurofibrosarcoma incidence J:18542
Nf1tm1Tyj/Nf1+
Suz12Gt(Betageo)1Khe/Suz12+
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6) 		increased hepatocellular carcinoma incidence J:217077
increased histiocytic sarcoma incidence J:217077
increased intestinal adenoma incidence J:217077
increased lymphoma incidence J:217077
increased neurofibroma incidence J:217077
increased neurofibrosarcoma incidence J:217077
Nf1tm1Tyj/Nf1+
Suz12Gt(Betageo)1Khe/Suz12+
Trp53tm1Tyj/Trp53+
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6) 		increased hemangiosarcoma incidence J:217077
increased histiocytic sarcoma incidence J:217077
increased lymphoma incidence J:217077
increased neurofibrosarcoma incidence J:217077
Nf1tm1Tyj/Nf1+
Tg(Th-MYCN)41Waw/0
(involves: 129S2/SvPas * BALB/c * C57BL/6J) 		increased neuroblastoma incidence J:41126
Nf1tm1Tyj/Nf1+
Trp53tm1Tyj/Trp53+
(involves: 129/Sv * C57BL/6) 		increased neurofibrosarcoma incidence J:58876
increased sarcoma incidence J:58876
Nf1tm1Tyj/Nf1+
Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas) 		increased neurofibrosarcoma incidence J:131914
Nf1tm1Tyj/Nf1+
Trp53tm1Tyj/Trp53+
(B6.129S2-Trp53tm1Tyj Nf1tm1Tyj/+ +) 		increased glioblastoma incidence J:64364
Nf1tm1Tyj/Nf1+
Trp53tm1Tyj/Trp53+
((C3H/HeJ x B6.129S2-Trp53tm1Tyj Nf1tm1Tyj/+ +)F1) 		increased glioblastoma incidence J:64364
Nf1tm1Tyj/Nf1+
Trp53tm1Tyj/Trp53+
((CAST/EiJ x B6.129S2-Trp53tm1Tyj Nf1tm1Tyj/+ +)F1) 		increased glioblastoma incidence J:64364
Nf1tm1Tyj/Nf1+
Trp53tm1Tyj/Trp53+
((SJL/J x B6.129S2-Trp53tm1Tyj Nf1tm1Tyj/+ +)F1) 		increased glioblastoma incidence J:64364
Nf1tm1Tyj/Nf1+
Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * C57BL/6) 		increased histiocytic sarcoma incidence J:217077
increased lymphoma incidence J:228258, J:217077
increased neuroblastoma incidence J:217077
increased neurofibrosarcoma incidence J:217077
increased sarcoma incidence J:228258
Nf1tm1Tyj/Nf1tm2Tyj
(chimera involves: 129S2/SvPas) 		increased neurofibroma incidence J:58876
Nf2tm1Gth/Nf2+
(involves: 129P2/OlaHsd * FVB/N) 		increased fibroadenoma incidence J:63264
increased lung adenocarcinoma incidence J:63264
increased mesothelioma incidence J:63264
increased neurofibroma incidence J:63264
increased neurofibrosarcoma incidence J:63264
increased osteosarcoma incidence J:63264
increased renal carcinoma incidence J:63264
increased sarcoma incidence J:63264
Nf2tm1Gth/Nf2tm2Gth
Tg(Mpz-cre)1Brn/0
(involves: 129P2/OlaHsd * FVB/N) 		increased hamartoma incidence J:63264
Nf2tm1Gth/Nf2tm2Gth
Tg(Mpz-cre)#Brn/0
(involves: 129P2/OlaHsd * FVB/N) 		increased mesothelioma incidence J:63264
increased neurofibrosarcoma incidence J:63264
increased odontoma incidence J:63264
increased odontosarcoma incidence J:63264
Nf2tm1Tyj/Nf2+
(either: (involves: 129S2/SvPas * 129S4/SvJae * C57BL/6) or (involves: 129S2/SvPas * C57BL/6J)) 		increased carcinoma incidence J:47282
increased fibrosarcoma incidence J:47282
increased lung adenocarcinoma incidence J:47282
increased lymphoma incidence J:47282
increased malignant tumor incidence J:47282
increased osteosarcoma incidence J:47282
increased sarcoma incidence J:47282
Nf2tm2.1Gth/Nf2+
(involves: 129P2/OlaHsd * FVB/N) 		increased fibrosarcoma incidence J:63264
increased lung adenocarcinoma incidence J:63264
increased osteosarcoma incidence J:63264
Nf2tm2Gth/Nf2+
Tg(Mpz-cre)#Brn/0
(involves: 129P2/OlaHsd * FVB/N) 		increased fibroadenoma incidence J:63264
increased lung adenocarcinoma incidence J:63264
Nf2tm2Gth/Nf2+
Trp53tm1Brd/Trp53+
Tg(Mpz-cre)3Brn/0
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * FVB/N) 		increased neurofibrosarcoma incidence J:92413
increased osteosarcoma incidence J:92413
Nf2tm2Gth/Nf2+
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S7/SvEvBrd) 		increased leukemia incidence J:132943
increased mesothelioma incidence J:132943
increased uterus leiomyoma incidence J:132943
Nf2tm2Gth/Nf2tm2Gth
Ptgdstm1.1(cre)Gvn/Ptgds+
(involves: 129P2/OlaHsd * FVB/N) 		increased pituitary adenoma incidence J:173718
Nf2tm2Gth/Nf2tm2Gth
Ptgdstm1.1(cre)Gvn/Ptgds+
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * FVB/N) 		increased osteosarcoma incidence J:173718
Nf2tm2Gth/Nf2tm2Gth
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129P2/OlaHsd * C57BL/6 * DBA) 		increased hepatocellular carcinoma incidence J:162628
Nf2tm2Gth/Nf2tm2Gth
Tg(Mpz-cre)2Brn/0
(involves: 129P2/OlaHsd * FVB/N) 		increased extremity angiosarcoma incidence J:92413
increased lung adenocarcinoma incidence J:92413
increased neurofibrosarcoma incidence J:92413
increased renal carcinoma incidence J:92413
Nf2tm2Gth/Nf2tm2Gth
Tg(Mpz-cre)3Brn/0
(involves: 129P2/OlaHsd * FVB/N) 		increased fibroadenoma incidence J:63264
increased lung adenocarcinoma incidence J:63264
increased neurofibrosarcoma incidence J:63264
increased odontoma incidence J:63264
increased osteosarcoma incidence J:63264
increased renal carcinoma incidence J:63264
increased sarcoma incidence J:63264
Nf2tm2Gth/Nf2tm2Gth
Tg(Mpz-cre)#Brn/0
(involves: 129P2/OlaHsd * FVB/N) 		increased neurofibrosarcoma incidence J:63264
increased odontoma incidence J:63264
increased odontosarcoma incidence J:63264
increased osteosarcoma incidence J:63264
increased renal carcinoma incidence J:63264
Nf2tm2Gth/Nf2tm2Gth
Tg(Mx1-cre)1Cgn/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA) 		increased renal carcinoma incidence J:150071
Nf2tm2Gth/Nf2tm2Gth
Tg(Postn-cre)1Sjc/0
(involves: 129P2/OlaHsd * FVB/NTac) 		increased neurofibrosarcoma incidence J:216420
Nf2tm2Gth/Nf2tm2Gth
Tg(Vil1-cre)20Syr/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2) 		increased renal carcinoma incidence J:150071
Nf2tm2Gth/Nf2tm2Gth
Trp53tm1Brd/Trp53+
Tg(Mpz-cre)2Brn/0
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * FVB/N) 		increased leiomyosarcoma incidence J:92413
increased neurofibroma incidence J:92413
increased neurofibrosarcoma incidence J:92413
increased sarcoma incidence J:92413
Nf2tm2Gth/Nf2tm2Gth
Trp53tm1Brd/Trp53+
Tg(Mpz-cre)3Brn/0
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * FVB/N) 		increased neurofibrosarcoma incidence J:92413
Nf2tm2Gth/Nf2tm2Gth
Trp53tm1Brd/Trp53tm1Brd
Tg(Mpz-cre)2Brn/0
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * FVB/N) 		increased extremity angiosarcoma incidence J:92413
increased neurofibrosarcoma incidence J:92413
increased osteosarcoma incidence J:92413
increased rhabdomyosarcoma incidence J:92413
increased sarcoma incidence J:92413
Nf2tm2Gth/Nf2tm2Gth
Trp53tm1Brn/Trp53+
(involves: 129P2/OlaHsd * 129S7/SvEvBrd) 		increased leukemia incidence J:132943
increased mesothelioma incidence J:132943
increased uterus leiomyoma incidence J:132943
Nf2tm2Gth/Nf2tm2Gth
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S7/SvEvBrd) 		increased leukemia incidence J:132943
increased mesothelioma incidence J:132943
increased rhabdomyosarcoma incidence J:132943
increased T cell derived lymphoma incidence J:132943
increased uterus leiomyoma incidence J:132943
Nf2tm2Gth/Nf2tm2Gth
Yap1tm2.1Dupa/Yap1tm2.1Dupa
(involves: 129P2/OlaHsd) 		increased hamartoma incidence J:223215
Nfe2tm1.1Hlpa/?
(involves: 129 * C57BL/6) 		increased acute myeloid leukemia incidence J:275444
increased myeloid sarcoma incidence J:275444
Nfe2l1tm1Jefc/Nfe2l1tm1Ywk
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129X1/SvJ * C57BL/6J) 		increased hepatocellular carcinoma incidence J:97188
increased liver adenoma incidence J:97188
Nhej1tm1Fwa/Nhej1tm1Fwa
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129) 		increased B cell derived lymphoma incidence J:138774
increased medulloblastoma incidence J:138774
increased T cell derived lymphoma incidence J:138774
Nkx2-1tm2Shk/Nkx2-1tm2Shk
Tg(TPO-cre)1Shk/0
(involves: 129X1/SvJ * FVB/NCr) 		increased adenoma incidence J:111027
Nkx2-9tm1Jlck/Nkx2-9tm1Jlck
(involves: 129/Sv * C57BL/6 * SJL) 		increased lung adenoma incidence J:115581
increased squamous cell carcinoma incidence J:115581
Nkx3-1tm4(cre/ERT2)Mms/Nkx3-1+
Ptentm1Hwu/Ptentm1Hwu
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6) 		increased prostate gland adenocarcinoma incidence J:153425
Nme1tm1Jyd/Nme1tm1Jyd
(involves: 129/Sv * C57BL/6) 		increased lymphoma incidence J:109190
Nmitm1.1Geno/Nmitm1.1Geno
Tg(KRT14-cre)1Amc/0
Tg(MMTVneu)202Mul/0
(involves: 129S/SvEv * C57BL/6 * CBA * FVB/N) 		increased mammary adenocarcinoma incidence J:261035
Nop53tm1Asuz/Nop53+
(B6.129P2-Nop53tm1Asuz) 		decreased papilloma incidence J:241062
Notch1tm2Rko/Notch1tm2Rko
Notch2tm1Rko/Notch2tm1Rko
Notch3Gt(PST033)Byg/Notch3Gt(PST033)Byg
Tg(Mx1-cre)1Cgn/0
(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * CBA) 		increased leukemia incidence J:172442
Notch1tm2Rko/Notch1tm3(cre)Rko
(involves: 129X1/SvJ * C57BL/6) 		increased hemangioma incidence J:171829
Npm1tm1Gsva/Npm1+
Tg(Mx1-cre)1Cgn/0
(involves: C57BL/6 * CBA) 		increased acute promyelocytic leukemia incidence J:172071
increased B cell derived lymphoma incidence J:172071
Npm1tm1Ppp/Npm1+
Tg(IghMyc)22Bri/0
(involves: 129S1/Sv * C57BL/6 * SJL) 		increased B cell derived lymphoma incidence J:101494
Nr1h2tm1.1Gstr/Nr1h2tm1.1Gstr
Nr1h3tm1.1Gstr/Nr1h3tm1.1Gstr
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6) 		increased lung squamous cell carcinoma incidence J:234268
Nr1h4tm1Gonz/Nr1h4tm1Gonz
(involves: 129X1/SvJ * C57BL/6N) 		increased hepatocellular carcinoma incidence J:121075
increased liver adenoma incidence J:121075
Nr1h4tm1Gonz/Nr1h4tm1Gonz
(involves: 129X1/SvJ * C57BL/6) 		increased hepatocellular carcinoma incidence J:118204
increased liver adenoma incidence J:118204
Nr4a1tm1Jmi/Nr4a1tm1Jmi
Nr4a3tm1Omc/Nr4a3tm1Omc
(involves: 129S/SvEv * 129S2/SvPas * C57BL/6) 		increased leukemia incidence J:121903
Nrastm1Tyj/Nrastm1Tyj
Tg(Mx1-cre)1Cgn/0
(involves: C57BL/6 * CBA) 		increased acute lymphoblastic leukemia incidence J:204263
Nrastm1Tyj/Nrastm1Tyj
Tg(Tyr-cre)1Lru/0
(involves: C57BL/6 * DBA/2) 		increased melanoma incidence J:198244
Nrbp1tm1.1Dja/Nrbp1tm1.1Dja
Gt(ROSA)26Sortm1(cre/ERT)Brn/Gt(ROSA)26Sor+
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6J) 		increased leukemia incidence J:184685
increased lung carcinoma incidence J:184685
increased lymphoma incidence J:184685
Nrbp1tm1.1Dja/Nrbp1tm1.2Dja
Gt(ROSA)26Sortm1(cre/ERT)Brn/Gt(ROSA)26Sor+
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * 129S7/SvEvBrd * C57BL/6J) 		increased leukemia incidence J:184685
increased lung carcinoma incidence J:184685
increased lymphoma incidence J:184685
Nsmce2Gt(AA0032)Wtsi/Nsmce2+
(involves: 129P2/OlaHsd * C57BL/6) 		increased histiocytic sarcoma incidence J:227197
increased lymphoma incidence J:227197
Nuak2tm1Esu/Nuak2+
(B6.129S4-Nuak2tm1Esu) 		increased intestinal adenoma incidence J:139603
Nudt1tm1Tts/Nudt1tm1Tts
(involves: 129S/SvEv * C57BL/6 * DBA/2) 		increased lung adenocarcinoma incidence J:71836
increased lung adenoma incidence J:71836
Ogg1tm1Yun/Ogg1tm1Yun
(involves: 129S/SvEv * C57BL/6J) 		increased lung adenoma incidence J:82287
increased lung carcinoma incidence J:82287
Ossc1C3H/HeJ/?
Ossc2102/El/?
(involves: 102/El * C3H/HeJ) 		increased sarcoma incidence J:75213
Ossc3BALB/c/Ossc3CBA/Ca
(involves: BALB/c * CBA/Ca) 		increased osteosarcoma incidence J:107725
Otulinem1Gvl/Otulintm1c(EUCOMM)Hmgu
Tg(KRT14-cre)1Cgn/0
(involves: C57BL/6 * C57BL/6J * C57BL/6N * DBA/2) 		increased squamous cell carcinoma incidence J:312394
Otulintm1c(EUCOMM)Hmgu/Otulintm1c(EUCOMM)Hmgu
Tg(KRT14-cre)1Cgn/0
(involves: C57BL/6 * C57BL/6N * DBA/2) 		increased skin squamous cell carcinoma incidence J:312394
Pak1em1Yuwa/Pak1+
(FVB/N-Pak1em1Yuwa) 		decreased papilloma incidence J:323200
Pak1em1Yuwa/Pak1em1Yuwa
(FVB/N-Pak1em1Yuwa) 		decreased papilloma incidence J:323200
Paqr3tm1Ychn/Paqr3+
(involves: 129 * C57BL/6J) 		increased skin papilloma incidence J:139058
Paqr3tm1Ychn/Paqr3tm1Ychn
(involves: 129 * C57BL/6J) 		increased carcinoma incidence J:139058
increased skin papilloma incidence J:139058
Par2A/JSlc/Par2BALB/cByJJcl
(involves: BALB/cByJJcl * A/JSlc) 		increased lung adenoma incidence J:70565
Par2BALB/cByJJcl/Par2BALB/cByJJcl
(involves: BALB/cByJJcl * A/JSlc) 		increased lung adenoma incidence J:70565
Parms1BALB/cByJ/Parms1C57BL/6NCrl
Ptch1tm1Zim/Ptch1+
(involves: 129/Sv * BALB/cByJ * C57BL/6NCrl) 		increased rhabdomyosarcoma incidence J:93364
Parms1C57BL/6NCrl/Parms1C57BL/6NCrl
Ptch1tm1Zim/Ptch1+
(involves: 129/Sv * BALB/cByJ * C57BL/6NCrl) 		increased rhabdomyosarcoma incidence J:93364
Pas1cBALB/cOlaHsd/Pas1cBALB/cOlaHsd
(involves: A/JOlaHsd * BALB/cOlaHsd) 		increased lung adenoma incidence J:50533
Pas5bA/JOlaHsd/Pas5bA/JOlaHsd
(involves: A/JOlaHsd * BALB/cOlaHsd) 		increased lung adenoma incidence J:50533
Pas7A/JOlaHsd/Pas7A/JOlaHsd
(involves: A/JOlaHsd * BALB/cOlaHsd) 		increased lung adenoma incidence J:50533
Pas8A/JOlaHsd/Pas8A/JOlaHsd
(involves: A/JOlaHsd * BALB/cOlaHsd) 		increased lung adenoma incidence J:50533
Pas8A/JOlaHsd/Pas8BALB/cOlaHsd
(involves: A/JOlaHsd * BALB/cOlaHsd) 		increased lung adenoma incidence J:50533
Pas9A/JOlaHsd/Pas9BALB/cOlaHsd
(involves: A/JOlaHsd * BALB/cOlaHsd) 		increased lung adenoma incidence J:50533
Pas9BALB/cOlaHsd/Pas9BALB/cOlaHsd
(involves: A/JOlaHsd * BALB/cOlaHsd) 		increased lung adenoma incidence J:50533
Pas14A/J/Pas14A/J
(involves: A/J * C57BL/6J) 		increased lung adenoma incidence J:21801
Pas19A/J/Pas19A/J
(involves: A/J * C57BL/6J) 		increased lung adenoma incidence J:21801
Pax5tm3Mbu/Pax5+
Tcf3tm1(PBX1)Mlc/Tcf3+
Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * C57BL/6) 		increased B cell acute lymphoblastic leukemia incidence J:226241
Pax6Sey-4H/Pax6+
(involves: 101/H * C3H/HeCrj * C3H/HeH) 		increased intestinal adenoma incidence J:124276
Pcbp4Gt(D136D11)Wrst/Pcbp4+
(involves: 129S2/SvPas * C57BL/6) 		increased B cell derived lymphoma incidence J:231514
increased lung adenocarcinoma incidence J:231514
Pcbp4Gt(D136D11)Wrst/Pcbp4Gt(D136D11)Wrst
(involves: 129S2/SvPas * C57BL/6) 		increased B cell derived lymphoma incidence J:231514
increased lung adenocarcinoma incidence J:231514
Pcsk2tm1Dfs/Pcsk2tm1Dfs
(B6;129-Pcsk2tm1Dfs/J) 		increased glucagonoma incidence J:236511
increased pancreatic ductal adenocarcinoma incidence J:236905
increased pancreatic islet cell adenoma incidence J:236905
PctmBALB/cAnPt/PctmDBA/2N
(involves: BALB/cAnPt * DBA/2N) 		increased plasmacytoma incidence J:15235
PctsBALB/cAnPt/PctsBALB/cAnPt
(involves: BALB/cAnPt * DBA/2N) 		increased plasmacytoma incidence J:15235
Pcyts1BALB/c/Pcyts1BALB/c
(involves: BALB/c * C57BL/6J) 		increased plasmacytoma incidence J:78523
Pcyts1BALB/c/Pcyts1C57BL/6J
(involves: BALB/c * C57BL/6J) 		increased plasmacytoma incidence J:78523
Pcyts2BALB/c/Pcyts2BALB/c
(involves: BALB/c * C57BL/6J) 		increased plasmacytoma incidence J:78523
Pcyts2BALB/c/Pcyts2C57BL/6J
(involves: BALB/c * C57BL/6J) 		increased plasmacytoma incidence J:78523
Pcyts3BALB/c/Pcyts3BALB/c
(involves: BALB/c * C57BL/6J) 		increased plasmacytoma incidence J:78523
Pcyts3BALB/c/Pcyts3C57BL/6J
(involves: BALB/c * C57BL/6J) 		increased plasmacytoma incidence J:78523
Pcyts4BALB/c/Pcyts4BALB/c
(involves: BALB/c * C57BL/6J) 		increased plasmacytoma incidence J:78523
Pcyts4BALB/c/Pcyts4C57BL/6J
(involves: BALB/c * C57BL/6J) 		increased plasmacytoma incidence J:78523
Pcyts5BALB/c/Pcyts5BALB/c
(involves: BALB/c * C57BL/6J) 		increased plasmacytoma incidence J:78523
Pcyts5BALB/c/Pcyts5C57BL/6J
(involves: BALB/c * C57BL/6J) 		increased plasmacytoma incidence J:78523
Pcyts6BALB/c/Pcyts6C57BL/6J
(involves: BALB/c * C57BL/6J) 		increased plasmacytoma incidence J:78523
Pcyts6C57BL/6J/Pcyts6C57BL/6J
(involves: BALB/c * C57BL/6J) 		increased plasmacytoma incidence J:78523
Pdcd4tm1.1Tosc/Pdcd4tm1.1Tosc
(involves: 129 * C57BL/6 * CD-1) 		increased papilloma incidence J:132696
Pdcd4tm1Yhcn/Pdcd4tm1Yhcn
(B6.129S6-Pdcd4tm1Yhcn) 		increased B cell derived lymphoma incidence J:120583
Pdcd10tm1Wami/Pdcd10tm1Wami
Emx1tm1(cre)Krj/Emx1+
(involves: 129 * 129S2/SvPas * C57BL/6) 		increased hemangioma incidence J:170480
Pdcd10tm1Wami/Pdcd10tm1Wami
Tg(GFAP-cre)25Mes/0
(involves: 129 * C57BL/6 * FVB/N) 		increased hemangioma incidence J:170480
Per2tm1Brd/Per2tm1Brd
(involves: 129S7/SvEvBrd * C57BL/6) 		increased lymphoma incidence J:79456
Perptm2Att/Perptm2Att
Tg(KRT14-cre/ERT2)1Ipc/0
(involves: 129S4/SvJae) 		increased skin squamous cell carcinoma incidence J:167545
Pex1tm1.1Hrw/Pex1tm1.1Hrw
(involves: C57BL/6NTac) 		increased liver adenoma incidence J:278655
Pgbd5tm1.1Aken/Pgbd5tm1.2Aken
Ptch1tm1Bjw/Ptch1tm1Bjw
Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129 * C57BL/6J * C57BL/6NTac * FVB/N * SW) 		increased medulloblastoma incidence J:346387
Pgbd5tm1.2Aken/Pgbd5tm1.2Aken
Ptch1tm1Bjw/Ptch1tm1Bjw
Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129 * C57BL/6J * C57BL/6NTac * FVB/N * SW) 		decreased classified tumor incidence J:346387
Pgrtm2(cre)Lyd/Pgr+
Ptentm1Hwu/Ptentm1Hwu
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6) 		increased endometrial carcinoma incidence J:139053
Pgrtm2(cre)Lyd/Pgr+
Ptentm1Hwu/Ptentm1Hwu
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ) 		increased endometrial carcinoma incidence J:162027, J:218222
increased papilloma incidence J:218222
Pgrtm2(cre)Lyd/Pgr+
Ptentm1Hwu/Ptentm1Hwu
Trp53tm1Brn/Trp53tm1Brn
(involves: 129 * C57BL/6) 		increased endometrial carcinoma incidence J:139053
Phf6tm1.1Avo/Y
Tg(Tek-cre)1Ywa/0
(involves: C57BL/6 * SJL) 		increased leukemia incidence J:276228
Phf6tm1.2Avo/Phf6+
(involves: BALB/cJ * C57BL/6) 		increased leukemia incidence J:276228
Pigatm1Bsl/Y
Tg(FES-cre)31Bsl/0
(involves: 129S1/Sv * C57BL/6 * CBA/Ca) 		increased B cell derived lymphoma incidence J:71354
increased hemangioma incidence J:71354
Pigatm1Bsl/Piga+
Tg(FES-cre)31Bsl/0
(involves: 129S1/Sv * C57BL/6 * CBA/Ca) 		increased B cell derived lymphoma incidence J:71354
increased hemangioma incidence J:71354
Pik3catm1.1Waph/Pik3ca+
Ptentm1Hwu/Ptentm1Hwu
(involves: 129S1/Sv * 129S4/SvJae * BALB/c * C57BL/6) 		increased adenocarcinoma incidence J:184382
Pik3catm1.1Waph/Pik3ca+
Tg(MMTV-cre)#Mam/0
(involves: 129S1/Sv * C57BL/6 * FVB) 		increased fibroadenoma incidence J:187299
increased mammary adenoacanthoma incidence J:187299
increased osteosarcoma incidence J:187299
increased sarcoma incidence J:187299
Pik3catm1Jjz/Pik3catm1Jjz
Ptentm1Hwu/Ptentm1Hwu
Tg(KRT14-cre)#Smr/0
(FVB.Cg-Pik3catm1Jjz Ptentm1Hwu Tg(KRT14-cre)#Smr) 		increased skin hamartoma incidence J:199362
Pik3cbtm1Jjz/Pik3cbtm1Jjz
Ptentm1Hwu/Ptentm1Hwu
Tg(KRT14-cre)#Smr/0
(FVB.Cg-Pik3cbtm1Jjz Ptentm1Hwu Tg(KRT14-cre)#Smr) 		increased skin hamartoma incidence J:199362
Pinx1tm1.1Kplu/Pinx1+
(involves: 129S7/SvEvBrd * C57BL/6 * FVB/N) 		increased carcinoma incidence J:171997
increased Harderian gland adenoma incidence J:171997
increased hemangiosarcoma incidence J:171997
increased hibernoma incidence J:171997
increased histiocytic sarcoma incidence J:171997
increased lymphoma incidence J:171997
increased sarcoma incidence J:171997
Pinx1tm1.1Kplu/Pinx1+
Trp53tm1Brd/Trp53+
(involves: 129S7/SvEvBrd * C57BL/6 * FVB/N) 		increased carcinoma incidence J:171997
increased hepatocellular carcinoma incidence J:171997
increased lung carcinoma incidence J:171997
increased lymphoma incidence J:171997
Pinx1tm1.1Kplu/Pinx1+
Trp53tm1Brd/Trp53tm1Brd
(involves: 129S7/SvEvBrd * C57BL/6 * FVB/N) 		increased carcinoma incidence J:171997
increased hepatocellular carcinoma incidence J:171997
increased lung carcinoma incidence J:171997
increased lymphoma incidence J:171997
Pkd1tm1.1Pcha/Pkd1tm1.1Pcha
(involves: 129S1/Sv * C57BL/6) 		increased renal hamartoma incidence J:193544
Pkn3tm1.1Mrl/Pkn3+
Ptentm1Hwu/Ptentm1Hwu
Tg(Mx1-cre)1Cgn/0
(involves: 129S4/SvJae * C57BL/6 * CBA/J) 		increased acute lymphoblastic leukemia incidence J:216983
Pkn3tm1.1Mrl/Pkn3tm1.1Mrl
Ptentm1Hwu/Ptentm1Hwu
Tg(Mx1-cre)1Cgn/0
(involves: 129S4/SvJae * C57BL/6 * CBA/J) 		increased acute lymphoblastic leukemia incidence J:216983
Pknox1tm1Ngc/Pknox1+
Tg(IghMyc)22Bri/0
(involves: C57BL * SJL) 		increased B cell derived lymphoma incidence J:192251
Plautm1Mlg/Plautm1Mlg
Tg(RIP1-Tag)2Dh/0
(involves: C57BL/6) 		increased carcinoma incidence J:65019
Plcg2tm1Jni/Plcg2tm1Jni
Tg(IghMyc)22Bri/0
(involves: 129P2/OlaHsd * C57BL * C57BL/6 * SJL) 		increased B cell derived lymphoma incidence J:117023
increased lymphoma incidence J:117023
Plgtm1Jld/Plgtm1Jld
Tg(MMTV-PyVT)634Mul/0
(involves: 129P2/OlaHsd * Black Swiss * FVB/N) 		increased mammary adenocarcinoma incidence J:48285
Plk1Gt(RRR358)Byg/Plk1+
(involves: 129P2/OlaHsd * C57BL/6) 		increased lung carcinoma incidence J:142593
increased lymphoma incidence J:142593
increased sarcoma incidence J:142593
increased squamous cell carcinoma incidence J:142593
Plk3tm1Dai/Plk3tm1Dai
(involves: 129S4/SvJae * C57BL/6) 		increased leiomyosarcoma incidence J:136425
increased lung adenocarcinoma incidence J:136425
Pmltm1(PML/RARA)Ley/Pml+
Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * BALB/cJ * C57BL/6) 		increased leukemia incidence J:172024
Pmltm1.1Ews/Pmltm1.1Ews
(involves: 129 * 129P2/OlaHsd) 		increased B cell derived lymphoma incidence J:262172
increased T cell derived lymphoma incidence J:262172
Pmltm1.1Ews/Pmltm1.1Ews
Tg(PML-RARA)556Kog/0
(FVB.Cg-Pmltm1.1Ews Tg(PML-RARA)556Kog) 		increased acute promyelocytic leukemia incidence J:262172
Pmltm1Ppp/Pml+
Trp53tm3.1Glo/Trp53+
(B6.129S7(Cg)-Pmltm1Ppp Trp53tm3.1Glo) 		increased B cell derived lymphoma incidence J:317504
increased carcinoma incidence J:317504
increased lymphoma incidence J:317504
increased osteosarcoma incidence J:317504
increased sarcoma incidence J:317504
increased T cell derived lymphoma incidence J:317504
Pmltm1Ppp/Pmltm1Ppp
(involves: 129S7/SvEvBrd) 		increased lymphoma incidence J:46381
Pmltm1Ppp/Pmltm1Ppp
Trp53tm3.1Glo/Trp53+
(B6.129S7(Cg)-Pmltm1Ppp Trp53tm3.1Glo) 		increased B cell derived lymphoma incidence J:317504
increased carcinoma incidence J:317504
increased lymphoma incidence J:317504
increased osteosarcoma incidence J:317504
increased sarcoma incidence J:317504
increased T cell derived lymphoma incidence J:317504
Pms2tm1.1Wed/Pms2tm1.1Wed
(involves: 129S6/SvEvTac * C57BL/6NCr) 		increased adenocarcinoma incidence J:162378
increased B cell derived lymphoma incidence J:162378
increased hemangioma incidence J:162378
increased liver adenoma incidence J:162378
increased lymphoma incidence J:162378
increased sarcoma incidence J:162378
increased T cell derived lymphoma incidence J:162378
Pms2tm1Lisk/Pms2tm1Lisk
(involves: 129S2/SvPas * C57BL/6) 		increased lymphoma incidence J:27389
increased sarcoma incidence J:27389
Pms2tm1Lisk/Pms2tm1Lisk
(involves: 129S2/SvPas) 		increased B cell derived lymphoma incidence J:162378
increased carcinoma incidence J:125218
increased lymphoma incidence J:125218
increased sarcoma incidence J:125218
Pms2tm1Lisk/Pms2tm1Lisk
Terctm1Rdp/Terctm1Rdp
(involves: 129/Sv * 129S2/SvPas * C57BL/6 * C57BL/6J * SJL) 		increased carcinoma incidence J:125218
increased lymphoma incidence J:125218
increased sarcoma incidence J:125218
Pold1tm1.1Bdp/Pold1tm1.1Bdp
(B6.129-Pold1tm1.1Bdp) 		increased intestinal adenocarcinoma incidence J:153684
increased intestinal adenoma incidence J:153684
increased lymphoma incidence J:153684
increased T cell derived lymphoma incidence J:153684
Pold1tm1.1Bdp/Pold1tm1.1Bdp
Poletm1.1Bdp/Poletm1.1Bdp
(B6.129-Poletm1.1Bdp Pold1tm1.1Bdp) 		increased T cell derived lymphoma incidence J:153684
Pold1tm1Bdp/Pold1tm1Bdp
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6) 		increased lung adenocarcinoma incidence J:100685
increased lymphoma incidence J:80306, J:100685
increased sarcoma incidence J:100685
increased squamous cell carcinoma incidence J:100685
increased T cell derived lymphoma incidence J:100685
Pole4tm1(KOMP)Vlcg/Pole4tm1(KOMP)Vlcg
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6NTac * FVB/N) 		increased lymphoma incidence J:261973
increased T cell derived lymphoma incidence J:261973
Pole4tm1(KOMP)Vlcg/Pole4tm1(KOMP)Vlcg
Trp53tm1Brd/Trp53+
(involves: C57BL/6J * C57BL/6NTac) 		increased T cell derived lymphoma incidence J:261973
Poletm1.1Bdp/Poletm1.1Bdp
(B6.129-Poletm1.1Bdp) 		increased adenoma incidence J:153684
increased colon adenocarcinoma incidence J:153684
increased histiocytic sarcoma incidence J:153684
increased intestinal adenocarcinoma incidence J:153684
increased intestinal adenoma incidence J:153684
increased lymphoma incidence J:153684
increased small intestine adenocarcinoma incidence J:153684
Polgtm1Jiha/Polg+
(involves: C57BL/6JJcl) 		increased B cell derived lymphoma incidence J:199416
Polhtm1.1Rak/Polhtm1.1Rak
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6) 		increased squamous cell carcinoma incidence J:105034
Pomctm1Low/Pomc+
(involves: 129S2/SvPas * 129X1/SvJ * C57BL/6 * DBA/2) 		increased pituitary adenoma incidence J:119240
Pomctm1Low/Pomc+
Tg(Pomc)#Low/0
(involves: 129 * C57BL/6 * CBA * DBA/2 * Swiss Webster) 		increased pituitary adenoma incidence J:119240
Pomctm1Low/Pomctm1Low
(involves: 129S2/SvPas * 129X1/SvJ * C57BL/6 * DBA/2) 		increased pituitary adenoma incidence J:119240
Pomctm1Low/Pomctm1Low
Tg(Pomc)#Low/0
(involves: 129 * C57BL/6 * CBA * DBA/2 * Swiss Webster) 		increased pituitary adenoma incidence J:119240
Ppardtm1Jps/Ppardtm1Jps
(involves: 129/Sv * C57BL/6N) 		increased intestinal adenocarcinoma incidence J:90217
increased sebaceous gland adenoma incidence J:90337
increased skin papilloma incidence J:90337
Ppp2r1atm1.2Wltr/Ppp2r1atm2.1Wltr
(FVB.129-Ppp2r1atm1.2Wltr/Ppp2r1atm2.1Wltr) 		increased lung adenocarcinoma incidence J:175748
increased lung adenoma incidence J:175748
Ppp5ctm1a(EUCOMM)Wtsi/Ppp5ctm1a(EUCOMM)Wtsi
(involves: C57BL/6 * C57BL/6N) 		increased lymphoma incidence J:213427
Prdm2tm1Shg/Prdm2+
(involves: 129S2/SvPas * C57BL/6) 		increased B cell derived lymphoma incidence J:71406
increased hemangiosarcoma incidence J:71406
increased lung adenocarcinoma incidence J:71406
increased lymphoma incidence J:71406
increased pituitary adenoma incidence J:71406
Prdm2tm1Shg/Prdm2tm1Shg
(involves: 129S2/SvPas * C57BL/6) 		increased B cell derived lymphoma incidence J:71406
increased hemangiosarcoma incidence J:71406
increased lung adenocarcinoma incidence J:71406
increased lymphoma incidence J:71406
increased pituitary adenoma incidence J:71406
Prdm11tm1.1Ahl/Prdm11tm1.1Ahl
Tg(IghMyc)22Bri/0
(B6.Cg-Prdm11tm1.1Ahl Tg(IghMyc)22Bri) 		increased B cell derived lymphoma incidence J:221379
Prdx1tm1Rave/Prdx1+
(involves: 129S6/SvEvTac * C57BL/6) 		increased fibrosarcoma incidence J:84677
increased hemangiosarcoma incidence J:84677
increased hepatocellular carcinoma incidence J:84677
increased histiocytic sarcoma incidence J:84677
increased lung adenocarcinoma incidence J:84677
increased lymphoma incidence J:84677
increased malignant tumor incidence J:84677
increased mammary adenocarcinoma incidence J:84677
increased osteosarcoma incidence J:84677
Prdx1tm1Rave/Prdx1tm1Rave
(involves: 129S6/SvEvTac * C57BL/6) 		increased adenoma incidence J:84677
increased B cell derived lymphoma incidence J:84677
increased carcinoma incidence J:84677
increased fibrosarcoma incidence J:84677
increased hemangiosarcoma incidence J:84677
increased hepatocellular carcinoma incidence J:84677
increased histiocytic sarcoma incidence J:84677
increased lung adenocarcinoma incidence J:84677
increased lymphoma incidence J:84677
increased mammary adenocarcinoma incidence J:84677
increased pancreatic islet cell adenoma incidence J:84677
increased sarcoma incidence J:84677
increased T cell derived lymphoma incidence J:84677
Prf1tm1Sdz/Prf1tm1Sdz
(C57BL/6-Prf1tm1Sdz) 		increased B cell derived lymphoma incidence J:77491
increased lymphoma incidence J:77491
Prf1tm1Sdz/Prf1tm1Sdz
(C.B6-Prf1tm1Sdz) 		increased lung adenocarcinoma incidence J:77491
increased lymphoma incidence J:77491
increased sarcoma incidence J:77491
increased T cell derived lymphoma incidence J:77491
Prkacatm1Gsm/Prkaca+
Prkar1atm1.1Lsk/Prkar1a+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6) 		increased osteosarcoma incidence J:160299
Prkar1atm1.1Lsk/Prkar1a+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6) 		increased osteosarcoma incidence J:160299
Prkar1atm1.2Lsk/Prkar1a+
Rb1tm2Brn/Rb1+
Tg(Col1a1-cre)1Kry/0
Trp53tm1Brn/Trp53tm1Brn
(involves: 129 * 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * FVB/N) 		increased osteosarcoma incidence J:234128
Prkar1atm1.2Lsk/Prkar1a+
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(Col1a1-cre)1Kry/0
(involves: 129 * 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * FVB/N) 		increased osteosarcoma incidence J:234128
Prkar1atm1.2Lsk/Prkar1a+
Tg(Bglap2-TAg)1Rkho/0
Tg(Col1a1-cre)1Kry/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/N) 		increased osteosarcoma incidence J:165282
Prkar1atm1.2Lsk/Prkar1a+
Tg(Col1a1-cre)1Kry/0
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * FVB/N) 		increased osteosarcoma incidence J:234128
Prkar1atm1.2Lsk/Prkar1atm1.2Lsk
Ptentm1.1Mwst/Ptentm1.1Mwst
Tg(TPO-cre)1Shk/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/NCr) 		increased thyroid carcinoma incidence J:225245
Prkar1atm1.2Lsk/Prkar1atm1.2Lsk
Tg(TPO-cre)1Shk/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/NCr) 		increased thyroid carcinoma incidence J:225245, J:241066
Prkar1atm1Gsm/Prkar1a+
(involves: 129X1/SvJ) 		increased fibrosarcoma incidence J:93393
increased hemangiosarcoma incidence J:93393
increased hepatocellular carcinoma incidence J:93393
increased sarcoma incidence J:93393
Prkcatm1Cda/Prkcatm1Cda
(involves: 129S/SvEv * C57BL/6) 		increased skin papilloma incidence J:100793
Prkchtm1Cda/Prkchtm1Cda
(involves: 129S/SvEv * C57BL/6J) 		increased skin papilloma incidence J:83498
Prkcqtm1Litt/Prkcqtm1Litt
Tg(Lck-Notch3)#Issc/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2) 		decreased lymphoma incidence J:96010
Prkdcscid/Prkdcscid
(C.BKa-Prkdcscid) 		increased T cell derived lymphoma incidence J:6958
Prkdcscid/Prkdcscid
(NOD.Cg-Prkdcscid) 		increased T cell derived lymphoma incidence J:109833, J:22026
Prkdctm1Gcl/Prkdctm1Gcl
(involves: 129S1/Sv * C57BL/6) 		increased T cell derived lymphoma incidence J:53765
Prltm1Hmn/Prltm1Hmn
(involves: 129S2/SvPas) 		increased pituitary adenoma incidence J:79661
Prlrtm1Cnp/Prlrtm1Cnp
(involves: 129/Sv * 129P2/OlaHsd) 		increased thyroid carcinoma incidence J:101609
Prmt1tm1a(EUCOMM)Wtsi/Prmt1tm1a(EUCOMM)Wtsi
Rb1tm3Tyj/Rb1tm3Tyj
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * CD-1) 		decreased osteosarcoma incidence J:245660
Prmt1tm1c(EUCOMM)Wtsi/Prmt1+
Rb1tm3Tyj/Rb1tm3Tyj
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * CD-1) 		increased osteosarcoma incidence J:245660
Pscatm1Witt/Psca+
Tg(TRAMP)8247Ng/0
(involves: 129/Sv * C57BL/6) 		increased prostate gland adenocarcinoma incidence J:133908
Pscatm1Witt/Pscatm1Witt
Tg(TRAMP)8247Ng/0
(involves: 129/Sv * C57BL/6) 		increased prostate gland adenocarcinoma incidence J:133908
Psmb9tm1Stl/Psmb9tm1Stl
(involves: 129P2/OlaHsd * C57BL/6) 		increased hepatocellular carcinoma incidence J:73945
increased leiomyosarcoma incidence J:73945
Psmb9tm1Stl/Psmb9tm1Stl
Trp53tm1Brd/Trp53tm1Brd
(involves: 129P2/OlaHsd * C57BL/6) 		increased lymphoma incidence J:67509
increased sarcoma incidence J:67509
Ptch1tm1.1Hahn/Ptch1+
(involves: 129 * BALB/c * C57BL/6 * FVB/N) 		increased medulloblastoma incidence J:149148
increased rhabdomyosarcoma incidence J:149148
Ptch1tm1Bjw/Ptch1tm1Bjw
Tg(Atoh1-cre)1Bfri/0
(involves: 129T2/SvEms * C57BL/6 * CBA) 		increased medulloblastoma incidence J:139573
Ptch1tm1Bjw/Ptch1tm1Bjw
Tg(Atoh1-cre/Esr1*)14Fsh/0
(involves: 129T2/SvEms * FVB/N) 		increased medulloblastoma incidence J:139573
Ptch1tm1Bjw/Ptch1tm1Bjw
Tg(GFAP-cre)25Mes/0
(involves: 129T2/SvEms * FVB/N) 		increased medulloblastoma incidence J:139573
Ptch1tm1Bjw/Ptch1tm1Bjw
Tg(KRT14-cre)8Brn/0
(involves: 129T2/SvEms * FVB/N) 		increased basal cell carcinoma incidence J:231264
Ptch1tm1Cklr/Ptch1+
Pax7tm1(cre)Mrc/Pax7+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL) 		increased medulloblastoma incidence J:159972
Ptch1tm1Cklr/Ptch1+
Trp53tm1Brn/?
Pax7tm1(cre)Mrc/Pax7+
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL) 		increased medulloblastoma incidence J:159972
Ptch1tm1Hahn/Ptch1+
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6) 		increased fibroma incidence J:149148
Ptch1tm1Hahn/Ptch1tm1Hahn
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6) 		increased basal cell carcinoma incidence J:149148
Ptch1tm1Hahn/Ptch1tm1Hahn
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ) 		increased basal cell carcinoma incidence J:158915
Ptch1tm1Hahn/Ptch1tm1Hahn
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6) 		increased basal cell carcinoma incidence J:149148
Ptch1tm1Mps/Ptch1+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6) 		increased hemangiosarcoma incidence J:205254
increased lymphoma incidence J:205254
increased medulloblastoma incidence J:205254
increased rhabdomyosarcoma incidence J:205254
Ptch1tm1Mps/Ptch1+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2) 		increased medulloblastoma incidence J:42441
Ptch1tm1Mps/Ptch1+
(involves: 129S1/Sv * 129X1/SvJ) 		increased medulloblastoma incidence J:144811, J:114992, J:102702
increased rhabdomyosarcoma incidence J:114992
Ptch1tm1Mps/Ptch1+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2J) 		increased basal cell carcinoma incidence J:58328
Ptch1tm1Mps/Ptch1+
Ptch2tm1Pmc/Ptch2+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6) 		increased basal cell carcinoma incidence J:112118
increased rhabdomyosarcoma incidence J:112118
increased testicular teratoma incidence J:112118
Ptch1tm1Mps/Ptch1+
Ptch2tm1Pmc/Ptch2tm1Pmc
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6) 		increased basal cell carcinoma incidence J:112118
increased medulloblastoma incidence J:112118
increased rhabdomyosarcoma incidence J:112118
Ptch1tm1Mps/Ptch1+
Tg(Atoh1-GFP)1Jejo/?
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2) 		increased medulloblastoma incidence J:144811
Ptch1tm1Mps/Ptch1+
Tg(Atoh1-sb11)1Mtay/0
TgTn(sb-T2/Onc3)12740Njen/0
(involves: 129S1/Sv * 129X1/SvJ * C3H * C57BL/6J * ICR) 		increased medulloblastoma incidence J:181542
Ptch1tm1Mps/Ptch1+
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129 * 129S2/SvPas * C57BL/6) 		increased medulloblastoma incidence J:125534
increased rhabdomyosarcoma incidence J:125534
Ptch1tm1Yy/Ptch1+
Trp53tm1Brd/Trp53+
Tg(BGLAP-cre)1Clem/0
(involves: 129S7/SvEvBrd * C57BL/6 * FVB/NJ) 		increased osteosarcoma incidence J:214349
Ptch1tm1Zim/Ptch1+
(either: (involves: 129 * C57BL/6) or (involves: 129 * CD-1)) 		increased medulloblastoma incidence J:47421
increased rhabdomyosarcoma incidence J:47421
Ptch1tm1Zim/Ptch1+
(involves: 129 * CD-1) 		increased medulloblastoma incidence J:79666, J:165388
Ptentm1.1Gle/Pten+
(involves: 129S6/SvEvTac * Black Swiss * FVB/N) 		increased lymphoma incidence J:158751
increased T cell derived lymphoma incidence J:158751
Ptentm1.1Hwu/Pten+
(involves: 129S4/SvJae * BALB/c) 		increased hemangioma incidence J:110567
increased mammary adenocarcinoma incidence J:110567
Ptentm1.1Hwu/Pten+
(involves: 129S4/SvJae * C57BL/6NTac) 		increased lymphoma incidence J:170965
increased thyroid adenoma incidence J:170965
Ptentm1.1Mwst/Ptentm1.1Mwst
Tg(MMTVneu)202Mul/0
Tg(S100a4-cre)1Gle/0
(involves: FVB/N) 		increased mammary adenocarcinoma incidence J:153747
Ptentm1.2Mwst/Pten+
(involves: 129S6/SvEvTac * Black Swiss * FVB/N) 		increased lymphoma incidence J:158751
increased mammary adenoacanthoma incidence J:158751
increased T cell derived lymphoma incidence J:158751
increased uterus carcinoma incidence J:158751
Ptentm1Hwu/Pten+
Tg(ARR2/Pbsn-FGF8)3Prb/0
Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * BALB/c * C57BL/6 * DBA/2) 		increased prostate gland adenocarcinoma incidence J:106650
Ptentm1Hwu/Pten+
Tg(KRT14-cre)#Smr/0
(involves: 129S4/SvJae * C57BL/6J * SJL/J) 		increased mammary adenocarcinoma incidence J:138927
Ptentm1Hwu/Pten+
Tmprss2tm2.1(ETV1)Sho/Tmprss2tm2.1(ETV1)Sho
Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2) 		increased prostate gland adenocarcinoma incidence J:212219
Ptentm1Hwu/Ptentm1Hwu
(involves: 129S4/SvJae) 		increased prostate gland adenocarcinoma incidence J:144810
Ptentm1Hwu/Ptentm1Hwu
Cop1tm2.1Vmd/Cop1tm2.1Vmd
Tg(Pbsn-cre)4Prb/0
(B6N.CgCop1tm2.1Vmd Ptentm1Hwu Tg(Pbsn-cre)4Prb) 		increased prostate gland adenocarcinoma incidence J:172653
Ptentm1Hwu/Ptentm1Hwu
Ptpn1tm1Bpk/Ptpn1tm1Bpk
Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2) 		increased prostate gland adenocarcinoma incidence J:231906
Ptentm1Hwu/Ptentm1Hwu
Rps6kb1tm1Gtho/Rps6kb1tm1Gtho
Tg(Mx1-cre)1Cgn/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * CBA) 		increased acute lymphoblastic leukemia incidence J:169097
Ptentm1Hwu/Ptentm1Hwu
Smad4tm2.1Cxd/Smad4tm2.1Cxd
Tg(Alb1-cre)1Dlr/0
(involves: 129S4/SvJae * 129S6/SvEvTac * FVB/N) 		increased cholangiocarcinoma incidence J:111718
Ptentm1Hwu/Ptentm1Hwu
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129S4/SvJae * C57BL/6 * DBA) 		increased cholangiocarcinoma incidence J:218587
increased hepatocellular carcinoma incidence J:218587
Ptentm1Hwu/Ptentm1Hwu
Tg(Alb1-cre)1Dlr/0
(involves: 129S4/SvJae * FVB/N) 		increased cholangiocarcinoma incidence J:111718
increased hepatocellular carcinoma incidence J:111718
Ptentm1Hwu/Ptentm1Hwu
Tg(CAG-EGFP,-PAX8/PPARG)1Rkoe/0
Tg(TPO-cre)1Shk/0
(involves: 129S4/SvJae * FVB/NCr * FVB/NJ) 		increased thyroid carcinoma incidence J:177181
Ptentm1Hwu/Ptentm1Hwu
Tg(CAG-MYC,-GFP*)#Rugg/0
Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * C57BL/6J * DBA/2) 		increased prostate gland adenocarcinoma incidence J:261540
Ptentm1Hwu/Ptentm1Hwu
Tg(Cdh5-cre)7Mlia/0
(involves: 129S4/SvJae * BALB/c * C57BL/6 * FVB/N) 		increased acute lymphoblastic leukemia incidence J:135172
increased acute promyelocytic leukemia incidence J:135172
Ptentm1Hwu/Ptentm1Hwu
Tg(Fabp1-cre)1Jig/0
(involves: 129S4/SvJae * FVB/N) 		increased carcinoma incidence J:106662
increased colon adenocarcinoma incidence J:106662
increased renal carcinoma incidence J:106662
increased squamous cell carcinoma incidence J:106662
increased urinary bladder carcinoma incidence J:106662
Ptentm1Hwu/Ptentm1Hwu
Tg(KRT14-cre)#Smr/0
(involves: 129S4/SvJae * C57BL/6J * SJL/J) 		increased mammary adenocarcinoma incidence J:138927
increased skin papilloma incidence J:138927
Ptentm1Hwu/Ptentm1Hwu
Tg(KRT14-cre)#Smr/0
(FVB.Cg-Ptentm1Hwu Tg(KRT14-cre)#Smr) 		increased skin hamartoma incidence J:199362
increased skin papilloma incidence J:199362
Ptentm1Hwu/Ptentm1Hwu
Tg(MMTV-cre)#Tfln/0
(involves: 129S4/SvJae) 		increased fibroadenoma incidence J:78415
increased mammary adenocarcinoma incidence J:78415
Ptentm1Hwu/Ptentm1Hwu
Tg(Mx1-cre)1Cgn/0
(involves: 129S4/SvJae * C57BL/6 * CBA) 		increased acute lymphoblastic leukemia incidence J:169097
Ptentm1Hwu/Ptentm1Hwu
Tg(Mx1-cre)1Cgn/0
(BKS.Cg-Ptprcb Thy1a Tg(Mx1-cre)1Cgn Ptentm1Hwu) 		increased acute lymphoblastic leukemia incidence J:109085
increased acute promyelocytic leukemia incidence J:109085
increased leukemia incidence J:109085
Ptentm1Hwu/Ptentm1Hwu
Tg(Mx1-cre)1Cgn/0
(B6.Cg-Tg(Mx1-cre)1Cgn Ptentm1Hwu) 		increased T cell acute lymphoblastic leukemia incidence J:232645
Ptentm1Hwu/Ptentm1Hwu
Tg(Nkx2-1-cre)2Sand/0
(B6.Cg-Ptentm1Hwu Tg(Nkx2-1-cre)2Sand) 		increased thyroid adenoma incidence J:197590
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)4Prb/0
(involves: 129 * 129S4/SvJae * C57BL/6 * DBA/2) 		increased prostate gland adenocarcinoma incidence J:142106
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2) 		increased carcinoma incidence J:268934
increased prostate gland adenocarcinoma incidence J:268934, J:184935, J:212219
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * BALB/c * C57BL/6 * DBA/2) 		increased prostate gland adenocarcinoma incidence J:93902, J:124208
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)20Fwan/?
(involves: 129S4/SvJae * C57BL/6 * FVB/NCrl) 		increased prostate gland adenocarcinoma incidence J:238768
Ptentm1Hwu/Ptentm1Hwu
Tg(Pdx1-cre)89.1Dam/0
(involves: 129S4/SvJae * C57BL/6 * CBA) 		increased malignant tumor incidence J:102226
increased pancreatic ductal adenocarcinoma incidence J:102226
Ptentm1Hwu/Ptentm1Hwu
Tg(Pdx1-cre)89.1Dam/0
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6 * CBA) 		increased pancreatic acinar cell carcinoma incidence J:102226
increased pancreatic ductal adenocarcinoma incidence J:102226
Ptentm1Hwu/Ptentm1Hwu
Tg(Pgc-cre,-secNluc)#Hcz/0
(involves: 129S4/SvJae) 		increased mammary adenocarcinoma incidence J:338079
Ptentm1Hwu/Ptentm1Hwu
Tgfbr1tm1.1Karl/Tgfbr1tm1.1Karl
Tg(KRT14-cre/ERT)20Efu/0
(involves: 129 * 129S4/SvJae * C57BL/6 * CD-1 * FVB/N) 		increased oral papilloma incidence J:194652
increased papilloma incidence J:194652
increased squamous cell carcinoma incidence J:209026, J:194652
Ptentm1Hwu/Ptentm1Hwu
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB) 		increased carcinoma incidence J:146760
increased urinary bladder carcinoma incidence J:146760
Ptentm1Hwu/Ptentm1Hwu
Trp53tm2Tyj/Trp53+
Amhr2tm3(cre)Bhr/Amhr2+
(involves: 129P2/OlaHsd * 129S4/SvJae * 129S7/SvEvBrd) 		increased ovarian carcinoma incidence J:222579
Ptentm1Hwu/Ptentm1Hwu
Vhltm1Jae/Vhltm1Jae
Tg(Cdh16-cre)91Igr/0
(involves: 129S4/SvJae * ICR) 		increased adenoma incidence J:137442
increased epididymal cystadenoma incidence J:137442
Ptentm1Mak/Pten+
(involves: 129P2/OlaHsd * C57BL/6J) 		increased carcinoma incidence J:50437
increased endometrial carcinoma incidence J:63478
increased fibroadenoma incidence J:63478
increased hamartoma incidence J:63478
increased leukemia incidence J:50437
increased lymphoma incidence J:63478
increased mammary adenocarcinoma incidence J:63478
increased T cell derived lymphoma incidence J:50437
Ptentm1Mak/Pten+
(B6.129P2-Ptentm1Mak) 		increased endometrial carcinoma incidence J:93530
increased lymphoma incidence J:93530
Ptentm1Mro/Pten+
Tg(KLK3-cre)D4Trp/0
(involves: 129P2/OlaHsd * FVB) 		increased prostate gland adenocarcinoma incidence J:99524
Ptentm1Mro/Ptentm1Mro
Tg(KRT14-cre)8Brn/0
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * DBA/2J * FVB/N) 		increased carcinoma incidence J:144831
Ptentm1Ppp/Pten+
(involves: 129S1/Sv * C57BL/6J) 		increased malignant tumor incidence J:49532
Ptentm1Ppp/Pten+
Tg(Pbsn-TAg)15Tvd/0
(involves: 129S1/Sv * C57BL/6 * DBA/2) 		increased prostate gland adenocarcinoma incidence J:103408
Ptentm1Rdp/Pten+
Trp53tm1Brn/Trp53tm1Brn
Tg(GFAP-cre)25Mes/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * FVB/N) 		increased glioblastoma incidence J:140704
Ptentm1Rdp/Ptentm1Rdp
Smad4tm1Rdp/Smad4tm1Rdp
Trp53tm1Brn/Trp53tm1Brn
Tg(Pbsn-cre)4Prb/0
(involves: 129 * C57BL/6 * DBA/2) 		increased prostate gland adenocarcinoma incidence J:186105
Ptentm1Rdp/Ptentm1Rdp
Terttm1Rdp/Tert+
Trp53tm1Brn/Trp53tm1Brn
Tg(Pbsn-cre)4Prb/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2) 		increased prostate gland adenocarcinoma incidence J:186105
Ptentm1Rdp/Ptentm1Rdp
Terttm3Rdp/Terttm3Rdp
Trp53tm1Brn/Trp53tm1Brn
Tg(Pbsn-cre)4Prb/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2) 		increased prostate gland adenocarcinoma incidence J:186105
Ptentm1Rdp/Ptentm1Rdp
Trp53tm1Brn/Trp53tm1Brn
Tg(Pbsn-cre)4Prb/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2) 		increased prostate gland adenocarcinoma incidence J:186105
Ptentm1Rps/Pten+
(involves: 129S1/Sv * C57BL/6J) 		increased leukemia incidence J:53065
increased liver adenoma incidence J:53065
increased lymphoma incidence J:53065
increased teratoma incidence J:53065
increased thyroid carcinoma incidence J:53065
Ptentm1Rps/Pten+
Tg(Wnt1)1Hev/0
(involves: 129S1/Sv * C57BL/6 * FVB/N * SJL) 		increased adenocarcinoma incidence J:67497
increased mammary adenocarcinoma incidence J:67497
increased mammary gland ductal carcinoma incidence J:67497
increased salivary adenocarcinoma incidence J:67497
Ptentm2.1Gle/Pten+
(involves: 129S6/SvEvTac * Black Swiss * FVB/N) 		increased lymphoma incidence J:158751
increased mammary adenoacanthoma incidence J:158751
increased T cell derived lymphoma incidence J:158751
Ptentm2.1Ppp/Pten+
Tg(Cnp-EGFR)10Nrat/0
Tg(Dhh-cre)1Mejr/0
(involves: 129S1/Sv * C57BL/6 * FVB/N * SJL) 		increased neurofibrosarcoma incidence J:195067
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(Cnp-EGFR)10Nrat/0
Tg(Dhh-cre)1Mejr/0
(involves: 129S1/Sv * C57BL/6 * FVB/N * SJL) 		increased neurofibrosarcoma incidence J:195067
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(Dhh-cre)1Mejr/0
(involves: 129S1/Sv * C57BL/6 * FVB/N * SJL) 		increased neurofibrosarcoma incidence J:195067
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * C57BL/6 * DBA/2) 		increased prostate gland adenocarcinoma incidence J:163589, J:100683
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(TPO-cre)1Shk/0
(129S1.Cg-Ptentm2.1Ppp Tg(TPO-cre)1Shk) 		increased thyroid adenoma incidence J:165293
increased thyroid carcinoma incidence J:165293
Ptentm2.1Ppp/Ptentm2.1Ppp
Trp53tm1Brn/Trp53tm1Brn
Tg(TPO-cre)1Shk/0
(129.Cg-Tg(TPO-cre)1Shk Trp53tm1Brn Ptentm2.1Ppp) 		increased thyroid carcinoma incidence J:211100
Ptentm2.1Ppp/Ptentm2.1Ppp
Trp53tm1Thl/Trp53tm1Thl
Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * C57BL/6 * DBA/2) 		increased carcinoma incidence J:100683
Ptentm2Mak/Ptentm2Mak
Smad4tm2.1Cxd/Smad4tm2.1Cxd
Tg(KRT5-cre)1Xya/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac) 		increased carcinoma incidence J:101602
increased skin papilloma incidence J:101602
Ptentm2Mak/Ptentm2Mak
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129P2/OlaHsd * C57BL/6 * DBA) 		increased hepatocellular carcinoma incidence J:138099
increased liver adenoma incidence J:138099
Ptentm2Mak/Ptentm2Mak
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * DBA) 		increased hepatocellular carcinoma incidence J:90905
increased liver adenoma incidence J:90905
Ptentm2Mak/Ptentm2Mak
Stk11tm1Keis/Stk11tm1Keis
Tg(Cyp1a1-cre/ERT)1Dwi/0
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * CBA) 		increased urinary bladder carcinoma incidence J:169565
Ptentm2Mak/Ptentm2Mak
Tg(Cyp1a1-cre)1Dwi/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA) 		increased hepatocellular carcinoma incidence J:143082
increased lymphoma incidence J:143082
Ptentm2Mak/Ptentm2Mak
Tg(Fabp1-cre)1Jig/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N) 		increased urinary bladder transitional cell carcinoma incidence J:113388
Ptentm2Mak/Ptentm2Mak
Tg(Gfap-cre)1Sbk/0
(involves: 129P2/OlaHsd) 		increased hamartoma incidence J:75500
Ptentm2Mak/Ptentm2Mak
Tg(GFAP-cre/Esr1*,-lacZ)ASbk/0
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * FVB/NJ) 		increased glioblastoma incidence J:290447
Ptentm2Mak/Ptentm2Mak
Tg(KLK3-cre)13Saa/0
(involves: 129P2/OlaHsd * C57BL/6) 		increased prostate gland adenocarcinoma incidence J:214242
Ptentm2Mak/Ptentm2Mak
Tg(MMTV-cre)#Tfln/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N) 		increased mammary adenocarcinoma incidence J:224955
increased myoepithelioma incidence J:224955
increased spindle cell carcinoma incidence J:224955
Ptentm2Mak/Ptentm2Mak
Tg(SFTPC-rtTA)5Jaw/0
Tg(tetO-cre)1Jaw/0
(involves: 129 * 129P2/OlaHsd * C57BL/6 * C57BL/6J) 		increased lung adenocarcinoma incidence J:127405
increased lung squamous cell carcinoma incidence J:127405
Ptentm2Mak/Ptentm2Mak
Tg(Wap-cre)11738Mam/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL) 		increased mammary adenocarcinoma incidence J:224955
increased myoepithelioma incidence J:224955
increased spindle cell carcinoma incidence J:224955
Ptentm2Mak/Ptentm2Mak
Trp53tm1Brn/Trp53tm1Brn
Tg(MMTV-cre)#Tfln/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N) 		increased mammary adenocarcinoma incidence J:224955
increased myoepithelioma incidence J:224955
increased spindle cell carcinoma incidence J:224955
Ptentm2Mak/Ptentm2Mak
Trp53tm1Brn/Trp53tm1Brn
Tg(Nes-cre/ERT2,-ALPP)1Sbk/0
(involves: 129P2/OlaHsd) 		increased medulloblastoma incidence J:237990
Ptentm2Mak/Ptentm2Mak
Trp53tm1Brn/Trp53tm1Brn
Tg(Wap-cre)11738Mam/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL) 		increased mammary adenocarcinoma incidence J:224955
increased myoepithelioma incidence J:224955
increased spindle cell carcinoma incidence J:224955
Pth1rtm1a(EUCOMM)Hmgu/Pth1rtm1a(EUCOMM)Hmgu
(C57BL/6N-Pth1rtm1a(EUCOMM)Hmgu/Wtsi) 		increased hemangioma incidence J:239583
Ptpn11tm1Ckq/Ptpn11+
Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J) 		increased acute promyelocytic leukemia incidence J:177285
Ptpn11tm1Ckq/Ptpn11+
Tg(Lck-cre)1Cwi/0
(involves: 129S6/SvEvTac * C57BL/6J) 		increased acute lymphoblastic leukemia incidence J:177285
increased lymphoblastic lymphoma incidence J:177285
Ptpn11tm1Ckq/Ptpn11+
Tg(Mx1-cre)1Cgn/0
(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * CBA) 		increased acute lymphoblastic leukemia incidence J:177285
increased acute promyelocytic leukemia incidence J:177285
increased B cell derived lymphoma incidence J:177285
increased leukemia incidence J:177285
increased lymphoblastic lymphoma incidence J:177285
Ptpn11tm1Gsf/Ptpn11tm1Gsf
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA) 		increased liver adenoma incidence J:172422
Ptprctm1Holm/Ptprctm1Holm
Tg(Lck*F505)2964Rmp/?
(involves: 129/Sv * C57BL/6 * DBA/2) 		increased T cell derived lymphoma incidence J:64671
Ptprctm1Holm/Ptprctm1Holm
Tg(Lck*F505)3073Rmp/?
(involves: 129/Sv * C57BL/6 * DBA/2) 		increased T cell derived lymphoma incidence J:64671
Ptprttm1Sata/Ptprttm1Sata
(B6.129P2-Ptprttm1Sata) 		increased colon adenoma incidence J:157542
Ptprz1tm1Schl/Ptprz1+
Trp53tm1Tyj/Trp53+
(involves: 129 * 129S2/SvPas * C57BL/6J) 		increased osteosarcoma incidence J:243104
Ptprz1tm1Schl/Ptprz1tm1Schl
(involves: 129) 		increased osteosarcoma incidence J:243104
Ptprz1tm1Schl/Ptprz1tm1Schl
Trp53tm1Tyj/Trp53+
(involves: 129 * 129S2/SvPas * C57BL/6J) 		increased osteosarcoma incidence J:243104
Puf60tm1.1Kmtsu/Puf60+
Trp53tm1Sia/Trp53tm1Sia
(involves: C57BL/6NCrlj * C57BL/6NCrSlc * CBA/JNCrlj) 		increased T cell derived lymphoma incidence J:233347
Rab11atm1.1Ngao/Rab11atm1.1Ngao
Tg(Vil1-cre)997Gum/0
(involves: 129S4/SvJae * C57BL/6J * SJL) 		increased intestinal adenoma incidence J:278932
Rab25tm1Jrgo/Rab25tm1Jrgo
Smad3tm1Par/Smad3+
(129-Rab25tm1Jrgo Smad3tm1Par) 		increased colon adenocarcinoma incidence J:158733
Rac3tm1Hkp/Rac3tm1Hkp
Tg(BCR/ABL)623Hkp/0
(involves: C57BL/6 * C57BL/6J * CBA) 		increased leukemia incidence J:99168
Rad9atm2Lieb/Rad9a+
Tg(KRT5-cre)1Xya/?
(involves: 129S/SvEv * C57BL/6) 		increased skin papilloma incidence J:138845
Rad9atm2Lieb/Rad9atm2Lieb
Tg(KRT5-cre)1Xya/?
(involves: 129S/SvEv * C57BL/6) 		increased skin papilloma incidence J:138845
Rad50tm1Jpt/Rad50tm2Jpt
(involves: 129S7/SvEvBrd * C57BL/6) 		increased lymphoma incidence J:103922
Rad50tm2Jpt/Rad50tm2Jpt
(either: (involves: 129S6/SvEvTac * 129S7/SvEvBrd) or (involves: 129S7/SvEvBrd * C57BL/6)) 		increased leukemia incidence J:78820
increased T cell derived lymphoma incidence J:78820
Rad50tm2Jpt/Rad50tm2Jpt
(involves: 129S7/SvEvBrd * C57BL/6) 		increased lymphoma incidence J:103922
Rad50tm2Jpt/Rad50tm2Jpt
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6) 		increased T cell derived lymphoma incidence J:78820
Rad50tm4.1Jpt/Rad50+
(involves: 129/Sv * C57BL/6) 		increased hepatoblastoma incidence J:209141
increased liver adenoma incidence J:209141
Rad50tm4Jpt/Rad50+
(involves: 129/Sv * C57BL/6) 		increased liver adenoma incidence J:209141
Rag1tm1Jsek/Rag1tm1Jsek
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129S6/SvEvTac) 		increased T cell derived lymphoma incidence J:146912
Rag1tm1Mom/Rag1+
Tg(LPV-TAg1135)11Tvd/0
(involves: 129/Sv * C57BL/6 * DBA/2) 		increased T cell derived lymphoma incidence J:47667
Rag1tm1Mom/Rag1+
Tg(LPV-TAg1135)11Tvd/0
Tg(TcrLCMV)327Sdz/0
(involves: 129S7/SvEvBrd * C57BL/6 * DBA/2) 		increased T cell derived lymphoma incidence J:47667
Rag1tm1Mom/Rag1tm1Mom
Prf1tm1Sdz/Prf1tm1Sdz
(NOD.Cg-Rag1tm1Mom Prf1tm1Sdz/Sz) 		increased T cell derived lymphoma incidence J:109843
Rag1tm1Mom/Rag1tm1Mom
Tg(LPV-TAg1135)11Tvd/0
(involves: 129/Sv * C57BL/6 * DBA/2) 		increased T cell derived lymphoma incidence J:47667
Rag1tm1Mom/Rag1tm1Mom
Tg(LPV-TAg1135)11Tvd/0
Tg(TcrLCMV)327Sdz/0
(involves: 129S7/SvEvBrd * C57BL/6 * DBA/2) 		increased T cell derived lymphoma incidence J:47667
Rag1tm1Mom/Rag1tm1Mom
Trp53tm1Brd/Trp53tm1Brd
(involves: 129S7/SvEvBrd * C57BL) 		increased hemangiosarcoma incidence J:141515
increased hepatocellular carcinoma incidence J:141515
increased medulloblastoma incidence J:141515
increased pituitary adenoma incidence J:141515
increased sarcoma incidence J:141515
increased T cell derived lymphoma incidence J:141515
Rag1tm1Mom/Rag1tm1Mom
Trp53tm1Brd/Trp53tm1Brd
Xrcc5tm1Dbr/Xrcc5tm1Dbr
(involves: 129S7/SvEvBrd * C57BL) 		increased medulloblastoma incidence J:141515
increased sarcoma incidence J:141515
increased T cell derived lymphoma incidence J:141515
Rag2tm1.1Desi/Rag2tm1.1Desi
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129X1/SvJ * C57BL/6) 		increased B cell derived lymphoma incidence J:168974
increased T cell derived lymphoma incidence J:168974
Rag2tm1.1Mss/Rag2tm1.1Mss
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129S6/SvEvTac) 		increased lymphoma incidence J:170462
increased T cell derived lymphoma incidence J:170462
Rag2tm1Fwa/Rag2+
Tg(LPV-TAg1135)11Tvd/0
(involves: 129S/SvEv * C57BL/6 * DBA/2) 		increased T cell derived lymphoma incidence J:47667
Rag2tm1Fwa/Rag2+
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S/SvEv * 129S2/SvPas * C57BL/6J) 		increased T cell derived lymphoma incidence J:47667
Rag2tm1Fwa/Rag2tm1Fwa
Stat1tm1Rds/Stat1tm1Rds
(involves: 129S/SvEv * 129S6/SvEvTac) 		increased mammary adenocarcinoma incidence J:216040
Rag2tm1Fwa/Rag2tm1Fwa
Tg(Cd4-NPM/ALK)N1Ingh/0
(involves: 129S/SvEv * C57BL/6 * Swiss Webster) 		increased T cell derived lymphoma incidence J:235890
Rag2tm1Fwa/Rag2tm1Fwa
Tg(Cd4-NPM/ALK)N1Ingh/0
Tg(TcraTcrb)1100Mjb/0
(involves: 129S/SvEv * C57BL/6 * Swiss Webster) 		increased hepatocellular carcinoma incidence J:235890
increased sarcoma incidence J:235890
Rag2tm1Fwa/Rag2tm1Fwa
Tg(LPV-TAg1135)11Tvd/0
(involves: 129S/SvEv * C57BL/6 * DBA/2) 		increased T cell derived lymphoma incidence J:47667
Rag2tm1Fwa/Rag2tm1Fwa
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S/SvEv * 129S2/SvPas * C57BL/6J) 		increased T cell derived lymphoma incidence J:47667
Rag2tm2.1Desi/Rag2tm2.1Desi
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129X1/SvJ * C57BL/6) 		increased T cell derived lymphoma incidence J:168974
Ralatm1a(EUCOMM)Wtsi/Ralatm1a(EUCOMM)Wtsi
(C57BL/6N-Ralatm1a(EUCOMM)Wtsi/Wtsi) 		increased hemangioma incidence J:239583
Ranbp2tm1Jvd/Ranbp2tm1.1Jvd
(involves: 129/Sv * C57BL/6) 		increased hepatocellular carcinoma incidence J:137482
increased lung carcinoma incidence J:137482
increased sarcoma incidence J:137482
Ranbp2tm1Jvd/Ranbp2tm1Jvd
(involves: 129/Sv * C57BL/6) 		increased hepatocellular carcinoma incidence J:137482
increased lung carcinoma incidence J:137482
increased sarcoma incidence J:137482
Raph1tm1.2Fbg/Raph1tm1.2Fbg
(involves: 129S4/SvJae * C57BL/6) 		increased carcinoma incidence J:238262
Rarres1tm1.2Mhl/Rarres1+
(involves: 129S1/SvImJ * C57BL/6 * FVB/N * NIH Black Swiss) 		increased follicular lymphoma incidence J:324270
Rarres1tm1.2Mhl/Rarres1tm1.2Mhl
(involves: 129S1/SvImJ * C57BL/6 * FVB/N * NIH Black Swiss) 		increased follicular lymphoma incidence J:324270
Rarres1tm1d(KOMP)Wtsi/Rarres1+
(involves: C57BL/6N) 		increased follicular lymphoma incidence J:324270
Rasal2Gt(463C12)Cmhd/Rasal2Gt(463C12)Cmhd
Tg(MMTVneu)202Mul/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6NCrl * FVB/N) 		increased mammary adenocarcinoma incidence J:202603
Rasal2Gt(463C12)Cmhd/Rasal2Gt(463C12)Cmhd
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S * 129X1/SvJ * C57BL/6 * C57BL/6NCrl) 		increased colon adenoma incidence J:202603
increased hepatocellular carcinoma incidence J:202603
increased lymphoma incidence J:202603
Rassf1tm1.2Brd/Rassf1tm1.2Brd
(involves: 129S7/SvEvBrd * C57BL/6) 		increased adenoma incidence J:101369
increased intestinal adenocarcinoma incidence J:101369
increased lymphoma incidence J:101369
Rassf1tm1Gpp/Rassf1+
(involves: 129S1/SvImJ * C57BL/6) 		increased lung adenoma incidence J:95683
Rassf1tm1Gpp/Rassf1tm1Gpp
(involves: 129S1/SvImJ * C57BL/6) 		increased B cell derived lymphoma incidence J:95683
increased lung adenoma incidence J:95683
Rassf1tm1Gpp/Rassf1tm1Gpp
(involves: 129S1/SvImJ) 		increased hepatocellular carcinoma incidence J:231761
increased liver adenoma incidence J:231761
Rassf1tm1Gpp/Rassf1tm1Gpp
Sav1tm1.1Gpp/Sav1+
(involves: 129S1/Sv * 129S1/SvImJ) 		increased hepatoblastoma incidence J:231761
increased hepatocellular carcinoma incidence J:231761
increased liver adenoma incidence J:231761
Rassf5tm1Kina/Rassf5tm1Kina
(B6.Cg-Rassf5tm1Kina) 		increased B cell derived lymphoma incidence J:168749
increased hepatocellular carcinoma incidence J:168749
increased lung adenocarcinoma incidence J:168749
Rb1tm1.1Jyjw/Rb1tm1.1Jyjw
Trp53tm1Tyj/Trp53tm1Tyj
(129S6.129-Trp53tm1Tyj Rb1tm1.1Jyjw) 		increased colon adenoma incidence J:102483
increased intestinal adenocarcinoma incidence J:102483
increased lymphoma incidence J:102483
increased teratoma incidence J:102483
increased testicular teratoma incidence J:102483
Rb1tm1Brd/Rb1+
(involves: 129S7/SvEvBrd * C57BL/6) 		increased pituitary adenoma incidence J:17434
Rb1tm1Brd/Rb1+
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J) 		increased thyroid C-cell carcinoma incidence J:79016
Rb1tm1Brn/Rb1+
Tg(Pomc-FLP)1aBrn/0
(involves: 129P2/OlaHsd * FVB/N) 		increased pituitary adenoma incidence J:48860
Rb1tm1Brn/Rb1tm1Brn
Tg(Pomc-FLP)1aBrn/0
(involves: 129P2/OlaHsd * FVB/N) 		increased pituitary adenoma incidence J:48860
Rb1tm1Brn/Rb1tm1Brn
X/Tg(Pomc-FLP)1bBrn
(involves: 129P2/OlaHsd * FVB/N) 		increased pituitary adenoma incidence J:48860
Rb1tm1Tyj/Rb1+
(involves: 129S2/SvPas * C57BL/6J) 		increased thyroid C-cell carcinoma incidence J:133299
Rb1tm1Tyj/Rb1+
Tg(Th-MYCN)41Waw/0
(involves: 129S2/SvPas * BALB/c * C57BL/6J) 		increased neuroblastoma incidence J:41126
Rb1tm1Tyj/Rb1+
Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * C57BL/6) 		increased leiomyosarcoma incidence J:19542
increased pancreatic islet cell carcinoma incidence J:19542
increased sarcoma incidence J:19542
Rb1tm1Tyj/Rb1tm2Brn
Rbl1tm1Tyj/Rbl1+
Tg(Chx10-EGFP/cre,-ALPP)2Clc/0
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL) 		increased retinoblastoma incidence J:120315
Rb1tm1Tyj/Rb1tm2Brn
Rbl1tm1Tyj/Rbl1+
Trp53tm1Brn/Trp53tm1Brn
Tg(Chx10-EGFP/cre,-ALPP)2Clc/0
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL) 		increased retinoblastoma incidence J:120315
Rb1tm1Tyj/Rb1tm2Brn
Rbl1tm1Tyj/Rbl1tm1Tyj
Trp53tm1Brn/Trp53tm1Brn
Tg(Chx10-EGFP/cre,-ALPP)2Clc/0
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL) 		increased retinoblastoma incidence J:120315
Rb1tm1Tyj/Rb1tm2Brn
Rbl1tm1Tyj/Rbl1tm1Tyj
Trp53tm1Brn/Trp53tm1Tyj
Tg(Chx10-EGFP/cre,-ALPP)2Clc/0
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL) 		increased retinoblastoma incidence J:120315
Rb1tm1Tyj/Rb1tm2Tyj
(chimera involves: 129S2/SvPas * C57BL/6) 		increased pituitary adenoma incidence J:59268
Rb1tm2Brn/Rb1+
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd) 		increased lung adenocarcinoma incidence J:86077
increased lung small cell carcinoma incidence J:86077
Rb1tm2Brn/Rb1+
Trp53tm1Brn/Trp53tm1Brn
Tg(Col1a1-cre)1Kry/0
(involves: 129 * 129P2/OlaHsd * FVB/N) 		increased osteosarcoma incidence J:234128
Rb1tm2Brn/Rb1tm2Brn
Rbl1tm1Tyj/Rbl1tm1Tyj
Rbl2tm2Tyj/Rbl2tm2Tyj
(involves: 129 * 129S2/SvPas * 129S4/SvJae) 		increased urinary bladder carcinoma incidence J:217195
Rb1tm2Brn/Rb1tm2Brn
Tg(Gfap-cre)2Brn/0
(involves: 129 * FVB/N) 		increased carcinoma incidence J:187257
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brd/Trp53tm1Brd
Tg(Gfap-cre)2Brn/0
(involves: 129 * 129S7/SvEvBrd * FVB/N) 		increased medulloblastoma incidence J:61961
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53+
(involves: 129P2/OlaHsd) 		increased lung adenocarcinoma incidence J:86077, J:157319
increased lung small cell carcinoma incidence J:86077, J:157319
increased thyroid carcinoma incidence J:86077, J:157319
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd) 		increased lung carcinoma incidence J:86077
increased lung small cell carcinoma incidence J:86077, J:157319
increased ovarian carcinoma incidence J:84345
increased thyroid carcinoma incidence J:86077, J:157319
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(BGLAP-cre)1Clem/0
(involves: 129 * 129P2/OlaHsd * FVB/NJ) 		increased osteosarcoma incidence J:326989
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(Col1a1-cre)1Kry/0
(involves: 129 * 129P2/OlaHsd * FVB/N) 		increased osteosarcoma incidence J:234128
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(Gfap-cre)2Brn/0
(involves: 129P2/OlaHsd * FVB/N) 		increased medulloblastoma incidence J:61961
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(Gfap-cre)2Brn/0
(involves: 129 * 129P2/OlaHsd * FVB/N) 		increased carcinoma incidence J:187257
increased medulloblastoma incidence J:187257
increased papilloma incidence J:187257
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(MMTV-cre)105Ayn/0
(FVB.Cg-Trp53tm1Brn Rb1tm2Brn Tg(MMTV-cre)105Ayn) 		increased carcinoma incidence J:165292
increased squamous cell carcinoma incidence J:165292
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(Ren-cre)#Kwg/0
(involves: 129 * 129P2/OlaHsd) 		increased glucagonoma incidence J:216559
increased pancreatic islet cell carcinoma incidence J:216559
increased sarcoma incidence J:216559
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Lejo/Trp53tm1Lejo
(involves: 129) 		increased lung small cell carcinoma incidence J:187012
Rb1tm3Fad/Rb1tm3Fad
(involves: 129S1/Sv * 129X1/SvJ) 		increased lymphoma incidence J:249124
Rb1tm3Tyj/Rb1+
Sox2tm4.1Skn/Sox2+
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129 * C57BL/6 * CD-1) 		decreased osteosarcoma incidence J:318885
Rb1tm3Tyj/Rb1+
Sox2tm4.1Skn/Sox2tm4.1Skn
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129 * C57BL/6 * CD-1) 		decreased osteosarcoma incidence J:318885
Rb1tm3Tyj/Rb1+
Trp53tm1Brn/Trp53+
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J * CD-1 * FVB/N) 		increased osteosarcoma incidence J:136693
Rb1tm3Tyj/Rb1+
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J * CD-1 * FVB/N) 		increased osteosarcoma incidence J:136693
Rb1tm3Tyj/Rb1+
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129 * C57BL/6 * CD-1) 		increased osteosarcoma incidence J:318885
Rb1tm3Tyj/Rb1tm3Tyj
Rbl1tm1Tyj/Rbl1tm1Tyj
Rbl2tm2.1Tyj/Rbl2tm2.1Tyj
(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6) 		increased hepatocellular carcinoma incidence J:177573
Rb1tm3Tyj/Rb1tm3Tyj
Rbl1tm1Tyj/Rbl1tm1Tyj
Tg(Pax6-cre,GFP)2Pgr/0
(involves: 129S2/SvPas * 129S4/SvJae * 129X1/SvJ * C57BL/6 * FVB/N) 		increased retinoblastoma incidence J:119919
Rb1tm3Tyj/Rb1tm3Tyj
Rbl2tm1Tyj/Rbl2tm1Tyj
Tg(Nes-cre)1Atp/0
(involves: 129S2/SvPas * 129S4/SvJae * FVB/N) 		increased retinoblastoma incidence J:91406
Rb1tm3Tyj/Rb1tm3Tyj
Rbl2tm2.1Tyj/Rbl2tm2.1Tyj
Tg(Pax6-cre,GFP)2Pgr/0
(involves: 129S4/SvJae * 129X1/SvJ * C57BL/6 * FVB/N) 		increased retinoblastoma incidence J:119919
Rb1tm3Tyj/Rb1tm3Tyj
Rbl2tm2Tyj/Rbl2tm2Tyj
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S4/SvJae) 		increased lung small cell carcinoma incidence J:160148
Rb1tm3Tyj/Rb1tm3Tyj
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
Tg(tetO-RNAi:Trp53)ASlowe/0
(involves: 129S4/SvJae * C57BL/6 * CD-1) 		increased osteosarcoma incidence J:199542
Rb1tm3Tyj/Rb1tm3Tyj
Tg(tetO-MYC)36aBop/0
Tg(Cebpb-tTA)5Bjd/0
(involves: FVB/N * NMRI) 		increased hepatocellular carcinoma incidence J:172430
Rb1tm3Tyj/Rb1tm3Tyj
Trp53tm1Brn/Trp53+
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J * CD-1 * FVB/N) 		increased osteosarcoma incidence J:136693
Rb1tm3Tyj/Rb1tm3Tyj
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S4/SvJae) 		increased lung small cell carcinoma incidence J:160148
Rb1tm3Tyj/Rb1tm3Tyj
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J * CD-1 * FVB/N) 		increased osteosarcoma incidence J:136693, J:318035
Rb1tm3Tyj/Rb1tm3Tyj
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * CD-1) 		increased hibernoma incidence J:199542
increased osteosarcoma incidence J:199542
Rb1tm3Tyj/Rb1tm3Tyj
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * 129S4/SvJae * CD-1) 		increased osteosarcoma incidence J:329449
Rbbp8tm1Whl/Rbbp8+
(Not Specified) 		increased lymphoma incidence J:97648
Rbm15tm1.1(MAL)Dgg/Rbm15tm1.1(MAL)Dgg
(B6.129-Rbm15tm1.1(MAL)Dgg) 		increased leukemia incidence J:149622
Rbm38tm1.1Xch/Rbm38tm1.1Xch
(involves: C57BL/6 * FVB/N) 		increased hemangiosarcoma incidence J:216929
increased lymphoma incidence J:216929
Rbm38tm1.1Xch/Rbm38tm1.1Xch
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6 * FVB/N) 		decreased sarcoma incidence J:216929
increased lymphoma incidence J:216929
Rc3h1san/Rc3h1+
(involves: C57BL/6JSfdAnu) 		increased T cell derived lymphoma incidence J:189087
Rcbtb2tm1.1Xyw/Rcbtb2+
(involves: C57BL/6 * CBA) 		increased histiocytic sarcoma incidence J:282928
increased lymphoma incidence J:282928
Rcbtb2tm1.1Xyw/Rcbtb2tm1.1Xyw
(involves: C57BL/6 * CBA) 		increased histiocytic sarcoma incidence J:282928
increased lymphoma incidence J:282928
Recql4tm1Glu/Recql4tm1Glu
(involves: 129S7/SvEvBrd * C57BL/6J) 		increased lymphoma incidence J:97101
increased sarcoma incidence J:97101
Rettm1Giro/Ret+
(129.129P2-Rettm1Giro) 		increased thyroid adenoma incidence J:141658
Rettm2.1Cos/?
Tg(Th-MYCN)41Waw/0
(involves: 129S1/Sv * BALB/c * C57BL/6J) 		increased neuroblastoma incidence J:261033
Rev3ltm1Rwd/Rev3ltm2.1Rwd
Tg(MMTV-cre)1Mam/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB) 		increased carcinoma incidence J:158922
Rev3ltm1Rwd/Rev3ltm2.1Rwd
Trp53tm1Brd/Trp53+
Tg(MMTV-cre)1Mam/0
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * FVB/N) 		increased carcinoma incidence J:158922
increased osteosarcoma incidence J:158922
Rev3ltm1Rwd/Rev3ltm2.1Rwd
Trp53tm1Brd/Trp53tm1Brd
Tg(MMTV-cre)1Mam/0
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * FVB/N) 		increased T cell derived lymphoma incidence J:158922
Rgs5tm1.1Rgan/Rgs5tm1.1Rgan
Tg(RIP1-Tag)5Dh/0
(C3.Cg-Rgs5tm1.1Rgan Tg(RIP1-Tag)5Dh) 		increased insulinoma incidence J:136259
Rgsc142/Rgsc142+
(involves: C57BL/6JJcl * DBA/2JJcl) 		increased leukemia incidence J:133634
increased T cell derived lymphoma incidence J:133634
Rgsc682/Rgsc682+
(involves: C57BL/6JJcl * DBA/2JJcl) 		increased squamous cell carcinoma incidence J:133634
Rgsc814/Rgsc814+
(involves: C57BL/6JJcl * DBA/2JJcl) 		increased squamous cell carcinoma incidence J:133634
Rgsc1033/Rgsc1033+
(involves: C57BL/6JJcl * DBA/2JJcl) 		increased pituitary adenoma incidence J:133634
increased thyroid carcinoma incidence J:133634
Rgsc1049/Rgsc1049+
(involves: C57BL/6JJcl * DBA/2JJcl) 		increased squamous cell carcinoma incidence J:133634
Rgsc1050/Rgsc1050+
(involves: C57BL/6JJcl * DBA/2JJcl) 		increased renal carcinoma incidence J:133634
Rgv1C57BL/6/Rgv1C57BL/6
(involves: C3Hf/Bi * C57BL/6) 		increased leukemia incidence J:5011
Rhoctm1Mak/Rhoctm1Mak
Tg(MMTV-PyVT)634Mul/0
(involves: 129P2/OlaHsd * FVB/N) 		increased mammary adenocarcinoma incidence J:100482
Rigitm1Zgwg/Rigitm1Zgwg
(involves: 129S1/Sv) 		increased chronic myelocytic leukemia incidence J:139016
Ril1A/J/Ril1A/J
(involves: A/J * C57BL/10ScSn) 		increased leukemia incidence J:6610
Ril1A/J/Ril1C57BL/10ScSn
(involves: A/J * C57BL/10ScSn) 		increased leukemia incidence J:6610
Ril2A/J/Ril2C57BL/10ScSn
(involves: A/J * C57BL/10ScSn) 		increased leukemia incidence J:6610
Ril2C57BL/10ScSn/Ril2C57BL/10ScSn
(involves: A/J * C57BL/10ScSn) 		increased leukemia incidence J:6610
Ril3A/J/Ril3C57BL/10ScSn
(involves: A/J * C57BL/10ScSn) 		increased leukemia incidence J:6610
Ril3C57BL/10ScSn/Ril3C57BL/10ScSn
(involves: A/J * C57BL/10ScSn) 		increased leukemia incidence J:6610
Ril4BALB/c/Ril4BALB/c
(B6.C-H30c/(HW105)ByJ) 		increased leukemia incidence J:7027
Rint1tm1Whl/Rint1+
(Not Specified) 		increased cystadenoma incidence J:122805
increased hemangioma incidence J:122805
increased hepatocellular carcinoma incidence J:122805
increased lung adenocarcinoma incidence J:122805
increased lymphoma incidence J:122805
increased mammary adenocarcinoma incidence J:122805
increased mesothelioma incidence J:122805
increased papilloma incidence J:122805
increased pituitary adenoma incidence J:122805
increased skin squamous cell carcinoma incidence J:122805
increased uterus leiomyoma incidence J:122805
Rnf8Gt(AS0574)Wtsi/Rnf8Gt(AS0574)Wtsi
(involves: 129P2/OlaHsd * C57BL/6) 		increased lymphoma incidence J:161240
increased mammary adenocarcinoma incidence J:161240
increased sarcoma incidence J:161240
increased T cell derived lymphoma incidence J:161240
Rnf8Gt(RRR260)Byg/Rnf8Gt(RRR260)Byg
(involves: 129P2/OlaHsd * C57BL/6) 		increased lymphoma incidence J:161240
increased mammary adenocarcinoma incidence J:161240
increased sarcoma incidence J:161240
increased T cell derived lymphoma incidence J:161240
Rnf20Gt(RRJ249)Byg/Rnf20+
(involves: 129P2/OlaHsd) 		increased colon adenocarcinoma incidence J:268221
increased large intestine adenocarcinoma incidence J:268221
Rnf43tm1Cle/Rnf43tm1Cle
Znrf3tm1Cle/Znrf3tm1Cle
Lgr5tm1(cre/ERT2)Cle/Lgr5+
(involves: 129P2/OlaHsd) 		increased intestinal adenoma incidence J:186765
Rnf43tm1Cle/Rnf43tm1Cle
Znrf3tm1Cle/Znrf3tm1Cle
Tg(Vil1-cre/ERT2)23Syr/0
(involves: C57BL/6 * DBA/2) 		increased intestinal adenoma incidence J:186765
Rnf168Gt(156B6)Cmhd/Rnf168Gt(156B6)Cmhd
Trp53tm1Brd/Trp53tm1Brd
(involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6) 		increased B cell derived lymphoma incidence J:198260
increased hemangiosarcoma incidence J:198260
increased sarcoma incidence J:198260
Rnf168Gt(405F11)Cmhd/Rnf168Gt(405F11)Cmhd
Trp53tm1Brd/Trp53tm1Brd
(involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6) 		increased B cell derived lymphoma incidence J:198260
increased hemangiosarcoma incidence J:198260
increased sarcoma incidence J:198260
Robo1tm1Phr/Robo1+
(involves: 129P2/OlaHsd * C57BL/6) 		increased carcinoma incidence J:93666
increased lung adenocarcinoma incidence J:93666
increased lymphoma incidence J:93666
Rpa1tm1Wed/Rpa1+
(involves: 129/Sv * C57BL/6J * SJL) 		increased lymphoma incidence J:99303
Rpl27aSfa/Rpl27a+
Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6J) 		decreased lymphoma incidence J:174216
Rps6kb2tm1Gtho/Rps6kb2tm1Gtho
Tg(Ins2-Akt1*)3Mbb/0
(B6.Cg-Rps6kb2tm1Gtho Tg(Ins2-Akt1*)3Mbb) 		increased insulinoma incidence J:144599
Rps27lGt(IST11658B7)Tigm/Rps27lGt(IST11658B7)Tigm
Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * C57BL/6N) 		increased B cell derived lymphoma incidence J:223276
increased T cell derived lymphoma incidence J:223276
Rps27lGt(IST11658B7)Tigm/Rps27lGt(IST11658B7)Tigm
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6N) 		increased lymphoma incidence J:223276
Rr420em1Itok/Rr420em1Itok
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * C57BL/6 * CD-1) 		decreased osteosarcoma incidence J:319454
Rr420tm1.1Itok/Rr420tm1.1Itok
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * C57BL/6 * CD-1) 		decreased osteosarcoma incidence J:319454
Rr149356tm1Che/Rr149356tm1Che
Tcrdtm1Mom/Tcrdtm1Mom
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129P2/OlaHsd * 129S2/SvPas * 129S4/SvJae * C57BL/6) 		increased T cell derived lymphoma incidence J:106246
Rr149356tm1Che/Rr149356tm1Che
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6) 		increased T cell derived lymphoma incidence J:106246
RrsvA/WySnJ/RrsvA/WySnJ
(involves: A/WySnJ * SW) 		increased sarcoma incidence J:6009
RrsvCBA/J/RrsvCBA/J
(involves: CBA/J * SW) 		increased sarcoma incidence J:6009
Rtel1tm2.1Hdin/Rtel1tm2.1Hdin
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6) 		increased lymphoma incidence J:202812
increased medulloblastoma incidence J:202812
increased sarcoma incidence J:202812
increased teratoma incidence J:202812
Rundc1tm1b(EUCOMM)Wtsi/Rundc1tm1b(EUCOMM)Wtsi
(C57BL/6N-Rundc1tm1b(EUCOMM)Wtsi/Wtsi) 		increased hemangioma incidence J:239583
Runx1tm1(RUNX1)Gcg/Runx1tm1(RUNX1)Gcg
Tg(Mx1-cre)1Cgn/0
(involves: 129S1/Sv * C57BL/6 * CBA) 		increased T cell derived lymphoma incidence J:106800
Runx1tm1Spe/Runx1+
(either: (involves: 129S4/SvJae * BALB/c * C57BL/6 * CBA/Ca) or (involves: 129S4/SvJae * C57BL/6 * CBA/Ca)) 		increased T cell derived lymphoma incidence J:80829
Runx1tm2Buch/Runx1tm2Buch
Tg(Mx1-cre)1Cgn/?
(involves: 129P2/OlaHsd * C57BL/6 * CBA) 		increased lymphoma incidence J:105709
increased T cell derived lymphoma incidence J:105709
Runx1tm3Dow/Runx1+
Tg(Mx1-cre)1Cgn/0
(involves: C57BL/6 * CBA) 		increased acute promyelocytic leukemia incidence J:77129
increased sarcoma incidence J:77129
increased T cell derived lymphoma incidence J:77129
Runx3tm1.1Itok/Runx3tm1.1Itok
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * C57BL/6 * CD-1) 		decreased osteosarcoma incidence J:319454
Runx3tm1Itan/Runx3+
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * C57BL/6 * CD-1) 		decreased osteosarcoma incidence J:319454
Rv2BALB/cJ/Rv2BALB/cJ
(B6.C-H7b/By) 		increased leukemia incidence J:7613
Rv2BALB/cJ/Rv2BALB/cJ
(B10.C-H7b/(47N)SnJ) 		increased leukemia incidence J:7613
Rv3C57BL/6J/Rv3C57BL/6J
(involves: C57BL/6J * CBA/Lac) 		increased leukemia incidence J:7613
Rv3C57BL/6J/Rv3CBA/Lac
(involves: C57BL/6J * CBA/Lac) 		increased leukemia incidence J:7613
Rv3CBA/Lac/Rv3CBA/Lac
(involves: C57BL/6J * CBA/Lac) 		increased leukemia incidence J:7613
Rvil1CE/J/Rvil1CE/J
(B10.CE-H3bb/(30NX)SnDcr) 		increased leukemia incidence J:7027
Ryr2tm1(CAG-KRAS*G12V,-lacZ)Nobs/Ryr2tm1(CAG-KRAS*G12V,-lacZ)Nobs
Trp53tm1Sia/Trp53+
(involves: 129X1/SvJ * C57BL/6 * CBA) 		increased rhabdomyosarcoma incidence J:117828
Ryr2tm1(CAG-KRAS*G12V,-lacZ)Nobs/Ryr2tm1(CAG-KRAS*G12V,-lacZ)Nobs
Trp53tm1Sia/Trp53tm1Sia
(involves: 129X1/SvJ * C57BL/6 * CBA) 		increased rhabdomyosarcoma incidence J:117828
S1pr2tm1Ajml/S1pr2tm1Ajml
(involves: 129S5/SvEvBrd * C57BL/6) 		increased B cell derived lymphoma incidence J:154439
S1pr2tm1Ajml/S1pr2tm1Ajml
(129S5/SvEvBrd-S1pr2tm1Ajml) 		increased B cell derived lymphoma incidence J:154439
S100a4tm1Amba/S100a4tm1Amba
(involves: 129S1/Sv * 129X1/SvJ * NMRI) 		increased fibrosarcoma incidence J:89563
increased hepatocellular carcinoma incidence J:89563
increased lung carcinoma incidence J:89563
increased lymphoma incidence J:89563
increased mammary adenocarcinoma incidence J:89563
Samd9ltm1Homy/Samd9l+
(involves: 129P2/OlaHsd) 		increased leukemia incidence J:180923, J:202604
Samd9ltm1Homy/Samd9ltm1Homy
(involves: 129P2/OlaHsd) 		increased leukemia incidence J:180923, J:202604
Samd9ltm1Homy/Samd9ltm1Homy
(B6N.129P2-Samd9ltm1Homy) 		increased leukemia incidence J:225110
Sav1tm1.1Gpp/Sav1+
(involves: 129S1/Sv) 		increased hepatocellular carcinoma incidence J:231761
increased liver adenoma incidence J:231761
Sav1tm1.1Rjo/Sav1tm1.1Rjo
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129S6/SvEvTac * C57BL/6 * CD-1 * DBA * SJL) 		increased carcinoma incidence J:156531
increased hepatocellular carcinoma incidence J:156531
Sav1tm1Dlim/Sav1+
(involves: 129S1/Sv * 129X1/SvJ) 		increased lymphoma incidence J:160325
increased osteosarcoma incidence J:160325
Sav1tm2.1Dlim/Sav1tm2.1Dlim
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: C57BL/6 * DBA) 		increased hepatocellular carcinoma incidence J:238319
Scc4BALB/cHeA/?
Scc5STS/A/Scc5STS/A
(involves: BALB/cHeA * STS/A) 		increased colon adenoma incidence J:36996
Scc4STS/A/Scc4STS/A
Scc5BALB/cHeA/?
(involves: BALB/cHeA * STS/A) 		increased colon adenoma incidence J:36996
Scc6STS/A/?
(involves: BALB/cHeA * STS/A) 		increased colon adenoma incidence J:57235
Scc7STS/A/?
Scc8STS/A/?
(involves: BALB/cHeA * STS/A) 		increased colon adenoma incidence J:57235
Scc8STS/A/?
(involves: BALB/cHeA * STS/A) 		increased colon adenoma incidence J:57235
Scc9STS/A/?
(involves: BALB/cHeA * CcS-5) 		increased colon adenoma incidence J:57235
Scribtm1.2Phum/Scrib+
(involves: FVB/N) 		increased lung adenocarcinoma incidence J:178461
increased lung adenoma incidence J:216266
increased lung non-small cell carcinoma incidence J:216266
SfnEr/Sfn+
(involves: 129/Sv * C57BL/6) 		increased skin papilloma incidence J:12025
increased squamous cell carcinoma incidence J:12025
Sipa1tm1Nm/Sipa1+
(involves: 129P2/OlaHsd * C57BL/6) 		increased chronic myelocytic leukemia incidence J:97239
Sipa1tm1Nm/Sipa1tm1Nm
(involves: 129P2/OlaHsd * C57BL/6) 		increased chronic myelocytic leukemia incidence J:97239
Sirt1tm1.1Cxd/Sirt1+
Trp53tm1Brd/Trp53+
(either: (involves: 129S6/SvEvTac * 129S7/SvEvBrd * Black Swiss * FVB/N) or (involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * FVB/N)) 		increased carcinoma incidence J:140089
increased lymphoma incidence J:140089
increased sarcoma incidence J:140089
increased teratoma incidence J:140089
Sirt2tm1.1Cxd/Sirt2tm1.1Cxd
(either: (involves: C57BL/6 * FVB/N) or (involves: FVB/N * NIH Black Swiss)) 		increased B cell derived lymphoma incidence J:177486
increased hepatocellular carcinoma incidence J:177486
Skitm1Cco/Ski+
(involves: 129P2/OlaHsd * C57BL/6) 		increased lymphoma incidence J:73349
Skiltm1Sis/Skil+
(involves: C57BL/6 * CBA) 		increased B cell derived lymphoma incidence J:62174
increased T cell derived lymphoma incidence J:62174
Skts13M. spretus/?
(involves: M. spretus * NIH/Ola) 		increased skin papilloma incidence J:84842
Skts-fp2FVB/NTac/Skts-fp2FVB/NTac
Skts-fp3FVB/NTac/Skts-fp3FVB/NTac
(involves: FVB/NTac * PWK/Rbrc) 		increased skin papilloma incidence J:125337
Slc20a2tm1a(EUCOMM)Wtsi/Slc20a2tm1a(EUCOMM)Wtsi
(C57BL/6N-Slc20a2tm1a(EUCOMM)Wtsi/Wtsi) 		increased hemangioma incidence J:239583
Slc29a3tm1Lex/Slc29a3tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6) 		increased histiocytic sarcoma incidence J:179286
Slc33a1tm1.1Lpu/Slc33a1+
(involves: 129S7/SvEvBrd * C57BL/6) 		increased lung adenoma incidence J:211266
increased lymphoma incidence J:211266
increased sarcoma incidence J:211266
Sluc10B10.O20/Dem/Sluc10B10.O20/Dem
Sluc25O20/A/Sluc25O20/A
(involves: B10.O20/Dem * O20/A) 		increased lung adenocarcinoma incidence J:71973
Sluc10O20/A/Sluc10O20/A
Sluc25O20/A/Sluc25O20/A
(involves: B10.O20/Dem * O20/A) 		increased lung adenocarcinoma incidence J:71973
Sluc18B10.O20/Dem/Sluc18B10.O20/Dem
Sluc26B10.O20/Dem/Sluc26B10.O20/Dem
(involves: B10.O20/Dem * O20/A) 		increased lung adenocarcinoma incidence J:71973
Sluc25O20/A/Sluc25O20/A
Sluc5B10.O20/Dem/Sluc5B10.O20/Dem
(involves: B10.O20/Dem * O20/A) 		increased lung adenocarcinoma incidence J:71973
Sluc25O20/A/Sluc25O20/A
Sluc9B10.O20/Dem/Sluc9O20/A
(involves: B10.O20/Dem * O20/A) 		increased lung adenocarcinoma incidence J:71973
Sluc25O20/A/Sluc25O20/A
Sluc9O20/A/Sluc9O20/A
(involves: B10.O20/Dem * O20/A) 		increased lung adenocarcinoma incidence J:71973
Smad3tm1Cxd/Smad3tm1Cxd
(either: (involves: 129S6/SvEvTac * C57BL/6) or (involves: 129S6/SvEvTac * NIH Black Swiss)) 		increased intestinal adenocarcinoma incidence J:53510
Smad3tm1Par/Smad3tm1Par
(either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)) 		increased intestinal adenocarcinoma incidence J:49839
Smad3tm1Par/Smad3tm1Par
(129-Smad3tm1Par/J) 		increased intestinal adenocarcinoma incidence J:106572
Smad4E6sad/Smad4+
(involves: 129P2/OlaHsd * C57BL/6) 		increased intestinal adenoma incidence J:81488
Smad4tm2.1Cxd/Smad4tm2.1Cxd
Tg(KRT5-cre)1Xya/0
(involves: 129S6/SvEvTac) 		increased carcinoma incidence J:101602
increased skin papilloma incidence J:101602
Smad4tm2.1Cxd/Smad4tm2.1Cxd
Trp53tm1Brn/Trp53tm1Brn
Tg(MMTV-cre)7Mul/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * FVB/N) 		increased mammary adenocarcinoma incidence J:212549
Smad4tm2.1Cxd/Smad4tm2.1Cxd
Trp53tm1Brn/Trp53tm1Brn
Tg(Vil1-cre)20Syr/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2) 		increased intestinal adenocarcinoma incidence J:212549
Smad9tm3Jfm/Smad9tm3Jfm
(involves: 129S4/SvJaeSor) 		increased lung adenoma incidence J:150213
Smap1tm1.1Sata/Smap1tm1.1Sata
(B6.Cg-Smap1tm1.1Sata) 		increased leukemia incidence J:196385
Smarca2tm1Mya/Smarca2tm1Mya
Smarca4tm1Mag/Smarca4+
(involves: 129S/Sv * 129S2/SvPas * C57BL/6J * CD-1) 		increased hemangiosarcoma incidence J:132091
Smarca4tm1Mag/Smarca4+
(involves: 129S/Sv * C57BL/6J * CD-1) 		increased mammary adenocarcinoma incidence J:132091
increased osteosarcoma incidence J:132091
Smarcb1tm1Gvk/Smarcb1+
(involves: 129/Sv * C57BL/6J * SJL/J) 		increased blastoma incidence J:101185
Smarcb1tm1Mya/Smarcb1+
(involves: 129S2/SvPas * C57BL/6) 		increased sarcoma incidence J:68501
Smarcb1tm1Sho/Smarcb1+
(involves: 129S6/SvEvTac * C57BL/6J * DBA/2J) 		increased malignant tumor incidence J:120820
Smarcb1tm1Sho/Smarcb1+
Tg(LPV-TAg121)2Tvd/0
(involves: 129S6/SvEvTac * C57BL/6J * DBA/2J) 		increased carcinoma incidence J:120820
increased malignant tumor incidence J:120820
Smarcb1tm1Sho/Smarcb1tm3Sho
Tg(Mx1-cre)1Cgn/?
(involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6 * CBA) 		increased lymphoma incidence J:80224
increased rhabdomyoma incidence J:80224
increased T cell derived lymphoma incidence J:80224
Smg1Gt(AG0297)Wtsi/Smg1+
(involves: 129P2/OlaHsd * C57BL/6) 		increased B cell derived lymphoma incidence J:193626
increased lung adenocarcinoma incidence J:193626
increased lymphoma incidence J:193626
Smurf2Gt(RRA098)Byg/Smurf2+
(involves: 129P2/OlaHsd * C57BL/6) 		increased lymphoma incidence J:189320
Smurf2Gt(RRA098)Byg/Smurf2Gt(RRA098)Byg
(involves: 129P2/OlaHsd * C57BL/6) 		increased B cell derived lymphoma incidence J:189320, J:245679
increased hepatocellular carcinoma incidence J:189320
increased lymphoma incidence J:189320
increased sarcoma incidence J:189320
increased small intestine adenocarcinoma incidence J:189320
Soat1ald/Soat1ald
(AKR/O) 		increased leukemia incidence J:12157
Sod1m1H/Sod1m1H
(involves: C3H/HeH * C57BL/6J) 		increased hepatocellular carcinoma incidence J:219360
Sod2tm1Cje/Sod2+
(B6.Cg-Sod2tm1Cje/Mmmh) 		increased lymphoma incidence J:87514
Spi1tm1.1Dgt/Spi1tm1.1Dgt
(involves: 129S1/Sv * 129X1/SvJ) 		increased leukemia incidence J:90331
increased T cell derived lymphoma incidence J:90331
Spi1tm1.3Dgt/Spi1tm1.3Dgt
(involves: 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6) 		increased leukemia incidence J:106040
increased T cell derived lymphoma incidence J:106040
Spi1tm1.3Dgt/Spi1tm1.3Dgt
(involves: 129 * BALB/c * C57BL/6) 		increased leukemia incidence J:90331
increased T cell derived lymphoma incidence J:90331
Sptbn1tm1Mish/Sptbn1+
(involves: 129S6/SvEvTac * C57BL/6) 		increased hepatocellular carcinoma incidence J:132133
Sptbn1tm1Mish/Sptbn1+
(involves: 129S6/SvEvTac) 		increased adenoma incidence J:166879
increased carcinoma incidence J:166879
increased hepatocellular carcinoma incidence J:166879
increased lung adenocarcinoma incidence J:166879
increased lymphoma incidence J:166879
increased renal carcinoma incidence J:166879
increased sarcoma incidence J:166879
increased thyroid carcinoma incidence J:166879
Srpxtm1Hzi/Srpx+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6) 		increased lymphoma incidence J:119999
Srpxtm1Hzi/Srpxtm1Hzi
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6) 		increased lung adenocarcinoma incidence J:119999
increased lymphoma incidence J:119999
increased sarcoma incidence J:119999
increased T cell derived lymphoma incidence J:119999
Ssbp2tm1Lana/Ssbp2tm1Lana
(involves: 129S/SvEv * C57BL/6) 		increased adenoma incidence J:162035
increased B cell derived lymphoma incidence J:162035
increased carcinoma incidence J:162035
increased jejunum adenocarcinoma incidence J:162035
increased lung adenoma incidence J:162035
increased lymphoma incidence J:162035
increased malignant tumor incidence J:162035
increased sarcoma incidence J:162035
increased squamous cell carcinoma incidence J:162035
Ssbp2tm1Lana/Ssbp2tm1Lana
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S/SvEv * 129S2/SvPas * BALB/c * C57BL/6) 		increased T cell derived lymphoma incidence J:162035
Ssic1C57BL/10J/Ssic1C57BL/10J
(involves: C57BL/10 * O20/A) 		increased small intestine adenocarcinoma incidence J:26873
Stag1Gt(P099A04)Wrst/Stag1+
(involves: 129S2/SvPas) 		increased carcinoma incidence J:184720
increased hepatocellular carcinoma incidence J:184720
increased histiocytic sarcoma incidence J:184720
increased lymphoma incidence J:184720
increased papilloma incidence J:184720
Stat1tm1Dlv/Stat1tm1Dlv
(B6.129S-Stat1tm1Dlv) 		increased mammary adenocarcinoma incidence J:216040
Stat1tm1Rds/Stat1tm1Rds
(129S6/SvEv-Stat1tm1Rds/Tac) 		increased mammary adenocarcinoma incidence J:216040
Stat3tm1Dlv/Stat3tm1Dlv
Tg(Csf1r-icre)1Jwp/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB) 		increased carcinoma incidence J:156593
Stat3tm4Vpo/Stat3tm4Vpo
Tg(MMTV-Erbb2)1Pv/0
(involves: 129P2/OlaHsd * BALB/cAn * C57BL/6 * CD-1 * DBA) 		increased mammary adenocarcinoma incidence J:157976
Stk3tm1.1Jav/Stk3+
Stk4Gt(AJ0315)Wtsi/Stk4Gt(AJ0315)Wtsi
(involves: 129 * C57BL/6) 		increased hepatocellular carcinoma incidence J:153945
Stk3tm1.1Jav/Stk3tm1.1Jav
Stk4Gt(AJ0315)Wtsi/Stk4+
(involves: 129 * C57BL/6) 		increased hepatocellular carcinoma incidence J:153945
Stk3tm1.1Jav/Stk3tm1Jav
Stk4Gt(AJ0315)Wtsi/Stk4Gt(AJ0315)Wtsi
(involves: 129 * C57BL/6) 		increased hepatocellular carcinoma incidence J:153945
Stk3tm1.1Rjo/Stk3tm1.1Rjo
Stk4tm1.1Rjo/Stk4tm1.1Rjo
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129S6/SvEvTac * C57BL/6 * CD-1 * DBA * SJL) 		increased hepatocellular carcinoma incidence J:156531
Stk3tm1.1Yy/Stk3tm1Yy
Stk4tm1.1Yy/Stk4tm1.1Yy
Tg(CAG-cre/Esr1*)5Amc/0
(involves: C57BL/6 * CBA) 		increased carcinoma incidence J:156541
increased hepatocellular carcinoma incidence J:156541
Stk3tm1Jav/Stk3tm1Jav
Stk4Gt(AJ0315)Wtsi/Stk4Gt(AJ0315)Wtsi
(involves: 129 * C57BL/6) 		increased hepatocellular carcinoma incidence J:153945
Stk3tm1Jav/Stk3tm1Jav
Stk4Gt(AJ0315)Wtsi/Stk4Gt(AJ0315)Wtsi
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129 * C57BL/6) 		increased hepatocellular carcinoma incidence J:153945
Stk3tm1Jav/Stk3tm1Jav
Stk4Gt(AJ0315)Wtsi/Stk4Gt(AJ0315)Wtsi
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129 * 129P2/OlaHsd * C57BL/6 * DBA) 		increased hepatocellular carcinoma incidence J:238319
Stk4Gt(AJ0315)Wtsi/Stk4Gt(AJ0315)Wtsi
(involves: 129 * C57BL/6) 		increased histiocytic sarcoma incidence J:153945
Stk11tm1.1Jish/Stk11+
(involves: 129S7/SvEvBrd * C57BL/6J) 		increased adenoma incidence J:77213
increased intestinal adenoma incidence J:77213
Stk11tm1.1Mlfr/Stk11+
(involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6J) 		increased hamartoma incidence J:104347
Stk11tm1.1Mlfr/Stk11+
Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6J) 		increased hamartoma incidence J:104347
increased lymphoma incidence J:104347
increased osteosarcoma incidence J:104347
increased sarcoma incidence J:104347
Stk11tm1.1Mlfr/Stk11+
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6J) 		increased hamartoma incidence J:104347
Stk11tm1.1Rdp/Stk11tm1.1Rdp
(involves: 129S6/SvEvTac * FVB/N) 		increased endometrial carcinoma incidence J:131865
Stk11tm1.1Rdp/Stk11tm1.1Rdp
Tg(KRT14-cre)1Ipc/0
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N * SJL) 		increased squamous cell carcinoma incidence J:131037
Stk11tm1.1Rdp/Stk11tm1.1Rdp
Tg(Sprr2f-cre)1Dcas/0
(involves: 129S6/SvEvTac * FVB/N) 		increased endometrial carcinoma incidence J:158190
Stk11tm1.2Rdp/Stk11+
(involves: 129S6/SvEvTac * FVB/N) 		increased endometrial carcinoma incidence J:131865
Stk11tm1.2Rdp/Stk11+
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N * SJL) 		increased hamartoma incidence J:78818
Stk11tm1Mmt/Stk11+
(involves: 129X1/SvJ) 		increased hamartoma incidence J:76202, J:107275
increased hepatocellular carcinoma incidence J:76202
Stk11tm1Mmt/Stk11+
Trp53tm1Brd/Trp53+
(involves: 129S7/SvEvBrd * 129X1/SvJ) 		increased hamartoma incidence J:107275
Stk11tm1Mmt/Stk11+
Trp53tm1Brd/Trp53tm1Brd
(involves: 129S7/SvEvBrd * 129X1/SvJ) 		increased hamartoma incidence J:107275
increased hepatocellular carcinoma incidence J:107275
Stk11tm1Tpm/Stk11+
(Not Specified) 		increased endometrial carcinoma incidence J:79074
increased hemangioma incidence J:79074
increased hepatocellular carcinoma incidence J:79074
increased liver adenoma incidence J:79074
Stk38tm1Hem/Stk38+
(involves: 129P2/Ola * C57BL/6) 		increased T cell derived lymphoma incidence J:185408
Stk38tm1Hem/Stk38tm1Hem
(involves: 129P2/Ola * C57BL/6) 		increased T cell derived lymphoma incidence J:185408
SufuGt(XB699)Byg/Sufu+
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6) 		increased lymphoma incidence J:125534
increased medulloblastoma incidence J:125534
increased rhabdomyosarcoma incidence J:125534
Suv39h1tm1Jnw/Suv39h1+
(involves: 129 * C57BL/6J) 		increased B cell derived lymphoma incidence J:72503
Suv39h1tm1Jnw/Suv39h1+
Suv39h2tm1Jnw/Suv39h2+
(involves: 129 * C57BL/6J) 		increased B cell derived lymphoma incidence J:72503
Suv39h1tm1Jnw/Suv39h1+
Suv39h2tm1Jnw/Suv39h2tm1Jnw
(involves: 129 * C57BL/6J) 		increased B cell derived lymphoma incidence J:72503
Suv39h1tm1Jnw/Suv39h1tm1Jnw
(involves: 129 * C57BL/6J) 		increased B cell derived lymphoma incidence J:72503
Suv39h1tm1Jnw/Suv39h1tm1Jnw
Suv39h2tm1Jnw/Suv39h2+
(involves: 129 * C57BL/6J) 		increased B cell derived lymphoma incidence J:72503
Suv39h2tm1Jnw/Suv39h2+
(involves: 129 * C57BL/6J) 		increased B cell derived lymphoma incidence J:72503
Suv39h2tm1Jnw/Suv39h2tm1Jnw
(involves: 129 * C57BL/6J) 		increased B cell derived lymphoma incidence J:72503
Suz12Gt(Betageo)1Khe/Suz12+
(involves: 129P2/OlaHsd) 		increased histiocytic sarcoma incidence J:217077
T(9;17)138Ca/T(9;17)138Ca
(Not Specified) 		increased adenocarcinoma incidence J:189952
Taf4tm1Idvd/Taf4tm1Idvd
Tg(KRT14-cre/ERT2)1Ipc/0
(involves: C57BL/6 * SJL) 		increased malignant tumor incidence J:124111
increased squamous cell carcinoma incidence J:124111
Tbrg1tm1a(KOMP)Wtsi/Tbrg1tm1a(KOMP)Wtsi
(C57BL/6N-Tbrg1tm1a(KOMP)Wtsi) 		increased B cell derived lymphoma incidence J:225146
increased Harderian gland adenoma incidence J:225146
increased hemangioma incidence J:225146
increased lung adenoma incidence J:225146
Tbx21tm1Glm/Tbx21tm1Glm
Tg(TRAMP)8247Ng/0
(involves: 129S6/SvEvTac * C57BL/6) 		increased prostate gland adenocarcinoma incidence J:88093
Tcf3tm1(PBX1)Mlc/Tcf3+
Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * C57BL/6) 		increased B cell acute lymphoblastic leukemia incidence J:226241
Tcf3tm1(PBX1)Mlc/Tcf3+
Cd79atm1(cre)Reth/Cd79a+
(involves: BALB/c * C57BL/6) 		increased B cell acute lymphoblastic leukemia incidence J:226241
Tcf3tm1(PBX1)Mlc/Tcf3+
Tg(Mx1-cre)1Cgn/0
(involves: C57BL/6 * C57BL/6J * CBA/J) 		increased B cell acute lymphoblastic leukemia incidence J:226241
Tcf3tm1(TCF3/HLF)Homy/Tcf3+
Tg(Emu-Zfp521)1Homy/0
Tg(Mx1-cre)1Cgn/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA) 		increased leukemia incidence J:160392
Tcf3tm1Wein/Tcf3tm1Wein
(involves: 129S4/SvJaeSor * C57BL/6) 		increased T cell derived lymphoma incidence J:44278
Tcf3tm2Wein/Tcf3tm2Wein
(Not Specified) 		increased T cell derived lymphoma incidence J:47671
Tcf7tm1Cle/Tcf7tm1Cle
(involves: 129P2/OlaHsd) 		increased intestinal adenoma incidence J:57721
increased mammary adenoacanthoma incidence J:57721
Tcra-Jtm1Tgi/Tcra-Jtm1Tgi
Tg(Pklr-Myc)73Ak/0
(B6.Cg-Tcra-Jtm1Tgi Tg(Pklr-Myc)73Ak) 		increased hepatocellular carcinoma incidence J:184496
increased malignant tumor incidence J:184496
Terctm1Rdp/Terctm1Rdp
(involves: 129/Sv * C57BL/6 * C57BL/6J * SJL) 		increased lymphoma incidence J:125218
Terctm1Rdp/Terctm1Rdp
Wrntm1Lgu/Wrntm1Lgu
(involves: 129/Sv * BALB/c * C57BL/6 * SLJ) 		increased osteosarcoma incidence J:91715
increased sarcoma incidence J:91715
Terf1tm1.1Blas/Terf1tm1.1Blas
Tg(KRT5-cre)1Tak/0
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129 * C3H * C57BL/6 * SJL) 		increased skin squamous cell carcinoma incidence J:152077
Testm1Cro/Tes+
(involves: 129X1/SvJ * C57BL/6J) 		increased carcinoma incidence J:100181
Testm1Cro/Testm1Cro
(involves: 129X1/SvJ * C57BL/6J) 		increased carcinoma incidence J:100181
Tet1tuft/Tet1tuft
(3H1/Lznf-Tet1tuft) 		increased lipoma incidence J:242827
Tet1tuft/Tet1tuft
(involves: 3H1/Lznf * BALB/c) 		increased lipoma incidence J:242827
Tet1tuft/Tet1tuft
(involves: 3H1/Lznf * M. m. castaneus) 		increased lipoma incidence J:242827
Tet2tm1.1Iaai/Tet2tm1.1Iaai
Tg(VAV1-cre)1Graf/0
(involves: 129S/SvEv * C57BL/6) 		increased chronic myelocytic leukemia incidence J:174053
Tet2tm1.1Mjxu/Tet2+
(involves: 129 * C57BL/6) 		increased chronic myelocytic leukemia incidence J:178415
increased leukemia incidence J:178415
Tet2tm1.1Mjxu/Tet2tm1.1Mjxu
(involves: 129 * C57BL/6) 		increased chronic myelocytic leukemia incidence J:178415
increased leukemia incidence J:178415
Tff1tm1Mrio/Tff1tm1Mrio
(involves: 129S2/SvPas * 129X1/SvJ) 		increased adenoma incidence J:35923
increased carcinoma incidence J:35923
Tg(Acta2-RAC1*G12V)33Pjgc/0
(involves: C57BL/6 * FVB/N) 		increased sarcoma incidence J:150015
Tg(Acta2-RAC1*G12V)33Pjgc/Tg(Acta2-RAC1*G12V)33Pjgc
(involves: C57BL/6 * FVB/N) 		increased sarcoma incidence J:150015
Tg(ACTB-Eif4e)#Ppp/?
(Not Specified) 		increased B cell derived lymphoma incidence J:89878
increased liver adenoma incidence J:89878
increased lung adenocarcinoma incidence J:89878
increased sarcoma incidence J:89878
Tg(ACTB-Eif4e)#Ppp/0
Tg(IghMyc)22Bri/0
(involves: C57BL * SJL) 		increased lymphoma incidence J:89878
Tg(ACTB-KRAS*G12V,-luc)#Lche/0
(involves: C57BL/6 * FVB/N) 		increased lung adenocarcinoma incidence J:199528
increased lung adenoma incidence J:199528
Tg(Alb1-Myc)#Sst/0
(involves: C57BL/6 * CBA) 		increased hepatocellular carcinoma incidence J:34434
increased liver adenoma incidence J:34434
Tg(Alb1-Myc)#Sst/0
Tg(MtTGFA)42Lmb/0
(involves: C57BL/6 * CBA * CD-1) 		increased hepatocellular carcinoma incidence J:34434
increased liver adenoma incidence J:34434
Tg(Alb1-Myc)#Sst/0
Tg(MtTGFA)Lmb/0
(involves: C57BL/6 * CBA * CD-1) 		increased hepatocellular carcinoma incidence J:176432
Tg(Alb1HBV)44Bri/0
(involves: C57BL/6J * SJL/J) 		increased hepatocellular carcinoma incidence J:86165
increased liver adenoma incidence J:86165
Tg(Alb1HBV)44Bri/0
(C57BL/6J-Tg(Alb1HBV)44Bri/J) 		increased hepatocellular carcinoma incidence J:223921
increased liver adenoma incidence J:223921
Tg(Alb-E2F1)8Sst/0
(involves: C57BL/6J * CBA/J) 		increased hepatocellular carcinoma incidence J:65354, J:101128
increased liver adenoma incidence J:65354
Tg(Alb-HBx)A112Tfts/0
(involves: C57BL/6) 		increased hepatocellular carcinoma incidence J:104728
Tg(Alb-HRAS*G12V)28Yu/0
(involves: C57BL/6J * CBA/J) 		increased hepatocellular carcinoma incidence J:107083, J:238319
increased liver adenoma incidence J:107083, J:238319
Tg(Alb-PDGFC)#Jcam/0
(involves: C57BL/6) 		increased hepatocellular carcinoma incidence J:96979, J:211984
Tg(Alb-SND1)3aDsar/0
(involves: C57BL/6 * CBA) 		increased hepatocellular carcinoma incidence J:242582
Tg(Alb-TAg)1Gjh/0
(C3.Cg-Tg(Alb-TAg)1Gjh) 		increased hepatocellular carcinoma incidence J:105110
Tg(Alb-TAg)#Arnd/0
(C3Fe.Cg-Tg(Alb-TAg)#Arnd) 		increased hepatocellular carcinoma incidence J:171880
Tg(AMH-Fshr)27Hht/0
(involves: FVB/N) 		increased ovarian teratoma incidence J:160015
Tg(AMH-Fshr*D580H)#Hht/0
(involves: FVB/N) 		increased ovarian carcinoma incidence J:160015
increased ovarian teratoma incidence J:160015
increased prolactinoma incidence J:160015
Tg(AMH-Fshr*D580Y)#Hht/0
(involves: FVB/N) 		increased ovarian teratoma incidence J:160015
Tg(Amh-SMAD2*)#Jebu/0
(FVB/N-Tg(Amh-SMAD2*)#Jebu) 		increased ovarian teratoma incidence J:200783
Tg(Amh-SMAD2*)#Jebu/0
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * FVB/N) 		increased ovarian teratoma incidence J:200783
Tg(Amhr2-SV40TAg)1Dcco/0
((C57BL/6 x C3H)F1) 		increased ovarian carcinoma incidence J:82550
Tg(Amy1TAg)354Knw/0
(C57BL/6J-Tg(Amy1TAg)354Knw) 		increased hibernoma incidence J:90326
Tg(Amy1TAg)501Knw/?
(C57BL/6-Tg(Amy1TAg)501Knw) 		increased osteosarcoma incidence J:90730
Tg(ARR2/Pbsn-MYC)7Key/?
(involves: FVB/N) 		increased prostate gland adenocarcinoma incidence J:223213, J:85480
Tg(Atoh1-sb11)1Mtay/0
TgTn(sb-T2/Onc3)12740Njen/0
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C3H * C57BL/6J * ICR) 		increased medulloblastoma incidence J:181542
Tg(Atp4b-TAg)#Jig/0
(involves: FVB/N) 		increased carcinoma incidence J:89240
Tg(BCL2)22Wehi/0
Tg(IghMyc)22Bri/0
(involves: C57BL/6 * C57BL/6JWehi * SJL/J * SJL/JWehi) 		increased lymphoma incidence J:69571
Tg(BCL2)25Wehi/0
Tg(Igkv3-5*-MYC)#Plbe/0
(involves: C57BL/6 * C57BL/6JWehi * SJL/JWehi) 		increased plasmacytoma incidence J:131912
Tg(BCL2)36Wehi/0
(involves: C57BL/6JWehi * SJL/JWehi) 		increased T cell derived lymphoma incidence J:93111
Tg(BCL2/IGH)#Jcre/0
Tg(H2-K/Igh-Traf2*)#Ywc/0
(involves: BALB/c * C57BL/6 * CBA/J * FVB/N * SJL/J * SWR/J) 		increased chronic lymphocytic leukemia incidence J:94116
increased small lymphocytic lymphoma incidence J:94116
Tg(BCL2OVARY)1Ah/0
(involves: FVB) 		increased ovarian teratoma incidence J:55158
Tg(BCR/ABL)623Hkp/0
(involves: C57BL/6 * CBA) 		increased acute lymphoblastic leukemia incidence J:160846
increased B cell derived lymphoma incidence J:89786
increased leukemia incidence J:89786
Tg(BCR/ABL)623Hkp/0
(involves: C57BL/6 * C57BL/6J * CBA) 		increased leukemia incidence J:99168
Tg(BCR/ABL)623Hkp/?
(involves: 129S1/Sv * 129X1/SvJ * Black Swiss * C57BL/6 * CBA) 		increased B cell derived lymphoma incidence J:76680
increased leukemia incidence J:76680
Tg(Bglap2-TAg)1Rkho/0
(FVB/N-Tg(Bglap2-TAg)1Rkho) 		increased osteosarcoma incidence J:165282
Tg(Bglap2-TAg)1Rkho/0
(involves: FVB/N) 		increased osteosarcoma incidence J:234128
Tg(Bglap2-TAg)1Rkho/0
Tg(Col1a1-cre)1Kry/0
Tnfrsf11atm1.1Pngr/Tnfrsf11atm1.1Pngr
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N) 		increased osteosarcoma incidence J:234128
Tg(Bglap2-TAg)1Rkho/0
Tnfsf11tm1Pngr/Tnfsf11+
(involves: 129P2/OlaHsd * FVB/N) 		increased osteosarcoma incidence J:234128
Tg(Bglap2-TAg)1Rkho/0
Tnfsf11tm1Pngr/Tnfsf11tm1Pngr
(involves: 129P2/OlaHsd * FVB/N) 		decreased osteosarcoma incidence J:234128
Tg(C3-1-TAg)cJeg/0
(involves: FVB/N) 		increased mammary adenocarcinoma incidence J:52786, J:46513
increased prostate gland adenocarcinoma incidence J:52786, J:46513, J:72324
Tg(CAG-Alk*F1174L,-luc)60Jhsc/0
Tg(Dbh-icre)1Gsc/0
(involves: C57BL/6 * FVB/N) 		increased neuroblastoma incidence J:186696
Tg(CAG-Alk*F1174L,-luc)60Jhsc/0
Tg(Dbh-icre)1Gsc/0
Tg(Th-MYCN)41Waw/0
(involves: 129X1/SvJ * BALB/c * C57BL/6 * C57BL/6J * FVB/N) 		increased neuroblastoma incidence J:186696
Tg(CAG-Alk*F1174L,-luc)60Jhsc/0
Thtm1(cre)Te/Th+
(involves: 129X1/SvJ * C57BL/6 * FVB/N) 		increased neuroblastoma incidence J:186696
Tg(CAG-Bgeo,-Tle1,-ALPP)1Lbe/0
Tg(CAG-cre)1Nagy/0
(involves: 129S1/Sv * 129X1/SvJ * CD-1) 		increased lung adenocarcinoma incidence J:106684
Tg(CAG-Bgeo,-tTA,-EGFP)2A11Kuw/0
Tg(Pdx1-cre)6Tuv/0
Tg(tetO-MYC)36Bop/0
(involves: 129P2/OlaHsd * FVB/N) 		increased pancreatic ductal adenocarcinoma incidence J:197052
Tg(CAG-Has2)99Nita/0
Tg(MMTV-cre)4Mam/0
Tg(MMTVneu)202Mul/0
(FVB.Cg-Tg(CAG-Has2)99Nita Tg(MMTV-cre)4Mam Tg(MMTVneu)202Mul) 		increased mammary adenocarcinoma incidence J:130531, J:164205
Tg(CAG-Has2)99Nita/0
Tg(MMTVneu)202Mul/0
(FVB.Cg-Tg(CAG-Has2)99Nita Tg(MMTVneu)202Mul) 		increased mammary adenocarcinoma incidence J:130531
Tg(CAG-lacZ,-SV40)#Bcv/0
(involves: FVB/N) 		increased ovarian carcinoma incidence J:158388
Tg(CAG-Ptafr)1Tksh/0
(B6;D2-Tg(CAG-Ptafr)1Tksh/TkshRbrc) 		increased cutaneous melanoma incidence J:38639
Tg(CAG-SAC/EGFP)35Rang/0
(involves: C3H * C57BL/6) 		decreased lymphoma incidence J:125633
Tg(CAG-Tle1,-ALPP)1Lbe/0
(involves: 129S1/Sv * 129X1/SvJ * CD-1) 		increased lung adenocarcinoma incidence J:106684
Tg(CAG-TRIM29)ADims/0
(FVB/NJ-Tg(CAG-TRIM29)ADims) 		increased urinary bladder carcinoma incidence J:226764
Tg(CD2-Lmo2)#Thr/0
(involves: C57BL/6 * CBA) 		increased acute lymphoblastic leukemia incidence J:102058
Tg(CD2-NPM/ALK)4Sudt/0
(involves: C57BL/6J * CBA) 		increased B cell derived lymphoma incidence J:181238
Tg(CD2-Tgfbr2)1Grs/?
(C57BL/6-Tg(CD2-Tgfbr2)1Grs/Nci) 		increased leukemia incidence J:93665
increased T cell derived lymphoma incidence J:93665
Tg(Cd4-NPM/ALK)N1Ingh/0
(either: (involves: BALB/c * Swiss Webster) or (involves: C57BL/6 * Swiss Webster)) 		increased lymphoblastic lymphoma incidence J:82127
increased myeloma incidence J:82127
increased plasmacytoma incidence J:82127
Tg(Cd4-NPM/ALK)N1Ingh/0
Tg(TcraTcrb)1100Mjb/0
(involves: C57BL/6 * Swiss Webster) 		increased hepatocellular carcinoma incidence J:235890
increased sarcoma incidence J:235890
increased T cell derived lymphoma incidence J:235890
Tg(Cd79b-TCL1A)BKTeit/0
(involves: C3H * C57BL/6) 		increased B cell derived lymphoma incidence J:79703
Tg(CEACAM5-Tag)L5496Wzm/0
(involves: C57BL/6 * CBA) 		increased gastric adenocarcinoma incidence J:62581
Tg(Cebpb-tTA)5Bjd/0
Tg(tetO-MYC,-OVAL)#Gtgm/0
(B6J.Cg-Tg(Cebpb-tTA)5Bjd Tg(tetO-MYC,-OVAL)#Gtgm) 		increased hepatocellular carcinoma incidence J:186226
Tg(Cela1-luc,Cela1-TAg)#Nzh/0
(involves: FVB/N) 		increased pancreatic acinar cell carcinoma incidence J:207960
Tg(CMV-SALL4_iB)#Chai/?
(Not Specified) 		increased leukemia incidence J:115037
Tg(CMV-Tsc2*)1Arbi/0
(involves: C57BL/6) 		increased hamartoma incidence J:96943
increased skin hamartoma incidence J:96943
Tg(CMV-tTA)3Bjd/0
Tg(tetO-Prkar1a*x2as)1Stra/0
(involves: C57BL/6 * NMRI * SJL) 		increased histiocytic sarcoma incidence J:94953
increased liver adenoma incidence J:94953
increased lymphoma incidence J:94953
increased papilloma incidence J:94953
increased skin papilloma incidence J:95465
increased spindle cell carcinoma incidence J:94953
increased thyroid adenoma incidence J:95465, J:94953
Tg(Cnp-EGFR)10Nrat/0
(involves: C57BL/6 * SJL) 		increased malignant triton tumor incidence J:95933
increased neurofibroma incidence J:95933
increased rhabdomyosarcoma incidence J:95933
Tg(CSTG-NPM1/RARA)#Sjch/0
(involves: C57BL/6) 		increased acute promyelocytic leukemia incidence J:55196
increased chronic myelocytic leukemia incidence J:55196
increased leukemia incidence J:55196
Tg(CTNNB1)1Efu/0
(involves: CD-1) 		increased trichofolliculoma incidence J:51296
Tg(CTSG-NUMA1/RARA)#Skr/0
(involves: C57BL/6) 		increased acute promyelocytic leukemia incidence J:88103
Tg(CTSG-PML/RARA)135Ley/?
(Not Specified) 		increased acute promyelocytic leukemia incidence J:77881
Tg(CTSG-PML/RARA)135Ley/?
(involves: C3H * C57BL/6) 		increased acute promyelocytic leukemia incidence J:59080
Tg(CTSG-PML/RARA)135Ley/0
Tg(CTSG-RARA/PML)2544Ley/0
(involves: C3H * C57BL/6) 		increased acute promyelocytic leukemia incidence J:59080
Tg(CTSG-PML/RARA)135Ley/0
Tg(CTSG-RARA/PML)#Ley/0
(involves: C3H * C57BL/6) 		increased acute promyelocytic leukemia incidence J:59080
Tg(CTSG-PML/RARA)6179Ppp/0
(Not Specified) 		increased acute promyelocytic leukemia incidence J:40373
increased leukemia incidence J:40373
Tg(CTSG-PML/RARA)#Ppp/0
(Not Specified) 		increased acute promyelocytic leukemia incidence J:78201, J:40373
increased leukemia incidence J:78201, J:40373
Tg(CTSG-RARA/ZBTB16)#Ppp/0
Tg(CTSG-ZBTB16/RARA)#Ppp/0
(Not Specified) 		increased acute promyelocytic leukemia incidence J:65878
increased leukemia incidence J:65878
Tg(CTSG-RARA/ZBTB16)#Sjch/0
Tg(CTSG-ZBTB16/RARA)#Sjch/0
(Not Specified) 		increased acute promyelocytic leukemia incidence J:194312
Tg(CTSG-ZBTB16/RARA)#Ppp/0
(Not Specified) 		increased chronic myelocytic leukemia incidence J:65878, J:78201
increased leukemia incidence J:78201
Tg(CTSG-ZBTB16/RARA)#Ppp/0
Zbtb16tm1Ppp/Zbtb16tm1Ppp
(involves: 129S1/Sv) 		increased acute promyelocytic leukemia incidence J:65878
Tg(CTSG-ZBTB16/RARA)#Sjch/0
(involves: C57BL/6) 		increased chronic myelocytic leukemia incidence J:55196
increased leukemia incidence J:55196
Tg(Cyp19)C2-3Rrte/0
(involves: BALB/c * C57BL/6) 		increased fibroadenoma incidence J:34063
Tg(Dct-Birc5)21Gros/0
Tg(Mt1-Hgf)19Lmb/0
(involves: C57BL/6 * CBA * FVB/N) 		increased melanoma incidence J:122181
Tg(Dct-Grm1)ESzc/0
(involves: C57BL/6J) 		increased cutaneous melanoma incidence J:83183
Tg(Dct-Grm1)ESzc/0
(C57BL/6J-Tg(Dct-Grm1)ESzc) 		increased intraocular melanoma incidence J:230115
Tg(ED-L2-IL1RN/IL1B)#Tcw/?
(B6.Cg-Tg(ED-L2-IL1RN/IL1B)#Tcw) 		increased adenocarcinoma incidence J:180282
Tg(Ela1-Myc)158Bri/0
(involves: C57BL/6 * SJL) 		increased pancreatic acinar cell carcinoma incidence J:76992
Tg(Ela1-Myc)159Bri/0
(involves: C57BL/6 * SJL) 		increased pancreatic acinar cell carcinoma incidence J:76992
Tg(Ela1-Myc)160Bri/0
(involves: C57BL/6 * SJL) 		increased pancreatic acinar cell carcinoma incidence J:76992
Tg(Ela1-TAg)18Bri/0
(involves: C57BL/6 * SJL) 		increased insulinoma incidence J:76995
increased pancreatic acinar cell carcinoma incidence J:76995
increased pancreatic islet cell adenoma incidence J:76995
Tg(Ela1-TAg)19Bri/0
(involves: C57BL/6 * SJL) 		increased insulinoma incidence J:76995
increased pancreatic acinar cell carcinoma incidence J:76995
Tg(Ela1-TAg*)79Mjt/0
(involves: C57BL/6 * DBA/2) 		increased pancreas adenoma incidence J:78026
increased pancreatic acinar cell carcinoma incidence J:78026
Tg(Ela1-TAg*)79Mjt/0
Tg(MUC1)79.24Gend/0
(involves: C57BL/6 * DBA/2) 		increased pancreas adenoma incidence J:64570
increased pancreatic acinar cell carcinoma incidence J:64570
Tg(Ela1-TAg*)289Mjt/0
(involves: C57BL/6 * DBA/2) 		increased pancreas adenoma incidence J:78026
increased pancreatic acinar cell carcinoma incidence J:78026
Tg(Ela1-Tgfa)150Bri/0
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * BALB/c * C57BL/6 * SJL) 		increased malignant tumor incidence J:67389
increased pancreatic ductal adenocarcinoma incidence J:67389
Tg(Emu-Pim1)64aBrn/0
(involves: C57BL/6LiA * CBA) 		increased lymphoma incidence J:79624
increased T cell derived lymphoma incidence J:79624
Tg(Emu-TXLNA)1Amjr/0
(B6.Cg-Tg(Emu-TXLNA)1Amjr) 		increased B cell derived lymphoma incidence J:117018
Tg(EmuSR-HDAC9)1468Kpet/0
(involves: C57BL/6 * CBA) 		increased B cell derived lymphoma incidence J:237420
increased histiocytic sarcoma incidence J:237420
increased leukemia incidence J:237420
increased splenic marginal zone lymphoma incidence J:237420
Tg(EmuSR-tTa)83Bop/0
Tg(IghMyc)22Bri/0
Tg(tetO-RNAi:Trp53)ASlowe/0
(involves: C57BL * C57BL/6 * FVB/N * SJL) 		increased lymphoma incidence J:123006
Tg(EmuSR-tTa)83Bop/Tg(EmuSR-tTa)83Bop
Tg(tetO-NPM1/ALK,-luc)2Gde/0
(involves: FVB/N) 		increased B cell derived lymphoma incidence J:160236
increased leukemia incidence J:160236
Tg(EmuSR-tTa)83Bop/Tg(EmuSR-tTa)83Bop
Tg(tetO-TPM3/ALK,-luc)2Gde/0
(involves: FVB/N) 		increased B cell derived lymphoma incidence J:160236
increased leukemia incidence J:160236
Tg(Erbb2)1Jek/0
(involves: C57BL/6 * SJL) 		increased papilloma incidence J:47225
Tg(Erbb2-Erbb2*V664E)#Led/0
(involves: FVB/N) 		increased mammary adenocarcinoma incidence J:62441
Tg(Fabp1-Ccnd1)2Rdb/0
(C57BL/6-Tg(Fabp1-Ccnd1)2Rdb) 		increased liver adenoma incidence J:70394
Tg(Fabp1-Ccnd1)4Rdb/0
(C57BL/6-Tg(Fabp1-Ccnd1)4Rdb/J) 		increased hepatocellular carcinoma incidence J:70394
increased liver adenoma incidence J:70394
Tg(Fabp4-Il22)#Ychn/0
(involves: ICR) 		increased liposarcoma incidence J:176141
Tg(Gcg-TAg)25Ddr/?
(involves: CD-1) 		increased large intestine adenocarcinoma incidence J:91490, J:101537
Tg(GFAP-tTA)67Pop/0
Tg(tetO-Ifng)184Pop/0
(B6.Cg-Tg(GFAP-tTA)67Pop Tg(tetO-Ifng)184Pop) 		increased medulloblastoma incidence J:94092
Tg(GFAP-tTA)67Pop/0
Tg(tetO-Ifng)184Pop/0
(involves: 129S/SvEv * C57BL/6 * DBA/2) 		increased medulloblastoma incidence J:94092
Tg(Ggamma-T)15Cps/0
(involves: C57BL/6J * CBA/J) 		increased hibernoma incidence J:38778
Tg(Ggamma-T)15Cps/Tg(Ggamma-T)15Cps
(involves: C57BL/6J * CBA/J) 		increased hibernoma incidence J:38778
Tg(Ggt1-Hif1a*)43Log/0
(involves: C57BL/6) 		increased renal carcinoma incidence J:177381
Tg(Ggt1-tTA)#Agoc/0
Tg(tetO-MYC)36aBop/0
(involves: FVB/N) 		increased renal carcinoma incidence J:222943
Tg(Gh-Gal)4599Vron/?
(involves: C57BL/6 * CD-1 * SJL) 		increased pituitary adenoma incidence J:86486
Tg(H2-D-Il15)3304Clgr/?
(FVB/N-Tg(H2-D-Il15)3304Clgr) 		increased leukemia incidence J:97873, J:67478
Tg(H2-K-BCL2)1Josd/0
Tg(SFTPC-RAF1-BxB)1Urr/0
(involves: 129S2/SvPas * C3H * C57BL/6 * DBA/2) 		increased lung adenoma incidence J:79696
Tg(H2-K-Fosl2,-EGFP)13Wag/0
(either: 129.Cg-Tg(H2-K-Fosl2,-EGFP)13Wag or B6.Cg-Tg(H2-K-Fosl2,-EGFP)13Wag) 		increased fibrosarcoma incidence J:139032
Tg(H2-K-Hmga1)#Lmsr/0
(involves: C57BL/6 * SJL) 		increased leukemia incidence J:121308
increased lymphoma incidence J:90252, J:121308
increased T cell acute lymphoblastic leukemia incidence J:90252
increased uterus leiomyoma incidence J:121308
Tg(H2-L-IL6)1Kish/Tg(H2-L-IL6)1Kish
(C57BL/6-Tg(H2-L-IL6)1Kish) 		increased plasmacytoma incidence J:138762
Tg(H2-L-IL6)46Kish/Tg(H2-L-IL6)46Kish
(C57BL/6-Tg(H2-L-IL6)46Kish) 		increased plasmacytoma incidence J:40405
Tg(H2-L-IL6)46Kish/Tg(H2-L-IL6)46Kish
(involves: BALB/c * C57BL/6) 		increased plasmacytoma incidence J:40405
Tg(H2-L-IL6)46Kish/Tg(H2-L-IL6)46Kish
(C.B6-Tg(H2-L-IL6)46Kish) 		increased B cell derived lymphoma incidence J:74377
increased follicular lymphoma incidence J:74377
increased plasmacytoma incidence J:74377
Tg(H-2K1-Lrp5/Fkbp1a,-luc*)#Dmps/0
(involves: FVB/N) 		increased prostate gland adenocarcinoma incidence J:206727, J:184212
Tg(H-2K1-Lrp5/Fkbp1a,-luc*)#Dmps/0
Tg(Pbsn-Fgfr1/Fkbp1a)#aDmsp/0
(involves: FVB/N) 		increased prostate gland adenocarcinoma incidence J:206727
increased spindle cell carcinoma incidence J:206727
Tg(Hba-x-v-Ha-ras)TG.ACLed/0
(involves: 129 * FVB/N * Black Swiss) 		increased papilloma incidence J:79056
Tg(Hba-x-v-Ha-ras)TG.ACLed/0
(involves: FVB/N) 		increased papilloma incidence J:79056
Tg(Hba-x-v-Ha-ras)TG.ACLed/0
Wrntm1Led/Wrntm1Led
(involves: 129 * FVB/N * Black Swiss) 		increased papilloma incidence J:79056
Tg(HBB-Myc)#Cos/0
(involves: C57BL/6J * CBA/J) 		increased adenoma incidence J:276641
Tg(HBV-HCV)21Kko/0
(C57BL/6N-Tg(HBV-HCV)21Kko) 		increased hepatocellular carcinoma incidence J:52686
increased liver adenoma incidence J:52686
Tg(HBV-HCV)49Kko/0
(C57BL/6N-Tg(HBV-HCV)49Kko) 		increased hepatocellular carcinoma incidence J:52686
increased liver adenoma incidence J:52686
Tg(HBV-HCV)Kko/0
(C57BL/6N-Tg(HBV-HCV)Kko) 		increased hepatocellular carcinoma incidence J:52686
increased liver adenoma incidence J:52686
Tg(HBVX*,-Myc)#Skp/0
(Not Specified) 		increased hepatocellular carcinoma incidence J:81098
Tg(HBVX*,-Myc)#Skp/Tg(HBVX*,-Myc)#Skp
(Not Specified) 		increased hepatocellular carcinoma incidence J:81098
Tg(HBx)3Yu/0
(involves: C57BL/6 * DBA) 		increased hepatocellular carcinoma incidence J:56196
Tg(HIV)26Aln/0
(involves: FVB/N) 		increased skin papilloma incidence J:90297
Tg(Hnf1a-RB1*)XMiu/?
(Not Specified) 		increased liver adenoma incidence J:180294
Tg(HRAS)2Jic/?
(involves: BALB/c * C57BL/6) 		increased adenocarcinoma incidence J:64968
increased classified tumor incidence J:64968
increased lung adenocarcinoma incidence J:64968
increased lymphoma incidence J:64968
increased sarcoma incidence J:64968
increased skin papilloma incidence J:64968
Tg(HRAS)7Mok/?
(involves: C57BL/6) 		increased adenocarcinoma incidence J:64968
increased lung adenocarcinoma incidence J:64968
increased lymphoma incidence J:64968
increased sarcoma incidence J:64968
Tg(IGF1)1Jdg/0
(involves: FVB * ICR) 		increased skin papilloma incidence J:39752
Tg(Igh*-Mir125b-1)5Toki/0
(Not Specified) 		increased B cell derived lymphoma incidence J:178816
increased lymphoma incidence J:178816
Tg(Igh*-Mir125b-1)116Toki/0
(Not Specified) 		increased B cell derived lymphoma incidence J:178816
increased lymphoma incidence J:178816
increased T cell derived lymphoma incidence J:178816
Tg(Igh-Abl1)40Sco/0
(involves: C57BL/6JWehi * SJL/JWehi) 		increased plasmacytoma incidence J:78204
Tg(Igh-Abl1)40Sco/0
Tg(IghMyc)22Bri/0
(involves: C57BL/6 * C57BL/6JWehi * SJL/J * SJL/JWehi) 		increased plasmacytoma incidence J:78204
Tg(Igh-HMGA2)#Cro/0
(FVB/N-Tg(Igh-HMGA2)#Cro) 		increased T cell acute lymphoblastic leukemia incidence J:233225
Tg(Igh-HOX11)11Idd/0
(CD-1) 		increased B cell derived lymphoma incidence J:52782
Tg(Igh-Maf)68Staka/0
(C57BL/6-Tg(Igh-Maf)68Staka) 		increased lymphoma incidence J:168074
Tg(Igh-Maf)524Staka/0
(involves: C57BL/6 * C57BL/6J * DBA/2) 		increased lymphoma incidence J:168074
Tg(Igh-Mir29a,-Mir29b-1,-hrGFP)#Cro/0
(FVB/N-Tg(Igh-Mir29a,-Mir29b-1,-hrGFP)#Cro) 		increased chronic lymphocytic leukemia incidence J:162077
Tg(Igh-Mir29a,-Mir29b-1,-hrGFP)#Cro/0
Tg(Igh-V186.2-TCL1A)3Cro/0
(involves: C3H * C57BL/6 * FVB/N) 		increased chronic lymphocytic leukemia incidence J:162077
Tg(Igh-Mir155)8Cro/0
(involves: FVB/N) 		increased B cell derived lymphoma incidence J:109591
increased lymphoblastic lymphoma incidence J:109591
Tg(Igh-Pim1)1Brn/0
(involves: C57BL/6LiA * CBA) 		increased lymphoma incidence J:79624
increased T cell derived lymphoma incidence J:79624
Tg(Igh-ROR1)1Kip/0
(C57BL/6-Tg(Igh-ROR1)1Kip) 		increased chronic lymphocytic leukemia incidence J:206368
Tg(Igh-ROR1)1Kip/0
Tg(Igh-V186.2-TCL1A)3Cro/0
(B6.Cg-Tg(Igh-ROR1)1Kip Tg(Igh-V186.2-TCL1A)3Cro) 		increased chronic lymphocytic leukemia incidence J:206368
Tg(Igh-TCL1A)1Ypek/0
(FVB/N-Tg(Igh-TCL1A)1Ypek) 		increased chronic lymphocytic leukemia incidence J:160184
Tg(Igh-V186.2-TCL1A)3Cro/0
(involves: C3H * C57BL/6) 		increased leukemia incidence J:76574
Tg(Igh-V186.2-TCL1A)3Cro/0
(B6.Cg-Tg(Igh-V186.2-TCL1A)3Cro) 		increased chronic lymphocytic leukemia incidence J:206368
Tg(IghMyc)22Bri/?
(involves: C57BL * C57BL/6 * SJL) 		increased lymphoma incidence J:121564
Tg(IghMyc)22Bri/0
(involves: C57BL/6 * SJL) 		increased B cell derived lymphoma incidence J:186117, J:78177
increased leukemia incidence J:78177
increased lymphoma incidence J:78177, J:223213
increased sarcoma incidence J:78177
Tg(IghMyc)22Bri/0
(B6.Cg-Tg(IghMyc)22Bri/J) 		increased lymphoma incidence J:164200
Tg(IghMyc)22Bri/0
(involves: C57BL * C57BL/6 * SJL) 		increased lymphoma incidence J:117023
Tg(IghMyc)22Bri/0
(involves: C57BL/6N * SJL) 		increased lymphoma incidence J:214383
Tg(IghMyc)22Bri/0
Tg(Igk-V21-Bax)1967Bvn/0
(involves: C57BL/6 * FVB/N) 		increased B cell derived lymphoma incidence J:89049
increased plasmacytoma incidence J:89049
Tg(IghMyc)22Bri/0
Tg(Lck/Emu-Eif4e)#Ppp/0
(involves: C57BL * SJL) 		increased lymphoma incidence J:89878
Tg(IghMyc)22Bri/0
Trp53tm1Tyj/Trp53+
(involves: 129/Sv * 129X1/SvJ * C57BL * C57BL/6 * SJL) 		increased B cell derived lymphoma incidence J:125164
Tg(Igkv3-5*-MYC)24Plbe/0
(C57BL/6J-Tg(Igkv3-5*-MYC)DLoxP4Plbe/PlbeMmmh) 		increased B cell derived lymphoma incidence J:131912
increased myeloma incidence J:131912
increased plasmacytoma incidence J:131912
Tg(Igkv3-5-MYC)#Plbe/0
(involves: C57BL/6) 		increased B cell derived lymphoma incidence J:131912
Tg(IGL-MYC)3Hm/0
(C57BL/6N-Tg(IGL-MYC)3Hm/Nci) 		increased B cell derived lymphoma incidence J:65245
Tg(Ins1-GAS)1Sbr/0
(involves: FVB/NTac) 		increased carcinoma incidence J:59575
Tg(Ins1-Tag,-luc)1Gcr/0
(FVB/N-Tg(Ins1-Tag,-luc)1Gcr) 		increased insulinoma incidence J:162648
Tg(Ins1-Tag,-luc)1Gcr/0
(involves: C57BL/6 * FVB/N) 		increased insulinoma incidence J:162648
Tg(Ins2-Akt1*)3Mbb/0
(B6.Cg-Tg(Ins2-Akt1*)3Mbb) 		increased insulinoma incidence J:144599
increased pancreatic islet cell carcinoma incidence J:144599
Tg(Ins2-IGF1R)1Dh/0
Tg(RIP1-Tag)2Dh/0
(involves: C3H * C57BL/6 * C57BL/6J * DBA/2J) 		increased insulinoma incidence J:205389
increased pancreatic islet cell carcinoma incidence J:205389
Tg(Ins2-rtTA)2Efr/0
Tg(tetO-TAg)1Efr/0
(involves: C3HeB/FeJ * C57BL/6 * CBA) 		increased insulinoma incidence J:130049
Tg(Ins2-TAg)1Lt/0
(NOD/ShiLt-Tg(Ins2-TAg)1Lt) 		increased insulinoma incidence J:92449
Tg(Ins2-Tag*,-flpe)#Gne/0
(involves: C57BL/6J) 		increased insulinoma incidence J:187012
increased pancreatic islet cell carcinoma incidence J:187012
Tg(Ins2-Tag*,-flpe)#Gne/0
(Not Specified) 		increased pancreatic islet cell carcinoma incidence J:188693
Tg(IRS1)1Mhep/0
Tg(SERPINA1-HBVX)1655Jtsb/0
(involves: C3H * C57BL/6 * FVB * ICR) 		increased hepatocellular carcinoma incidence J:227278
Tg(K5-Ptgs2)19Kmd/0
(involves: NMRI) 		increased sebaceous gland adenoma incidence J:79071
increased skin papilloma incidence J:79071
increased squamous cell carcinoma incidence J:79071
Tg(K5-Ptgs2)667Kmd/0
(involves: NMRI) 		increased sebaceous gland adenoma incidence J:79071
increased skin papilloma incidence J:79071
increased squamous cell carcinoma incidence J:79071
Tg(K6ODCtr)55Tgo/0
(involves: C3H * C57BL/6) 		increased skin papilloma incidence J:29098
Tg(Kit*D814V)1Roer/0
Tg(Mx1-cre)1Cgn/0
(involves: C57BL/6 * CBA) 		increased chronic myelocytic leukemia incidence J:169611
increased leukemia incidence J:169611
Tg(Kit*D814V)3Roer/0
Tg(Mx1-cre)1Cgn/0
(involves: C57BL/6 * CBA) 		increased leukemia incidence J:169611
Tg(Krt1-14-GLI)1Oro/0
(involves: C57BL/6 * CBA) 		increased trichofolliculoma incidence J:82653
Tg(KRT5-Akt1*)Jmpa/0
(involves: C57BL/6 * DBA/2 * DBA/2J * FVB/N) 		increased adenocarcinoma incidence J:144831
increased carcinoma incidence J:144831
increased squamous cell carcinoma incidence J:144831
Tg(KRT5-rtTA)#Glk/0
Tg(tetO/CMV-Dek,-luc)317Siwe/0
(involves: FVB/N) 		increased squamous cell carcinoma incidence J:261249
Tg(KRT5-Terf2)PMBlas/Y
(involves: C57BL/6 * CBA) 		increased skin squamous cell carcinoma incidence J:102653
Tg(KRT5-Terf2)POBlas/0
(involves: C57BL/6 * CBA) 		increased skin squamous cell carcinoma incidence J:102653
Tg(KRT14-cre)8Brn/0
Tg(KRT5-Akt1*)Jmpa/0
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * DBA/2J * FVB/N) 		increased carcinoma incidence J:144831
increased squamous cell carcinoma incidence J:144831
Tg(KRT14-Fyn*)aJsey/0
(involves: C57BL/6 * CBA) 		increased skin squamous cell carcinoma incidence J:155536
Tg(KRT14-Fyn*)aJsey/0
(involves: C57BL/6 * CBA * FVB/N) 		increased skin squamous cell carcinoma incidence J:155536
Tg(KRT14-HPV8)9Vuc/0
(FVB.Cg-Tg(KRT14-HPV8)9Vuc) 		increased skin papilloma incidence J:96784
increased skin squamous cell carcinoma incidence J:96784
Tg(KRT14-HPV8)9Vuc/0
(involves: C57BL/6 * DBA * FVB/N) 		increased skin papilloma incidence J:96784
Tg(KRT14-HPV8)61Vuc/0
(involves: C57BL/6 * DBA) 		increased skin papilloma incidence J:96784
Tg(KRT14-HPV8)85Vuc/0
(FVB.Cg-Tg(KRT14-HPV8)85Vuc) 		increased skin papilloma incidence J:96784
increased skin squamous cell carcinoma incidence J:96784
Tg(KRT14-HPV8)85Vuc/0
(B6.Cg-Tg(KRT14-HPV8)85Vuc) 		increased skin papilloma incidence J:96784
Tg(KRT14-HPV8)#Vuc/0
(involves: C57BL/6 * DBA * FVB/N) 		increased skin papilloma incidence J:96784
increased skin squamous cell carcinoma incidence J:96784
Tg(KRT14-HPV16)wt1Dh/0
(FVB.Cg-Tg(KRT14-HPV16)wt1Dh/Nci) 		increased skin squamous cell carcinoma incidence J:65699
Tg(KRT14-HPV16)wt1Dh/0
(either: FVB.Cg-Tg(KRT14-HPV16)wt1Dh or (involves: C57BL/6 * DBA/2 * FVB/N)) 		increased skin squamous cell carcinoma incidence J:20130
increased spindle cell carcinoma incidence J:20130
Tg(KRT14-HPV16E7)2304Plam/0
(involves: FVB/N) 		increased skin squamous cell carcinoma incidence J:86018
Tg(KRT14-HPV16E7)2326Plam/0
(involves: FVB/N) 		increased skin squamous cell carcinoma incidence J:86018
Tg(KRT14-Shh)#Cobm/0
(involves: C57BL/6 * CBA) 		increased basal cell carcinoma incidence J:150375
Tg(KRT14-Snai1)1Efu/0
(involves: CD-1) 		increased basal cell carcinoma incidence J:229072
increased skin squamous cell carcinoma incidence J:229072
Tg(Krt18-EGFP,-TAg121)36Ysng/0
(involves: C57BL/6 * DBA/2) 		increased ovarian carcinoma incidence J:189304
Tg(Krt19-Ptgs2,Krt19-Ptges)8Tko/0
Tg(Krt19-Wnt1)2Maos/0
(involves: C3H * C57BL/6) 		increased gastric adenocarcinoma incidence J:116782
Tg(KRT19-TAg)7Eps/0
(involves: FVB/N) 		increased mesothelioma incidence J:64395
increased urinary bladder transitional cell carcinoma incidence J:64395
Tg(LANA,vFLIP,vCYC)801Dtmr/?
(involves: C57BL/6) 		increased lymphoma incidence J:196403
Tg(Lck)4220Rmp/0
(involves: C57BL/6J * DBA/2) 		increased T cell derived lymphoma incidence J:88120
Tg(Lck-Akt1*)M-1Pnt/0
(involves: C3H/He * C57BL/6) 		increased T cell derived lymphoma incidence J:73487
Tg(Lck-Akt1*E40K)E-3Pnt/0
(involves: C3H/He * C57BL/6) 		increased T cell derived lymphoma incidence J:73487
Tg(Lck-Akt1*E40K)E-3Pnt/0
(Not Specified) 		increased T cell derived lymphoma incidence J:144975
Tg(Lck-Akt2*)#Test/0
(Not Specified) 		increased lymphoma incidence J:154583
increased T cell derived lymphoma incidence J:153923
Tg(Lck-Id1)28Xhsu/0
(Not Specified) 		increased T cell derived lymphoma incidence J:58607
Tg(Lck-LMO1)11Sjk/0
Tg(STIL-TAL1)A5(3)Alpa/0
(involves: C3H * C3H/HeRos * C57BL/6 * C57BL/10Ros) 		increased leukemia incidence J:40868
increased T cell derived lymphoma incidence J:40868
Tg(Lck-Map3k8)3456Ngc/?
(involves: C3H/HeJ * C57BL/6J) 		increased T cell derived lymphoma incidence J:39450
Tg(Lck-Notch3)#Issc/0
(involves: C57BL/6 * DBA/2) 		increased acute lymphoblastic leukemia incidence J:63300
increased lymphoblastic lymphoma incidence J:63300
increased T cell derived lymphoma incidence J:96010
Tg(Lck-Tal1)4709Led/0
(FVB/N-Tg(Lck-Tal1)4709Led) 		increased leukemia incidence J:36076
increased lymphoblastic lymphoma incidence J:36076
Tg(Lck-Tax)53Hall/0
(involves: C57BL/6) 		increased leukemia incidence J:129531
increased T cell derived lymphoma incidence J:129531
Tg(Lck-TNFSF13)3919Mhah/0
(B6.Cg-Tg(Lck-TNFSF13)3919Mhah) 		increased chronic lymphocytic leukemia incidence J:94628
Tg(LckNotch1)9Erob/?
(involves: C57BL/6 * CBA/J) 		increased T cell derived lymphoma incidence J:93005
Tg(LCKprBCL2)36Sjk/?
(involves: C3H * C57BL/6) 		increased T cell derived lymphoma incidence J:28635
Tg(LPV-TAg121)2Tvd/0
(involves: 129S6/SvEvTac * C57BL/6J * DBA/2J) 		increased carcinoma incidence J:120820
Tg(Ly6a-BCR/ABL1)IS1AIsg/0
(involves: C57BL/6J * CBA) 		increased chronic myelocytic leukemia incidence J:144382
increased lung adenocarcinoma incidence J:144382
increased osteosarcoma incidence J:144382
Tg(Ly6a-BCR/ABL1)IS1AIsg/0
Tg(Ly6a-BCR/ABL1)IS1BIsg/0
(involves: C57BL/6J * CBA) 		increased leukemia incidence J:144382
Tg(Ly6a-BCR/ABL1)IS1BIsg/0
(involves: C57BL/6J * CBA) 		increased chronic myelocytic leukemia incidence J:144382
increased lung adenocarcinoma incidence J:144382
increased osteosarcoma incidence J:144382
Tg(Ly6a-TK,-BCR/ABL1)IS9AIsg/0
(involves: C57BL/6J * CBA) 		increased chronic myelocytic leukemia incidence J:144382
Tg(Ly6e-MALT1)#Isg/0
(involves: C57BL/6 * CBA) 		increased B cell derived lymphoma incidence J:185590
Tg(MCL1)8Caig/0
(involves: C57BL/6 * SJL) 		increased follicular lymphoma incidence J:69755
increased lymphoma incidence J:69755
increased T cell derived lymphoma incidence J:69755
Tg(Mdm2)1Snj/0
(involves: 129S7/SvEvBrd * C57BL/6) 		increased adenocarcinoma incidence J:51661
increased hemangiosarcoma incidence J:51661
increased lymphoma incidence J:51661
increased pituitary adenoma incidence J:51661
increased rhabdomyosarcoma incidence J:51661
increased sarcoma incidence J:51661
Tg(Mdm2)1Snj/0
Trp53tm1Brd/Trp53tm1Brd
(involves: 129S7/SvEvBrd * C57BL/6) 		increased hemangiosarcoma incidence J:51661
increased lymphoma incidence J:51661
increased medulloblastoma incidence J:51661
increased osteosarcoma incidence J:51661
increased squamous cell carcinoma incidence J:51661
Tg(MGMT)3Bec/Tg(MGMT)3Bec
(involves: NMRI) 		increased skin papilloma incidence J:92925
Tg(MMTV-AURKA)#Cxd/?
(involves: FVB/N) 		increased mammary adenocarcinoma incidence J:145680
Tg(MMTV-AURKA)#Cxd/?
Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * FVB/N) 		increased mammary adenocarcinoma incidence J:145680
Tg(MMTV-CCND1)1Esmp/0
(Not Specified) 		increased mammary adenoacanthoma incidence J:70571
increased mammary adenocarcinoma incidence J:70571
increased sarcoma incidence J:70571
Tg(MMTV-CCND1)1Esmp/0
Tg(MMTV-Cdc37)1Stp/0
(involves: C57BL/6 * DBA/2 * FVB/N) 		increased mammary adenocarcinoma incidence J:62465
Tg(MMTV-Cdc37)1Stp/0
(involves: C57BL/6 * DBA/2 * FVB/N) 		increased lymphoma incidence J:62465
increased mammary adenoacanthoma incidence J:62465
increased mammary adenocarcinoma incidence J:62465
Tg(MMTV-Cdc37)1Stp/0
Tg(MMTV-Myc)141-3Led/0
(involves: C57BL/6 * CD-1 * DBA/2 * FVB/N) 		increased lymphoma incidence J:62465
increased mammary adenocarcinoma incidence J:62465
increased salivary adenocarcinoma incidence J:62465
Tg(MMTV-Cdc37)2Stp/0
(involves: C57BL/6 * DBA/2 * FVB/N) 		increased lymphoma incidence J:62465
increased mammary adenoacanthoma incidence J:62465
increased sarcoma incidence J:62465
Tg(MMTV-ENPP2)20Gbm/0
(FVB/N-Tg(MMTV-ENPP2)20Gbm) 		increased mammary adenocarcinoma incidence J:149661
Tg(MMTV-ENPP2)21Gbm/0
(FVB/N-Tg(MMTV-ENPP2)21Gbm) 		increased mammary adenocarcinoma incidence J:149661
Tg(MMTV-ENPP2)#Gbm/0
(FVB/N-Tg(MMTV-ENPP2)#Gbm) 		increased mammary adenocarcinoma incidence J:149661
Tg(MMTV-Erbb2)1Pv/0
(involves: BALB/c * C57BL/6 * CD-1 * DBA) 		increased mammary adenocarcinoma incidence J:234420
Tg(MMTV-ERBB2)5Erick/?
(FVB/N-Tg(MMTV-ERBB2)5Erick) 		increased Harderian gland adenoma incidence J:90202
increased mammary adenocarcinoma incidence J:90202
Tg(MMTV-Erbb2)9Pjo/0
(involves: BALB/c * C3H * C57BL/6) 		increased mammary adenocarcinoma incidence J:72129
Tg(MMTV-Erbb2)10Pjo/0
(involves: BALB/c * C3H * C57BL/6) 		increased mammary adenocarcinoma incidence J:72129
Tg(MMTV-Erbb2)12Pjo/0
(involves: BALB/c * C3H * C57BL/6) 		increased mammary adenocarcinoma incidence J:72129
Tg(MMTV-Erbb2)17Pjo/0
(involves: BALB/c * C3H * C57BL/6) 		increased mammary adenocarcinoma incidence J:72129
Tg(MMTV-Erbb2)NA1Mul/0
(involves: FVB/N) 		increased mammary adenocarcinoma incidence J:48632
Tg(MMTV-Erbb2)NF1Mul/0
(involves: FVB/N) 		increased mammary adenocarcinoma incidence J:48632
Tg(MMTV-Erbb2)NF1Mul/0
(involves: CD-1 * FVB/N) 		increased mammary adenocarcinoma incidence J:48632
Tg(MMTV-Erbb2)NF1Mul/0
(FVB/N-Tg(MMTV-Erbb2)NF1Mul) 		increased mammary adenocarcinoma incidence J:48632
Tg(MMTV-Erbb2)NK1Mul/0
(involves: FVB/N) 		increased mammary adenocarcinoma incidence J:48632
Tg(MMTV-Erbb2)NK1Mul/Tg(MMTV-Erbb2)NK1Mul
(involves: 129 * C57BL/6 * FVB/N) 		increased mammary adenocarcinoma incidence J:117336
Tg(MMTV-ERBB2*,-luc)6157Aami/0
(FVB-Tg(MMTV-ERBB2*,-luc)6157Aami) 		increased mammary adenocarcinoma incidence J:172352
Tg(MMTV-ERBB3)1Slg/0
(involves: FVB) 		increased lung adenocarcinoma incidence J:80974
Tg(MMTV-ERBB3)1Slg/0
Tg(MMTVneu)202Mul/0
(involves: FVB) 		increased lung adenocarcinoma incidence J:80974
Tg(MMTV-Espl1)1Pati/0
(involves: C57BL/6) 		increased mammary adenocarcinoma incidence J:216267
Tg(MMTV-KLF4)1Rup/0
Trp53tm1Brd/Trp53+
(involves: 129S7/SvEvBrd * C57BL/6NTac * FVB/NJ * SJL) 		increased sarcoma incidence J:96886
Tg(MMTV-KRAS*G12V)3025Mrl/0
(involves: C57BL/6 * FVB * SJL) 		increased mammary adenocarcinoma incidence J:77272
Tg(MMTV-LPAR1)2Gbm/Tg(MMTV-LPAR1)2Gbm
(FVB/N-Tg(MMTV-LPAR1)2Gbm) 		increased mammary adenocarcinoma incidence J:149661
Tg(MMTV-LPAR1)7Gbm/Tg(MMTV-LPAR1)7Gbm
(FVB/N-Tg(MMTV-LPAR1)7Gbm) 		increased mammary adenocarcinoma incidence J:149661
Tg(MMTV-LPAR1)27Gbm/Tg(MMTV-LPAR1)27Gbm
(FVB/N-Tg(MMTV-LPAR1)27Gbm) 		increased mammary adenocarcinoma incidence J:149661
Tg(MMTV-LPAR1)#Gbm/Tg(MMTV-LPAR1)#Gbm
(FVB/N-Tg(MMTV-LPAR1)#Gbm) 		increased mammary adenocarcinoma incidence J:149661
Tg(MMTV-LPAR2)3Gbm/Tg(MMTV-LPAR2)3Gbm
(FVB/N-Tg(MMTV-LPAR2)3Gbm) 		increased mammary adenocarcinoma incidence J:149661
Tg(MMTV-LPAR2)6Gbm/Tg(MMTV-LPAR2)6Gbm
(FVB/N-Tg(MMTV-LPAR2)6Gbm) 		increased mammary adenocarcinoma incidence J:149661
Tg(MMTV-LPAR2)#Gbm/Tg(MMTV-LPAR2)#Gbm
(FVB/N-Tg(MMTV-LPAR2)#Gbm) 		increased mammary adenocarcinoma incidence J:149661
Tg(MMTV-LPAR3)3Gbm/Tg(MMTV-LPAR3)3Gbm
(FVB/N-Tg(MMTV-LPAR3)3Gbm) 		increased mammary adenocarcinoma incidence J:149661
Tg(MMTV-LPAR3)22Gbm/Tg(MMTV-LPAR3)22Gbm
(FVB/N-Tg(MMTV-LPAR3)22Gbm) 		increased mammary adenocarcinoma incidence J:149661
Tg(MMTV-LPAR3)#Gbm/Tg(MMTV-LPAR3)#Gbm
(FVB/N-Tg(MMTV-LPAR3)#Gbm) 		increased mammary adenocarcinoma incidence J:149661
Tg(MMTV-Myc)141-3Led/0
(involves: C57BL/6J * CD-1) 		increased B cell derived lymphoma incidence J:62465
Tg(MMTV-Myc)WT13Jrn/0
(involves: FVB/N) 		increased mammary adenocarcinoma incidence J:153233
Tg(MMTV-Myc)WT21Jrn/0
(involves: FVB/N) 		increased mammary adenocarcinoma incidence J:153233
Tg(MMTV-Myc*T58A)TA14Jrn/0
(involves: FVB/N) 		increased mammary adenocarcinoma incidence J:153233
Tg(MMTV-Myc*T58A)TA41Jrn/0
(involves: FVB/N) 		increased mammary adenocarcinoma incidence J:153233
Tg(MMTV-NCOA3)#Mybr/0
(FVB/N-Tg(MMTV-NCOA3)#Mybr) 		increased leiomyosarcoma incidence J:93548
increased lung adenocarcinoma incidence J:93548
increased mammary adenocarcinoma incidence J:93548
increased pituitary adenoma incidence J:93548
Tg(MMTV-neu/OT-I/OT-II)CBnel/?
Tg(Trp53R172H)8512Jmr/?
(involves: C57BL/6 * FVB) 		increased mammary adenocarcinoma incidence J:122846
Tg(MMTV-Notch4)3Rnc/0
(involves: FVB/N) 		increased mammary adenocarcinoma incidence J:11644
increased salivary adenocarcinoma incidence J:11644
Tg(MMTV-PTGS2)#Thla/0
(involves: CD-1) 		increased adenocarcinoma incidence J:68565
increased mammary adenocarcinoma incidence J:68565
increased mammary gland ductal carcinoma incidence J:68565
Tg(MMTV-PyVT)634Mul/0
(FVB/N-Tg(MMTV-PyVT)634Mul/Nci) 		increased mammary adenocarcinoma incidence J:46460, J:51424, J:87544, J:48285
Tg(MMTV-PyVT)634Mul/0
(multiple strains) 		increased mammary adenocarcinoma incidence J:48854
Tg(MMTV-PyVT)634Mul/0
(involves: 129 * C57BL/6 * FVB/N) 		increased mammary adenocarcinoma incidence J:117336
Tg(MMTV-PyVT)#Mul/0
(B6.FVB-Tg(MMTV-PyVT)#Mul) 		increased mammary adenocarcinoma incidence J:147923
Tg(MMTV-PyVT*Y250F)250-2Mul/?
(FVB/N-Tg(MMTV-PyVT*Y250F)250-2Mul) 		increased mammary adenocarcinoma incidence J:56327
Tg(MMTV-PyVT*Y315F*Y322F)Db-1Mul/?
(FVB/N-Tg(MMTV-PyVT*Y315F*Y322F)Db-1Mul) 		increased mammary adenocarcinoma incidence J:56327
Tg(MMTV-rtTA)1Lach/0
Tg(TetO-Erbb2)1Lach/0
(involves: FVB) 		increased mammary adenocarcinoma incidence J:81083
Tg(MMTV-rtTA)1Lach/0
Tg(tetO-ERBB2)#Jjz/0
(involves: FVB/N) 		increased mammary adenocarcinoma incidence J:231766
Tg(MMTV-rtTA)1Lach/0
Tg(tetO-Esr1)#Paf/0
(involves: FVB/N) 		increased mammary gland ductal carcinoma incidence J:96383
Tg(MMTV-rtTA)1Lach/0
Tg(tetO-IGF1R)1Ramo/0
(involves: FVB) 		increased mammary adenocarcinoma incidence J:121069
Tg(MMTV-rtTA)1Lach/0
Tg(tetO-MYC)1Lach/0
(involves: FVB) 		increased mammary adenocarcinoma incidence J:67498
Tg(MMTV-rtTA)1Lach/0
Tg(tetO-PIK3CA*H1047R,-luc)2239Jjz/0
(involves: FVB/N) 		increased mammary adenocarcinoma incidence J:175839
Tg(MMTV-rtTA)1Lach/0
Tg(tetO-PyVT,-cre)1Mul/0
(FVB/N-Tg(MMTV-rtTA)1Lach Tg(tetO-PyVT,-cre)#Mul) 		increased mammary adenocarcinoma incidence J:231983
Tg(MMTV-TGFBR2)7Hlm/?
Tg(MMTVTGFA)29Rjc/?
(involves: C57BL/6 * DBA) 		increased mammary adenocarcinoma incidence J:85799
Tg(MMTV-TGFBR2)7Hlm/Tg(MMTV-TGFBR2)7Hlm
(involves: C57BL/6 * DBA) 		increased mammary adenocarcinoma incidence J:85799
Tg(MMTV-vHaras)SH1Led/Tg(MMTV-vHaras)SH1Led
(involves: 129X1/SvJ * C57BL/6J * CD-1 * FVB) 		increased carcinoma incidence J:86074
increased mammary adenocarcinoma incidence J:86074
Tg(MMTVneu)202Mul/0
(FVB/N-Tg(MMTVneu)202Mul) 		increased mammary adenocarcinoma incidence J:56332
Tg(MMTVneu)202Mul/0
Tg(Trp53R172H)8512Jmr/0
(C.FVB-Tg(MMTVneu)202Mul Tg(Trp53R172H)8512Jmr) 		increased mammary adenocarcinoma incidence J:115041
Tg(MMTVTGFA)29Rjc/0
(involves: C57BL/6 * DBA/2) 		increased mammary adenocarcinoma incidence J:72085, J:72080, J:28453, J:71696
increased squamous cell carcinoma incidence J:72080
Tg(MMTVTGFA)254Rjc/0
(involves: C57BL/6 * DBA/2) 		increased mammary adenocarcinoma incidence J:72085
Tg(Msmb-TAg)183-2Xuan/0
(either: (involves: C57BL/6 * CBA) or (involves: C57BL/6 * CBA * CD-1)) 		increased carcinoma incidence J:96884
Tg(Msmb-TAg)183-2Xuan/0
(involves: C57BL/6 * CBA) 		increased prostate gland adenocarcinoma incidence J:80313
Tg(Msmb-TAg)186-3Xuan/0
(either: (involves: C57BL/6 * CBA) or (involves: C57BL/6 * CBA * CD-1)) 		increased carcinoma incidence J:96884
Tg(Msmb-TAg)186-3Xuan/0
(involves: C57BL/6 * CBA) 		increased carcinoma incidence J:80313
Tg(Mt1-Hgf)19Lmb/0
(involves: FVB/N) 		increased cutaneous melanoma incidence J:50947
increased melanoma incidence J:50947
Tg(Mt1-RET)304Ina/0
(B6.C-Tg(Mt1-RET)304Ina) 		increased cutaneous melanoma incidence J:50392
Tg(Mt1-RET)304Ina/0
(involves: BALB/c * C57BL/6) 		increased cutaneous melanoma incidence J:88074, J:155735
increased melanoma incidence J:155735
Tg(Mt1-Tgfa)147Bri/0
(involves: C57BL/6 * SJL) 		increased mammary adenocarcinoma incidence J:56318
Tg(MtTGFA)42Lmb/Tg(MtTGFA)42Lmb
(involves: CD-1) 		increased hepatocellular carcinoma incidence J:28452
Tg(MtTGFA)100Lmb/0
(involves: FVB/N) 		increased mammary adenocarcinoma incidence J:72083
Tg(MtTPRMET)243Lng/0
(FVB/N-Tg(MtTPRMET)243Lng) 		increased lymphoma incidence J:71573
increased osteosarcoma incidence J:71573
increased sarcoma incidence J:71573
Tg(MtTPRMET)773Lng/0
(FVB/N-Tg(MtTPRMET)773Lng) 		increased sarcoma incidence J:71573
Tg(Mup3-Plau)350-2Eps/?
(C57BL/6-Tg(Mup3-Plau)350-2Eps) 		increased hepatocellular carcinoma incidence J:233146
increased liver adenoma incidence J:233146
Tg(Mx1-cre)1Cgn/0
Tg(Tal1-tTA)19Dgt/0
Tg(tetO-BCR/ABL1)2Dgt/0
TgTn(pb-sb-GrOnc)#aGsva/0
(involves: C57BL/6 * CBA/J * DBA/2 * FVB/N) 		increased chronic myelocytic leukemia incidence J:227558
Tg(Myl2-FGF19)1Dfre/?
(involves: FVB) 		increased hepatocellular carcinoma incidence J:187236, J:77160
Tg(Neurod2-Smo*A1)199Jols/0
(C57BL/6-Tg(Neurod2-Smo*A1)199Jols) 		increased medulloblastoma incidence J:93861
Tg(Neurod2-Smo*A1)199Jols/0
(involves: C57BL/6) 		increased medulloblastoma incidence J:221990
Tg(Neurod2-Smo*A1)199Jols/Tg(Neurod2-Smo*A1)199Jols
(C57BL/6-Tg(Neurod2-Smo*A1)199Jols) 		increased medulloblastoma incidence J:133312, J:189258
Tg(Neurod2-Smo*A2)#Jols/0
(C57BL/6-Tg(Neurod2-Smo*A2)#Jols) 		increased medulloblastoma incidence J:189258
Tg(OMP-SV40T)13Bse/0
(involves: C57BL/6 * SJL) 		increased neuroblastoma incidence J:54269
Tg(Pax6-TAg)1796Hur/0
(involves: FVB) 		increased retinoblastoma incidence J:196814
Tg(Pax8-rtTA2S*M2)1Koes/0
Tg(tetO-MYC)36aBop/0
(involves: C57BL/6 * DBA * FVB/N) 		increased adenoma incidence J:140925
increased renal carcinoma incidence J:140925
Tg(Pbsn-Ar*E231G)7353Ng/0
(involves: FVB/N) 		increased prostate gland adenocarcinoma incidence J:96117
Tg(Pbsn-ERG*)1Vv/0
(involves: 129S1/SvImJ * C57BL/6J * CBA) 		increased prostate gland adenocarcinoma incidence J:222916
Tg(Pbsn-Fgfr1/Fkbp1a)#aDmsp/0
(FVB-Tg(Pbsn-Fgfr1/Fkbp1a)#aDmsp) 		increased prostate gland adenocarcinoma incidence J:130340
increased sarcoma incidence J:130340
Tg(Pbsn-Fgfr1/Fkbp1a)#aDmsp/0
Tg(Pbsn-Lrp5/Fkbp1a,-luc*)#Dmps/0
(involves: FVB/N) 		increased prostate gland adenocarcinoma incidence J:206727
Tg(Pbsn-Hpn,-GFP)DVv/0
Tg(Pbsn-Tag)12T7fRjm/0
(involves: C57BL/6J * CBA * CD-1) 		increased prostate gland adenocarcinoma incidence J:92562
Tg(Pbsn-MYC)6Key/?
(involves: FVB) 		increased prostate gland adenocarcinoma incidence J:85480
Tg(Pbsn-MYC)#Tt/?
(involves: C57BL/6J) 		increased prostate gland adenocarcinoma incidence J:205395
Tg(Pbsn-Tag)12T7fRjm/0
(involves: CD-1) 		increased prostate gland adenocarcinoma incidence J:48623
Tg(Pbsn-Tag)12T10Rjm/0
(involves: CD-1) 		increased prostate gland adenocarcinoma incidence J:68483, J:48623
Tg(Pbsn-TAg)15Tvd/0
(involves: C57BL/6 * DBA/2) 		increased prostate gland adenocarcinoma incidence J:103408
Tg(Pim1-Il9)5Jcrd/0
(involves: FVB/N) 		increased T cell derived lymphoma incidence J:17848
Tg(Pklr-HRAS*G12V)23Ak/0
(involves: C57BL/6 * DBA/2) 		increased hepatocellular carcinoma incidence J:44803
Tg(Pklr-Myc)73Ak/0
(involves: C57BL/6 * DBA) 		increased hepatocellular carcinoma incidence J:185488
Tg(Pklr-Myc)73Ak/0
(B6.Cg-Tg(Pklr-Myc)73Ak) 		increased hepatocellular carcinoma incidence J:184496
Tg(Pklr-SV40)1Ak/0
(involves: C57BL/6 * DBA) 		increased adenocarcinoma incidence J:185488
increased hepatocellular carcinoma incidence J:185488
increased insulinoma incidence J:185488
increased osteosarcoma incidence J:185488
Tg(PML-RARA)556Kog/?
(involves: FVB/N) 		increased acute promyelocytic leukemia incidence J:39327
increased skin papilloma incidence J:39327
Tg(PML-RARA)556Kog/0
(FVB/N-Tg(PML-RARA)556Kog) 		increased acute promyelocytic leukemia incidence J:262172
Tg(Prl-EGFR)#Sme/0
(Not Specified) 		increased prolactinoma incidence J:219654
Tg(PTH-CCND1)PC2Anar/0
(FVB/N-Tg(PTH-CCND1)PC2Anar) 		increased parathyroid adenoma incidence J:69423
Tg(PyLT)1Vb/0
(Not Specified) 		increased pituitary adenoma incidence J:55528
Tg(RasE)290Biat/0
(involves: C57BL/6 * DBA/2) 		increased lung adenocarcinoma incidence J:226601
Tg(Rbp3-SV40)IT-2Jjw/?
(involves: BALB/c * C57BL/6) 		increased retinoblastoma incidence J:60231
Tg(Ren2-TAg)4Kwg/?
(involves: C3H/HeRos * C57BL/10Ros) 		increased sarcoma incidence J:36423
Tg(RIP1-Tag)2Dh/?
(C3.Cg-Tg(RIP1-Tag)2Dh/Nci) 		increased insulinoma incidence J:80168
Tg(RIP1-Tag)2Dh/0
(involves: C57BL/6) 		increased insulinoma incidence J:162648
Tg(RIP1-Tag)2Dh/0
(involves: C57BL/6J * DBA/2J) 		increased insulinoma incidence J:205389
increased pancreatic islet cell carcinoma incidence J:205389
Tg(RIP1-Tag)5Dh/?
(C3HeB/FeJ-Tg(RIP1-Tag)5Dh) 		increased insulinoma incidence J:80168
Tg(RIP1-Tag)5Dh/0
(C3.Cg-Rgs5tm1.1Rgan Tg(RIP1-Tag)5Dh) 		increased insulinoma incidence J:136259
Tg(rTH-Tag)20Dmc/0
(involves: C57BL/6NTac * DBA/2NTac) 		increased neuroblastoma incidence J:90323
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-EGFR*delta19)11Hev/0
(involves: C57BL/6 * CBA) 		increased lung adenocarcinoma incidence J:109092
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-EGFR*L858R)56Hev/0
(involves: C57BL/6 * CBA) 		increased lung adenocarcinoma incidence J:109092
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-EGFR*L858R)57Hev/0
(involves: C57BL/6 * CBA) 		increased lung adenocarcinoma incidence J:109092
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-EGFR*L858R)#Hev/0
(involves: 129 * C57BL/6 * CBA) 		increased lung adenocarcinoma incidence J:128700, J:213447
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-EGFR*T790M)8Paow/0
(involves: 129 * C57BL/6 * FVB/N) 		increased lung adenocarcinoma incidence J:128700
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-EGFR*T790M*L858R)19Kkw/0
(involves: 129 * C57BL/6 * FVB/N) 		increased lung adenocarcinoma incidence J:122849
increased lung carcinoma incidence J:122849
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-EGFR*T790M*L858R)51Paow/0
(involves: 129 * C57BL/6 * FVB/N) 		increased lung adenocarcinoma incidence J:128700
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-ERBB2*)5BKkw/0
(involves: FVB/N) 		increased lung carcinoma incidence J:143874
increased lung non-small cell carcinoma incidence J:143874
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-ERBB2*)26Kkw/0
(involves: FVB/N) 		increased lung carcinoma incidence J:143874
increased lung non-small cell carcinoma incidence J:143874
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-IGF1R)1Ramo/0
(involves: 129 * C57BL/6 * FVB) 		increased lung adenoma incidence J:271820
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-Kras2)12Hev/0
(involves: 129 * C57BL/6 * FVB/N) 		increased lung adenocarcinoma incidence J:73468
increased lung adenoma incidence J:73468
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-Kras2)12Hev/0
Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * C57BL/6 * FVB/N) 		increased lung adenocarcinoma incidence J:73468
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-MYC)36Bop/0
(involves: 129 * C57BL/6) 		increased lung adenocarcinoma incidence J:169920
increased lung adenoma incidence J:169920
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-PIK3CA*H1047R)13Lca/0
(involves: 129 * C57BL/6 * FVB/N) 		increased lung adenocarcinoma incidence J:142254
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-PTPN11*E76K)#Jiwu/0
(involves: 129 * C57BL/6 * FVB/N) 		increased lung adenoma incidence J:212505
increased lung non-small cell carcinoma incidence J:212505
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO/CMV-KRAS*G12C)9.1Msmi/0
(involves: FVB/N) 		increased lung adenocarcinoma incidence J:102839
increased lung adenoma incidence J:102839
Tg(SERPINA1-TAg)1812Jtsb/0
(involves: C3H * C57BL/6 * ICR) 		increased hepatocellular carcinoma incidence J:101633
Tg(SERPINC1-SV40)A1Pbr/0
(involves: C57BL/6 * DBA/2) 		increased hepatocellular carcinoma incidence J:101541
Tg(SERPINC1-SV40)A1Pbr/Tg(SERPINC1-SV40)A1Pbr
(involves: C57BL/6 * DBA/2) 		increased hepatocellular carcinoma incidence J:101541
X/Tg(SERPINC1-SV40)BPbr
(involves: C57BL/6 * DBA/2) 		increased hepatocellular carcinoma incidence J:84204, J:101541
increased liver adenoma incidence J:84204
Tg(SFTPC-CCNE1)1Edm/?
(involves: FVB/N) 		increased lung adenocarcinoma incidence J:122698
Tg(SFTPC-CCNE1*T62A*T380A)3Edm/?
(involves: FVB/N) 		increased lung adenocarcinoma incidence J:122698
Tg(SFTPC-CCNE1*T62A*T380A)4Edm/?
(involves: FVB/N) 		increased lung adenocarcinoma incidence J:122698
Tg(SFTPC-CD74/ROS1)125Tno/0
(C57BL/6J-Tg(SFTPC-CD74/ROS1)125Tno) 		increased lung adenocarcinoma incidence J:231770
increased lung adenoma incidence J:231770
increased lung non-small cell carcinoma incidence J:231770
Tg(SFTPC-EGFR*L858R)4-3Kkiu/0
(involves: C57BL/6Cr) 		increased lung adenocarcinoma incidence J:152157
increased lung carcinoma incidence J:152157
Tg(SFTPC-EML4/ALK)502-4Hima/0
(involves: C57BL/6J) 		increased lung adenocarcinoma incidence J:142679
Tg(SFTPC-env)1Yhch/0
(FVB/N-Tg(SFTPC-env)1Yhch) 		increased lung adenocarcinoma incidence J:153538, J:247986
Tg(SFTPC-EZR/ROS1)AShiba/0
(C57BL/6-Tg(SFTPC-EZR/ROS1)AShiba) 		increased lung adenocarcinoma incidence J:199415
Tg(SFTPC-KIF5B/RET)1Tkoh/0
(involves: C57BL/6J) 		increased lung adenocarcinoma incidence J:215989
increased lung adenoma incidence J:215989
Tg(SFTPC-MST1R)71Mhw/0
(involves: C3H * C57BL/6) 		increased lung adenocarcinoma incidence J:79080
increased lung adenoma incidence J:79080
Tg(SFTPC-RAF1)87Urr/0
(involves: C57BL/6 * DBA/2) 		increased lung adenoma incidence J:80895
Tg(SFTPC-RAF1-BxB)1Urr/0
(involves: 129S2/SvPas * C57BL/6 * DBA/2) 		increased lung adenoma incidence J:79696
Tg(SFTPC-RAF1-BxB)1Urr/0
(involves: C57BL/6 * DBA/2) 		increased lung adenoma incidence J:80895
Tg(SFTPC-rtTA)5Jaw/0
Tg(tetO-Fgf9,-EGFP)#Dor/0
(involves: FVB) 		increased blastoma incidence J:224791
increased lung adenocarcinoma incidence J:204282
increased lung adenoma incidence J:204282
increased malignant tumor incidence J:204282
Tg(SFTPC-rtTA)5Jaw/0
Tg(tetO-IGF1R)1Ramo/0
(involves: FVB) 		increased lung adenoma incidence J:271820
Tg(SFTPC-rtTA)5Jaw/0
Tg(tetO-MYC)36Bop/0
(Not Specified) 		increased lung adenocarcinoma incidence J:169920
increased lung adenoma incidence J:169920
Tg(SFTPC-rtTA)5Jaw/0
Tg(tetO/CMV-KRAS*G12C)9.1Msmi/0
(involves: FVB/N) 		increased lung adenoma incidence J:102839
Tg(SFTPC-SDC4/ROS1)141Tno/0
(C57BL/6J-Tg(SFTPC-SDC4/ROS1)141Tno) 		increased lung adenocarcinoma incidence J:231770
increased lung adenoma incidence J:231770
increased lung non-small cell carcinoma incidence J:231770
Tg(Slc1a2-tTA)#Waw/0
Tg(tetO-MYCN,-luc)#Waw/0
(involves: FVB/NJ) 		increased malignant tumor incidence J:160518
increased medulloblastoma incidence J:160518
Tg(Slc1a2-tTA)#Waw/0
Tg(tetO-MYCN,-luc)#Waw/Tg(tetO-MYCN,-luc)#Waw
(involves: FVB/NJ) 		increased malignant tumor incidence J:160518
increased medulloblastoma incidence J:160518
Tg(Smgb-TAg)8Mir/Tg(Smgb-TAg)8Mir
(involves: BALB/cJ * C57BL/6J) 		increased salivary adenocarcinoma incidence J:66189
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
Tg(tetO-RNAi:Trp53)ASlowe/0
(involves: C57BL/6 * CD-1) 		increased osteosarcoma incidence J:199542
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
Trp53tm1Brn/Trp53tm1Brn
(involves: 129 * 129P2/OlaHsd * C57BL/6J * CD-1 * FVB/N) 		increased osteosarcoma incidence J:136693
Tg(SV40-NRAS*G12D)1Sco/?
(Not Specified) 		increased sarcoma incidence J:125150
increased T cell derived lymphoma incidence J:125150
Tg(SV)419Bri/Tg(SV)419Bri
(C57BL/6J-Tg(SV)419Bri) 		increased T cell derived lymphoma incidence J:147031
Tg(TagRb)1Plm/?
(involves: BALB/cJ * C57BL/6J) 		increased retinoblastoma incidence J:10320
Tg(Tal1-cre/ERT)1Jrg/0
Tsc1tm1Djk/Tsc1tm1Djk
(involves: 129S4/SvJae * C57BL/6) 		increased extremity angiosarcoma incidence J:231316
increased hemangiosarcoma incidence J:231316
Tg(TCF3/HLF)1Mlc/0
(involves: FVB/N) 		increased B cell derived lymphoma incidence J:55022
increased T cell derived lymphoma incidence J:55022
Tg(Tcra2B4)1Mmd/?
(involves: C3H/HeJ * C57BL/6) 		increased lymphoma incidence J:92992
Tg(Tcrb-TCF3/PBX1)19Gusa/0
(involves: C3H * C57BL/6 * C57BL/6J) 		increased acute lymphoblastic leukemia incidence J:95693
increased leukemia incidence J:95693
Tg(Tcrb-TCF3/PBX1)23Gusa/0
(involves: C3H * C57BL/6 * C57BL/6J) 		increased acute lymphoblastic leukemia incidence J:95693
increased leukemia incidence J:95693
Tg(Tek-cre)1Ywa/0
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * C57BL/6 * CD-1 * SJL) 		increased T cell derived lymphoma incidence J:263520
Tg(tetO-BCR/ABL1)2Dgt/0
Tg(MMTVtTA)1Mam/0
(involves: C57BL/6 * FVB/N * SJL) 		increased leukemia incidence J:72377
Tg(tetO-BCR/ABL1)2Dgt/0
Tg(Tal1-tTA)19Dgt/0
(involves: C57BL/6 * DBA/2 * FVB/N) 		increased lymphoma incidence J:96511
increased sarcoma incidence J:96511
Tg(tetO-BCR/ABL1)27Dgt/0
Tg(MMTVtTA)1Mam/0
(involves: C57BL/6 * FVB/N * SJL) 		increased leukemia incidence J:72377
Tg(tetO-BRAF*V600E)26Jaf/0
Tg(TG-rtTA)30Jaf/0
(involves: FVB/N) 		increased thyroid carcinoma incidence J:184420
Tg(tetO-MET)23Rwng/0
Tg(Cebpb-tTA)5Bjd/0
(involves: FVB/N * NMRI) 		increased hepatocellular carcinoma incidence J:69731
Tg(tetO-MYC)36aBop/0
Tg(Cebpb-tTA)5Bjd/0
(involves: FVB/N * NMRI) 		increased hepatoblastoma incidence J:93899
increased hepatocellular carcinoma incidence J:172430, J:186226, J:190067, J:93899
Tg(tetO-TAg)2-5Hiwa/0
(involves: C57BL/6) 		increased neuroblastoma incidence J:156984, J:175962
Tg(tetO-TAg,CMV-rtTA)123Yihu/0
(involves: FVB/N) 		increased medulloblastoma incidence J:141623
Tg(TetOp-Polb/tTA)2Sbl/0
(B6.Cg-Tg(TetOp-Polb/tTA)2Sbl) 		increased intestinal adenoma incidence J:152481
increased osteosarcoma incidence J:152481
Tg(Tff3-Tmem207)1Tamo/0
(C57BL/6-Tg(Tff3-Tmem207)1Tamo) 		increased carcinoma incidence J:217436
Tg(TG-BRAF*V600E)2Jaf/0
(FVB/N-Tg(TG-BRAF*V600E)2Jaf) 		increased thyroid carcinoma incidence J:98550
Tg(TG-BRAF*V600E)3Jaf/0
(FVB/N-Tg(TG-BRAF*V600E)3Jaf) 		increased thyroid carcinoma incidence J:98550
Tg(TG-NRAS*Q61K)#Msnt/0
(Not Specified) 		increased thyroid adenoma incidence J:210016
increased thyroid carcinoma incidence J:210016
Tg(TG-RET/CCDC6)1Cled/0
(involves: FVB/N) 		increased thyroid carcinoma incidence J:55883, J:93679
Tg(TG-RET/CCDC6)42Cled/0
(involves: FVB/N) 		increased thyroid carcinoma incidence J:55883, J:93679
Tg(TG-RET/NCOA4)3209Rstn/0
(involves: C57BL/6) 		increased thyroid carcinoma incidence J:51366
Tg(TG-SV40)#Cled/0
(involves: C57BL/6J * DBA/2J) 		increased thyroid carcinoma incidence J:209788
Tg(TG-TPR/NTRK1)5215Rstn/0
(involves: C3H * C57BL/6) 		increased thyroid carcinoma incidence J:67120
Tg(TG-TPR/NTRK1)#Rstn/0
(involves: 129S4/SvJaeSor * C3H * C57BL/6 * C57BL/6J) 		increased thyroid carcinoma incidence J:210015
Tg(Tgfa)1Efu/0
(Not Specified) 		increased skin papilloma incidence J:65045
Tg(Th-ALK*F1174L)2Loch/0
Tg(Th-MYCN)41Waw/0
(involves: 129X1/SvJ * BALB/c * C57BL/6J * CBA) 		increased neuroblastoma incidence J:191012
Tg(Th-MYCN)41Waw/0
(involves: BALB/c * C57BL/6J) 		increased neuroblastoma incidence J:41126
Tg(Th-MYCN)41Waw/0
(involves: BALB/c * C57BL/6J * FVB/N) 		increased neuroblastoma incidence J:41126
Tg(Th-MYCN)41Waw/0
(involves: 129X1/SvJ * BALB/c * C57BL/6J) 		increased neuroblastoma incidence J:172448
Tg(Th-MYCN)41Waw/0
Trp53tm1Brd/Trp53+
(involves: 129S7/SvEvBrd * BALB/c * C57BL/6J * FVB/N) 		increased neuroblastoma incidence J:41126
Tg(Th-MYCN)41Waw/Tg(Th-MYCN)41Waw
(involves: BALB/c * C57BL/6J) 		increased neuroblastoma incidence J:41126
Tg(Thy1-cmyc)6Kio/0
(Not Specified) 		increased T cell derived lymphoma incidence J:129440
Tg(Thy1-cmyc)6LKio/0
(Not Specified) 		increased T cell derived lymphoma incidence J:129440
Tg(Thy1/THY1)hT13Gsv/0
(involves: C57BL/10 * CBA) 		increased papilloma incidence J:133943
Tg(TRAMP)8247Ng/0
(involves: C57BL/6) 		increased prostate gland adenocarcinoma incidence J:217920, J:65303
Tg(TRAMP)8247Ng/0
(involves: C3H * C57BL/6) 		increased prostate gland adenocarcinoma incidence J:125633
Tg(TRAMP)8247Ng/0
(involves: 129/Sv * C57BL/6) 		increased prostate gland adenocarcinoma incidence J:133908
Tg(TRAMP)8247Ng/0
Usp11tm1Tac/Y
(involves: 129 * C57BL/6) 		increased prostate gland adenocarcinoma incidence J:270214
Tg(TRP53)4Dgj/0
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * FVB) 		decreased lymphoma incidence J:162466
increased osteosarcoma incidence J:162466
Tg(TRP53*R72P)7Dgj/0
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * FVB) 		decreased lymphoma incidence J:162466
increased hemangiosarcoma incidence J:162466
Tg(Trp53A135V)L3Ber/0
(involves: C57BL/6 * CD-1) 		increased lung adenocarcinoma incidence J:73757
Tg(Trp53R172H)8512Jmr/0
(involves: FVB) 		increased mammary adenocarcinoma incidence J:46426
Tg(Tyr-BRAF*V600E)470Fgh/0
(involves: C57BL/6J * CBA) 		increased malignant tumor incidence J:151455
Tg(Tyr-BRAF*V600E)476Fgh/0
(involves: C57BL/6J * CBA) 		increased malignant tumor incidence J:151455
Tg(UPII-SV40T)2Xrw/0
(involves: FVB/N) 		increased urinary bladder carcinoma incidence J:56305
increased urinary bladder transitional cell carcinoma incidence J:56305
Tg(UPII-SV40T)9Xrw/0
(involves: FVB/N) 		increased urinary bladder carcinoma incidence J:56305
Tg(UPII-SV40T)29Xrw/0
(involves: FVB/N) 		increased urinary bladder carcinoma incidence J:56305
increased urinary bladder transitional cell carcinoma incidence J:56305
Tg(Upk2-TAg)1Rkl/0
(involves: C57BL/6) 		increased urinary bladder carcinoma incidence J:173505
increased urinary bladder transitional cell carcinoma incidence J:173505
Tg(Utg-TAg)7593Fjd/?
(involves: FVB) 		increased lung adenocarcinoma incidence J:70785
Tg(Utg-TAg)7736Fjd/?
(involves: FVB) 		increased lung adenocarcinoma incidence J:70785
Tg(Utg-TAg)#Fjd/?
(involves: FVB) 		increased lung adenocarcinoma incidence J:70785
Tg(Vav1-Asxl1*Y588X)#Fcy/0
(C57BL/6-Tg(Vav1-Asxl1*Y588X)#Fcy) 		increased acute myeloid leukemia incidence J:257690
increased myeloid sarcoma incidence J:257690
Tg(Vav1-ERG)#Jpim/0
(involves: C57BL/6) 		increased acute lymphoblastic leukemia incidence J:203438, J:174808
increased leukemia incidence J:203438, J:174808
Tg(Vav1-Lin28b)C3Apla/0
(involves: C57BL/6) 		increased T cell derived lymphoma incidence J:189197
Tg(Vav1-NUP98/HOXD13)C1Apla/0
(FVB/N-Tg(Vav1-NUP98/HOXD13)C1Apla) 		increased leukemia incidence J:107446
Tg(Vav1-NUP98/HOXD13)G2Apla/0
(C57BL/6-Tg(Vav1-NUP98/HOXD13)G2Apla) 		increased leukemia incidence J:107446
Tg(Vav1-STAT5B*N642H)726Biat/0
(C57BL/6NCrl-Tg(Vav1-STAT5B*N642H)726Biat) 		increased leukemia incidence J:257519
increased lymphoma incidence J:257519
Tg(Vav-BCL2)69Jad/0
(involves: C57BL/6J) 		increased B cell derived lymphoma incidence J:88565, J:228913
increased follicular lymphoma incidence J:88565, J:228913
increased histiocytic sarcoma incidence J:88565
increased lymphoma incidence J:88565
increased T cell derived lymphoma incidence J:88565
Tg(Vil1-Lin28b,-tdTomato)HiAru/0
(involves: C57BL/6J * SJL) 		increased intestinal adenoma incidence J:202923
increased small intestine adenocarcinoma incidence J:202923
Tg(Vil1-Lin28b,-tdTomato)MedAru/0
(involves: C57BL/6J * SJL) 		increased intestinal adenoma incidence J:202923
increased small intestine adenocarcinoma incidence J:202923
Tg(Vil-SLC3A2)HEMerl/0
(involves: FVB/N) 		increased colon adenoma incidence J:173946
Tg(Wap-Hgf)402Mig/0
(involves: FVB/N) 		increased mammary adenocarcinoma incidence J:86776
Tg(Wap-Hgf)402Mig/0
(FVB/N-Tg(Wap-Hgf)402Mig) 		increased mammary adenocarcinoma incidence J:206839
X/Tg(Wap-HRAS)69Lln
(involves: C57BL/6 * SJL) 		increased adenocarcinoma incidence J:72262
increased salivary adenocarcinoma incidence J:46458
Tg(Wap-TAg)1Depp/0
(involves: BALB/c * C57BL/6) 		increased mammary gland ductal carcinoma incidence J:61012
Tg(Wap-tAg)1Gmn/?
(involves: NMRI) 		increased mammary adenocarcinoma incidence J:69711
Tg(Wap-TAg)NP8Depp/0
(involves: BALB/c * C57BL/6) 		increased mammary gland ductal carcinoma incidence J:61012
Tg(Wap-Tsg101)4389Kuw/0
(FVB/N-Tg(Wap-Tsg101)4389Kuw) 		increased mammary adenocarcinoma incidence J:121475
Tg(WapMyc)212Bri/0
(involves: C57BL/6 * SJL) 		increased mammary adenocarcinoma incidence J:56318
Tg(WapNotch4)10Rnc/0
(involves: FVB/N) 		increased mammary adenocarcinoma incidence J:33193
Tg(WapTAg)1Knw/0
(C57BL/6J-Tg(WapTAg)1Knw/J) 		increased mammary adenocarcinoma incidence J:53175
increased sarcoma incidence J:53175
Tg(WapTAg)3Knw/0
(C57BL/6J-Tg(WapTAg)3Knw) 		increased adenocarcinoma incidence J:53175
increased mammary adenocarcinoma incidence J:53175
increased osteosarcoma incidence J:53175
increased sarcoma incidence J:53175
Tg(WapTgfa)215Bri/0
(involves: C57BL/6 * SJL) 		increased mammary adenocarcinoma incidence J:56318
Tg(WapTgfa)215Bri/0
(B6.Cg-Tg(WapTgfa)215Bri) 		increased lymphoma incidence J:123146
Tg(Wnt1)1Hev/0
(involves: 129P2/OlaHsd * C57BL/6 * SJL) 		increased mammary adenocarcinoma incidence J:54215
Tg(Wnt1)1Hev/0
(involves: C57BL/6 * SJL) 		increased mammary adenocarcinoma incidence J:61009
Tgfb1tm1Rif/Tgfb1tm1Rif
(either: (involves: 129) or (involves: 129S/SvEv * C57BL/6)) 		increased anal adenocarcinoma incidence J:142353
increased colon adenocarcinoma incidence J:142353
increased gastric adenocarcinoma incidence J:142353
increased large intestine adenocarcinoma incidence J:142353
increased rectum adenocarcinoma incidence J:142353
Tgfbitm1Zhao/Tgfbitm1Zhao
(involves: 129 * C57BL/6J) 		increased lung adenocarcinoma incidence J:143036
increased lymphoma incidence J:143036
increased malignant tumor incidence J:143036
Tgfbr2tm1.2Hlm/Tgfbr2tm1.2Hlm
Tg(Col1a2-cre/ERT,-ALPP)7Cpd/0
(involves: 129S6/SvEvTac * C57BL/6 * DBA/2) 		increased prostate gland adenocarcinoma incidence J:204736
Thbs1tm1Hyn/Thbs1tm1Hyn
Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * C57BL/6) 		increased adenocarcinoma incidence J:72391
increased adenoma incidence J:72391
increased carcinoma incidence J:72391
increased fibrosarcoma incidence J:72391
increased histiocytic sarcoma incidence J:72391
increased liver adenocarcinoma incidence J:72391
increased lung adenocarcinoma incidence J:72391
increased lymphoma incidence J:72391
increased mammary adenocarcinoma incidence J:72391
increased osteosarcoma incidence J:72391
increased papilloma incidence J:72391
increased sarcoma incidence J:72391
increased squamous cell carcinoma incidence J:72391
Thbs1tm1Hyn/Thbs1tm1Hyn
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6) 		increased adenocarcinoma incidence J:72391
increased carcinoma incidence J:72391
increased fibrosarcoma incidence J:72391
increased hemangiosarcoma incidence J:72391
increased histiocytic sarcoma incidence J:72391
increased lymphoma incidence J:72391
increased sarcoma incidence J:72391
increased small intestine adenocarcinoma incidence J:72391
ThimTg(Myh6-TGFB1)1Ljf/Thim+
(involves: C3HeB/FeJ) 		increased T cell derived lymphoma incidence J:59903
Thrbtm1.1Syc/Thrbtm1.1Syc
(involves: 129S6/SvEvTac * 129X1/SvJ * C57BL/6) 		increased pituitary adenoma incidence J:95391
Thrbtm1.1Syc/Thrbtm1.1Syc
(involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6 * C57BL/6J) 		increased thyroid carcinoma incidence J:92629
Thrbtm1Df/Thrbtm1.1Syc
(involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6 * C57BL/6J) 		increased thyroid carcinoma incidence J:92629
Thyls2MSM/Thyls2MSM
(involves: BALB/c * MSM) 		increased T cell derived lymphoma incidence J:87704
Tiam1tm1Jgc/Tiam1tm1Jgc
(involves: 129P2/OlaHsd * FVB) 		increased malignant tumor incidence J:77148
increased squamous cell carcinoma incidence J:77148
Tlag2AKR/J/Tlag2C57L/J
(involves: AKR/J * C57L/J) 		increased T cell derived lymphoma incidence J:74369
Tlag2AKR/J/Tlag2C57L/J
Tlag1AKR/J/Tlag1AKR/J
(involves: AKR/J * C57L/J) 		increased T cell derived lymphoma incidence J:74369
Tle5tm1.1Mmt/Tle5tm1.1Mmt
Apctm1Mmt/Apc+
Tg(Vil1-cre/ERT2)23Syr/0
(involves: 129S2/SvPas * C57BL/6 * DBA * SJL) 		increased colon adenocarcinoma incidence J:168065
increased small intestine adenocarcinoma incidence J:168065
Tlr2tm1Kir/Tlr2tm1Kir
(B6.129-Tlr2tm1Kir) 		increased carcinoma incidence J:165105
increased colon adenoma incidence J:165105
Tlr7em2Anu/Y
(C57BL/6NCrl-Tlr7em2Anu) 		increased splenic marginal zone lymphoma incidence J:324448
Tlr7em2Anu/Tlr7em2Anu
(C57BL/6NCrl-Tlr7em2Anu) 		increased splenic marginal zone lymphoma incidence J:324448
Tlsm1AKR/JMs/Tlsm1AKR/JMs
(involves: AKR/JMs * SL/Kh) 		increased T cell derived lymphoma incidence J:21741, J:41197, J:33016
Tlsm1AKR/JMs/Tlsm1SL/Kh
(involves: AKR/JMs * SL/Kh) 		increased T cell derived lymphoma incidence J:21741, J:41197, J:33016
Tmigd1em1Gpt/Tmigd1em1Gpt
(C57BL/6NGpt-Tmigd1em1Gpt/Gpt) 		increased intestinal adenoma incidence J:300338
Tmprss11dtm1Bug/Tmprss11dtm1Bug
(involves: 129S1/Sv * 129X1/SvJ * NIH Black Swiss) 		increased lymphoma incidence J:175364
Tnfrsf1atm1Imx/Tnfrsf1atm1Imx
(C57BL/6-Tnfrsf1atm1Imx) 		increased skin papilloma incidence J:89088
Tnfrsf1btm1Imx/Tnfrsf1btm1Imx
(involves: 129S7/SvEvBrd * C57BL/6) 		increased skin papilloma incidence J:89088
Tnfrsf13btm1Vmd/Tnfrsf13btm1Vmd
(involves: C57BL/6) 		increased leukemia incidence J:82331
Tnk1tm1Sksuf/Tnk1+
(involves: 129X1/SvJ * C57BL/6) 		increased carcinoma incidence J:140639
increased hepatocellular carcinoma incidence J:140639
increased intestinal adenocarcinoma incidence J:140639
increased intestinal adenoma incidence J:140639
increased lung adenoma incidence J:140639
increased lymphoma incidence J:140639
increased malignant tumor incidence J:140639
Tnk1tm1Sksuf/Tnk1tm1Sksuf
(involves: 129X1/SvJ * C57BL/6) 		increased B cell derived lymphoma incidence J:140639
increased hemangiosarcoma incidence J:140639
increased hepatocellular carcinoma incidence J:140639
increased lung adenocarcinoma incidence J:140639
increased lymphoma incidence J:140639
Tom1l2Gt(XG909)Byg/Tom1l2Gt(XG909)Byg
(involves: 129P2/OlaHsd * C57BL/6J) 		increased adenoma incidence J:133892
increased basal cell carcinoma incidence J:133892
Tpx2Gt(D028B03)Wrst/Tpx2+
(involves: 129S2/SvPas * C57BL/6J) 		increased hepatocellular carcinoma incidence J:184948
increased intestinal adenoma incidence J:184948
increased lung adenocarcinoma incidence J:184948
increased lung adenoma incidence J:184948
increased lymphoma incidence J:184948
Trappc9tm1a(EUCOMM)Wtsi/Trappc9tm1a(EUCOMM)Wtsi
(C57BL/6N-Trappc9tm1a(EUCOMM)Wtsi/Wtsi) 		increased hemangioma incidence J:239583
Trim24tm1.1Los/Trim24tm1.1Los
(involves: 129/Sv * C57BL/6 * SJL) 		increased hepatocellular carcinoma incidence J:130210
increased liver adenoma incidence J:130210
Trim37Gt(RRO307)Byg/Trim37Gt(RRO307)Byg
(B6J.129P2-Trim37Gt(RRO307)Byg) 		increased carcinoma incidence J:232482
increased lymphoma incidence J:232482
increased medulloblastoma incidence J:232482
Trim62tm1Akil/Trim62+
(involves: 129S/SvEv * C57BL/6) 		increased adenocarcinoma incidence J:204336
increased hepatocellular carcinoma incidence J:204336
increased liver adenocarcinoma incidence J:204336
increased lung adenocarcinoma incidence J:204336
increased lymphoma incidence J:204336
increased mammary adenocarcinoma incidence J:204336
increased sarcoma incidence J:204336
increased spindle cell carcinoma incidence J:204336
Trim62tm1Akil/Trim62tm1Akil
(involves: 129S/SvEv * C57BL/6) 		increased adenocarcinoma incidence J:204336
increased liver adenocarcinoma incidence J:204336
increased lung adenocarcinoma incidence J:204336
increased lymphoma incidence J:204336
increased mammary adenocarcinoma incidence J:204336
increased sarcoma incidence J:204336
increased squamous cell carcinoma incidence J:204336
Trp53Bbl/Trp53+
(C57BL/6JSfdAnu-Trp53Bbl/Anu) 		increased fibrosarcoma incidence J:104190
increased hemangiosarcoma incidence J:104190
increased lymphoma incidence J:104190
increased osteosarcoma incidence J:104190
increased T cell derived lymphoma incidence J:104190
increased teratoma incidence J:104190
Trp53Bbl/Trp53Bbl
(C57BL/6JSfdAnu-Trp53Bbl/Anu) 		increased B cell derived lymphoma incidence J:104190
increased leukemia incidence J:104190
Trp53bhy/Trp53+
(C57BL/6JSfdAnu-Trp53bhy/Anu) 		increased fibrosarcoma incidence J:104190
increased hemangiosarcoma incidence J:104190
increased lymphoma incidence J:104190
increased osteosarcoma incidence J:104190
increased T cell derived lymphoma incidence J:104190
increased teratocarcinoma incidence J:104190
Trp53bhy/Trp53bhy
(C57BL/6JSfdAnu-Trp53bhy/Anu) 		increased leukemia incidence J:104190
Trp53tm1.1Awbr/Trp53tm1.1Awbr
(involves: C57BL/6) 		increased B cell derived lymphoma incidence J:173271
increased fibrosarcoma incidence J:169434
increased follicular lymphoma incidence J:169434
increased histiocytic sarcoma incidence J:173271
increased osteosarcoma incidence J:173271
increased T cell derived lymphoma incidence J:173271
Trp53tm1.1Brn/Trp53tm3Tyj
Tg(KRT14-cre)8Brn/?
(involves: 129P2/OlaHsd * 129S4/SvJae * FVB/N * SKH1) 		increased lymphoma incidence J:121734
Trp53tm1.1Thst/Trp53+
Tg(IghMyc)22Bri/0
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL * SJL) 		increased lymphoma incidence J:198482
Trp53tm1.1Thst/Trp53tm1.1Thst
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ) 		increased carcinoma incidence J:198482
increased hemangiosarcoma incidence J:198482
increased leiomyosarcoma incidence J:198482
increased T cell derived lymphoma incidence J:198482
Trp53tm1.1Umol/Trp53tm1.1Umol
(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NTac) 		increased B cell derived lymphoma incidence J:228632
increased T cell derived lymphoma incidence J:228632
Trp53tm1.1Xlu/Trp53tm1.1Xlu
(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * FVB/N) 		increased lymphoma incidence J:166152
Trp53tm1.2Awbr/Trp53+
(involves: C57BL/6) 		increased B cell derived lymphoma incidence J:173271
increased hamartoma incidence J:173271
increased hibernoma incidence J:173271
increased intestinal adenoma incidence J:173271
increased lung adenoma incidence J:173271
increased osteosarcoma incidence J:173271
Trp53tm1.2Awbr/Trp53tm1.2Awbr
(involves: C57BL/6) 		increased B cell derived lymphoma incidence J:173271
increased hibernoma incidence J:173271
increased histiocytic sarcoma incidence J:173271
increased intestinal adenoma incidence J:173271
increased lung adenoma incidence J:173271
increased osteosarcoma incidence J:173271
increased T cell derived lymphoma incidence J:173271
Trp53tm1Adv/Trp53+
(involves: 129S4/SvJae * C57BL/6) 		increased skin papilloma incidence J:93328
Trp53tm1Adv/Trp53tm1Adv
(involves: 129S4/SvJae * C57BL/6) 		increased skin papilloma incidence J:93328
Trp53tm1Brd/Trp53+
(involves: 129S7/SvEvBrd * C57BL/6) 		increased carcinoma incidence J:73757
increased lymphoma incidence J:73757
increased osteosarcoma incidence J:73757
increased sarcoma incidence J:73757
Trp53tm1Brd/Trp53tm1Brd
(involves: 129S7/SvEvBrd) 		increased carcinoma incidence J:51661
increased lymphoma incidence J:51661
increased osteosarcoma incidence J:51661
increased rhabdomyosarcoma incidence J:51661
increased sarcoma incidence J:51661
Trp53tm1Brd/Trp53tm1Brd
(involves: 129S7/SvEvBrd * C57BL/6) 		increased hemangiosarcoma incidence J:1999
increased lymphoma incidence J:1999
increased osteosarcoma incidence J:1999
increased sarcoma incidence J:1999, J:126497
increased T cell derived lymphoma incidence J:126497
Trp53tm1Brd/Trp53tm1Brd
Tg(Lck-cre)1Cwi/0
(involves: 129S7/SvEvBrd) 		increased T cell derived lymphoma incidence J:157041
Trp53tm1Brd/Trp53tm1Brd
Tg(Nes-cre)1Kln/0
(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * SJL) 		increased T cell derived lymphoma incidence J:109585
Trp53tm1Brd/Trp53tm1Brd
Xrcc4tm2.1Fwa/Xrcc4tm2Fwa
Tg(Nes-cre)1Kln/0
(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * SJL) 		increased medulloblastoma incidence J:109585
Trp53tm1Brd/Trp53tm1Brd
Xrcc5tm1Dbr/Xrcc5tm1Dbr
(involves: 129S7/SvEvBrd * C57BL) 		increased lymphoma incidence J:141515
increased medulloblastoma incidence J:141515
Trp53tm1Brd/Trp53tm1Ldo
(involves: 129S7/SvEvBrd * C57BL/6) 		increased sarcoma incidence J:73757
increased T cell derived lymphoma incidence J:73757
Trp53tm1Brn/Trp53+
Tg(MMTV-cre)#Tfln/0
(involves: 129P2/OlaHsd) 		increased mammary adenocarcinoma incidence J:170898
Trp53tm1Brn/Trp53+
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129 * 129P2/OlaHsd * C57BL/6J * CD-1 * FVB/N) 		increased osteosarcoma incidence J:136693
Trp53tm1Brn/Trp53tm1.1Brn
(involves: 129P2/OlaHsd) 		increased lung adenocarcinoma incidence J:86077, J:157319
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd) 		increased lung adenocarcinoma incidence J:86077, J:157319
Trp53tm1Brn/Trp53tm1Brn
Tg(Cdh16-cre)91Igr/0
(involves: 129P2/OlaHsd * C57BL/6J * FVB/N * ICR) 		increased endometrial carcinoma incidence J:214850, J:215149
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT5-cre/PGR)1Der/0
(involves: 129P2/OlaHsd * C57BL/6N * FVB/N * ICR) 		increased skin squamous cell carcinoma incidence J:216813
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/0
(involves: 129P2/OlaHsd * FVB/N) 		increased mammary adenocarcinoma incidence J:116152
increased squamous cell carcinoma incidence J:116152
Trp53tm1Brn/Trp53tm1Brn
Tg(MMTV-cre)105Ayn/0
(FVB.Cg-Trp53tm1Brn Tg(MMTV-cre)105Ayn) 		increased carcinoma incidence J:165292
increased squamous cell carcinoma incidence J:165292
Trp53tm1Brn/Trp53tm1Brn
Tg(MMTV-cre)#Mam/0
(involves: 129P2/OlaHsd * FVB) 		increased lymphoma incidence J:162126
Trp53tm1Brn/Trp53tm1Brn
Tg(MMTV-cre)#Tfln/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N) 		increased mammary adenocarcinoma incidence J:224955
increased myoepithelioma incidence J:224955
increased spindle cell carcinoma incidence J:224955
Trp53tm1Brn/Trp53tm1Brn
Tg(Nes-cre/ERT2,-ALPP)1Sbk/0
(involves: 129P2/OlaHsd) 		increased medulloblastoma incidence J:237990
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * C57BL/6 * CD-1) 		increased osteosarcoma incidence J:199542
Trp53tm1Brn/Trp53tm1Brn
Tg(Tyr-cre/ERT2)13Bos/0
Tg(Tyr-NRAS*Q61K)1Bee/0
(FVB.Cg-Tg(Tyr-cre/ERT2)13Bos Trp53tm1Brn Tg(Tyr-NRAS*Q61K)1Bee) 		increased cutaneous melanoma incidence J:222847
Trp53tm1Brn/Trp53tm1Brn
Tg(Wap-cre)51Nki/0
(involves: 129P2/OlaHsd * FVB/N) 		increased mammary adenocarcinoma incidence J:171765
Trp53tm1Brn/Trp53tm1Brn
Tsc1tm1Djk/Tsc1tm1Djk
(involves: 129P2/OlaHsd * 129S4/SvJae) 		increased mesothelioma incidence J:212578
Trp53tm1Brn/Trp53tm1Tyj
Tg(Nes-cre)1Kln/0
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL) 		increased medulloblastoma incidence J:102702
Trp53tm1Elee/Trp53tm1Elee
Tg(GFAP-cre)25Mes/0
(involves: 129S4/SvJae * FVB/N) 		increased medulloblastoma incidence J:149662
increased sarcoma incidence J:149662
Trp53tm1Elee/Trp53tm1Elee
Tg(MMTV-cre)AElee/0
(involves: 129S4/SvJae * C57BL/6) 		increased lymphoma incidence J:90247
increased mammary adenocarcinoma incidence J:90247
Trp53tm1Elee/Trp53tm1Elee
Tg(MMTV-cre)BElee/0
(involves: 129S4/SvJae * C57BL/6) 		increased mammary adenocarcinoma incidence J:90247
Trp53tm1Elee/Trp53tm1Elee
Tg(Wap-rtTA-cre)10Whl/0
(involves: 129S4/SvJae * C57BL/6) 		increased mammary adenocarcinoma incidence J:90247
Trp53tm1Elee/Trp53tm1Tyj
Tg(GFAP-cre)25Mes/0
(involves: 129S2/SvPas * 129S4/SvJae * FVB/N) 		increased medulloblastoma incidence J:149662
increased sarcoma incidence J:149662
Trp53tm1Gev/Trp53tm1Gev
(involves: 129P2/OlaHsd * C57BL/6) 		increased T cell derived lymphoma incidence J:99305
Trp53tm1Glo/Trp53+
(involves: 129S7/SvEvBrd * C57BL/6) 		increased carcinoma incidence J:61683
increased fibrosarcoma incidence J:61683
increased hemangiosarcoma incidence J:61683
increased lymphoma incidence J:61683
increased osteosarcoma incidence J:61683
increased sarcoma incidence J:61683
increased squamous cell carcinoma incidence J:61683
Trp53tm1Glo/Trp53+
(involves: 129S7/SvEvBrd) 		increased carcinoma incidence J:129627
increased lymphoma incidence J:129627
increased osteosarcoma incidence J:129627
increased sarcoma incidence J:129627
increased squamous cell carcinoma incidence J:129627
Trp53tm1Glo/Trp53tm1Glo
(involves: 129S7/SvEvBrd * C57BL/6) 		increased T cell derived lymphoma incidence J:61683
Trp53tm1Glo/Trp53tm4Glo
(involves: 129S7/SvEvBrd * C57BL/6) 		increased adenocarcinoma incidence J:171821
increased lipoma incidence J:171821
increased lymphoma incidence J:171821
increased sarcoma incidence J:171821
increased spindle cell carcinoma incidence J:171821
increased T cell derived lymphoma incidence J:171821
Trp53tm1Ldo/Trp53+
(involves: 129S7/SvEvBrd * C57BL/6) 		increased lung adenoma incidence J:73757
Trp53tm1Sia/Trp53tm1Sia
(involves: C57BL/6 * CBA) 		increased T cell derived lymphoma incidence J:36762
Trp53tm1Sia/Trp53tm1Sia
(involves: C57BL/6NCrlj * CBA/JNCrlj) 		increased T cell derived lymphoma incidence J:233347
Trp53tm1Thst/Trp53+
Tg(IghMyc)22Bri/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL * SJL) 		increased lymphoma incidence J:198482
Trp53tm1Thst/Trp53tm1Thst
(involves: 129S1/Sv * 129X1/SvJ) 		increased carcinoma incidence J:198482
increased T cell derived lymphoma incidence J:198482
increased teratoma incidence J:198482
Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * C57BL/6) 		increased adenocarcinoma incidence J:72391
increased adenoma incidence J:72391
increased carcinoma incidence J:72391, J:95318
increased fibrosarcoma incidence J:17728
increased hemangiosarcoma incidence J:72391, J:17728
increased histiocytic sarcoma incidence J:72391
increased leiomyosarcoma incidence J:17728
increased leukemia incidence J:135509
increased lung adenocarcinoma incidence J:72391
increased lymphoma incidence J:72391, J:17728
increased mammary adenocarcinoma incidence J:72391
increased osteosarcoma incidence J:72391, J:17728
increased rhabdomyosarcoma incidence J:17728
increased sarcoma incidence J:72391, J:17728, J:95318
increased squamous cell carcinoma incidence J:72391
Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas) 		increased carcinoma incidence J:95316
Trp53tm1Tyj/Trp53+
Trp53bp2tm1Xlu/Trp53bp2+
(involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6J) 		increased lymphoma incidence J:108701
Trp53tm1Tyj/Trp53+
Trp63tm1Fmc/Trp63+
(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6) 		increased chronic myelocytic leukemia incidence J:98958
increased mammary adenocarcinoma incidence J:98958
increased osteosarcoma incidence J:98958
increased rhabdomyosarcoma incidence J:98958
increased squamous cell carcinoma incidence J:98958
increased T cell derived lymphoma incidence J:98958
increased urinary bladder transitional cell carcinoma incidence J:98958
Trp53tm1Tyj/Trp53+
Trp73tm1Fmc/Trp73+
(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6) 		increased hepatocellular carcinoma incidence J:98958
increased lung adenocarcinoma incidence J:98958
increased pancreatic acinar cell carcinoma incidence J:98958
increased sarcoma incidence J:98958
increased T cell derived lymphoma incidence J:98958
Trp53tm1Tyj/Trp53+
Uimc1tm1.2Amj/Uimc1tm1.2Amj
(involves: 129S2/SvPas * BALB/cJ * C57BL/6) 		increased lymphoma incidence J:191827
Trp53tm1Tyj/Trp53+
Xrcc2tm1Pmc/Xrcc2tm1Pmc
(involves: 129S1/Sv * 129S2/SvPas * C57BL/6) 		increased T cell derived lymphoma incidence J:111068
Trp53tm1Tyj/Trp53tm1.1Umol
(involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6 * C57BL/6NTac) 		increased B cell derived lymphoma incidence J:228632
increased carcinoma incidence J:228632
increased leukemia incidence J:228632
increased lymphoma incidence J:228632
increased sarcoma incidence J:228632
increased T cell derived lymphoma incidence J:228632
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6) 		increased carcinoma incidence J:72391
increased fibrosarcoma incidence J:72391
increased hemangioma incidence J:72391
increased hemangiosarcoma incidence J:72391, J:17728
increased lymphoma incidence J:72391, J:17728, J:95318
increased osteosarcoma incidence J:72391, J:17728
increased rhabdomyosarcoma incidence J:17728
increased sarcoma incidence J:72391, J:17728, J:95318
increased squamous cell carcinoma incidence J:72391
increased T cell derived lymphoma incidence J:87501, J:17728
increased teratoma incidence J:17728
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas) 		increased hemangiosarcoma incidence J:95316
increased lymphoma incidence J:221224
increased medulloblastoma incidence J:102702
increased T cell derived lymphoma incidence J:251434, J:221224, J:88120, J:95316
Trp53tm1Tyj/Trp53tm1Tyj
(129S6.129-Trp53tm1Tyj Rb1tm1.1Jyjw) 		increased lymphoma incidence J:102483
increased teratoma incidence J:102483
increased testicular teratoma incidence J:102483
Trp53tm1Tyj/Trp53tm1Tyj
Tg(Ly6e-MALT1)#Isg/0
(involves: 129S2/SvPas * C57BL/6 * CBA) 		increased B cell derived lymphoma incidence J:185590
Trp53tm1Tyj/Trp53tm1Tyj
Tg(Prrx1-FUS/DDIT3)1Mete/0
(involves: 129S2/SvPas * C57BL/6 * CBA) 		increased liposarcoma incidence J:184491
increased sarcoma incidence J:184491
Trp53tm1Tyj/Trp53tm1Tyj
Xrcc2tm1Pmc/Xrcc2tm1Pmc
(involves: 129S1/Sv * 129S2/SvPas * C57BL/6) 		increased lymphoma incidence J:111068
increased medulloblastoma incidence J:111068
increased sarcoma incidence J:111068
increased T cell derived lymphoma incidence J:111068
Trp53tm1Tyj/Trp53tm1Tyj
Xrcc2tm2Pmc/Xrcc2tm2Pmc
Tg(Nes-cre)1Kln/0
(involves: 129S1/Sv * 129S2/SvPas * C57BL/6 * SJL) 		increased medulloblastoma incidence J:144617
Trp53tm1Tyj/Trp53tm1Tyj
Xrcc4tm1Fwa/Xrcc4tm1Fwa
(involves: 129P2/OlaHsd * 129S2/SvPas) 		increased B cell derived lymphoma incidence J:61973
Trp53tm1Tyj/Trp53tm2.1Tyj
(involves: 129S2/SvPas * 129S4/SvJae) 		increased carcinoma incidence J:95316
increased hemangiosarcoma incidence J:95316
increased T cell derived lymphoma incidence J:95316
Trp53tm1Tyj/Trp53tm2.1Umol
(involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6 * C57BL/6NTac) 		increased B cell derived lymphoma incidence J:228632
increased carcinoma incidence J:228632
increased lymphoma incidence J:228632
increased sarcoma incidence J:228632
increased T cell derived lymphoma incidence J:228632
Trp53tm1Tyj/Trp53tm3.1Tyj
(involves: 129S2/SvPas * 129S4/SvJae) 		increased carcinoma incidence J:95316
increased T cell derived lymphoma incidence J:95316
Trp53tm1Yjc/Trp53tm1Yjc
(B6.129S1-Trp53tm1Yjc) 		increased sarcoma incidence J:195018
increased splenic marginal zone lymphoma incidence J:195018
Trp53tm2.1Thst/Trp53tm2.1Thst
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ) 		increased B cell derived lymphoma incidence J:282255
increased carcinoma incidence J:282255
increased sarcoma incidence J:282255
increased T cell derived lymphoma incidence J:282255
Trp53tm2.1Umol/Trp53tm2.1Umol
(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NTac) 		increased B cell derived lymphoma incidence J:228632
increased T cell derived lymphoma incidence J:228632
Trp53tm2Glo/Trp53tm2Glo
(involves: 129/Sv * C57BL/6) 		increased lymphoma incidence J:87501
increased sarcoma incidence J:87501
Trp53tm2Thst/Trp53tm2.1Thst
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ) 		increased B cell derived lymphoma incidence J:282255
increased carcinoma incidence J:282255
increased sarcoma incidence J:282255
increased T cell derived lymphoma incidence J:282255
Trp53tm3.1Glo/Trp53+
(B6.129S7-Trp53tm3.1Glo) 		increased B cell derived lymphoma incidence J:317504
increased carcinoma incidence J:317504, J:95318
increased lymphoma incidence J:317504, J:95318
increased osteosarcoma incidence J:317504
increased sarcoma incidence J:317504, J:95318
increased T cell derived lymphoma incidence J:317504
Trp53tm3.1Glo/Trp53tm3.1Glo
(B6.129S7-Trp53tm3.1Glo) 		increased lymphoma incidence J:95318
increased sarcoma incidence J:95318
Trp53tm3.1Glo/Trp53tm4Glo
(involves: 129S7/SvEvBrd * C57BL/6) 		increased adenocarcinoma incidence J:171821
increased lymphoma incidence J:171821
increased sarcoma incidence J:171821
increased spindle cell carcinoma incidence J:171821
Trp53tm3.1Tyj/Trp53+
(involves: 129S4/SvJae) 		increased B cell derived lymphoma incidence J:95316
increased carcinoma incidence J:95316
increased hepatocellular carcinoma incidence J:95316
increased lung adenocarcinoma incidence J:95316
increased squamous cell carcinoma incidence J:95316
Trp53tm3.1Tyj/Trp53+
(involves: 129S4/SvJae * SKH1) 		increased mammary adenocarcinoma incidence J:121734
Trp53tm3Tyj/Trp53+
Tg(KRT14-cre)8Brn/?
(involves: 129S4/SvJae * FVB/N * SKH1) 		increased hemangioma incidence J:121734
increased lymphoma incidence J:121734
Trp53tm3Tyj/Trp53+
Tg(Wap-cre)11738Mam/0
(involves: 129S4/SvJae * C57BL/6 * SJL) 		increased lymphoma incidence J:101617
increased mammary adenocarcinoma incidence J:101617
increased sarcoma incidence J:101617
Trp53tm4Glo/Trp53tm4Glo
(involves: 129S7/SvEvBrd * C57BL/6) 		increased adenocarcinoma incidence J:171821
increased lymphoma incidence J:171821
increased sarcoma incidence J:171821
increased spindle cell carcinoma incidence J:171821
increased T cell derived lymphoma incidence J:171821
Trp53tm4Tyj/Trp53tm4Tyj
(involves: 129S4/SvJae * C57BL/6) 		increased B cell derived lymphoma incidence J:92917
increased sarcoma incidence J:92917
Trp53tm4Xu/Trp53tm4Xu
(Not Specified) 		increased lymphoma incidence J:126497
increased sarcoma incidence J:126497
increased T cell derived lymphoma incidence J:126497
Trp53tm6Xu/Trp53tm6Xu
Tg(Lck-cre)1Cwi/0
(involves: 129S4/SvJae) 		increased lymphoma incidence J:157041
increased T cell derived lymphoma incidence J:157041
Trp53tm7.1Xu/Trp53tm7.1Xu
(Not Specified) 		increased lymphoma incidence J:160414
increased sarcoma incidence J:160414
Trp53bp1tm1Jc/Trp53bp1tm1Jc
(involves: 129 * C57BL/6) 		increased lymphoma incidence J:82512
increased T cell derived lymphoma incidence J:82512
Trp53bp2tm1Cdlo/Trp53bp2+
Tg(EmuSR-tTa)83Bop/0
Tg(tetO-MYC)36aBop/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N) 		increased T cell derived lymphoma incidence J:146764
Trp53bp2tm1Xlu/Trp53bp2+
(involves: 129S6/SvEvTac * C57BL/6J) 		increased hemangiosarcoma incidence J:108701
increased lymphoma incidence J:108701
increased rhabdomyosarcoma incidence J:108701
increased squamous cell carcinoma incidence J:108701
increased T cell derived lymphoma incidence J:108701
Trp53inp1tm1Acar/Trp53inp1tm1Acar
(involves: 129/Sv * C57BL/6) 		increased colon adenoma incidence J:118867
Trp63tm1Fmc/Trp63+
(involves: 129S4/SvJae * C57BL/6) 		increased histiocytic sarcoma incidence J:98958
increased lung adenoma incidence J:98958
increased malignant tumor incidence J:98958
increased squamous cell carcinoma incidence J:98958
Trp63tm1Fmc/Trp63+
Trp73tm1Fmc/Trp73+
(involves: 129S4/SvJae * C57BL/6) 		increased carcinoma incidence J:98958
increased chronic myelocytic leukemia incidence J:98958
increased hemangiosarcoma incidence J:98958
increased lung adenocarcinoma incidence J:98958
increased lung adenoma incidence J:98958
increased mammary adenocarcinoma incidence J:98958
increased salivary gland adenoma incidence J:98958
increased squamous cell carcinoma incidence J:98958
increased T cell derived lymphoma incidence J:98958
Trp73tm1Fmc/Trp73+
(involves: 129S4/SvJae * C57BL/6) 		increased hemangiosarcoma incidence J:98958
increased lung adenocarcinoma incidence J:98958
increased lung adenoma incidence J:98958
increased malignant tumor incidence J:98958
increased T cell derived lymphoma incidence J:98958
Trp73tm1Fmc/Trp73tm1Fmc
(involves: 129S4/SvJae * C57BL/6) 		increased lung adenocarcinoma incidence J:98958
Trp73tm1Mak/Trp73+
(involves: 129P2/OlaHsd * C57BL/6J) 		increased carcinoma incidence J:142848
increased hemangiosarcoma incidence J:142848
increased lung adenocarcinoma incidence J:142848
increased lymphoma incidence J:142848
increased T cell derived lymphoma incidence J:142848
Trp73tm1Mak/Trp73tm1Mak
(involves: 129P2/OlaHsd * C57BL/6J) 		increased carcinoma incidence J:142848
increased lung adenocarcinoma incidence J:142848
increased lymphoma incidence J:142848
increased T cell derived lymphoma incidence J:142848
Ts(16C-tel)1Cje/0
(involves: C57BL/6J * Rb(11.16)2H * Rb(16.17)32Lub) 		increased follicular lymphoma incidence J:174270
increased lymphoma incidence J:174270
Ts(1716)65Dn/0
(involves: C3H/HeJ * C57BL/6J * DBA/2J) 		increased follicular lymphoma incidence J:174270
increased lymphoma incidence J:174270
increased malignant tumor incidence J:174270
Tsc1tm1.1Djk/Tsc1+
(either: 129S4/SvJae-Tsc1tm1Djk or (involves: 129S4/SvJae * BALB/cJ) or (involves: 129S4/SvJae * C57BL/6J)) 		increased hemangiosarcoma incidence J:75243
increased hepatic hemangioma incidence J:75243
increased renal carcinoma incidence J:75243
increased renal cystadenoma incidence J:75243
Tsc1tm1Chdl/Tsc1+
(involves: 129P2/OlaHsd * C57BL/6JOlaHsd) 		increased hepatic hemangioma incidence J:99796
increased renal carcinoma incidence J:99796
increased renal cystadenoma incidence J:99796
Tsc1tm1Chdl/Tsc1+
(involves: 129P2/OlaHsd * Balb/cOlaHsd * C57BL/6JOlaHsd) 		increased hepatic hemangioma incidence J:99796
increased renal carcinoma incidence J:99796
increased renal cystadenoma incidence J:99796
Tsc1tm1Chdl/Tsc1+
(involves: 129P2/OlaHsd * C3H/HeNHsd * C57BL/6JOlaHsd) 		increased hepatic hemangioma incidence J:99796
increased renal cystadenoma incidence J:99796
Tsc1tm1Hin/Tsc1+
(involves: 129S4/SvJae * C57BL/6J) 		increased hemangioma incidence J:70463
increased hepatic hemangioma incidence J:70463
increased leiomyosarcoma incidence J:70463
increased renal carcinoma incidence J:70463
increased renal cystadenoma incidence J:70463
increased uterus leiomyoma incidence J:70463
Tsc2tm1.1Mjg/Tsc2tm1.1Mjg
Pgrtm2(cre)Lyd/Pgr+
(involves: 129S1/Sv * 129X1/SvJ) 		increased uterus leiomyoma incidence J:221228
Tsc2tm1.2Mjg/Tsc2+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL) 		increased adenoma incidence J:121748
Tsc2tm1Djk/Tsc2+
(either: (involves: 129S4/SvJae * BALB/cJ) or (involves: 129S4/SvJae * Black Swiss) or (involves: 129S4/SvJae * C57BL/6J)) 		increased extremity angiosarcoma incidence J:57631
increased hepatic hemangioma incidence J:57631
increased lung adenoma incidence J:57631
increased renal carcinoma incidence J:57631
increased renal cystadenoma incidence J:57631
Tsc2tm1Tno/Tsc2+
(involves: 129S4/SvJae * C57BL/6J) 		increased hepatic hemangioma incidence J:52464
increased renal carcinoma incidence J:52464
Tsc2tm2.2Djk/Tsc2+
(involves: 129S4/SvJae * C57BL/6) 		increased renal cystadenoma incidence J:149326
TsilTg(Myc)12ALvn/Tsil+
(involves: C57BL/6 * SJL/J) 		increased lymphoma incidence J:33857
Tspan3Gt(NPX312)Byg/Tspan3Gt(NPX312)Byg
(involves: 129P2/OlaHsd * C57BL/6) 		decreased leukemia incidence J:231800
Ttc7fsn/Ttc7fsn
(involves: A/J) 		increased papilloma incidence J:2777
Tusc2tm1Avi/Tusc2+
(involves: 129S1/Sv * C57BL/6J) 		increased hemangioma incidence J:119985
increased hemangiosarcoma incidence J:119985
increased leukemia incidence J:119985
increased lymphoma incidence J:119985
Tusc2tm1Avi/Tusc2tm1Avi
(involves: 129S1/Sv * C57BL/6J) 		increased hemangioma incidence J:119985
increased hemangiosarcoma incidence J:119985
increased lymphoma incidence J:119985
increased squamous cell carcinoma incidence J:119985
TxnipHyplip1/Txnip+
(involves: CAST/Ei * HcB19/Dem) 		increased hepatocellular carcinoma incidence J:112292
TxnipHyplip1/TxnipHyplip1
(HcB19/Dem-TxnipHyplip1) 		increased hepatocellular carcinoma incidence J:112292
TxnipHyplip1/TxnipHyplip1
(involves: CAST/Ei * HcB19/Dem) 		increased hepatocellular carcinoma incidence J:112292
Uacatm1Kiy/Uacatm1Kiy
(B6.129P2-Uacatm1Kiy) 		increased hepatocellular carcinoma incidence J:157049
Ube2otm1.1(KOMP)Mbp/Ube2otm1.1(KOMP)Mbp
Ptentm1Ppp/Ptentm1Ppp
(involves: 129S1/Sv * C57BL/6 * C57BL/6N * FVB/N) 		increased lymphoma incidence J:239679
Ube2otm1.1(KOMP)Mbp/Ube2otm1.1(KOMP)Mbp
Tg(IghMyc)22Bri/0
(involves: C57BL * C57BL/6N * FVB/N * SJL) 		increased B cell derived lymphoma incidence J:239679
Uimc1Gt(RRN158)Byg/Uimc1Gt(RRN158)Byg
(involves: 129P2/OlaHsd * C57BL/6) 		increased B cell derived lymphoma incidence J:188388
Uimc1tm1.2Amj/Uimc1tm1.2Amj
(involves: BALB/cJ * C57BL/6) 		increased B cell derived lymphoma incidence J:191827
increased lymphoma incidence J:191827
increased T cell derived lymphoma incidence J:191827
Ungtm1Tld/Ungtm1Tld
(Not Specified) 		increased B cell derived lymphoma incidence J:85353
Unktm1a(KOMP)Wtsi/Unktm1a(KOMP)Wtsi
(C57BL/6N-Unktm1a(KOMP)Wtsi/Wtsi) 		increased hemangioma incidence J:239583
Urahplt2/Urahplt2
(C57BL/6-Urahplt2) 		increased hepatocellular carcinoma incidence J:164423
Usp24Gt(XB614)Byg/Usp24+
(involves: 129P2/OlaHsd * C57BL/6) 		increased lipoma incidence J:303991
Usp44tm1.2Pjgl/Usp44tm1.2Pjgl
(involves: 129S4/SvJae * 129S7/SvEvBrd) 		increased lung adenoma incidence J:193965
increased lymphoma incidence J:193965
increased sarcoma incidence J:193965
Vhltm1.1Jae/Vhl+
(involves: 129S4/SvJae * BALB/c) 		increased hepatic hemangioma incidence J:67505
Vhltm1.1Lss/Vhl+
(involves: BALB/c) 		increased hepatic hemangioma incidence J:85513
Vhltm1.1Wkr/Vhl+
(involves: 129S4/SvJae * C57BL/6) 		increased adenocarcinoma incidence J:157369
Vhltm1Lss/Vhltm1.1Lss
(involves: 129X1/SvJ * C57BL/6) 		increased hepatic hemangioma incidence J:85513
Vhltm1Lss/Vhltm1.1Lss
Tg(ACTB-cre)1Tes/0
(involves: 129X1/SvJ * C3H * C57BL/6) 		increased hepatic hemangioma incidence J:85513
Vhltm1Lss/Vhltm1Lss
Tg(Pdx1-cre)89.1Dam/0
(involves: 129X1/SvJ * C57BL/6 * CBA) 		increased pancreas adenoma incidence J:148174
Wif1tm1Dmth/Wif1tm1Dmth
(involves: 129 * C57BL/6) 		increased osteosarcoma incidence J:149607
increased sarcoma incidence J:149607
WwoxGt(XG218)Byg/WwoxGt(XG218)Byg
(involves: 129P2/OlaHsd) 		increased B cell derived lymphoma incidence J:132078
increased malignant tumor incidence J:132078
Wwoxtm1Ria/Wwoxtm1Ria
(involves: 129X1/SvJ * C57BL/6) 		increased osteosarcoma incidence J:120064
Xpatm1Tnka/Xpatm1Tnka
(involves: C57BL/6 * CBA) 		increased lung adenocarcinoma incidence J:62877
increased lung adenoma incidence J:62877
increased papilloma incidence J:28709
increased skin squamous cell carcinoma incidence J:28709
Xpatm1Tnka/Xpatm1Tnka
(C3.Cg-Xpatm1Tnka) 		increased liver adenoma incidence J:76206
Xpctm1Ecf/Xpctm1Ecf
(involves: 129 * C57BL/6) 		increased lung adenocarcinoma incidence J:101421
increased lung adenoma incidence J:101421
Xpnpep1tm1a(KOMP)Wtsi/Xpnpep1tm1a(KOMP)Wtsi
(C57BL/6N-Xpnpep1tm1a(KOMP)Wtsi/Wtsi) 		increased hemangioma incidence J:239583
Xrcc1tm1Pmc/Xrcc1tm1Pmc
Trp53tm1Tyj/Trp53+
Tg(Nes-cre)1Kln/0
(involves: 129S1/Sv * 129S2/SvPas * C57BL/6 * SJL) 		increased medulloblastoma incidence J:152528
Xrcc1tm1Pmc/Xrcc1tm1Pmc
Trp53tm1Tyj/Trp53tm1Tyj
Tg(Nes-cre)1Kln/0
(involves: 129S1/Sv * 129S2/SvPas * C57BL/6 * SJL) 		increased medulloblastoma incidence J:152528
Xrcc6tm1Fwa/Xrcc6tm1Fwa
(involves: 129S6/SvEvTac * C57BL/6J) 		increased T cell derived lymphoma incidence J:44361
Yy1tm2.1Yshi/Yy1tm2.1Yshi
Tg(Nkx2-1-cre)2Sand/0
(involves: 129S4/SvJae * C57BL/6J) 		increased blastoma incidence J:239777
Zdhhc9tm1Lex/Y
Nrastm1Tyj/Nrastm1Tyj
Tg(Mx1-cre)1Cgn/0
(involves: 129S5/SvEvBrd * C57BL/6 * CBA) 		decreased leukemia incidence J:231488
Zeb1tm1Yhi/Zeb1tm1Yhi
(either: (involves: 129 * C3H * C57BL/6) or (involves: 129 * C57BL/6 * ICR)) 		increased T cell derived lymphoma incidence J:139194
Zfand2btm1Otin/Zfand2btm1Otin
(involves: 129S7/SvEvBrd * C57BL/6) 		increased chronic myelocytic leukemia incidence J:233169
Zfp14tm1Xch/Zfp14+
(involves: C57BL/6) 		increased B cell derived lymphoma incidence J:331393
Zfp14tm1Xch/Zfp14tm1Xch
(involves: C57BL/6) 		increased B cell derived lymphoma incidence J:331393
Zfp36l1tm1.1Tnr/Zfp36l1tm1.1Tnr
Zfp36l2tm1.1Tnr/Zfp36l2tm1.1Tnr
Tg(CD2-icre)4Kio/0
(involves: C57BL/6 * C57BL/10 * CBA/Ca * SJL) 		increased leukemia incidence J:162388
increased T cell derived lymphoma incidence J:162388
Zfp871tm1a(EUCOMM)Wtsi/Zfp871+
(C57BL/6N-Zfp871tm1a(EUCOMM)Wtsi/BayMmucd) 		decreased lymphoma incidence J:317166
increased B cell derived lymphoma incidence J:317166
Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
12/10/2024
MGI 6.24 		The Jackson Laboratory